Introducing PHARMAC

Part I

General Rules

Part II

Alimentary Tract and Metabolism
Blood and Blood Forming Organs
Cardiovascular System
Dermatologicals
Genito-Urinary System
Hormone Preparations
Infections
Musculoskeletal System
Nervous System
Oncology Agents and Immunosuppressants
Respiratory System and Allergies
Sensory Organs
Various
Extemporaneous Compounds (ECPs)
Special Foods
Vaccines

Part III

Optional Pharmaceuticals

Index
Introducing PHARMAC
The Pharmaceutical Management Agency (PHARMAC) makes decisions that help control Government spending on pharmaceu-
ticals. This includes community pharmaceuticals, hospital pharmaceuticals, vaccines and increasingly, hospital medical devices.
PHARMAC negotiates prices, sets subsidy levels and conditions, and makes decisions on changes to the subsidised list. The
funding for pharmaceuticals comes from District Health Boards.

PHARMAC’s role:

“Secure for eligible people in need of pharmaceuticals, the best health outcomes that can reasonably be
achieved, and from within the amount of funding provided.”

New Zealand Public Health and Disability Act 2000

To ensure our decisions are as fair and robust as possible we use a decision-making process that incorporates clinical, economic and
commercial issues. We also seek the views of users and the wider community through consultation. The processes we generally
use are outlined in our Operating Policies and Procedures.
Further information about PHARMAC and the way we make funding decisions can be found on the PHARMAC website at
http://www.pharmac.health.nz/about.

Glossary

Units of Measure
gram.................................................. g  microgram................................. mcg  millimole................................. mmol
kilogram......................................... kg  milligram................................. mg  unit............................................... u
international unit......................... iu  millilitre........................................ ml

Abbreviations
application ........................................ app  enteric coated.............................. EC  solution........................................... soln
capsule ........................................... cap  granules................................. grans  suppository................................. suppos
cream............................................ crm  injection................................. inj  tablet........................................... tab
dispersible ................................. disp  liquid........................................ liq  tincture........................................ tinc
effervescent................................. eff  lotion........................................... lotn
emulsion................................. emul  ointment........................................ oint

HSS  Hospital Supply Status
Guide to Section H listings

Example

<table>
<thead>
<tr>
<th>ANATOMICAL HEADING</th>
<th>Price (ex man. Excl. GST)</th>
<th>Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>CHEMICAL A</td>
<td>Restricted see terms below</td>
<td>10.00</td>
<td>100 Brand A</td>
</tr>
<tr>
<td>Presentation A</td>
<td>Restricted</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CHEMICAL B</td>
<td>Some items restricted see terms below</td>
<td>1,589,00</td>
<td>1 Brand B1</td>
</tr>
<tr>
<td>Presentation B1</td>
<td>Restricted</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Presentation B2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CHEMICAL C</td>
<td>Restricted see terms below</td>
<td>15.00</td>
<td>28 Brand C</td>
</tr>
<tr>
<td>Presentation C</td>
<td>1% DV Limit Jan-12 to 2014</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CHEMICAL D</td>
<td>Restricted see terms below</td>
<td>38.65</td>
<td>500 Brand D</td>
</tr>
<tr>
<td>Presentation D</td>
<td>-1% DV Limit Mar-13 to 2014</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CHEMICAL E</td>
<td>Restricted</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Presentation E</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Indicates only presentation B1 is Restricted

From 1 January 2012 to 30 June 2014, at least 99% of the total volume of this item purchased must be Brand C

Standard national price excluding GST

Limited to five weeks' treatment

Either:
1. For the prophylaxis of venous thromboembolism following a total hip replacement; or
2. For the prophylaxis of venous thromboembolism following a total knee replacement.

Not a contracted product

Items restricted (see above); Items restricted (see below)

Products with Hospital Supply Status (HSS) are in bold
General Rules for Section H of the Pharmaceutical Schedule are included in Section A General Rules and are located on the PHARMAC website
<table>
<thead>
<tr>
<th>Antacids and Antiflatulents</th>
</tr>
</thead>
</table>

**Antacids and Reflux Barrier Agents**

**ALUMINIUM HYDROXIDE WITH MAGNESIUM HYDROXIDE AND SIMETICONE**
- Tab 200 mg with magnesium hydroxide 200 mg and simeticone 20 mg
- Oral liq 400 mg with magnesium hydroxide 400 mg and simeticone 30 mg per 5 ml
  - e.g. Mylanta
  - e.g. Mylanta Double Strength

**SIMETICONE**
- Oral drops 100 mg per ml
- Oral drops 20 mg per 0.3 ml
- Oral drops 40 mg per ml

**SODIUM ALGINATE WITH MAGNESIUM ALGINATE**
- Powder for oral soln 225 mg with magnesium alginate 87.5 mg, sachet
  - e.g. Gaviscon Infant

**SODIUM ALGINATE WITH SODIUM BICARBONATE AND CALCIUM CARBONATE**
- Tab 500 mg with sodium bicarbonate 267 mg and calcium carbonate 160 mg
  - e.g. Gaviscon Double Strength
- Oral liq 500 mg with sodium bicarbonate 267 mg and calcium carbonate 160 mg per 10 ml
  - 4.95 500 ml Acidex

**SODIUM CITRATE**
- Oral liq 8.8% (300 mmol/l)

**Phosphate Binding Agents**

**ALUMINIUM HYDROXIDE**
- Tab 600 mg

**CALCIUM CARBONATE**
- Restricted see terms below
  - Oral liq 250 mg per ml (100 mg elemental per ml)
    - 39.00 500 ml Roxane
  - Restricted (RS1698)

**Initiation**
Only when prescribed for patients unable to swallow calcium carbonate tablets or where calcium carbonate tablets are inappropriate.

**Antidiarrhoeals and Intestinal Anti-Inflammatory Agents**

**Antipropulsives**

**DIPHENOXYLATE HYDROCHLORIDE WITH ATROPINE SULPHATE**
- Tab 2.5 mg with atropine sulphate 25 mcg

**LOPERAMIDE HYDROCHLORIDE**
- Tab 2 mg
  - 10.75 400 Nodia
- Cap 2 mg – 1% DV Oct-19 to 2022
  - 6.25 400 Diamide Relief

**Rectal and Colonic Anti-Inflammatories**

**BUDESONIDE**
- Restricted see terms on the next page
  - Cap 3 mg

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
Restricted (RS1026)

Initiation – Crohn’s disease
Both:
1. Mild to moderate ileal, ileocaecal or proximal Crohn’s disease; and
2. Any of the following:
   2.1 Diabetes; or
   2.2 Cushingoid habitus; or
   2.3 Osteoporosis where there is significant risk of fracture; or
   2.4 Severe acne following treatment with conventional corticosteroid therapy; or
   2.5 History of severe psychiatric problems associated with corticosteroid treatment; or
   2.6 History of major mental illness (such as bipolar affective disorder) where the risk of conventional corticosteroid treatment causing relapse is considered to be high; or
   2.7 Relapse during pregnancy (where conventional corticosteroids are considered to be contraindicated).

Initiation – Collagenous and lymphocytic colitis (microscopic colitis)
Patient has a diagnosis of microscopic colitis (collagenous or lymphocytic colitis) by colonoscopy with biopsies.

Initiation – Gut Graft versus Host disease
Patient has gut Graft versus Host disease following allogenic bone marrow transplantation.

HYDROCORTISONE ACETATE
Rectal foam 10%, CFC free (14 applications).................................................26.55 21.1 g Colifoam

HYDROCORTISONE ACETATE WITH PRAMOXINE HYDROCHLORIDE
Topical Aerosol foam, 1% with pramoxine hydrochloride 1%

MESALAZINE
Tab EC 400 mg.................................................................49.50 100 Asacol
Tab EC 500 mg.................................................................49.50 100 Asamax
Tab long-acting 500 mg..................................................59.05 100 Pentasa
Tab 800 mg.................................................................85.50 90 Asacol
Modified release granules 1 g..........................................141.72 120 g Pentasa
Suppos 500 mg..............................................................22.80 20 Asacol
Suppos 1 g.................................................................54.60 30 Pentasa
Enema 1 g per 100 ml..................................................41.30 7 Pentasa

OLSALAZINE
Tab 500 mg.................................................................93.37 100 Dipentum
Cap 250 mg...............................................................53.00 100 Dipentum

SODIUM CROMOGLICATE
Cap 100 mg

SULFASALAZINE
Tab 500 mg.................................................................14.00 100 Salazopyrin
Tab EC 500 mg – 1% DV Dec-19 to 2022.............................................15.53 100 Salazopyrin EN

Local Preparations for Anal and Rectal Disorders

Antihaeorrhoidal Preparations

CINCHOCAINE HYDROCHLORIDE WITH HYDROCORTISONE
Oint 5 mg with hydrocortisone 5 mg per g.................................................15.00 30 g Proctosedyl
Suppos 5 mg with hydrocortisone 5 mg per g.............................................9.90 12 Proctosedyl
ALIMENTARY TRACT AND METABOLISM

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per</td>
<td></td>
</tr>
</tbody>
</table>

**FLUCORTOLONE CAPROATE WITH FLUCORTOLONE PIVALATE AND CINCHOCAINE**

- **Oint 950 mcg with fluocortolone pivalate 920 mcg and cinchocaine hydrochloride 5 mcg per g**
  - 6.35 30 g Ultraproct

- **Suppos 630 mcg with fluocortolone pivalate 610 mcg and cinchocaine hydrochloride 1 mcg**
  - 2.66 12 Ultraproct

**Management of Anal Fissures**

**GLYCERYL TRINITRATE**

- **Oint 0.2%**
  - 22.00 30 g Rectogesic

**Rectal Sclerosants**

**OILY PHENOL [PHENOL OILY]**

- **Inj 5%, 5 ml vial**

**Antispasmodics and Other Agents Altering Gut Motility**

**GLYCOPYRRONIUM BROMIDE**

- **Inj 200 mcg per ml, 1 ml ampoule**
  - 17.14 10 Max Health

**HYOSCINE BUTYLBROMIDE**

- **Tab 10 mg – 1% DV Dec-17 to 2020**
  - 8.75 100 Buscopan

- **Inj 20 mg, 1 ml ampoule**
  - 9.57 5 Buscopan

**MEBEVERINE HYDROCHLORIDE**

- **Tab 135 mg**
  - 18.00 90 Colofac

**Antiulcerants**

**Antisecretory and Cytoprotective**

**MISOPROSTOL**

- **Tab 200 mcg**
  - 41.50 120 Cytotec

**H2 Antagonists**

**CIMETIDINE**

- **Tab 200 mg**
- **Tab 400 mg**

**FAMOTIDINE**

- **Tab 20 mg**
- **Tab 40 mg**

- **Inj 10 mg per ml, 4 ml vial**

**RANITIDINE – Restricted see terms below**

- **Tab 150 mg – 1% DV Oct-17 to 2020**
  - 12.91 500 Ranitidine Relief

- **Tab 300 mg – 1% DV Oct-17 to 2020**
  - 18.21 500 Ranitidine Relief

- **Oral liq 150 mg per 10 ml – 1% DV Oct-17 to 2020**
  - 5.14 300 ml Peptisoothe

- **Inj 25 mg per ml, 2 ml ampoule**
  - 13.40 5 Zantac

**Initiation**

- Either:
  1. For continuation use; or
  2. Routine prevention of allergic reactions..

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
## Proton Pump Inhibitors

<table>
<thead>
<tr>
<th>Drug</th>
<th>Brand or Manufacturer</th>
<th>Price (ex man. excl. GST) $ Per</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>LANSOPRAZOLE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cap 15 mg – 1% DV Sep-18 to 2021</td>
<td>Lanzol Relief</td>
<td>4.58 100</td>
</tr>
<tr>
<td>Cap 30 mg – 1% DV Sep-18 to 2021</td>
<td>Lanzol Relief</td>
<td>5.41 100</td>
</tr>
<tr>
<td><strong>OMEPRAZOLE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab dispersible 20 mg – Restricted (RS1027)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cap 10 mg – 1% DV Mar-18 to 2020</td>
<td>Omeprazole actavis 10</td>
<td>1.98 90</td>
</tr>
<tr>
<td>Cap 20 mg – 1% DV Mar-18 to 2020</td>
<td>Omeprazole actavis 20</td>
<td>1.96 90</td>
</tr>
<tr>
<td>Cap 40 mg – 1% DV Mar-18 to 2020</td>
<td>Omeprazole actavis 40</td>
<td>3.12 90</td>
</tr>
<tr>
<td>Powder for oral liq.</td>
<td>Midwest</td>
<td>42.50 5 g</td>
</tr>
<tr>
<td>Inj 40 mg ampoule with diluent – 1% DV Oct-19 to 2022</td>
<td>Dr Reddy's Omeprazole</td>
<td>33.98 5</td>
</tr>
<tr>
<td>Inj 40 mg vial – 1% DV Oct-19 to 2022</td>
<td>Omezol IV</td>
<td>11.46 5</td>
</tr>
<tr>
<td><strong>PANTOPRAZOLE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab EC 20 mg – 1% DV Oct-19 to 2022</td>
<td>Panzop Relief</td>
<td>2.02 100</td>
</tr>
<tr>
<td>Tab EC 40 mg – 1% DV Oct-19 to 2022</td>
<td>Panzop Relief</td>
<td>2.85 100</td>
</tr>
<tr>
<td>Inj 40 mg vial</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

## Site Protective Agents

<table>
<thead>
<tr>
<th>Drug</th>
<th>Price (ex man. excl. GST) $</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>COLLOIDAL BISMUTH SUBCITRATE</strong></td>
<td></td>
</tr>
<tr>
<td>Tab 120 mg</td>
<td>14.51 50 Gastrodenol</td>
</tr>
<tr>
<td><strong>SUCRALFATE</strong></td>
<td></td>
</tr>
<tr>
<td>Tab 1 g</td>
<td></td>
</tr>
</tbody>
</table>

## Bile and Liver Therapy

<table>
<thead>
<tr>
<th>Drug</th>
<th>Price (ex man. excl. GST) $</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>L-ORNITHINE L-ASPARTATE</strong></td>
<td></td>
</tr>
<tr>
<td>Grans for oral liquid 3 g</td>
<td></td>
</tr>
<tr>
<td>Tab 550 mg – 1% DV Sep-17 to 2020</td>
<td>625.00 56 Xifaxan</td>
</tr>
</tbody>
</table>

## Diabetes

### Alpha Glucosidase Inhibitors

<table>
<thead>
<tr>
<th>Drug</th>
<th>Price (ex man. excl. GST) $ Per</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ACARBOSE</strong></td>
<td></td>
</tr>
<tr>
<td>Tab 50 mg – 1% DV Sep-18 to 2021</td>
<td>3.50 90 Glucobay</td>
</tr>
<tr>
<td>Tab 100 mg – 1% DV Sep-18 to 2021</td>
<td>6.40 90 Glucobay</td>
</tr>
</tbody>
</table>
# Hyperglycaemic Agents

<table>
<thead>
<tr>
<th>Product</th>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>DIAZOXIDE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cap 25 mg.</td>
<td>Proglicem</td>
<td>110.00</td>
</tr>
<tr>
<td>Cap 100 mg.</td>
<td>Proglicem</td>
<td>280.00</td>
</tr>
<tr>
<td>Oral liq 50 mg per ml</td>
<td>Proglycem</td>
<td>620.00</td>
</tr>
<tr>
<td><strong>GLUCAGON HYDROCHLORIDE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 1 mg syringe kit</td>
<td>Glucagen Hypokit</td>
<td>32.00</td>
</tr>
<tr>
<td><strong>GLUCOSE [DEXTROSE]</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 1.5 g</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 3.1 g</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 4 g</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gel 40%</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>GLUCOSE WITH SUCROSE AND FRUCTOSE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gel 19.7% with sucrose 35% and fructose 19.7%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

## Insulin - Intermediate-Acting Preparations

<table>
<thead>
<tr>
<th>Product</th>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>INSULIN ASPART WITH INSULIN ASPART PROTAMINE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj insulin aspart 30% with insulin aspart protamine 70%, 100 u per ml, 3 ml prefilled pen</td>
<td>NovoMix 30 FlexPen</td>
<td>52.15</td>
</tr>
<tr>
<td><strong>INSULIN ISOPHANE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj insulin human 100 u per ml, 10 ml vial</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj insulin human 100 u per ml, 3 ml cartridge</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>INSULIN LISPRO WITH INSULIN LISPRO PROTAMINE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj insulin lispro 25% with insulin lispro protamine 75%, 100 u per ml, 3 ml cartridge</td>
<td>Humalog Mix 25</td>
<td>42.66</td>
</tr>
<tr>
<td>Inj insulin lispro 50% with insulin lispro protamine 50%, 100 u per ml, 3 ml cartridge</td>
<td>Humalog Mix 50</td>
<td>42.66</td>
</tr>
<tr>
<td><strong>INSULIN NEUTRAL WITH INSULIN ISOPHANE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj insulin neutral 30% with insulin isophane 70%, 100 u per ml, 10 ml vial</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj insulin neutral 30% with insulin isophane 70%, 100 u per ml, 3 ml cartridge</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj insulin neutral 40% with insulin isophane 60%, 100 u per ml, 3 ml cartridge</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj insulin neutral 50% with insulin isophane 50%, 100 u per ml, 3 ml cartridge</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

## Insulin - Long-Acting Preparations

<table>
<thead>
<tr>
<th>Product</th>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>INSULIN GLARGINE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 100 u per ml, 3 ml disposable pen</td>
<td>Lantus SoloStar</td>
<td>94.50</td>
</tr>
<tr>
<td>Inj 100 u per ml, 3 ml cartridge</td>
<td>Lantus</td>
<td>94.50</td>
</tr>
<tr>
<td>Inj 100 u per ml, 10 ml vial</td>
<td>Lantus</td>
<td>63.00</td>
</tr>
</tbody>
</table>
### Insulin - Rapid-Acting Preparations

<table>
<thead>
<tr>
<th>Insulin</th>
<th>Formulation</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>INSULIN ASPART</strong></td>
<td>Inj 100 u per ml, 10 ml vial</td>
<td>51.19</td>
<td>NovoRapid FlexPen</td>
</tr>
<tr>
<td></td>
<td>Inj 100 u per ml, 3 ml cartridge</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inj 100 u per ml, 3 ml syringe</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>INSULIN GLULISINE</strong></td>
<td>Inj 100 u per ml, 10 ml vial</td>
<td>27.03</td>
<td>Apidra</td>
</tr>
<tr>
<td></td>
<td>Inj 100 u per ml, 3 ml cartridge</td>
<td>46.07</td>
<td>Apidra</td>
</tr>
<tr>
<td></td>
<td>Inj 100 u per ml, 3 ml disposable pen</td>
<td>46.07</td>
<td>Apidra Solostar</td>
</tr>
<tr>
<td><strong>INSULIN LISPRO</strong></td>
<td>Inj 100 u per ml, 10 ml vial</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inj 100 u per ml, 3 ml cartridge</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Insulin - Short-Acting Preparations

<table>
<thead>
<tr>
<th>Insulin</th>
<th>Formulation</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>INSULIN NEUTRAL</strong></td>
<td>Inj human 100 u per ml, 10 ml vial</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inj human 100 u per ml, 3 ml cartridge</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Oral Hypoglycaemic Agents

<table>
<thead>
<tr>
<th>Drug</th>
<th>Formulation</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>GLIBENCLAMIDE</strong></td>
<td>Tab 5 mg – 1% DV Oct-18 to 2021</td>
<td>6.00</td>
<td>Daonil</td>
</tr>
<tr>
<td><strong>GLICLAZIDE</strong></td>
<td>Tab 80 mg – 1% DV Sep-17 to 2020</td>
<td>10.29</td>
<td>Glizide</td>
</tr>
<tr>
<td><strong>GLIPIZIDE</strong></td>
<td>Tab 5 mg – 1% DV Dec-18 to 2021</td>
<td>3.27</td>
<td>Minidiab</td>
</tr>
<tr>
<td><strong>METFORMIN HYDROCHLORIDE</strong></td>
<td>Tab immediate-release 500 mg – 1% DV Feb-19 to 2021</td>
<td>8.63</td>
<td>Apotex</td>
</tr>
<tr>
<td></td>
<td>Tab immediate-release 850 mg – 1% DV Feb-19 to 2021</td>
<td>7.04</td>
<td>Apotex</td>
</tr>
<tr>
<td><strong>PIOGLITAZONE</strong></td>
<td>Tab 15 mg – 1% DV Oct-18 to 2021</td>
<td>3.47</td>
<td>Vexazone</td>
</tr>
<tr>
<td></td>
<td>Tab 30 mg – 1% DV Oct-18 to 2021</td>
<td>5.06</td>
<td>Vexazone</td>
</tr>
<tr>
<td></td>
<td>Tab 45 mg – 1% DV Oct-18 to 2021</td>
<td>7.10</td>
<td>Vexazone</td>
</tr>
<tr>
<td><strong>VILDAGLIPTIN</strong></td>
<td>Tab 50 mg</td>
<td>40.00</td>
<td>Galvus</td>
</tr>
<tr>
<td><strong>VILDAGLIPTIN WITH METFORMIN HYDROCHLORIDE</strong></td>
<td>Tab 50 mg with 1,000 mg metformin hydrochloride</td>
<td>40.00</td>
<td>Galvumet</td>
</tr>
<tr>
<td></td>
<td>Tab 50 mg with 850 mg metformin hydrochloride</td>
<td>40.00</td>
<td>Galvumet</td>
</tr>
</tbody>
</table>
ALIMENTARY TRACT AND METABOLISM

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$</td>
<td>Per</td>
</tr>
</tbody>
</table>

### Digestives Including Enzymes

#### PANCREATIC ENZYME

- Cap pancreatin (175 mg (25,000 U lipase, 22,500 U amylase, 1,250 U protease))
- Cap pancreatin 150 mg (amylase 8,000 Ph Eur U, lipase 10,000 Ph Eur U, total protease 600 Ph Eur U) – 1% DV Sep-18 to 2021 .......... 34.93 100 Creon 10000
- Cap pancreatin 300 mg (amylase 18,000 Ph Eur U, lipase 25,000 Ph Eur U, total protease 1,000 Ph Eur U) – 1% DV Sep-18 to 2021 .......... 94.38 100 Creon 25000
- Powder pancreatin 60.12 mg (3,600 Ph. Eur. u/amylase, 5,000 Ph. Eur. u/lipase and 200 Ph. Eur. u/protease)

**URSODEOXYCHOLIC ACID** – Restricted see terms below

- Cap 250 mg – 1% DV Sep-17 to 2020 .................................................. 37.95 100 Ursosan

→ Restricted (RS1647)

**Initiation – Alagille syndrome or progressive familial intrahepatic cholestasis**

Either:
1. Patient has been diagnosed with Alagille syndrome; or
2. Patient has progressive familial intrahepatic cholestasis.

**Initiation – Chronic severe drug induced cholestatic liver injury**

All of the following:
1. Patient has chronic severe drug induced cholestatic liver injury; and
2. Cholestatic liver injury not due to Total Parenteral Nutrition (TPN) use in adults; and
3. Treatment with ursodeoxycholic acid may prevent hospital admission or reduce duration of stay.

**Initiation – Primary biliary cholangitis**

Both:
1. Primary biliary cholangitis confirmed by antimitochondrial antibody titre (AMA) > 1:80, and raised cholestatic liver enzymes with or without raised serum IgM or, if AMA is negative by liver biopsy; and
2. Patient not requiring a liver transplant (bilirubin > 100 umol/l; decompensated cirrhosis.

**Initiation – Pregnancy**

Patient diagnosed with cholestasis of pregnancy.

**Initiation – Haematological transplant**

Both:
1. Patient at risk of veno-occlusive disease or has hepatic impairment and is undergoing conditioning treatment prior to allogenic stem cell or bone marrow transplantation; and
2. Treatment for up to 13 weeks.

**Initiation – Total parenteral nutrition induced cholestasis**

Both:
1. Paediatric patient has developed abnormal liver function as indicated on testing which is likely to be induced by TPN; and
2. Liver function has not improved with modifying the TPN composition.

### Laxatives

#### Bowel-Cleansing Preparations

**CITRIC ACID WITH MAGNESIUM OXIDE AND SODIUM PICOSULFATE**

Powder for oral soln 12 g with magnesium oxide 3.5 g and sodium picosulfate 10 mg per sachet  

*e.g. PicoPrep*

---

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
### ALIMENTARY TRACT AND METABOLISM

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST) $ Per</th>
<th></th>
</tr>
</thead>
</table>

### MACROGOL 3350 WITH ASCORBIC ACID, POTASSIUM CHLORIDE AND SODIUM CHLORIDE

Powder for oral soln 755.68 mg with ascorbic acid 85.16 mg, potassium chloride 10.55 mg, sodium chloride 37.33 mg and sodium sulphate 80.62 mg per g, 210 g sachet  

*Example brand:* Glycoprep-C

Powder for oral soln 755.68 mg with ascorbic acid 85.16 mg, potassium chloride 10.55 mg, sodium chloride 37.33 mg and sodium sulphate 80.62 mg per g, 70 g sachet  

*Example brand:* Glycoprep-C

### MACROGOL 3350 WITH POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE AND SODIUM SULPHATE

Powder for oral soln 59 g with potassium chloride 0.7425 g, sodium bicarbonate 1.685 g, sodium chloride 1.465 g and sodium sulphate 5.685 g per sachet – 1% DV Aug-19 to 2022  

*Example brand:* Klean Prep

### Bulk-Forming Agents

**ISPAGHULA (PSYLLIUM) HUSK**

Powder for oral soln – 1% DV Oct-17 to 2020  

*Example brand:* Konsyl-D

**STERCULIA WITH FRANGULA**  

*Restricted: For continuation only*

- Powder for oral soln

### Faecal Softeners

**DOCUSATE SODIUM**

Tab 50 mg – 1% DV Sep-17 to 2020  

*Example brand:* Coloxyl

Tab 120 mg – 1% DV Sep-17 to 2020  

*Example brand:* Coloxyl

**DOCUSATE SODIUM WITH SENNOSIDES**

Tab 50 mg with sennosides 8 mg – 1% DV Jun-18 to 2021  

*Example brand:* Laxsol

**PARAFFIN**

Oral liquid 1 mg per ml  

Enema 133 ml

**POLOXAMER**

Oral drops 10% – 1% DV Sep-17 to 2020  

*Example brand:* Coloxyl

### Opioid Receptor Antagonists - Peripheral

**METHYLNALTREXONE BROMIDE**  

*Restricted* see terms below

<sup>1</sup> Inj 12 mg per 0.6 ml vial  

*Example brand:* Relistor

&  

*Restricted (RS1601)*

Initiation – Opioid induced constipation

Both:

1. The patient is receiving palliative care; and
2. Either:
   1. Oral and rectal treatments for opioid induced constipation are ineffective; or
   2. Oral and rectal treatments for opioid induced constipation are unable to be tolerated.

### Osmotic Laxatives

**GLYCEROL**

Suppos 1.27 g  

Suppos 2.55 g  

Suppos 3.6 g – 1% DV Oct-18 to 2021  

*Example brand:* PSM

---

<sup>e.g. Brand</sup> indicates brand example only. It is not a contracted product.
### LACTULOSE

Oral liq 10 g per 15 ml – **1% DV Nov-19 to 2022**

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$3.33</td>
<td><strong>500 ml Laevolac</strong></td>
</tr>
</tbody>
</table>

### MACROGOL 3350 WITH POTASSIUM CHLORIDE, SODIUM BICARBONATE AND SODIUM CHLORIDE

Powder for oral soln 6.563 g with potassium chloride 23.3 mg, sodium bicarbonate 89.3 mg and sodium chloride 175.4 mg

Powder for oral soln 13.125 g with potassium chloride 46.6 mg, sodium bicarbonate 178.5 mg and sodium chloride 350.7 mg – **1% DV**

| Expiry date of HSS period is 30 June of the year indicated unless otherwise stated. |

| February 18 to 2020 | 6.78 | 30 Molaxole |

### SODIUM CITRATE WITH SODIUM LAURYL SULPHOACETATE

Enema 90 mg with sodium lauryl sulphoacetate 9 mg per ml, 5 ml – **1% DV Nov-19 to 2022**

<table>
<thead>
<tr>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$29.98</td>
<td><strong>30 Micolette</strong></td>
</tr>
</tbody>
</table>

### SODIUM PHOSPHATE WITH PHOSPHORIC ACID

Oral liq 16.4% with phosphoric acid 25.14%

Enema 10% with phosphoric acid 6.58%

<table>
<thead>
<tr>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$2.50</td>
<td><strong>1 Fleet Phosphate Enema</strong></td>
</tr>
</tbody>
</table>

### Stimulant Laxatives

### BISACODYL

Tab 5 mg – **1% DV Sep-18 to 2021**

<table>
<thead>
<tr>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$5.99</td>
<td><strong>200 Lax-Tabs</strong></td>
</tr>
</tbody>
</table>

Suppos 10 mg – **1% DV Sep-18 to 2021**

<table>
<thead>
<tr>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$3.74</td>
<td><strong>10 Lax-Suppositories</strong></td>
</tr>
</tbody>
</table>

### SENNOSIDES

Tab 7.5 mg

### Metabolic Disorder Agents

**ALGLUCOSIDASE ALFA** – **Restricted** see terms **below**

Inj 50 mg vial

<table>
<thead>
<tr>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$1,142.60</td>
<td><strong>1 Myozyme</strong></td>
</tr>
</tbody>
</table>

**Initiation**

Metabolic physician

**Re-assessment required after 12 months**

All of the following:

1. The patient is aged up to 24 months at the time of initial application and has been diagnosed with infantile Pompe disease; and
2. Any of the following:
   1. Diagnosis confirmed by documented deficiency of acid alpha-glucosidase by prenatal diagnosis using chorionic villus biopsies and/or cultured amniotic cells; or
   2. Documented deficiency of acid alpha-glucosidase, and urinary tetrasaccharide testing indicating a diagnostic elevation of glucose tetrasaccharides; or
   3. Documented deficiency of acid alpha-glucosidase, and documented molecular genetic testing indicating a disease-causing mutation in the acid alpha-glucosidase gene (GAA gene); or
   4. Documented urinary tetrasaccharide testing indicating a diagnostic elevation of glucose tetrasaccharides, and molecular genetic testing indicating a disease-causing mutation in the GAA gene; and
3. Patient has not required long-term invasive ventilation for respiratory failure prior to starting enzyme replacement therapy (ERT); and
4. Patient does not have another life-threatening or severe disease where the prognosis is unlikely to be influenced by ERT or might be reasonably expected to compromise a response to ERT; and
5. Alglucosidase alfa to be administered at doses no greater than 20 mg/kg every 2 weeks.

**continued…**
continued…

Continuation
Metabolic physician

Re-assessment required after 12 months

All of the following:

1. The treatment remains appropriate for the patient and the patient is benefiting from treatment; and
2. Alglucosidase alfa to be administered at doses no greater than 20 mg/kg every 2 weeks; and
3. Patient has not had severe infusion-related adverse reactions which were not preventable by appropriate pre-medication and/or adjustment of infusion rates; and
4. Patient has not developed another life threatening or severe disease where the long term prognosis is unlikely to be influenced by ERT; and
5. Patient has not developed another medical condition that might reasonably be expected to compromise a response to ERT; and
6. There is no evidence of life threatening progression of respiratory disease as evidenced by the needed for > 14 days of invasive ventilation; and
7. There is no evidence of new or progressive cardiomyopathy.

ARGinine

Powder

Inj 600 mg per ml, 25 ml vial

BETAINE – Restricted see terms below

< Restricted (RS1639)

Initiation
Metabolic physician

Re-assessment required after 12 months

All of the following:

1. The patient has a confirmed diagnosis of homocystinuria; and
2. Any of the following:
   a. A cystathionine beta-synthase (CBS) deficiency; or
   b. A 5,10-methylene-tetrahydrofolate reductase (MTHFR) deficiency; or
   c. A disorder of intracellular cobalamin metabolism; and
3. An appropriate homocysteine level has not been achieved despite a sufficient trial of appropriate vitamin supplementation.

Continuation
Metabolic physician

Re-assessment required after 12 months

The treatment remains appropriate and the patient is benefiting from treatment.

BIOTIN – Restricted see terms below

< Restricted (RS1330)

Metabolic physician or metabolic disorders dietitian

GALSULFase – Restricted see terms below

< Restricted (RS1523)

Initiation
Metabolic physician

Re-assessment required after 12 months

Both:

continued…
continued...

1. The patient has been diagnosed with mucopolysaccharidosis VI; and
2. Either:
   2.1. Diagnosis confirmed by demonstration of N-acetyl-galactosamine-4-sulfatase (arylsulfatase B) deficiency confirmed by either enzyme activity assay in leukocytes or skin fibroblasts; or
   2.2. Detection of two disease causing mutations and patient has a sibling who is known to have mucopolysaccharidosis VI.

Continuation
Metabolic physician
Re-assessment required after 12 months

All of the following:

1. The treatment remains appropriate for the patient and the patient is benefiting from treatment; and
2. Patient has not had severe infusion-related adverse reactions which were not preventable by appropriate pre-medication and/or adjustment of infusion rates; and
3. Patient has not developed another life threatening or severe disease where the long term prognosis is unlikely to be influenced by Enzyme Replacement Therapy (ERT); and
4. Patient has not developed another medical condition that might reasonably be expected to compromise a response to ERT.

HAEM ARGINATE
Inj 25 mg per ml, 10 ml ampoule

IDURSULFASE – Restricted see terms below

- Inj 2 mg per ml, 3 ml vial

- Restricted (RS1546)

Initiation
Metabolic physician
Limited to 24 weeks treatment

All of the following:

1. The patient has been diagnosed with Hunter Syndrome (mucopolysaccharidosis II); and
2. Either:
   2.1. Diagnosis confirmed by demonstration of iduronate 2-sulfatase deficiency in white blood cells by either enzyme assay in cultured skin fibroblasts; or
   2.2. Detection of a disease causing mutation in the iduronate 2-sulfatase gene; and
3. Patient is going to proceed with a haematopoietic stem cell transplant (HSCT) within the next 3 months and treatment with idursulfase would be bridging treatment to transplant; and
4. Patient has not required long-term invasive ventilation for respiratory failure prior to starting Enzyme Replacement Therapy (ERT); and
5. Idursulfase to be administered for a total of 24 weeks (equivalent to 12 weeks pre- and 12 weeks post-HSCT) at doses no greater than 0.5 mg/kg every week.

LARONIDASE – Restricted see terms below

- Inj 100 U per ml, 5 ml vial

- Restricted (RS1607)

Initiation
Metabolic physician
Limited to 24 weeks treatment

All of the following:

1. The patient has been diagnosed with Hurler Syndrome (mucopolysaccharidosis I-H); and
2. Either:

continued…
continued...

2.1 Diagnosis confirmed by demonstration of alpha-L-iduronidase deficiency in white blood cells by either enzyme assay in cultured skin fibroblasts; or

2.2 Detection of two disease causing mutations in the alpha-L-iduronidase gene and patient has a sibling who is known to have Hurler syndrome; and

3 Patient is going to proceed with a haematopoietic stem cell transplant (HSCT) within the next 3 months and treatment with laronidase would be bridging treatment to transplant; and

4 Patient has not required long-term invasive ventilation for respiratory failure prior to starting Enzyme Replacement Therapy (ERT); and

5 Laronidase to be administered for a total of 24 weeks (equivalent to 12 weeks pre- and 12 post-HSCT) at doses no greater than 100 units/kg every week.

LEVOCARNITINE – Restricted see terms below

- Cap 500 mg
- Oral soln 1,000 mg per 10 ml
- Inj 200 mg per ml, 5 ml vial

⇒ Restricted (RS1035)
Neurologist, metabolic physician or metabolic disorders dietitian

PYRIDOXAL-5-PHOSPHATE – Restricted see terms below

- Tab 50 mg

⇒ Restricted (RS1331)
Neurologist, metabolic physician or metabolic disorders dietitian

SAPROPTERIN DIHYDROCHLORIDE – Restricted see terms below

- Tab soluble 100 mg ....................................................................................1,452.70 30 Kuvan

⇒ Restricted (RS1656)
Initiation
Metabolic physician

Re-assessment required after 1 month
All of the following:

1 Patient has phenylketonuria (PKU) and is pregnant or actively planning to become pregnant; and

2 Treatment with sapropterin is required to support management of PKU during pregnancy; and

3 Sapropterin to be administered at doses no greater than a total daily dose of 20 mg/kg; and

4 Sapropterin to be used alone or in combination with PKU dietary management; and

5 Total treatment duration with sapropterin will not exceed 22 months for each pregnancy (includes time for planning and becoming pregnant) and treatment will be stopped after delivery.

Continuation
Metabolic physician or any relevant practitioner on the recommendation of a metabolic physician

Re-assessment required after 12 months
All of the following:

1 Either:

1.1 Following the initial one-month approval, the patient has demonstrated an adequate response to a 2 to 4 week trial of sapropterin with a clinically appropriate reduction in phenylalanine levels to support management of PKU during pregnancy; or

1.2 On subsequent renewal applications, the patient has previously demonstrated response to treatment with sapropterin and maintained adequate phenylalanine levels to support management of PKU during pregnancy; and

2 Any of the following:

2.1 Patient continues to be pregnant and treatment with sapropterin will not continue after delivery; or

2.2 Patient is actively planning a pregnancy and this is the first renewal for treatment with sapropterin; or

continued…
continued...

2.3 Treatment with sapropterin is required for a second or subsequent pregnancy to support management of their PKU during pregnancy; and

3 Sapropterin to be administered at doses no greater than a total daily dose of 20 mg/kg; and

4 Sapropterin to be used alone or in combination with PKU dietary management; and

5 Total treatment duration with sapropterin will not exceed 22 months for each pregnancy (includes time for planning and becoming pregnant) and treatment will be stopped after delivery.

SODIUM BENZOATE
- Cap 500 mg
- Powder
- Soln 100 mg per ml
- Inj 20%, 10 ml ampoule

SODIUM PHENYLACETATE – Some items restricted see terms below
- Tab 500 mg
  - Grans 483 mg per g……………………………………………1,920.00 174 g Pheburane
  - Oral liq 250 mg per ml
  - Inj 200 mg per ml, 10 ml ampoule

  → Restricted (RS1526)

Initiation
Metabolic physician
Re-assessment required after 12 months
For the chronic management of a urea cycle disorder involving a deficiency of carbamylphosphate synthetase, ornithine transcarbamylase or argininosuccinate synthetase.

Continuation
Metabolic physician
Re-assessment required after 12 months
The treatment remains appropriate and the patient is benefiting from treatment.

TALIGLUCERASE ALFA – Restricted see terms below
- Inj 200 unit vial……………………………….1,072.00 1 Elelyso

  → Restricted (RS1034)

Initiation
Only for use in patients with approval by the Gaucher Treatment Panel.

TRIENTINE DIHYDROCHLORIDE
- Cap 300 mg

Minerals

Calcium

CALCIUM CARBONATE
- Tab 1.25 g (500 mg elemental) – 1% DV Mar-18 to 2020 ………………..7.52 250 Arrow-Calcium
- Tab eff 1.75 g (1 g elemental)

Fluoride

SODIUM FLUORIDE
- Tab 1.1 mg (0.5 mg elemental)

Iodine

POTASSIUM IODATE
- Tab 253 mcg (150 mcg elemental iodine) – 1% DV Mar-19 to 2020 …………4.69 90 NeuroTabs

Products with Hospital Supply Status (HSS) are in bold
Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
**Iron**

**FERRIC CARBOXYMALTOSE** – *Restricted* see terms below
- Inj 50 mg per ml, 10 ml vial.................................................................................. $150.00 1 Ferinject

*Item restricted (see above)*; *Item restricted (see below)*

**Initiation**
Treatment with oral iron has proven ineffective or is clinically inappropriate.

**FERROUS FUMARATE**
- Tab 200 mg (65 mg elemental) – 1% DV Jan-19 to 2021............................... $3.09 100 Ferro-tab

**FERROUS FUMARATE WITH FOLIC ACID**
- Tab 310 mg (100 mg elemental) with folic acid 350 mcg – 1% DV Jun-18 to 2021.............................................................. $4.68 60 Ferro-F-Tabs

**FERROUS GLUCONATE WITH ASCORBIC ACID**
- Tab 170 mg (20 mg elemental) with ascorbic acid 40 mg

**FERROUS SULFATE**
- Oral liq 30 mg (6 mg elemental) per ml – 1% DV Nov-19 to 2022.............. $12.08 500 ml Ferodan

**FERROUS SULPHATE**
- Tab long-acting 325 mg (105 mg elemental) – 1% DV Jun-18 to 2021........ $2.06 30 Ferrograd

**FERROUS SULPHATE WITH ASCORBIC ACID**
- Tab long-acting 325 mg (105 mg elemental) with ascorbic acid 500 mg

**IRON POLYMALTOSE**
- Inj 50 mg per ml, 2 ml ampoule ........................................................................... $34.50 5 Ferrosig
  - 15.22 Ferrum H

*(Ferrum H Inj 50 mg per ml, 2 ml ampoule to be delisted 1 February 2020)*

**IRON SUCROSE**
- Inj 20 mg per ml, 5 ml ampoule .......................................................................... $100.00 5 Venofer

**Magnesium**

**MAGNESIUM AMINO ACID CHELATE**
- Cap 750 mg (150 mg elemental)

**MAGNESIUM CHLORIDE**
- Inj 1 mmol per 1 ml, 100 ml bag

**MAGNESIUM HYDROXIDE**
- Tab 311 mg (130 mg elemental)

**MAGNESIUM OXIDE**
- Cap 663 mg (400 mg elemental)
  - Cap 696 mg (420 mg elemental)

**MAGNESIUM OXIDE WITH MAGNESIUM ASPARTATE, MAGNESIUM AMINO ACID CHELATE AND MAGNESIUM CITRATE**
- Cap 500 mg with magnesium aspartate 100 mg, magnesium amino acid chelate 100 mg and magnesium citrate 100 mg (360 mg elemental magnesium)

**MAGNESIUM SULPHATE**
- Inj 0.4 mmol per ml, 250 ml bag
- Inj 2 mmol per ml, 5 ml ampoule – 1% DV Sep-17 to 2020.............................. $10.21 10 DBL
### ALIMENTARY TRACT AND METABOLISM

**Price (ex man. excl. GST) $ Per Brand or Generic Manufacturer**

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price</th>
<th>Expiry Date</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zinc</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zinc</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zinc (Oral liq 5 mg per 5 drops)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zinc Chloride (Inj 5.3 mg per ml (5.1 mg per ml elemental), 2 ml ampoule)</td>
<td></td>
<td>1% DV Dec-19 to 2022</td>
<td>11.00 100 Zincaps</td>
</tr>
<tr>
<td>Zinc Sulphate (Cap 137.4 mg (50 mg elemental))</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mouth and Throat</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Agents Used in Mouth Ulceration</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Benzydamine Hydrochloride</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Soln 0.15%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Spray 0.15%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Spray 0.3%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Benzydamine Hydrochloride with Cetylpyridinium Chloride</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lozenge 3 mg with cetylpyridinium chloride</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Carboxymethylcellulose</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oral spray</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Carmellose Sodiuim with Pectin and Gelatine</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Paste</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Powder</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chlorhexidine Gluconate</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mouthwash 0.2%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CHLORHEXIDINE GLUCONATE</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mouthwash 0.2%</td>
<td>2.57 200 ml healthE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Choline Salicylate with Cetalkonium Chloride</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adhesive gel 8.7% with cetalkonium chloride 0.01%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dichlorobenzyl Alcohol with Amylmetacresol</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lozenge 1.2 mg with amylmetacresol 0.6 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Triamcinolone Acetonide</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Paste 0.1%</td>
<td>5.33 5 g Kenalog in Orabase</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1% DV Sep-17 to 2020</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oropharyngeal Anti-Infectives</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amphotericin B</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lozenge 10 mg</td>
<td>5.86 20</td>
<td>Fungilin</td>
<td></td>
</tr>
<tr>
<td>Miconazole</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oral gel 20 mg per g – 1% DV Sep-18 to 2021</td>
<td>4.74 40 g Decozol</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NySTATIN</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oral liquid 100,000 u per ml – 1% DV Oct-17 to 2020</td>
<td>1.95 24 ml Nilstat</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other Oral Agents</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hyaluronic Acid with LidoCAINE [LignoCAINE]</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 20 mg per ml</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sodium Hyaluronate [Hyaluronic Acid] – Restricted see terms below</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sodium Hyaluronate [Hyaluronic Acid] – Restricted</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 20 mg per ml, 1 ml syringe</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Restricted (RS1175)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Otolaryngologist</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Products with Hospital Supply Status (HSS) are in **bold**.*

*Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.*
THYMOL GLYCERIN
Compound, BPC ........................................................................................................ 9.15 500 ml PSM

Vitamins

Multivitamin Preparations

MULTIVITAMIN AND MINERAL SUPPLEMENT – Restricted see terms below
Cap ..................................................................................................................... 23.35 180 Clinicians Multivit & Mineral Boost

→ Restricted (RS1498)
Initiation
Limited to 3 months treatment
Both:
1. Patient was admitted to hospital with burns; and
2. Any of the following:
   2.1 Burn size is greater than 15% of total body surface area (BSA) for all types of burns; or
   2.2 Burn size is greater than 10% of BSA for mid-dermal or deep dermal burns; or
   2.3 Nutritional status prior to admission or dietary intake is poor.

MULTIVITAMIN RENAL – Restricted see terms below
Cap ..................................................................................................................... 6.49 30 Clinicians Renal Vit

→ Restricted (RS1499)
Initiation
Either:
1. The patient has chronic kidney disease and is receiving either peritoneal dialysis or haemodialysis; or
2. The patient has chronic kidney disease grade 5, defined as patient with an estimated glomerular filtration rate of < 15 ml/min/1.73m$^2$ body surface area (BSA).

MULTIVITAMINS
Tab (BPC cap strength) – 1% DV Mar-20 to 2022............................................ 11.45 1,000 Mvite
Cap vitamin A 2500 u, betacarotene 3 mg, cholecalciferol 11 mcg, alpha tocopherol 150 u, phytonadione 150 mcg, folic acid 0.2 mg, ascorbic acid 100 mg, thiamine 1.5 mg, pantothenic acid 12 mg, riboflavin 1.7 mg, niacin 20 mg, pyridoxine hydrochloride 1.9 mg, cyanocobalamin 3 mcg, zinc 7.5 mg and biotin 100 mcg e.g. Vitabdeck

→ Restricted (RS1620)
Initiation
Any of the following:
1. Patient has cystic fibrosis with pancreatic insufficiency; or
2. Patient is an infant or child with liver disease or short gut syndrome; or
3. Patient has severe malabsorption syndrome.

Powder vitamin A 4200 mcg with vitamin D 155.5 mcg, vitamin E 21.4 mg, vitamin C 400 mg, vitamin K1 166 mcg thiamine 3.2 mg, riboflavin 4.4 mg, niacin 35 mg, vitamin B6 3.4 mg, folic acid 303 mcg, vitamin B12 8.6 mcg, biotin 214 mcg, pantothenic acid 17 mg, choline 350 mg and inositol 700 mg e.g. Paediatric Seravit

→ Restricted (RS1178)
Initiation
Patient has inborn errors of metabolism.
**ALIMENTARY TRACT AND METABOLISM**

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) $</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
</table>

Inj thiamine hydrochloride 250 mg with riboflavin 4 mg and pyridoxine hydrochloride 50 mg, 5 ml ampoule (1) and inj ascorbic acid 500 mg with nicotinamide 160 mg and glucose 1000 mg, 5 ml ampoule (1)  
Inj thiamine hydrochloride 250 mg with riboflavin 4 mg and pyridoxine hydrochloride 50 mg, 5 ml ampoule (1) and inj ascorbic acid 500 mg with nicotinamide 160 mg, 2 ml ampoule (1)  
Inj thiamine hydrochloride 500 mg with riboflavin 8 mg and pyridoxine hydrochloride 100 mg, 10 ml ampoule (1) and inj ascorbic acid 1000 mg with nicotinamide 320 mg and glucose 2000 mg, 10 ml ampoule (1)  

**Vitamin A**

**RETINOL**  
Tab 10,000 iu  
Cap 25,000 iu  
Oral liq 150,000 iu per ml  
Oral liq 5,000 iu per drop, 30 ml

**Vitamin B**

**HYDROXOCOBALAMIN**  
Inj 1 mg per ml, 1 ml ampoule  – 1% DV Sep-18 to 2021  
Inj 1 mg per ml, 1 ml vial  
Inj 1 mg per ml, 2 ml vial  
Inj 1 mg per ml, 3 ml vial  

**PYRIDOXINE HYDROCHLORIDE**  
Tab 25 mg  – 1% DV Jan-18 to 2020  
Tab 50 mg  – 1% DV Oct-17 to 2020  
Inj 100 mg per ml, 1 ml ampoule  
Inj 100 mg per ml, 2 ml vial  
Inj 100 mg per ml, 3 ml vial

**THIAMINE HYDROCHLORIDE**  
Tab 50 mg  – 1% DV Nov-18 to 2020  
Tab 100 mg  
Inj 100 mg per ml, 1 ml ampoule  
Inj 100 mg per ml, 2 ml vial

**VITAMIN B COMPLEX**  
Tab strong, BPC

**Vitamin C**

**ASCORBIC ACID**  
Tab 100 mg  – 1% DV Mar-20 to 2022  
Tab chewable 250 mg

**Vitamin D**

**ALFACALCIDOL**  
Cap 0.25 mcg  – 1% DV Aug-17 to 2020  
Cap 1 mcg  – 1% DV Aug-17 to 2020  
Oral drops 2 mcg per ml  – 1% DV Aug-17 to 2020

---

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
ALIMENTARY TRACT AND METABOLISM

<table>
<thead>
<tr>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per</td>
<td></td>
</tr>
<tr>
<td>(ex man. excl. GST)</td>
<td></td>
</tr>
</tbody>
</table>

**CALCITRIOL**

- Cap 0.25 mcg – 1% DV Oct-19 to 2022 .................................................. 7.95 100 Calcitriol-AFT
- Cap 0.5 mcg – 1% DV Oct-19 to 2022 .................................................. 13.75 100 Calcitriol-AFT
- Oral liq 1 mcg per ml
- Inj 1 mcg per ml, 1 ml ampoule

**COLECALCIFEROL**

- Cap 1.25 mg (50,000 iu) – 1% DV Oct-17 to 2020 ........................................ 2.50 12 Vit.D3
- Oral liq 188 mcg per ml (7,500 iu per ml) .......................................... 9.00 4.8 ml Puria

**Vitamin E**

**ALPHA TOCOPHERYL** – Restricted see terms below

- Oral liq 156 u per ml

  - Restricted (RS1632)

  **Initiation – Cystic fibrosis**
  Both:
  1. Cystic fibrosis patient; and
  2. Either:
     2.1 Patient has tried and failed the other available funded fat soluble vitamin A,D,E,K supplement (Vitabdeck); or
     2.2 The other available funded fat soluble vitamin A,D,E,K supplement (Vitabdeck) is contraindicated or clinically inappropriate for the patient.

  **Initiation – Osteoradionecrosis**
  For the treatment of osteoradionecrosis.

  **Initiation – Other indications**
  All of the following:
  1. Infant or child with liver disease or short gut syndrome; and
  2. Requires vitamin supplementation; and
  3. Either:
     3.1 Patient has tried and failed the other available funded fat soluble vitamin A,D,E,K supplements (Vitabdeck); or
     3.2 The other available funded fat soluble vitamin A,D,E,K supplement (Vitabdeck) is contraindicated or clinically inappropriate for patient.

**ALPHA TOCOPHERYL ACETATE** – Restricted see terms below

- Cap 100 u
- Cap 500 u
- Oral liq 156 u per ml

  - Restricted (RS1176)

  **Initiation – Cystic fibrosis**
  Both:
  1. Cystic fibrosis patient; and
  2. Either:
     2.1 Patient has tried and failed the other available funded fat soluble vitamin A,D,E,K supplement (Vitabdeck); or
     2.2 The other available funded fat soluble vitamin A,D,E,K supplement (Vitabdeck) is contraindicated or clinically inappropriate for the patient.

  **Initiation – Osteoradionecrosis**
  For the treatment of osteoradionecrosis.

  **Initiation – Other indications**
  All of the following:
  1. Infant or child with liver disease or short gut syndrome; and

continued…

e.g. Brand indicates brand example only. It is not a contracted product.

Item restricted (see ➥ above); Item restricted (see ➥ below)
continued...

2 Requires vitamin supplementation; and

3 Either:
   3.1 Patient has tried and failed the other available funded fat soluble vitamin A,D,E,K supplements (Vitabdeck); or
   3.2 The other available funded fat soluble vitamin A,D,E,K supplement (Vitabdeck) is contraindicated or clinically
       inappropriate for patient.
Antianaeemics

Hypoplastic and Haemolytic

EPOETIN ALFA – Restricted see terms below

- Inj 1,000 iu in 0.5 ml syringe – 1% DV Apr-19 to 2022........................250.00 6 Binocrit
- Inj 2,000 iu in 1 ml syringe – 1% DV Apr-19 to 2022..........................100.00 6 Binocrit
- Inj 3,000 iu in 0.3 ml syringe – 1% DV Apr-19 to 2022.........................150.00 6 Binocrit
- Inj 4,000 iu in 0.4 ml syringe – 1% DV Apr-19 to 2022.........................96.50 6 Binocrit
- Inj 5,000 iu in 0.5 ml syringe – 1% DV Apr-19 to 2022.........................125.00 6 Binocrit
- Inj 6,000 iu in 0.6 ml syringe – 1% DV Apr-19 to 2022.........................145.00 6 Binocrit
- Inj 8,000 iu in 0.8 ml syringe – 1% DV Apr-19 to 2022........................175.00 6 Binocrit
- Inj 10,000 iu in 1 ml syringe – 1% DV Apr-19 to 2022.........................197.50 6 Binocrit
- Inj 40,000 iu in 1 ml syringe – 1% DV Apr-19 to 2022.........................250.00 1 Binocrit

Initiation – chronic renal failure

All of the following:
1. Patient in chronic renal failure; and
2. Haemoglobin is less than or equal to 100g/L; and
3. Either:
   - 3.1 Both:
     - 3.1.1 Patient does not have diabetes mellitus; and
     - 3.1.2 Glomerular filtration rate is less than or equal to 30ml/min; or
   - 3.2 Both:
     - 3.2.1 Patient has diabetes mellitus; and
     - 3.2.2 Glomerular filtration rate is less than or equal to 45ml/min; and
4. Patient is on haemodialysis or peritoneal dialysis.

Initiation – myelodysplasia*

Re-assessment required after 2 months

All of the following:
1. Patient has a confirmed diagnosis of myelodysplasia (MDS); and
2. Has had symptomatic anaemia with haemoglobin < 100g/L and is red cell transfusion-dependent; and
3. Patient has very low, low or intermediate risk MDS based on the WHO classification-based prognostic scoring system for myelodysplastic syndrome (WPSS); and
4. Other causes of anaemia such as B12 and folate deficiency have been excluded; and
5. Patient has a serum epoetin level of < 500 IU/L; and
6. The minimum necessary dose of epoetin would be used and will not exceed 80,000 iu per week.

Continuation – myelodysplasia*

Re-assessment required after 12 months

All of the following:
1. The patient's transfusion requirement continues to be reduced with epoetin treatment; and
2. Transformation to acute myeloid leukaemia has not occurred; and
3. The minimum necessary dose of epoetin would be used and will not exceed 80,000 iu per week.

Initiation – all other indications

Haematologist

For use in patients where blood transfusion is not a viable treatment alternative.

Note: Indications marked with * are unapproved indications
EPOETIN BETA – Restricted see terms below

Note: Epoetin beta is considered a Discretionary Variance Pharmaceutical for epoetin alfa.

- Inj 2,000 iu in 0.3 ml syringe
- Inj 3,000 iu in 0.3 ml syringe
- Inj 4,000 iu in 0.3 ml syringe
- Inj 5,000 iu in 0.3 ml syringe
- Inj 6,000 iu in 0.3 ml syringe
- Inj 10,000 iu in 0.6 ml syringe

Initiation – chronic renal failure

All of the following:
1. Patient in chronic renal failure; and
2. Haemoglobin is less than or equal to 100g/L; and
3. Either:
   3.1 Both:
      3.1.1 Patient does not have diabetes mellitus; and
      3.1.2 Glomerular filtration rate is less than or equal to 30ml/min; or
   3.2 Both:
      3.2.1 Patient has diabetes mellitus; and
      3.2.2 Glomerular filtration rate is less than or equal to 45ml/min; and
4. Patient is on haemodialysis or peritoneal dialysis.

Initiation – myelodysplasia*

Re-assessment required after 12 months

All of the following:
1. Patient has a confirmed diagnosis of myelodysplasia (MDS); and
2. Has had symptomatic anaemia with haemoglobin < 100g/L and is red cell transfusion-dependent; and
3. Patient has very low, low or intermediate risk MDS based on the WHO classification-based prognostic scoring system for myelodysplastic syndrome (WPSS); and
4. Other causes of anaemia such as B12 and folate deficiency have been excluded; and
5. Patient has a serum epoetin level of < 500 IU/L; and
6. The minimum necessary dose of epoetin would be used and will not exceed 80,000 iu per week.

Continuation – myelodysplasia*

Re-assessment required after 2 months

All of the following:
1. The patient's transfusion requirement continues to be reduced with epoetin treatment; and
2. Transformation to acute myeloid leukaemia has not occurred; and
3. The minimum necessary dose of epoetin would be used and will not exceed 80,000 iu per week.

Initiation – all other indications

Haematologist.

For use in patients where blood transfusion is not a viable treatment alternative.

*Note: Indications marked with * are unapproved indications.

Megaloblastic

FOLIC ACID

<table>
<thead>
<tr>
<th>Product</th>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 0.8 mg – 1% DV Oct-18 to 2021</td>
<td>21.84  $</td>
<td>Apo-Folic Acid</td>
</tr>
<tr>
<td>Tab 5 mg – 1% DV Oct-18 to 2021</td>
<td>12.12  $</td>
<td>Apo-Folic Acid</td>
</tr>
<tr>
<td>Oral liq 50 mcg per ml</td>
<td>26.00  $</td>
<td>Biomed</td>
</tr>
<tr>
<td>Inj 5 mg per ml, 10 ml vial</td>
<td>25 ml Biomed</td>
<td></td>
</tr>
</tbody>
</table>

*Note: Indications marked with * are unapproved indications.*
Antifibrinolytics, Haemostatics and Local Sclerosants

ALUMINIUM CHLORIDE – Restricted see terms below
- Topical soln 20% w/v
- Restricted (RS1500)

Initiation
For use as a haemostatis agent.

APROTININ – Restricted see terms below
- Inj 10,000 kIU per ml (equivalent to 200 mg per ml), 50 ml vial
- Restricted (RS1332)

Initiation
Cardiac anaesthetist
Either:
1 Paediatric patient undergoing cardiopulmonary bypass procedure; or
2 Adult patient undergoing cardiac surgical procedure where the significant risk of massive bleeding outweighs the potential adverse effects of the drug.

ELTROMBOPAG – Restricted see terms below
- Tab 25 mg .................................................................1,550.00 28 Revolade
- Tab 50 mg .................................................................3,100.00 28 Revolade
- Restricted (RS1648)

Initiation – idiopathic thrombocytopenic purpura - post-splenectomy
Haematologist
Re-assessment required after 6 weeks
All of the following:
1 Patient has had a splenectomy; and
2 Two immunosuppressive therapies have been trialled and failed after therapy of 3 months each (or 1 month for rituximab); and
3 Any of the following:
   3.1 Patient has a platelet count of 20,000 to 30,000 platelets per microlitre and has evidence of significant mucocutaneous bleeding; or
   3.2 Patient has a platelet count of less than or equal to 20,000 platelets per microlitre and has evidence of active bleeding; or
   3.3 Patient has a platelet count of less than or equal to 10,000 platelets per microlitre.

Initiation – idiopathic thrombocytopenic purpura - preparation for splenectomy
Haematologist
Limited to 6 weeks treatment
The patient requires eltrombopag treatment as preparation for splenectomy.

Continuation – idiopathic thrombocytopenic purpura - post-splenectomy
Haematologist
Re-assessment required after 12 months
The patient has obtained a response (see Note) from treatment during the initial approval or subsequent renewal periods and further treatment is required.

Note: Response to treatment is defined as a platelet count of > 30,000 platelets per microlitre

Initiation – idiopathic thrombocytopenic purpura contraindicated to splenectomy
Haematologist
Re-assessment required after 3 months
All of the following:
1 Patient has a significant and well-documented contraindication to splenectomy for clinical reasons; and
continued...

2 Two immunosuppressive therapies have been trialled and failed after therapy of 3 months each (or 1 month for rituximab); and

3 Either:
   3.1 Patient has immune thrombocytopenic purpura* with a platelet count of less than or equal to 20,000 platelets per microliter; or
   3.2 Patient has immune thrombocytopenic purpura* with a platelet count of 20,000 to 30,000 platelets per microlitre and significant mucocutaneous bleeding.

**Continuation – idiopathic thrombocytopenic purpura contraindicated to splenectomy**

Haematologist

*Re-assessment required after 12 months*

All of the following:

1. The patient’s significant contraindication to splenectomy remains; and
2. The patient has obtained a response from treatment during the initial approval period; and
3. Patient has maintained a platelet count of at least 50,000 platelets per microlitre on treatment; and
4. Further treatment with eltrombopag is required to maintain response.

**Initiation – severe aplastic anaemia**

Haematologist

*Re-assessment required after 3 months*

Both:

1. Two immunosuppressive therapies have been trialled and failed after therapy of at least 3 months duration; and
2. Either:
   2.1 Patient has severe aplastic anaemia with a platelet count of less than or equal to 20,000 platelets per microliter; or
   2.2 Patient has severe aplastic anaemia with a platelet count of 20,000 to 30,000 platelets per microlitre and significant mucocutaneous bleeding.

**Continuation – severe aplastic anaemia**

Haematologist

*Re-assessment required after 12 months*

Both:

1. The patient has obtained a response from treatment of at least 20,000 platelets per microlitre above baseline during the initial approval period; and
2. Platelet transfusion independence for a minimum of 8 weeks during the initial approval period.

**FERRIC SUBSULFATE**

Gel 25.9%
Soln 500 ml

**POLIDOCANOL**

Inj 0.5%, 30 ml vial

**SODIUM TETRADECYL SULPHATE**

Inj 3%, 2 ml ampoule

**THROMBIN**

Powder

**TRANEXAMIC ACID**

Tab 500 mg – 1% DV May-20 to 2022..............................................20.67 100 Cyklokapron
..............................................9.45 60 Mercury Pharma

Inj 100 mg per ml, 5 ml ampoule – 1% DV Sep-18 to 2021.........................6.95 5 Tranexamic-AFT

Inj 100 mg per ml, 10 ml ampoule – 1% DV Sep-18 to 2021.......................10.95 5 Tranexamic-AFT

(Cyklokapron Tab 500 mg to be delisted 1 May 2020)
BLOOD AND BLOOD FORMING ORGANS

<table>
<thead>
<tr>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>(ex man. excl. GST) $ Per</td>
<td></td>
</tr>
</tbody>
</table>

### Anticoagulant Reversal Agents

**IDARUCIZUMAB** – **Restricted** see terms below

- **Inj 50 mg per ml, 50 ml vial**: $4,250.00 2 Praxbind

**Initiation**
For the reversal of the anticoagulant effects of dabigatran when required in situations of life-threatening or uncontrolled bleeding, or for emergency surgery or urgent procedures.

### Blood Factors

**EFTRENONACOG ALFA [RECOMBINANT FACTOR IX]** – **Restricted** see terms below

- **Inj 250 iu vial**: $612.50 1 Alprolix
- **Inj 500 iu vial**: $1,225.00 1 Alprolix
- **Inj 1,000 iu vial**: $2,450.00 1 Alprolix
- **Inj 2,000 iu vial**: $4,900.00 1 Alprolix
- **Inj 3,000 iu vial**: $7,350.00 1 Alprolix

**Initiation**
For patients with haemophilia B receiving prophylaxis treatment. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.

**EPTACOG ALFA [RECOMBINANT FACTOR VIIA]** – **Restricted** see terms below

- **Inj 1 mg syringe**: $1,178.30 1 NovoSeven RT
- **Inj 2 mg syringe**: $2,356.60 1 NovoSeven RT
- **Inj 5 mg syringe**: $5,891.50 1 NovoSeven RT
- **Inj 8 mg syringe**: $9,426.40 1 NovoSeven RT

**Initiation**
For patients with haemophilia. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group. Rare Clinical Circumstances Brand of bypassing agent for > 14 days predicted use. Access to funded treatment for > 14 days predicted use is by named patient application to the Haemophilia Treaters Group, subject to access criteria.

**FACTOR EIGHT INHIBITOR BYPASSING FRACTION** – **Restricted** see terms below

- **Inj 500 U**: $1,315.00 1 FEIBA NF
- **Inj 1,000 U**: $2,630.00 1 FEIBA NF
- **Inj 2,500 U**: $6,575.00 1 FEIBA NF

**Initiation**
For patients with haemophilia. Preferred Brand of bypassing agent for > 14 days predicted use. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.

**MOROCTOCOG ALFA [RECOMBINANT FACTOR VIII]** – **Restricted** see terms below

- **Inj 250 iu prefilled syringe**: $287.50 1 Xyntha
- **Inj 500 iu prefilled syringe**: $575.00 1 Xyntha
- **Inj 1,000 iu prefilled syringe**: $1,150.00 1 Xyntha
- **Inj 2,000 iu prefilled syringe**: $2,300.00 1 Xyntha
- **Inj 3,000 iu prefilled syringe**: $3,450.00 1 Xyntha

**Initiation**
For patients with haemophilia. Rare Clinical Circumstances Brand of short half-life recombinant factor VIII. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group, subject to criteria.

---

*Item restricted (see ➥ above); Item restricted (see ➥ below)*

*e.g. Brand indicates brand example only. It is not a contracted product.*
<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>NONACOG GAMMA, [RECOMBINANT FACTOR IX]</td>
<td>$435.00</td>
<td>1 RIXUBIS</td>
</tr>
<tr>
<td>Inj 500 iu vial</td>
<td>$435.00</td>
<td>1 RIXUBIS</td>
</tr>
<tr>
<td>Inj 1,000 iu vial</td>
<td>$870.00</td>
<td>1 RIXUBIS</td>
</tr>
<tr>
<td>Inj 2,000 iu vial</td>
<td>$1,740.00</td>
<td>1 RIXUBIS</td>
</tr>
<tr>
<td>Inj 3,000 iu vial</td>
<td>$2,610.00</td>
<td>1 RIXUBIS</td>
</tr>
<tr>
<td>OCTOCOG ALFA [RECOMBINANT FACTOR VIII] (ADVATE)</td>
<td>$210.00</td>
<td>1 Advate</td>
</tr>
<tr>
<td>Inj 250 iu vial</td>
<td>$210.00</td>
<td>1 Advate</td>
</tr>
<tr>
<td>Inj 500 iu vial</td>
<td>$420.00</td>
<td>1 Advate</td>
</tr>
<tr>
<td>Inj 1,000 iu vial</td>
<td>$840.00</td>
<td>1 Advate</td>
</tr>
<tr>
<td>Inj 1,500 iu vial</td>
<td>$1,260.00</td>
<td>1 Advate</td>
</tr>
<tr>
<td>Inj 2,000 iu vial</td>
<td>$1,680.00</td>
<td>1 Advate</td>
</tr>
<tr>
<td>Inj 3,000 iu vial</td>
<td>$2,520.00</td>
<td>1 Advate</td>
</tr>
<tr>
<td>OCTOCOG ALFA [RECOMBINANT FACTOR VIII] (KOGENATE FS)</td>
<td>$237.50</td>
<td>1 Kogenate FS</td>
</tr>
<tr>
<td>Inj 250 iu vial</td>
<td>$237.50</td>
<td>1 Kogenate FS</td>
</tr>
<tr>
<td>Inj 500 iu vial</td>
<td>$475.00</td>
<td>1 Kogenate FS</td>
</tr>
<tr>
<td>Inj 1,000 iu vial</td>
<td>$950.00</td>
<td>1 Kogenate FS</td>
</tr>
<tr>
<td>Inj 2,000 iu vial</td>
<td>$1,900.00</td>
<td>1 Kogenate FS</td>
</tr>
<tr>
<td>Inj 3,000 iu vial</td>
<td>$2,850.00</td>
<td>1 Kogenate FS</td>
</tr>
<tr>
<td>PHYTOMENADIONE</td>
<td>$8.00</td>
<td>5 Konakion MM</td>
</tr>
<tr>
<td>Inj 2 mg in 0.2 ml ampoule</td>
<td>$8.00</td>
<td>5 Konakion MM</td>
</tr>
<tr>
<td>Inj 10 mg per ml, 1 ml ampoule</td>
<td>$9.21</td>
<td>5 Konakion MM</td>
</tr>
</tbody>
</table>

For patients with haemophilia. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.

Initiation

For patients with haemophilia. Preferred Brand of short half-life recombinant factor VIII. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.

Initiation

For patients with haemophilia. Rare Clinical Circumstances Brand of short half-life recombinant factor VIII. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group, subject to criteria.

Initiation

For patients with haemophilia A receiving prophylaxis treatment. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.

Vitamin K

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>PHYTOMENADIONE</td>
<td>$8.00</td>
<td>5 Konakion MM</td>
</tr>
<tr>
<td>Inj 2 mg in 0.2 ml ampoule</td>
<td>$8.00</td>
<td>5 Konakion MM</td>
</tr>
<tr>
<td>Inj 10 mg per ml, 1 ml ampoule</td>
<td>$9.21</td>
<td>5 Konakion MM</td>
</tr>
</tbody>
</table>

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
### Antithrombotics

#### Anticoagulants

**BIVALIRUDIN** – **Restricted** see terms below
- **Inj 250 mg vial**
- **Restricted (RS1181)**

**Initiation**
Either:
1. For use in heparin-induced thrombocytopenia, heparin resistance or heparin intolerance; or
2. For use in patients undergoing endovascular procedures.

**CITRATE SODIUM**
- **Inj 4% (200 mg per 5 ml), 5 ml ampoule**
- **Inj 46.7% (1.4 g per 3 ml), 3 ml syringe**
- **Inj 46.7% (2.36 g per 5 ml), 5 ml ampoule**

**DABIGATRAN**
- **Cap 75 mg**
- **Cap 110 mg**
- **Cap 150 mg**

**DALTEPARIN**
- **Inj 2,500 iu in 0.2 ml syringe**
- **Inj 5,000 iu in 0.2 ml syringe**
- **Inj 7,500 iu in 0.75 ml syringe**
- **Inj 10,000 iu in 1 ml syringe**
- **Inj 12,500 iu in 0.5 ml syringe**
- **Inj 15,000 iu in 0.6 ml syringe**
- **Inj 18,000 iu in 0.72 ml syringe**

(Fragmin Inj 2,500 iu in 0.2 ml syringe to be delisted 1 April 2020)
(Fragmin Inj 5,000 iu in 0.2 ml syringe to be delisted 1 April 2020)
(Fragmin Inj 7,500 iu in 0.75 ml syringe to be delisted 1 April 2020)
(Fragmin Inj 10,000 iu in 1 ml syringe to be delisted 1 April 2020)
(Fragmin Inj 12,500 iu in 0.5 ml syringe to be delisted 1 January 2020)
(Fragmin Inj 15,000 iu in 0.6 ml syringe to be delisted 1 January 2020)
(Fragmin Inj 18,000 iu in 0.72 ml syringe to be delisted 1 January 2020)

**DANAPAROID** – **Restricted** see terms below
- **Inj 750 u in 0.6 ml ampoule**
- **Restricted (RS1182)**

**Initiation**
For use in heparin-induced thrombocytopenia, heparin resistance or heparin intolerance.

**DEFIBROTIDE** – **Restricted** see terms below
- **Inj 80 mg per ml, 2.5 ml ampoule**
- **Restricted (RS1183)**

**Initiation**
Haematologist
Patient has moderate or severe sinusoidal obstruction syndrome as a result of chemotherapy or regimen-related toxicities.

**DEXTROSE WITH SODIUM CITRATE AND CITRIC ACID [ACID CITRATE DEXTROSE A]**
- **Inj 24.5 mg with sodium citrate 22 mg and citric acid 7.3 mg per ml,**
- **100 ml bag**
<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ENOXAPARIN SODIUM</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 20 mg in 0.2 ml syringe</td>
<td>27.93</td>
<td>Clexane</td>
</tr>
<tr>
<td>Inj 40 mg in 0.4 ml syringe</td>
<td>37.27</td>
<td>Clexane</td>
</tr>
<tr>
<td>Inj 60 mg in 0.6 ml syringe</td>
<td>56.18</td>
<td>Clexane</td>
</tr>
<tr>
<td>Inj 80 mg in 0.8 ml syringe</td>
<td>74.90</td>
<td>Clexane</td>
</tr>
<tr>
<td>Inj 100 mg in 1 ml syringe</td>
<td>93.80</td>
<td>Clexane</td>
</tr>
<tr>
<td>Inj 120 mg in 0.8 ml syringe</td>
<td>116.55</td>
<td>Clexane</td>
</tr>
<tr>
<td>Inj 150 mg in 1 ml syringe</td>
<td>133.20</td>
<td>Clexane</td>
</tr>
<tr>
<td><strong>FONDAPARINUX SODIUM – Restricted</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 2.5 mg in 0.5 ml syringe</td>
<td>26.85</td>
<td></td>
</tr>
<tr>
<td>Inj 7.5 mg in 0.6 ml syringe</td>
<td>33.33</td>
<td></td>
</tr>
<tr>
<td><strong>HEPARIN SODIUM</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 100 iu per ml, 250 ml bag</td>
<td>9.83</td>
<td>Hospira</td>
</tr>
<tr>
<td>Inj 1,000 iu per ml, 1 ml ampoule</td>
<td></td>
<td>Pfizer</td>
</tr>
<tr>
<td>Inj 1,000 iu per ml, 5 ml ampoule</td>
<td></td>
<td>Pfizer</td>
</tr>
<tr>
<td>Inj 5,000 iu in 0.2 ml ampoule</td>
<td>28.60</td>
<td>Hospira</td>
</tr>
<tr>
<td>Inj 5,000 iu per ml, 1 ml ampoule</td>
<td></td>
<td>Pfizer</td>
</tr>
<tr>
<td>Inj 5,000 iu per ml, 5 ml ampoule</td>
<td></td>
<td>Pfizer</td>
</tr>
<tr>
<td><strong>HEPARINISED SALINE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 10 iu per ml, 5 ml ampoule</td>
<td>56.94</td>
<td>Pfizer</td>
</tr>
<tr>
<td>Inj 100 iu per ml, 2 ml ampoule</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 100 iu per ml, 5 ml ampoule</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>PHENINDIONE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 10 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 25 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 50 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>PROTAMINE SULPHATE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 10 mg per ml, 5 ml ampoule</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>RIVAROXABAN</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 10 mg</td>
<td>83.10</td>
<td>Xarelto</td>
</tr>
<tr>
<td>Tab 15 mg</td>
<td>77.56</td>
<td>Xarelto</td>
</tr>
<tr>
<td>Tab 20 mg</td>
<td>77.56</td>
<td>Xarelto</td>
</tr>
<tr>
<td><strong>SODIUM CITRATE WITH SODIUM CHLORIDE AND POTASSIUM CHLORIDE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 4.2 mg with sodium chloride 5.7 mg and potassium chloride 74.6 mcg per ml, 5,000 ml bag</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>WARFARIN SODIUM</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 1 mg</td>
<td>7.60</td>
<td>Marevan</td>
</tr>
<tr>
<td>Tab 2 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 3 mg</td>
<td>11.80</td>
<td>Marevan</td>
</tr>
<tr>
<td>Tab 5 mg</td>
<td>13.50</td>
<td>Marevan</td>
</tr>
<tr>
<td><strong>Antiplatelets</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>ASPIRIN</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 100 mg – 10% DV Nov-19 to 2022</td>
<td>1.95</td>
<td>Ethics Aspirin EC</td>
</tr>
<tr>
<td>Suppos 300 mg</td>
<td>10.80</td>
<td>Ethics Aspirin EC</td>
</tr>
</tbody>
</table>

Products with Hospital Supply Status (HSS) are in bold

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
CLOPIDOGREL
Tab 75 mg – 1% DV May-20 to 2022.................................................................5.44 84 Arrow - Clopid
4.60 Clopidogrel Multichem

(Arrow - Clopid Tab 75 mg to be delisted 1 May 2020)

DIPYRIDAMOLE
Tab 25 mg
Tab long-acting 150 mg – 1% DV Oct-19 to 2022.......................................10.90 60 Pytazen SR
Inj 5 mg per ml, 2 ml ampoule

EPTIFIBATIDE – Restricted see terms below
¶ Inj 2 mg per ml, 10 ml vial – 1% DV Nov-18 to 2021.................................138.75 1 Integrillin
¶ Inj 750 mcg per ml, 100 ml vial – 1% DV Nov-18 to 2021.....................405.00 1 Integrillin

LYSINE ACETYLSALICYLATE [LYSINE ASPRIN] – Restricted see terms below
¶ Inj 500 mg e.g. Aspegic

PRASUGREL – Restricted see terms below
¶ Tab 5 mg.......................................................................................................108.00 28 Effient
¶ Tab 10 mg.....................................................................................................120.00 28 Effient

TICAGRELOR – Restricted see terms below
¶ Tab 90 mg.......................................................................................................90.00 56 Brilinta

TICLOPIDINE
Tab 250 mg
Fibrinolytic Agents

| ALTEPLASE | Inj 2 mg vial | $ | 8,740.00 | 1 | Mozobil |
| | Inj 10 mg vial | | | | |
| | Inj 50 mg vial | | | | |
| TENECTEPLASE | Inj 50 mg vial | | | | |
| UROKINASE | Inj 5,000 iu vial | | | | |
| | Inj 10,000 iu vial | | | | |
| | Inj 50,000 iu vial | | | | |
| | Inj 100,000 iu vial | | | | |
| | Inj 500,000 iu vial | | | | |

Colony-Stimulating Factors

Drugs Used to Mobilise Stem Cells

| PLERIXAFOR – Restricted see terms below | Inj 20 mg per ml, 1.2 ml vial | $ | 8,740.00 | 1 | Mozobil |
| | Restricted (RS1536) | | | | |

Initiation – Autologous stem cell transplant
Haematologist
Limited to 3 days treatment
All of the following:
1 Patient is to undergo stem cell transplantation; and
2 Patient has not had a previous unsuccessful mobilisation attempt with plerixafor; and
3 Any of the following:
   3.1 Both:
      3.1.1 Patient is undergoing G-CSF mobilisation; and
      3.1.2 Either:
         3.1.2.1 Has a suboptimal peripheral blood CD34 count of less than or equal to $10 \times 10^6$/L on day 5 after 4 days of G-CSF treatment; or
         3.1.2.2 Efforts to collect $> 1 \times 10^6$ CD34 cells/kg have failed after one apheresis procedure; or
   3.2 Both:
      3.2.1 Patient is undergoing chemotherapy and G-CSF mobilisation; and
      3.2.2 Any of the following:
         3.2.2.1 Both:
            3.2.2.1.1 Has rising white blood cell counts of $> 5 \times 10^9$/L; and
            3.2.2.1.2 Has a suboptimal peripheral blood CD34 count of less than or equal to $10 \times 10^6$/L; or
         3.2.2.2 Efforts to collect $> 1 \times 10^6$ CD34 cells/kg have failed after one apheresis procedure; or
         3.2.2.3 The peripheral blood CD34 cell counts are decreasing before the target has been received; or
   3.3 A previous mobilisation attempt with G-CSF or G-CSF plus chemotherapy has failed.

Granulocyte Colony-Stimulating Factors

| FILGRASSTIM – Restricted see terms on the next page | Inj 300 mcg in 0.5 ml prefilled syringe – 1% DV May-19 to 2021 | $ | 96.22 | 10 | Nivestim |
| | Inj 300 mcg in 1 ml vial | | | | |
| | Inj 480 mcg in 0.5 ml prefilled syringe – 1% DV Mar-19 to 2021 | | | | |

Products with Hospital Supply Status (HSS) are in bold
Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
### Fluids and Electrolytes

#### Intravenous Administration

<table>
<thead>
<tr>
<th>Fluid Type</th>
<th>Brand</th>
<th>Price (excl. GST)</th>
<th>Per Unit</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CALCIUM CHLORIDE</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 100 mg per ml, 10 ml vial</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 100 mg per ml, 50 ml syringe</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>CALCIUM GLUCONATE</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 10%, 10 ml ampoule</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>COMPOUND ELECTROLYTES</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj sodium 140 mmol/l, potassium 5 mmol/l, magnesium 1.5 mmol/l, chloride 98 mmol/l, acetate 27 mmol/l, gluconate 23 mmol/l, 500 ml bag – 1% DV Jun-18 to 2021</td>
<td></td>
<td>19.76</td>
<td>18</td>
</tr>
<tr>
<td>Inj sodium 140 mmol/l, potassium 5 mmol/l, magnesium 1.5 mmol/l, chloride 98 mmol/l, acetate 27 mmol/l, gluconate 23 mmol/l, 1,000 ml bag – 1% DV Jun-18 to 2021</td>
<td></td>
<td>39.20</td>
<td>12</td>
</tr>
<tr>
<td><strong>COMPOUND ELECTROLYTES WITH GLUCOSE [DEXTROSE]</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj sodium 140 mmol/l, potassium 5 mmol/l, magnesium, 98 mmol/l chloride, 27 mmol/l acetate and 23 mmol/l gluconate, glucose 23 mmol/l (5%), 1,000 ml bag – 1% DV Jun-18 to 2021</td>
<td></td>
<td>211.92</td>
<td>12</td>
</tr>
<tr>
<td><strong>COMPOUND SODIUM LACTATE [HARTMANN’S SOLUTION]</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj sodium 131 mmol/l with potassium 5 mmol/l, calcium 2 mmol/l, bicarbonate 29 mmol/l, chloride 111 mmol/l, 500 ml bag – 1% DV Jun-18 to 2021</td>
<td></td>
<td>23.40</td>
<td>18</td>
</tr>
<tr>
<td>Inj sodium 131 mmol/l with potassium 5 mmol/l, calcium 2 mmol/l, bicarbonate 29 mmol/l, chloride 111 mmol/l, 1,000 ml bag – 1% DV Jun-18 to 2021</td>
<td></td>
<td>15.72</td>
<td>12</td>
</tr>
<tr>
<td><strong>GLUCOSE [DEXTROSE]</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 5%, 1,000 ml bag – 1% DV Aug-18 to 2021</td>
<td></td>
<td>16.80</td>
<td>10</td>
</tr>
<tr>
<td>Inj 5%, 100 ml bag – 1% DV Aug-18 to 2021</td>
<td></td>
<td>77.50</td>
<td>50</td>
</tr>
<tr>
<td>Inj 5%, 250 ml bag – 1% DV Aug-18 to 2021</td>
<td></td>
<td>26.50</td>
<td>30</td>
</tr>
<tr>
<td>Inj 5%, 50 ml bag – 1% DV Jun-18 to 2021</td>
<td></td>
<td>143.40</td>
<td>60</td>
</tr>
<tr>
<td>Inj 5%, 100 ml bag – 1% DV Aug-18 to 2021</td>
<td></td>
<td>24.00</td>
<td>20</td>
</tr>
<tr>
<td>Inj 10%, 1,000 ml bag – 1% DV Jun-18 to 2021</td>
<td></td>
<td>111.96</td>
<td>12</td>
</tr>
<tr>
<td>Inj 10%, 500 ml bag – 1% DV Jun-18 to 2021</td>
<td></td>
<td>109.98</td>
<td>18</td>
</tr>
<tr>
<td>Inj 50%, 10 ml ampoule – 1% DV Oct-17 to 2020</td>
<td></td>
<td>29.50</td>
<td>5</td>
</tr>
<tr>
<td>Inj 50%, 500 ml bag – 1% DV Jun-18 to 2021</td>
<td></td>
<td>337.32</td>
<td>18</td>
</tr>
<tr>
<td>Inj 50%, 90 ml bottle – 1% DV Oct-17 to 2020</td>
<td></td>
<td>14.50</td>
<td>1</td>
</tr>
</tbody>
</table>

*Note: *Febrile neutropenia risk greater than or equal to 20%* after taking into account other risk factors as defined by the European Organisation for Research and Treatment of Cancer (EORTC) guidelines.*

---

**BLOOD AND BLOOD FORMING ORGANS**

---

**PEGFILGRASTIM** – **Restricted** see terms **below**

*Inj 6 mg per 0.6 ml syringe* ................................................................. 1,080.00 1 Neulastim

**Restricted (RS1188)**

Haematologist or oncologist

**Initiation**

For prevention of neutropenia in patients undergoing high risk chemotherapy for cancer (febrile neutropenia risk greater than or equal to 20%*).

Note: *Febrile neutropenia risk greater than or equal to 20% after taking into account other risk factors as defined by the European Organisation for Research and Treatment of Cancer (EORTC) guidelines.*

---

**Fluids and Electrolytes**

---

**Intravenous Administration**

---

**CALCIUM CHLORIDE**

Inj 100 mg per ml, 10 ml vial

Inj 100 mg per ml, 50 ml syringe

**CALCIUM GLUCONATE**

Inj 10%, 10 ml ampoule

**COMPOUND ELECTROLYTES**

Inj sodium 140 mmol/l, potassium 5 mmol/l, magnesium 1.5 mmol/l, chloride 98 mmol/l, acetate 27 mmol/l, gluconate 23 mmol/l, 500 ml bag – 1% DV Jun-18 to 2021 ................................................................. 44.10 18 Plasma-Lyte 148

Inj sodium 140 mmol/l, potassium 5 mmol/l, magnesium 1.5 mmol/l, chloride 98 mmol/l, acetate 27 mmol/l, gluconate 23 mmol/l, 1,000 ml bag – 1% DV Jun-18 to 2021 ................................................................. 27.24 12 Plasma-Lyte 148

**COMPOUND ELECTROLYTES WITH GLUCOSE [DEXTROSE]**

Inj sodium 140 mmol/l, potassium 5 mmol/l, magnesium, 98 mmol/l chloride, 27 mmol/l acetate and 23 mmol/l gluconate, glucose 23 mmol/l (5%), 1,000 ml bag – 1% DV Jun-18 to 2021........211.92 12 Plasma-Lyte 148 & 5% Glucose

**COMPOUND SODIUM LACTATE [HARTMANN’S SOLUTION]**

Inj sodium 131 mmol/l with potassium 5 mmol/l, calcium 2 mmol/l, bicarbonate 29 mmol/l, chloride 111 mmol/l, 500 ml bag – 1% DV Jun-18 to 2021................................. 23.40 18 Baxter

Inj sodium 131 mmol/l with potassium 5 mmol/l, calcium 2 mmol/l, bicarbonate 29 mmol/l, chloride 111 mmol/l, 1,000 ml bag – 1% DV Jun-18 to 2021................................. 15.72 12 Baxter

**GLUCOSE [DEXTROSE]**

Inj 5%, 1,000 ml bag – 1% DV Aug-18 to 2021....................................................... 16.80 10 Fresenius Kabi

Inj 5%, 100 ml bag – 1% DV Aug-18 to 2021.................................................. 77.50 50 Fresenius Kabi

Inj 5%, 250 ml bag – 1% DV Aug-18 to 2021............................................. 26.50 30 Fresenius Kabi

Inj 5%, 50 ml bag – 1% DV Jun-18 to 2021................................................ 143.40 60 Baxter Glucose 5%

Inj 5%, 100 ml bag – 1% DV Aug-18 to 2021............................................. 24.00 20 Fresenius Kabi

Inj 10%, 1,000 ml bag – 1% DV Jun-18 to 2021................................. 111.96 12 Baxter Glucose 10%

Inj 10%, 500 ml bag – 1% DV Jun-18 to 2021................................. 109.98 18 Baxter Glucose 10%

Inj 50%, 10 ml ampoule – 1% DV Oct-17 to 2020................................. 29.50 5 Biomed

Inj 50%, 500 ml bag – 1% DV Jun-18 to 2021................................. 337.32 18 Baxter Glucose 50%

Inj 50%, 90 ml bottle – 1% DV Oct-17 to 2020........................................ 14.50 1 Biomed

---

*Item restricted (see ➤ above); Item restricted (see ➤ below)*

*e.g. Brand indicates brand example only. It is not a contracted product.*
## BLOOD AND BLOOD FORMING ORGANS

<table>
<thead>
<tr>
<th>GLUCOSE WITH POTASSIUM CHLORIDE</th>
<th>Inj 10% glucose with 20 mmol/l potassium chloride, 500 ml bag</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>GLUCOSE WITH POTASSIUM CHLORIDE AND SODIUM CHLORIDE</th>
<th>Inj 2.5% glucose with potassium chloride 20 mmol/l and sodium chloride 0.45%, 3,000 ml bag</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>GLUCOSE WITH SODIUM CHLORIDE</th>
<th>Inj glucose 2.5% with sodium chloride 0.45%, 500 ml bag</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>POTASSIUM CHLORIDE</th>
<th>Inj 75 mg (1 mmol) per ml, 10 ml ampoule</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>POTASSIUM CHLORIDE WITH SODIUM CHLORIDE</th>
<th>Inj 10 mmol potassium chloride with 0.29% sodium chloride, 100 ml bag</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>RINGER’S SOLUTION</th>
<th>Inj sodium 147 mmol/l with potassium 4 mmol/l, calcium 2.2 mmol/l, chloride 156 mmol/l, 1,000 ml bag</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>SODIUM ACETATE</th>
<th>Inj 4 mmol per ml, 20 ml ampoule</th>
</tr>
</thead>
</table>

| SODIUM BICARBONATE | Inj 8.4%, 10 ml vial |

<table>
<thead>
<tr>
<th></th>
<th>Inj 8.4%, 50 ml vial</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th></th>
<th>Inj 8.4%, 100 ml vial</th>
</tr>
</thead>
</table>

---

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
<table>
<thead>
<tr>
<th>SODIUM CHLORIDE</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 0.9%, 5 ml ampoule – 1% DV Dec-19 to 2022</td>
<td>2.80 20 Fresenius Kabi</td>
</tr>
<tr>
<td>Inj 0.9%, 10 ml ampoule – 1% DV Dec-19 to 2022</td>
<td>5.40 50 Fresenius Kabi</td>
</tr>
<tr>
<td>Inj 0.9%, 3 ml syringe, non-sterile pack – 1% DV Sep-18 to 2021</td>
<td>160.90 480 BD PosiFlush</td>
</tr>
<tr>
<td><strong>Restricted (RS1297)</strong></td>
<td></td>
</tr>
</tbody>
</table>

**Initiation**

For use in flushing of in-situ vascular access devices only.

| Inj 0.9%, 5 ml syringe, non-sterile pack – 1% DV Sep-18 to 2021 | 162.91 480 BD PosiFlush |
| **Restricted (RS1297)** |  |

**Initiation**

For use in flushing of in-situ vascular access devices only.

| Inj 0.9%, 10 ml syringe, non-sterile pack – 1% DV Sep-18 to 2021 | 170.35 480 BD PosiFlush |
| **Restricted (RS1297)** |  |

**Initiation**

For use in flushing of in-situ vascular access devices only.

| Inj 0.9%, 20 ml ampoule – 1% DV Dec-19 to 2022 | 5.00 20 Fresenius Kabi |
| Inj 23.4% (4 mmol/ml), 20 ml ampoule | 33.00 5 Biomed |
| Inj 0.45%, 500 ml bag | 71.28 18 Baxter |
| Inj 3%, 1,000 ml bag | 91.20 12 Baxter |
| Inj 0.9%, 50 ml bag | 109.80 60 Baxter |
| Inj 0.9%, 100 ml bag | 78.24 48 Baxter |
| Inj 0.9%, 250 ml bag | 44.64 24 Baxter |
| Inj 0.9%, 500 ml bag | 22.14 18 Baxter |
| Inj 0.9%, 1,000 ml bag | 15.12 12 Baxter |
| Inj 1.8%, 500 ml bottle | |

**SODIUM DIHYDROGEN PHOSPHATE [SODIUM ACID PHOSPHATE]**

Inj 1 mmol per ml, 20 ml ampoule – 1% DV Oct-18 to 2021

| 48.70 5 Biomed |

**WATER**

| Inj 5 ml ampoule | 7.00 50 InterPharma |
| Inj 10 ml ampoule | 6.63 50 Pfizer |
| Inj 20 ml ampoule | 5.00 20 Fresenius Kabi |
| Inj 500 ml bag | 7.50 30 InterPharma |
| Inj, 1,000 ml bag | 5.00 20 Multichem |

| Inj 250 ml bag | |
| Inj 500 ml bag | |
| Inj, 1,000 ml bag | 19.08 12 Baxter |

**Oral Administration**

**CALCIUM POLYSTYRENE SULPHONATE**

Powder

| 169.85 300 g Calcium Resonium |

**COMPOUND ELECTROLYTES**

Powder for oral soln – 1% DV Apr-20 to 2022

| 9.77 50 Electral |

*Enerlyte Powder for oral soln to be delisted 1 April 2020*

**COMPOUND ELECTROLYTES WITH GLUCOSE [DEXTROSE]**

Soln with electrolytes (2 x 500 ml) – 1% DV Nov-18 to 2021

| 6.55 1,000 ml Pedalyte - Bubblegum |

**PHOSPHORUS**

Tab eff 500 mg (16 mmol)
<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>POTASSIUM CHLORIDE</strong></td>
<td>$8.90 200</td>
<td><strong>Span-K</strong></td>
</tr>
<tr>
<td>Tab eff 548 mg (14 mmol) with chloride 285 mg (8 mmol)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab long-acting 600 mg (8 mmol) – 1% DV Oct-18 to 2021</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oral liq 2 mmol per ml</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>SODIUM BICARBONATE</strong></td>
<td>$8.52 100</td>
<td><strong>Sodibic</strong></td>
</tr>
<tr>
<td>Cap 840 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>SODIUM CHLORIDE</strong></td>
<td>$8.52 100</td>
<td><strong>Sodibic</strong></td>
</tr>
<tr>
<td>Tab 600 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oral liq 2 mmol/ml</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>SODIUM POLYSTYRENE SULPHONATE</strong></td>
<td>$84.65 454 g</td>
<td><strong>Resonium A</strong></td>
</tr>
<tr>
<td>Powder – 1% DV Sep-18 to 2021</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Plasma Volume Expanders

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>GELATINE, SUCCINYLATED</strong></td>
<td>$120.00 10</td>
<td><strong>Gelofusine</strong></td>
</tr>
<tr>
<td>Inj 4%, 500 ml bag – 1% DV Jun-18 to 2021</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### CARDIOVASCULAR SYSTEM

#### Agents Affecting the Renin-Angiotensin System

**ACE Inhibitors**

<table>
<thead>
<tr>
<th>Brand or Manufacturer</th>
<th>Price (ex man. excl. GST) $</th>
<th>Per</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CAPTOPRIL</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oral liq 5 mg per ml</td>
<td>94.99</td>
<td>95 ml</td>
</tr>
</tbody>
</table>

- **Restricted (RS1263)**

Initiation

Any of the following:
1. For use in children under 12 years of age; or
2. For use in tube-fed patients; or
3. For management of rebound transient hypertension following cardiac surgery.

<table>
<thead>
<tr>
<th>Brand or Manufacturer</th>
<th>Price (ex man. excl. GST) $</th>
<th>Per</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CILAZAPRIL</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 0.5 mg – 1% DV Sep-19 to 2022</td>
<td>2.09</td>
<td>90</td>
</tr>
<tr>
<td>Tab 2.5 mg – 1% DV Feb-20 to 2022</td>
<td>7.20</td>
<td>200</td>
</tr>
<tr>
<td>Tab 5 mg – 1% DV Feb-20 to 2022</td>
<td>12.00</td>
<td>200</td>
</tr>
</tbody>
</table>

(Apo-Cilazapril Tab 2.5 mg to be delisted 1 February 2020)
(Apo-Cilazapril Tab 5 mg to be delisted 1 February 2020)

<table>
<thead>
<tr>
<th>Brand or Manufacturer</th>
<th>Price (ex man. excl. GST) $</th>
<th>Per</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ENALAPRIL MALEATE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 5 mg</td>
<td>3.84</td>
<td>100</td>
</tr>
<tr>
<td>Tab 10 mg</td>
<td>4.96</td>
<td>100</td>
</tr>
<tr>
<td>Tab 20 mg</td>
<td>7.12</td>
<td>100</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Brand or Manufacturer</th>
<th>Price (ex man. excl. GST) $</th>
<th>Per</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>LISINOPRIL</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 5 mg – 1% DV Dec-18 to 2021</td>
<td>2.07</td>
<td>90</td>
</tr>
<tr>
<td>Tab 10 mg – 1% DV Dec-18 to 2021</td>
<td>2.36</td>
<td>90</td>
</tr>
<tr>
<td>Tab 20 mg – 1% DV Dec-18 to 2021</td>
<td>3.17</td>
<td>90</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Brand or Manufacturer</th>
<th>Price (ex man. excl. GST) $</th>
<th>Per</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PERINDOPRIL</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 2 mg – 1% DV Sep-17 to 2020</td>
<td>3.75</td>
<td>30</td>
</tr>
<tr>
<td>Tab 4 mg – 1% DV Sep-17 to 2020</td>
<td>4.80</td>
<td>30</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Brand or Manufacturer</th>
<th>Price (ex man. excl. GST) $</th>
<th>Per</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>QUINAPRIL</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 5 mg – 1% DV Nov-18 to 2021</td>
<td>6.01</td>
<td>90</td>
</tr>
<tr>
<td>Tab 10 mg – 1% DV Nov-18 to 2021</td>
<td>3.16</td>
<td>90</td>
</tr>
<tr>
<td>Tab 20 mg – 1% DV Nov-18 to 2021</td>
<td>4.89</td>
<td>90</td>
</tr>
</tbody>
</table>

**ACE Inhibitors with Diuretics**

<table>
<thead>
<tr>
<th>Brand or Manufacturer</th>
<th>Price (ex man. excl. GST) $</th>
<th>Per</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CILAZAPRIL WITH HYDROCHLOROTHIAZIDE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 5 mg with hydrochlorothiazide 12.5 mg</td>
<td>10.18</td>
<td>100</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Brand or Manufacturer</th>
<th>Price (ex man. excl. GST) $</th>
<th>Per</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>QUINAPRIL WITH HYDROCHLOROTHIAZIDE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 10 mg with hydrochlorothiazide 12.5 mg – 1% DV Dec-18 to 2021</td>
<td>3.83</td>
<td>30</td>
</tr>
<tr>
<td>Tab 20 mg with hydrochlorothiazide 12.5 mg – 1% DV Dec-18 to 2021</td>
<td>4.92</td>
<td>30</td>
</tr>
</tbody>
</table>
### Angiotensin II Antagonists

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST)</th>
<th>Product Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Candestar</td>
<td>$1.90</td>
<td>Tab 4 mg – 1% DV Sep-18 to 2021</td>
</tr>
<tr>
<td></td>
<td>$2.28</td>
<td>Tab 8 mg – 1% DV Sep-18 to 2021</td>
</tr>
<tr>
<td></td>
<td>$3.67</td>
<td>Tab 16 mg – 1% DV Sep-18 to 2021</td>
</tr>
<tr>
<td></td>
<td>$6.39</td>
<td>Tab 32 mg – 1% DV Sep-18 to 2021</td>
</tr>
<tr>
<td>Losartan Actavis</td>
<td>$1.39</td>
<td>Tab 12.5 mg – 1% DV Nov-17 to 2020</td>
</tr>
<tr>
<td></td>
<td>$1.63</td>
<td>Tab 25 mg – 1% DV Nov-17 to 2020</td>
</tr>
<tr>
<td></td>
<td>$2.00</td>
<td>Tab 50 mg – 1% DV Nov-17 to 2020</td>
</tr>
<tr>
<td></td>
<td>$2.31</td>
<td>Tab 100 mg – 1% DV Nov-17 to 2020</td>
</tr>
</tbody>
</table>

### Angiotensin II Antagonists with Diuretics

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST)</th>
<th>Product Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arrow-Losartan &amp; Hydrochlorothiazide</td>
<td>$1.88 30</td>
<td>Tab 50 mg with hydrochlorothiazide 12.5 mg – 1% DV Jan-19 to 2021</td>
</tr>
</tbody>
</table>

### Angiotensin II Antagonists with Neprilysin Inhibitors

#### SACUBITRIL WITH VALSARTAN

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Product Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>$190.00 56</td>
<td>Tab 24.3 mg with valsartan 25.7 mg – Restricted RS1649</td>
</tr>
<tr>
<td>$190.00 56</td>
<td>Tab 48.6 mg with valsartan 51.4 mg – Restricted RS1649</td>
</tr>
<tr>
<td>$190.00 56</td>
<td>Tab 97.2 mg with valsartan 102.8 mg – Restricted RS1649</td>
</tr>
</tbody>
</table>

### Alpha-Adrenoceptor Blockers

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST)</th>
<th>Product Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Apo-Doxazosin</td>
<td>$6.75 500</td>
<td>Tab 2 mg – 1% DV Sep-17 to 2020</td>
</tr>
<tr>
<td></td>
<td>$9.09 500</td>
<td>Tab 4 mg – 1% DV Sep-17 to 2020</td>
</tr>
</tbody>
</table>

#### PHENOXYBENZAMINE HYDROCHLORIDE

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Product Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>$500</td>
<td>Cap 10 mg</td>
</tr>
<tr>
<td></td>
<td>Inj 50 mg per ml, 1 ml ampoule</td>
</tr>
<tr>
<td></td>
<td>Inj 50 mg per ml, 2 ml ampoule</td>
</tr>
</tbody>
</table>
## Cardiovascular System

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per Brand or Generic Manufacturer</td>
<td></td>
</tr>
</tbody>
</table>

### Phentolamine Mesylate

<table>
<thead>
<tr>
<th>Strength</th>
<th>Formulation</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 5 mg per ml, 1 ml ampoule</td>
<td>5.53</td>
<td>100 Apo-Prazosin</td>
</tr>
<tr>
<td>Inj 10 mg per ml, 1 ml ampoule</td>
<td>7.00</td>
<td>100 Apo-Prazosin</td>
</tr>
<tr>
<td>Tab 1 mg</td>
<td>11.70</td>
<td>100 Apo-Prazosin</td>
</tr>
</tbody>
</table>

### Prazosin

<table>
<thead>
<tr>
<th>Strength</th>
<th>Formulation</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 1 mg</td>
<td>5.09</td>
<td>28 Actavis</td>
</tr>
<tr>
<td>Tab 2 mg</td>
<td>7.50</td>
<td>500 Apo-Terazosin</td>
</tr>
<tr>
<td>Tab 5 mg</td>
<td>10.90</td>
<td>500 Apo-Terazosin</td>
</tr>
</tbody>
</table>

### Terazosin

<table>
<thead>
<tr>
<th>Strength</th>
<th>Formulation</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 1 mg</td>
<td>0.59</td>
<td>28 Actavis</td>
</tr>
<tr>
<td>Tab 2 mg</td>
<td>7.50</td>
<td>500 Apo-Terazosin</td>
</tr>
<tr>
<td>Tab 5 mg</td>
<td>10.90</td>
<td>500 Apo-Terazosin</td>
</tr>
</tbody>
</table>

### Antiarrhythmics

### Adenosine

<table>
<thead>
<tr>
<th>Strength</th>
<th>Formulation</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 3 mg per ml, 2 ml vial</td>
<td>62.73</td>
<td>6 Adenocor</td>
</tr>
<tr>
<td>Inj 3 mg per ml, 10 ml vial</td>
<td>62.73</td>
<td>Adenocor</td>
</tr>
<tr>
<td>Restricted (RS1266)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Initiation**

For use in cardiac catheterisation, electrophysiology and MRI.

### Ajmaline – Restricted see terms below

<table>
<thead>
<tr>
<th>Strength</th>
<th>Formulation</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 5 mg per ml, 10 ml ampoule</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Restricted (RS1001)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Cardiologist**

### Amiodarone Hydrochloride

<table>
<thead>
<tr>
<th>Strength</th>
<th>Formulation</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 100 mg</td>
<td>3.80</td>
<td>30 Aratac</td>
</tr>
<tr>
<td>Tab 200 mg</td>
<td>5.25</td>
<td>30 Aratac</td>
</tr>
<tr>
<td>Inj 50 mg per ml, 3 ml ampoule</td>
<td>11.98</td>
<td>6 Cordarone-X</td>
</tr>
<tr>
<td>9.98</td>
<td>5 Lodi</td>
<td></td>
</tr>
<tr>
<td>16.37</td>
<td>10 Max Health</td>
<td></td>
</tr>
</tbody>
</table>

(Cordarone-X Inj 50 mg per ml, 3 ml ampoule to be delisted 1 February 2020)

(Lodi Inj 50 mg per ml, 3 ml ampoule to be delisted 1 February 2020)

### Atropine Sulfate

<table>
<thead>
<tr>
<th>Strength</th>
<th>Formulation</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 600 mcg per ml, 1 ml ampoule</td>
<td>12.07</td>
<td>10 Martindale</td>
</tr>
</tbody>
</table>

### Digoxin

<table>
<thead>
<tr>
<th>Strength</th>
<th>Formulation</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 62.5 mcg</td>
<td>7.00</td>
<td>240 Lanoxin PG</td>
</tr>
<tr>
<td>Tab 250 mcg</td>
<td>15.20</td>
<td>240 Lanoxin</td>
</tr>
</tbody>
</table>

### Disopyramide Phosphate

<table>
<thead>
<tr>
<th>Strength</th>
<th>Formulation</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cap 100 mg</td>
<td>19.95</td>
<td>60 Flecainide BNM</td>
</tr>
<tr>
<td>Cap long-acting 100 mg</td>
<td>38.95</td>
<td>Tambocor</td>
</tr>
<tr>
<td>Cap long-acting 200 mg</td>
<td>39.51</td>
<td>Flecainide Controlled Release Teva</td>
</tr>
<tr>
<td>Inj 10 mg per ml, 15 ml ampoule</td>
<td>61.06</td>
<td>Flecainide Controlled Release Teva</td>
</tr>
</tbody>
</table>

(Tambocor Tab 50 mg to be delisted 1 February 2020)
IVABRADINE – Restricted see terms below

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST) Per</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$</td>
</tr>
<tr>
<td>Tab 5 mg</td>
<td></td>
</tr>
<tr>
<td>Restricted (RS1566)</td>
<td></td>
</tr>
</tbody>
</table>

Initiation

Both:

1. Patient is indicated for computed tomography coronary angiography; and
2. Either:
   2.1 Patient has a heart rate of greater than 70 beats per minute while taking a maximally tolerated dose of beta blocker; or
   2.2 Patient is unable to tolerate beta blockers.

MEXILETINE HYDROCHLORIDE

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST) Per</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$</td>
</tr>
<tr>
<td>Cap 150 mg</td>
<td>162.00 100 Mexiletine Hydrochloride USP</td>
</tr>
<tr>
<td>Cap 250 mg</td>
<td>202.00 100 Mexiletine Hydrochloride USP</td>
</tr>
</tbody>
</table>

PROPAFENONE HYDROCHLORIDE

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST) Per</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$</td>
</tr>
<tr>
<td>Tab 150 mg</td>
<td></td>
</tr>
</tbody>
</table>

Antihypotensives

MIDODRINE – Restricted see terms below

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST) Per</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$</td>
</tr>
<tr>
<td>Tab 2.5 mg</td>
<td></td>
</tr>
<tr>
<td>Tab 5 mg</td>
<td></td>
</tr>
<tr>
<td>Restricted (RS1427)</td>
<td></td>
</tr>
</tbody>
</table>

Initiation

Patient has disabling orthostatic hypotension not due to drugs.

Beta-Adrenoceptor Blockers

ATENOLOL

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST) Per</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$</td>
</tr>
<tr>
<td>Tab 50 mg – 1% DV Sep-18 to 2021</td>
<td>4.26 500 Mylan Atenolol</td>
</tr>
<tr>
<td>Tab 100 mg – 1% DV Sep-18 to 2021</td>
<td>7.30 500 Mylan Atenolol</td>
</tr>
<tr>
<td>Oral liq 5 mg per ml</td>
<td>21.25 300 ml Atenolol-AFT</td>
</tr>
</tbody>
</table>

BISOPROLOL FUMARATE

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST) Per</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$</td>
</tr>
<tr>
<td>Tab 2.5 mg – 1% DV Dec-17 to 2020</td>
<td>3.53 90 Bosvate</td>
</tr>
<tr>
<td>Tab 5 mg – 1% DV Dec-17 to 2020</td>
<td>5.15 90 Bosvate</td>
</tr>
<tr>
<td>Tab 10 mg – 1% DV Dec-17 to 2020</td>
<td>9.40 90 Bosvate</td>
</tr>
</tbody>
</table>

CARVEDILOL

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST) Per</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$</td>
</tr>
<tr>
<td>Tab 6.25 mg – 1% DV Dec-17 to 2020</td>
<td>2.24 60 Carvediol Sandoz</td>
</tr>
<tr>
<td>Tab 12.5 mg – 1% DV Dec-17 to 2020</td>
<td>2.30 60 Carvediol Sandoz</td>
</tr>
<tr>
<td>Tab 25 mg – 1% DV Dec-17 to 2020</td>
<td>2.95 60 Carvediol Sandoz</td>
</tr>
</tbody>
</table>

CELIPROLOL

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST) Per</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$</td>
</tr>
<tr>
<td>Tab 200 mg</td>
<td>21.40 180 Celol</td>
</tr>
</tbody>
</table>

ESMOLOL HYDROCHLORIDE

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST) Per</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$</td>
</tr>
<tr>
<td>Inj 10 mg per ml, 10 ml vial</td>
<td></td>
</tr>
</tbody>
</table>

LABETALOL

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST) Per</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$</td>
</tr>
<tr>
<td>Tab 100 mg</td>
<td>11.36 100 Presolol</td>
</tr>
<tr>
<td>Tab 200 mg</td>
<td>29.74 100 Hybloc</td>
</tr>
</tbody>
</table>

Inj 5 mg per ml, 20 ml ampoule

(Hybloc Tab 200 mg to be delisted 1 February 2020)
<table>
<thead>
<tr>
<th>CARDIOVASCULAR SYSTEM</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Price (ex man. excl. GST)</strong> $</td>
</tr>
<tr>
<td>-----------------------------</td>
</tr>
</tbody>
</table>

**METOPROLOL SUCCINATE**
- Tab long-acting 23.75 mg – 1% DV Mar-18 to 2020: 1.03 30 Betaloc CR
- Tab long-acting 47.5 mg – 1% DV Mar-18 to 2020: 1.25 30 Betaloc CR
- Tab long-acting 95 mg – 1% DV Mar-18 to 2020: 1.99 30 Betaloc CR
- Tab long-acting 190 mg – 1% DV Mar-18 to 2020: 3.00 30 Betaloc CR

**METOPROLOL TARTRATE**
- Tab 50 mg – 1% DV Oct-18 to 2021: 5.66 100 Apo-Metoprolol
- Tab 100 mg – 1% DV Oct-18 to 2021: 7.55 60 Apo-Metoprolol
- Tab long-acting 200 mg: 23.40 28 Slow-Lopresor
- Inj 1 mg per ml, 5 ml vial – 1% DV Feb-19 to 31 Jan 2022: 29.50 5 Metroprolol IV Mylan

**NADOLOL**
- Tab 40 mg – 1% DV Oct-18 to 2021: 16.69 100 Apo-Nadolol
- Tab 80 mg – 1% DV Oct-18 to 2021: 26.43 100 Apo-Nadolol

**PINDOLOL**
- Tab 5 mg – 1% DV Oct-18 to 2021: 13.22 100 Apo-Pindolol
- Tab 10 mg – 1% DV Oct-18 to 2021: 23.12 100 Apo-Pindolol
- Tab 15 mg – 1% DV Oct-18 to 2021: 33.31 100 Apo-Pindolol

**PROPRANOLOL**
- Tab 10 mg – 1% DV Oct-18 to 2021: 4.64 100 Apo-Propranolol
- Tab 40 mg – 1% DV Oct-18 to 2021: 5.72 100 Apo-Propranolol
- Cap long-acting 160 mg: 18.17 100 Cardinol LA
- Oral liq 4 mg per ml: 18.17 100 Cardinol LA
- Inj 1 mg per ml, 1 ml ampoule: 18.17 100 Cardinol LA

**SOTALOL**
- Tab 80 mg – 1% DV Oct-19 to 2022: 32.58 500 Mylan
- Tab 160 mg – 1% DV Oct-19 to 2022: 10.98 100 Mylan

**TIMOLOL MALEATE**
- Tab 10 mg

---

## Calcium Channel Blockers

### Dihydropyridine Calcium Channel Blockers

**AMLODIPINE**
- Tab 2.5 mg – 1% DV Sep-17 to 2020: 1.72 100 Apo-Amlodipine
- Tab 5 mg – 1% DV Sep-17 to 2020: 3.33 250 Apo-Amlodipine
- Tab 10 mg – 1% DV Sep-17 to 2020: 4.40 250 Apo-Amlodipine

**FELODIPINE**
- Tab long-acting 2.5 mg – 1% DV Sep-18 to 2021: 1.45 30 Plendil ER
- Tab long-acting 5 mg – 1% DV Dec-18 to 2021: 3.93 90 Felo 5 ER
- Tab long-acting 10 mg – 1% DV Dec-18 to 2021: 4.32 90 Felo 10 ER

**ISRADIPINE**
- Tab 2.5 mg
- Cap 2.5 mg

**NICARDIPINE HYDROCHLORIDE** – Restricted see terms below
- Inj 2.5 mg per ml, 10 ml vial
- Restricted (RS1699)

Initiation
Anaesthetist, intensivist, cardiologist or paediatric cardiologist
Any of the following: continued…

---

Item restricted (see ➥ above); Item restricted (see ➥ below)
e.g. Brand indicates brand example only. It is not a contracted product.
Continued...

1. Patient has hypertension requiring urgent treatment with an intravenous agent; or
2. Patient has excessive ventricular afterload; or
3. Patient is awaiting or undergoing cardiac surgery using cardiopulmonary bypass.

**NIFEDIPINE**

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab long-acting 10 mg – 1% DV Aug-17 to 2020</td>
<td>$10.63 60</td>
<td>Adalat 10</td>
</tr>
<tr>
<td>Tab long-acting 20 mg</td>
<td>$9.59 100</td>
<td>Nyefax Retard</td>
</tr>
<tr>
<td>Tab long-acting 30 mg</td>
<td>$3.14 30</td>
<td>Adalat Oros</td>
</tr>
<tr>
<td>Tab long-acting 60 mg – 1% DV Dec-17 to 2020</td>
<td>$5.67 30</td>
<td>Adalat Oros</td>
</tr>
<tr>
<td>Cap 5 mg</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**NIMODIPINE**

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 30 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 200 mcg per ml, 50 ml vial</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Other Calcium Channel Blockers

**DILTIAZEM HYDROCHLORIDE**

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 30 mg</td>
<td>$4.60 100</td>
<td>Dilzem</td>
</tr>
<tr>
<td>Tab 60 mg</td>
<td>$8.50 100</td>
<td>Dilzem</td>
</tr>
<tr>
<td>Cap long-acting 120 mg – 1% DV Oct-18 to 2021</td>
<td>$33.42 500</td>
<td>Apo-Diltiazem CD</td>
</tr>
<tr>
<td>Cap long-acting 180 mg – 1% DV Oct-18 to 2021</td>
<td>$50.05 500</td>
<td>Apo-Diltiazem CD</td>
</tr>
<tr>
<td>Cap long-acting 240 mg – 1% DV Oct-18 to 2021</td>
<td>$66.76 500</td>
<td>Apo-Diltiazem CD</td>
</tr>
<tr>
<td>Inj 5 mg per ml, 5 ml vial</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**PERHEXILINE MALEATE**

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 100 mg – 1% DV Oct-19 to 2022</td>
<td>$62.90 100</td>
<td>Pexsig</td>
</tr>
</tbody>
</table>

**VERAPAMIL HYDROCHLORIDE**

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 40 mg</td>
<td>$7.01 100</td>
<td>Isoptin</td>
</tr>
<tr>
<td>Tab 80 mg</td>
<td>$11.74 100</td>
<td>Isoptin</td>
</tr>
<tr>
<td>Tab long-acting 120 mg</td>
<td>$36.02 250</td>
<td>Verpamil SR</td>
</tr>
<tr>
<td></td>
<td>$15.20 250</td>
<td>Verpamil SR</td>
</tr>
<tr>
<td>Tab long-acting 240 mg</td>
<td>$25.00 5</td>
<td>Isoptin</td>
</tr>
<tr>
<td>Inj 2.5 mg per ml, 2 ml ampoule</td>
<td>$25.00 5</td>
<td></td>
</tr>
</tbody>
</table>

(Verpamil SR Tab long-acting 120 mg to be delisted 1 May 2020)

### Centrally-Acting Agents

**CLONIDINE**

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patch 2.5 mg, 100 mcg per day – 1% DV Sep-17 to 2020</td>
<td>$7.40 4</td>
<td>Mylan</td>
</tr>
<tr>
<td>Patch 5 mg, 200 mcg per day – 1% DV Sep-17 to 2020</td>
<td>$10.04 4</td>
<td>Mylan</td>
</tr>
<tr>
<td>Patch 7.5 mg, 300 mcg per day – 1% DV Sep-17 to 2020</td>
<td>$12.34 4</td>
<td>Mylan</td>
</tr>
</tbody>
</table>

**CLONIDINE HYDROCHLORIDE**

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 25 mcg – 1% DV Oct-18 to 2021</td>
<td>$8.75 112</td>
<td>Clonidine BNM</td>
</tr>
<tr>
<td>Tab 150 mcg</td>
<td>$34.32 100</td>
<td>Catapres</td>
</tr>
<tr>
<td>Inj 150 mcg per ml, 1 ml ampoule – 1% DV Oct-18 to 2021</td>
<td>$25.96 10</td>
<td>Medsurge</td>
</tr>
</tbody>
</table>

**METHYLDOPA**

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 250 mg</td>
<td>$15.10 100</td>
<td>Methyldopa Mylan</td>
</tr>
</tbody>
</table>

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
<table>
<thead>
<tr>
<th>Diuretics</th>
<th>Price (ex man. excl. GST) $ Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Loop Diuretics</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>BUMETANIDE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 1 mg</td>
<td>.................................................................</td>
<td>16.36</td>
</tr>
<tr>
<td>Inj 500 mcg per ml, 4 ml vial</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>FUROSEMIDE [FRUSEMIDE]</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 40 mg – 1% DV Dec-19 to 2022</td>
<td>.................................................................</td>
<td>7.24</td>
</tr>
<tr>
<td>Tab 500 mg – 1% DV Mar-19 to 2021</td>
<td>.................................................................</td>
<td>25.00</td>
</tr>
<tr>
<td>Oral liq 10 mg per ml – 1% DV Jan-20 to 2022</td>
<td>.................................................................</td>
<td>11.20</td>
</tr>
<tr>
<td>Inj 10 mg per ml, 2 ml ampoule – 1% DV Oct-19 to 2022</td>
<td>.................................................................</td>
<td>1.15</td>
</tr>
<tr>
<td>Inj 10 mg per ml, 25 ml ampoule – 1% DV Jan-20 to 2022</td>
<td>.................................................................</td>
<td>60.65</td>
</tr>
<tr>
<td><strong>Osmotic Diuretics</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>MANNITOL</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 10%, 1,000 ml bag – 1% DV Jun-18 to 2021</td>
<td>.................................................................</td>
<td>747.24</td>
</tr>
<tr>
<td>Inj 20%, 500 ml bag – 1% DV Jun-18 to 2021</td>
<td>.................................................................</td>
<td>1,096.92</td>
</tr>
<tr>
<td><strong>Potassium Sparing Combination Diuretics</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>AMILORIDE HYDROCHLORIDE WITH FUROSEMIDE</strong></td>
<td>Tab 5 mg with furosemide 40 mg</td>
<td></td>
</tr>
<tr>
<td><strong>AMILORIDE HYDROCHLORIDE WITH HYDROCHLOROTHIAZIDE</strong></td>
<td>Tab 5 mg with hydrochlorothiazide 50 mg</td>
<td></td>
</tr>
<tr>
<td><strong>Potassium Sparing Diuretics</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>AMILORIDE HYDROCHLORIDE</strong></td>
<td>Tab 5 mg</td>
<td></td>
</tr>
<tr>
<td>Oral liq 1 mg per ml</td>
<td>.................................................................</td>
<td>30.00</td>
</tr>
<tr>
<td><strong>EPLERENONE</strong> – Restricted see terms below</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 25 mg – 1% DV Sep-18 to 2021</td>
<td>.................................................................</td>
<td>11.87</td>
</tr>
<tr>
<td>Tab 50 mg – 1% DV Dec-18 to 2021</td>
<td>.................................................................</td>
<td>17.00</td>
</tr>
<tr>
<td><strong>Restricted (RS1640)</strong></td>
<td>Initiation</td>
<td>Both: 1 Patient has heart failure with ejection fraction less than 40%; and 2 Either: 2.1 Patient is intolerant to optimal dosing of spironolactone; or 2.2 Patient has experienced a clinically significant adverse effect while on optimal dosing of spironolactone.</td>
</tr>
<tr>
<td><strong>SPIRONOLACTONE</strong></td>
<td>Tab 25 mg</td>
<td>.................................................................</td>
</tr>
<tr>
<td>Tab 100 mg</td>
<td>.................................................................</td>
<td>11.80</td>
</tr>
<tr>
<td>Oral liq 5 mg per ml – 1% DV Nov-19 to 2022</td>
<td>.................................................................</td>
<td>30.60</td>
</tr>
<tr>
<td><strong>Thiazide and Related Diuretics</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>BENDROFLUMETHIAZIDE [BENDROFLUAZIDE]</strong></td>
<td>Tab 2.5 mg – 1% DV Mar-18 to 2020</td>
<td>.................................................................</td>
</tr>
<tr>
<td>Tab 5 mg – 1% DV Mar-18 to 2020</td>
<td>.................................................................</td>
<td>20.42</td>
</tr>
</tbody>
</table>
# CARDIOVASCULAR SYSTEM

<table>
<thead>
<tr>
<th>CHLOROTHIAZIDE</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral liq 50 mg per ml</td>
<td>$26.00</td>
<td>Biomed</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CHLORTALIDONE [CHLORTHALIDONE]</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 25 mg – 1% DV Dec-19 to 2022</td>
<td>$6.50 50</td>
<td>Hygroton</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>INDAPAMIDE</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 2.5 mg</td>
<td>$2.60 90</td>
<td>Dapa-Tabs</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>METOLAZONE</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 5 mg</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

## Lipid-Modifying Agents

### Fibrates

<table>
<thead>
<tr>
<th>BEZAFIBRATE</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 200 mg – 1% DV Dec-18 to 2021</td>
<td>$19.01 90</td>
<td>Bezalip</td>
</tr>
<tr>
<td>Tab long-acting 400 mg – 1% DV Dec-18 to 2021</td>
<td>$12.89 30</td>
<td>Bezalip Retard</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>GEMFIBROZIL</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 600 mg</td>
<td>$19.56 60</td>
<td>Lipazil</td>
</tr>
</tbody>
</table>

### HMG CoA Reductase Inhibitors (Statins)

<table>
<thead>
<tr>
<th>ATORVASTATIN</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 10 mg – 1% DV Sep-18 to 2021</td>
<td>$6.96 500</td>
<td>Lorstat</td>
</tr>
<tr>
<td>Tab 20 mg – 1% DV Sep-18 to 2021</td>
<td>$9.99 500</td>
<td>Lorstat</td>
</tr>
<tr>
<td>Tab 40 mg – 1% DV Sep-18 to 2021</td>
<td>$15.93 500</td>
<td>Lorstat</td>
</tr>
<tr>
<td>Tab 80 mg – 1% DV Sep-18 to 2021</td>
<td>$27.19 500</td>
<td>Lorstat</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PRAVASTATIN</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 10 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 20 mg – 1% DV Mar-18 to 2020</td>
<td>$4.72 100</td>
<td>Apo-Pravastatin</td>
</tr>
<tr>
<td>Tab 40 mg – 1% DV Mar-18 to 2020</td>
<td>$8.06 100</td>
<td>Apo-Pravastatin</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SIMVASTATIN</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 10 mg – 1% DV Mar-18 to 2020</td>
<td>$0.95 90</td>
<td>Simvastatin Mylan</td>
</tr>
<tr>
<td>Tab 20 mg – 1% DV Mar-18 to 2020</td>
<td>$1.52 90</td>
<td>Simvastatin Mylan</td>
</tr>
<tr>
<td>Tab 40 mg – 1% DV Mar-18 to 2020</td>
<td>$2.63 90</td>
<td>Simvastatin Mylan</td>
</tr>
<tr>
<td>Tab 80 mg – 1% DV Mar-18 to 2020</td>
<td>$6.00 90</td>
<td>Simvastatin Mylan</td>
</tr>
</tbody>
</table>

### Resins

| CHOLESTYRAMINE | Powder for oral liq 4 g |                               |

| COLESTIPOL HYDROCHLORIDE | Grans for oral liq 5 g |

### Selective Cholesterol Absorption Inhibitors

<table>
<thead>
<tr>
<th>EZETIMIBE – Restricted see terms below</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 10 mg – 1% DV Mar-18 to 2020</td>
<td>$2.00 30</td>
<td>Ezetimibe Sandoz</td>
</tr>
</tbody>
</table>

**Initiation**

All of the following:

- **Restricted (RS1005)**

Products with Hospital Supply Status (HSS) are in **bold**.

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
continued...

1. Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 years; and
2. Patient's LDL cholesterol is 2.0 mmol/litre or greater; and
3. Any of the following:
   3.1 The patient has rhabdomyolysis (defined as muscle aches and creatine kinase more than 10 × normal) when treated with one statin; or
   3.2 The patient is intolerant to both simvastatin and atorvastatin; or
   3.3 The patient has not reduced their LDL cholesterol to less than 2.0 mmol/litre with the use of the maximal tolerated dose of atorvastatin.

**EZETIMIBE WITH SIMVASTATIN – Restricted see terms below**

- Tab 10 mg with simvastatin 10 mg .......................... 5.15 30 Zimybe
- Tab 10 mg with simvastatin 20 mg .......................... 6.15 30 Zimybe
- Tab 10 mg with simvastatin 40 mg .......................... 7.15 30 Zimybe
- Tab 10 mg with simvastatin 80 mg .......................... 8.15 30 Zimybe

**Initiation**

All of the following:

1. Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 years; and
2. Patient's LDL cholesterol is 2.0 mmol/litre or greater; and
3. The patient has not reduced their LDL cholesterol to less than 2.0 mmol/litre with the use of the maximal tolerated dose of atorvastatin.

### Other Lipid-Modifying Agents

**ACIPIMOX**

- Cap 250 mg

**NICOTINIC ACID**

- Tab 50 mg – 1% DV Oct-17 to 2020 ........................................ 4.12 100 Apo-Nicotinic Acid
- Tab 500 mg – 1% DV Oct-17 to 2020 ...................................... 17.89 100 Apo-Nicotinic Acid

### Nitrates

**GLYCERYL TRINITRATE**

- Inj 1 mg per ml, 5 ml ampoule
- Inj 1 mg per ml, 10 ml ampoule
- Inj 1 mg per ml, 50 ml vial
- Inj 5 mg per ml, 10 ml ampoule ........................................ 100.00 5 Hospira
- Oral pump spray, 400 mcg per dose .................................. 4.45 250 dose Nitrolingual Pump Spray
- Oral spray, 400 mcg per dose ........................................... 4.45 200 dose Glytrin
- Patch 25 mg, 5 mg per day ............................................. 15.73 30 Nitroderm TTS 5
- Patch 50 mg, 10 mg per day .......................................... 18.62 30 Nitroderm TTS 10

*(Glytrin Oral spray, 400 mcg per dose to be delisted 1 May 2020)*

**ISOSORBIDE MONONITRATE**

- Tab 20 mg – 1% DV Oct-17 to 2020 ................................. 18.80 100 Ismo-20
- Tab long-acting 40 mg .................................................. 7.50 30 Ismo 40 Retard
- Tab long-acting 60 mg – 1% DV Sep-17 to 2020 ............. 8.29 90 Duride

### Other Cardiac Agents

**LEVOSIMENDAN – Restricted see terms on the next page**

- Inj 2.5 mg per ml, 5 ml vial
- Inj 2.5 mg per ml, 10 ml vial
### Sympathomimetics

#### ADRENALINE
- Inj 1 in 1,000, 1 ml ampoule ................................................................. $4.98 5 Aspen Adrenaline
- Inj 1 in 1,000, 30 ml vial
- Inj 1 in 10,000, 10 ml ampoule ............................................................... $49.00 10 Aspen Adrenaline
- Inj 1 in 10,000, 10 ml syringe

#### DOBUTAMINE
- Inj 12.5 mg per ml, 20 ml ampoule – 1% DV Jan-19 to 2021 .......................... $61.13 5 Dobutamine-hameIn

#### DOPAMINE HYDROCHLORIDE
- Inj 40 mg per ml, 5 ml ampoule – 1% DV Sep-18 to 2021 ............................ $29.73 10 Max Health Ltd

#### EPHEDRINE
- Inj 3 mg per ml, 10 ml syringe
- Inj 30 mg per ml, 1 ml ampoule – 1% DV Sep-17 to 2020 ........................... $36.04 10 Max Health

#### ISOPRENALINE [ISOPROTERENOL]
- Inj 200 mcg per ml, 1 ml ampoule
- Inj 200 mcg per ml, 5 ml ampoule

#### METARAMINOL
- Inj 0.5 mg per ml, 10 ml syringe
- Inj 0.5 mg per ml, 20 ml syringe
- Inj 0.5 mg per ml, 5 ml syringe
- Inj 1 mg per ml, 1 ml ampoule
- Inj 1 mg per ml, 10 ml syringe
- Inj 10 mg per ml, 1 ml ampoule

#### NORADRENALINE
- Inj 0.06 mg per ml, 100 ml bag
- Inj 0.06 mg per ml, 50 ml syringe
- Inj 0.1 mg per ml, 100 ml bag
- Inj 0.1 mg per ml, 50 ml syringe
- Inj 0.12 mg per ml, 100 ml bag
- Inj 0.12 mg per ml, 50 ml syringe
- Inj 0.16 mg per ml, 50 ml syringe
- Inj 1 mg per ml, 100 ml bag
- Inj 1 mg per ml, 4 ml ampoule – 1% DV Oct-19 to 2022 .............................. $45.00 10 Noradrenaline BNM

#### PHENYLEPHRINE HYDROCHLORIDE
- Inj 10 mg per ml, 1 ml ampoule ................................................................ $115.50 25 Neosynephrine HCL
### Cardiovacular System

#### Vasodilators

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Per ($)</th>
<th>Item description</th>
<th>Price Code</th>
<th>Expiry</th>
<th>VAT free</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ALPROSTADIL HYDROCHLORIDE</strong></td>
<td></td>
<td>Inj 500 mcg per ml, 1 ml ampoule</td>
<td>1% DV Dec-18 to 2021</td>
<td>1,765.50</td>
<td>5</td>
<td>Prostin VR</td>
</tr>
<tr>
<td><strong>DIAZOXIDE</strong></td>
<td></td>
<td>Inj 15 mg per ml, 20 ml ampoule</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>HYDRAZINE HYDROCHLORIDE</strong></td>
<td></td>
<td>Tab 25 mg</td>
<td>Restricted (RS1008)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| | | Initiation | Either:
| | | For the treatment of refractory hypertension; or
| | | For the treatment of heart failure, in combination with a nitrate, in patients who are intolerant or have not responded to ACE inhibitors and/or angiotensin receptor blockers. | | | |
| | | Inj 20 mg ampoule | | 25.90 | 5 | Apresoline |
| **MILRINONE** |         | Inj 1 mg per ml, 10 ml ampoule | 1% DV Sep-18 to 2021 | 99.00 | 10 | Primacor |
| **MINOXIDIL** |         | Tab 10 mg | | 70.00 | 100 | Loniten |
| **NICORANDIL** |         | Tab 10 mg | 1% DV Dec-19 to 2022 | 25.57 | 60 | Ikorel |
| | | Tab 20 mg | 1% DV Dec-19 to 2022 | 32.28 | 60 | Ikorel |
| **PAPAVERINE HYDROCHLORIDE** |         | Inj 30 mg per ml, 1 ml vial | | | | |
| | | Inj 12 mg per ml, 10 ml ampoule | | 217.90 | 5 | Hospira |
| **PENTOXIFYLLINE [OXPENTIFYLLINE]** |         | Tab 400 mg | | | | |
| **SODIUM NITROPRUSSIDE** |         | Inj 50 mg vial | | | | |

#### Endothelin Receptor Antagonists

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Per ($)</th>
<th>Item description</th>
<th>Price Code</th>
<th>Expiry</th>
<th>VAT free</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>AMBRISENTAN</strong> – Restricted see terms below</td>
<td></td>
<td>Tab 5 mg</td>
<td></td>
<td>4,585.00</td>
<td>30</td>
<td>Volibris</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Tab 10 mg</td>
<td></td>
<td>4,585.00</td>
<td>30</td>
<td>Volibris</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Restricted (RS1621)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>BOSENTAN</strong> – Restricted see terms below</td>
<td></td>
<td>Tab 62.5 mg</td>
<td>1% DV Dec-18 to 2021</td>
<td>141.00</td>
<td>60</td>
<td>Bosentan Dr Reddy’s</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Tab 125 mg</td>
<td>1% DV Dec-18 to 2021</td>
<td>141.00</td>
<td>60</td>
<td>Bosentan Dr Reddy’s</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Restricted (RS1622)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| **AMBRISENTAN** | | Initiation | Either:
| | | For use in patients with a valid Special Authority approval for ambrisentan by the Pulmonary Arterial Hypertension Panel; or
| | | In-hospital stabilisations in emergency situations. | | | |
| | | Re-assessment required after 6 months | | | | |

*Item restricted (see ➥ above); Item restricted (see ➥ below) e.g. Brand indicates brand example only. It is not a contracted product.*
continued...

1 All of the following:
   1.1 Patient has pulmonary arterial hypertension (PAH); and
   1.2 PAH is in Group 1, 4 or 5 of the WHO (Venice) clinical classifications; and
   1.3 PAH is at NYHA/WHO functional class II, III, or IV; and
   1.4 Any of the following:
      1.4.1 Both:
         1.4.1.1 Bosentan is to be used as PAH monotherapy; and
         1.4.1.2 Either:
            1.4.1.2.1 Patient is intolerant or contraindicated to sildenafil; or
            1.4.1.2.2 Patient is a child with idiopathic PAH or PAH secondary to congenital heart disease; or
      1.4.2 Both:
         1.4.2.1 Bosentan is to be used as PAH dual therapy; and
         1.4.2.2 Either:
            1.4.2.2.1 Patient has tried a PAH monotherapy for at least three months and failed to respond; or
            1.4.2.2.2 Patient deteriorated while on a PAH monotherapy; or
      1.4.3 Both:
         1.4.3.1 Bosentan is to be used as PAH triple therapy; and
         1.4.3.2 Any of the following:
            1.4.3.2.1 Patient is on the lung transplant list; or
            1.4.3.2.2 Patient is presenting acutely with idiopathic pulmonary arterial hypertension (IPAH) in New York Heart Association/World Health Organization (NYHA/WHO) Functional Class IV; or
            1.4.3.2.3 Patient is deteriorating rapidly to NYHA/WHO Functional Class IV who may be lung transplant recipients in the future, if their disease is stabilised; or
            1.4.3.2.4 Patient has PAH associated with the scleroderma spectrum of diseases (APAHSSD) who have no major morbidities and are deteriorating despite combination therapy; or

2 In-hospital stabilisation in emergency situations.

Continuation – Pulmonary arterial hypertension
Re-assessment required after 6 months

Any of the following:

1 Both:
   1.1 Bosentan is to be used as PAH monotherapy; and
   1.2 Patient is stable or has improved while on bosentan; or

2 Both:
   2.1 Bosentan is to be used as PAH dual therapy; and
   2.2 Patient has tried a PAH monotherapy for at least three months and either failed to respond or later deteriorated; or

3 Both:
   3.1 Bosentan is to be used as PAH triple therapy; and
   3.2 Any of the following:
      3.2.1 Patient is on the lung transplant list; or
      3.2.2 Patient is presenting acutely with idiopathic pulmonary arterial hypertension (IPAH) in New York Heart Association/World Health Organization (NYHA/WHO) Functional Class IV; or
      3.2.3 Patient is deteriorating rapidly to NYHA/WHO Functional Class IV who may be lung transplant recipients in the future, if their disease is stabilised; or
      3.2.4 Patient has PAH associated with the scleroderma spectrum of diseases (APAHSSD) who have no major morbidities and are deteriorating despite combination therapy.
Phosphodiesterase Type 5 Inhibitors

SILDENAFIL – Restricted see terms below
- Tab 25 mg – 1% DV Sep-18 to 2021 ...............................................................0.64 4 Vedafil
- Tab 50 mg – 1% DV Sep-18 to 2021 ...............................................................0.64 4 Vedafil
- Tab 100 mg – 1% DV Sep-18 to 2021 .............................................................6.60 12 Vedafil
- Inj 0.8 mg per ml, 12.5 ml vial

Initiation – tablets Raynaud’s Phenomenon
All of the following:
1 Patient has Raynaud’s phenomenon; and
2 Patient has severe digital ischaemia (defined as severe pain requiring hospital admission or with a high likelihood of digital ulceration; digital ulcers; or gangrene); and
3 Patient is following lifestyle management (proper body insulation, avoidance of cold exposure, smoking cessation support, avoidance of sympathomimetic drugs); and
4 Patient has persisting severe symptoms despite treatment with calcium channel blockers and nitrates (unless contraindicated or not tolerated).

Initiation – tablets Pulmonary arterial hypertension
Any of the following:
1 All of the following:
   1.1 Patient has pulmonary arterial hypertension (PAH); and
   1.2 Any of the following:
      1.2.1 PAH is in Group 1 of the WHO (Venice) clinical classifications; or
      1.2.2 PAH is in Group 4 of the WHO (Venice) clinical classifications; or
      1.2.3 PAH is in Group 5 of the WHO (Venice) clinical classifications; and
   1.3 Any of the following:
      1.3.1 PAH is in NYHA/WHO functional class II; or
      1.3.2 PAH is in NYHA/WHO functional class III; or
      1.3.3 PAH is in NYHA/WHO functional class IV; and
   1.4 Either:
      1.4.1 All of the following:
         1.4.1.1 Patient has a pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg; and
         1.4.1.2 Either:
            1.4.1.2.1 Patient has a mean pulmonary artery pressure (PAPm) > 25 mmHg; or
            1.4.1.2.2 Patient is peri Fontan repair; and
         1.4.1.3 Patient has a pulmonary vascular resistance (PVR) of at least 3 Wood Units or at least 240 International Units (dyn s cm-5); or
      1.4.2 Testing for PCWP, PAPm, or PVR cannot be performed due to the patient’s young age; or
   2 For use in neonatal units for persistent pulmonary hypertension of the newborn (PPHN); or
   3 In-hospital stabilisation in emergency situations.

Initiation – tablets other conditions
Any of the following:
1 For use in weaning patients from inhaled nitric oxide; or
2 For perioperative use in cardiac surgery patients; or
3 For use in intensive care as an alternative to nitric oxide; or
4 For use in the treatment of erectile dysfunction secondary to spinal cord injury in patients being treated in a spinal unit.

Initiation – injection
Both:

continued…
continued...

1 For use in the treatment of pulmonary hypertension in infants or children being treated in paediatric intensive care units and neonatal intensive care units when the enteral route is not accessible; and

2 Any of the following:
   2.1 For perioperative use following cardiac surgery; or
   2.2 For use in persistent pulmonary hypertension of the newborn (PPHN); or
   2.3 For use in congenital diaphragmatic hernia.

**Prostacyclin Analogues**

**EPOPROSTENOL – Restricted** see terms below

- **Inj 500 mcg vial** .................................................................36.61 1 Veletri
- **Inj 1.5 mg vial** ........................................................................73.21 1 Veletri

**Initiation**

Either:

1 For use in patients with a valid Special Authority approval for epoprostenol by the Pulmonary Arterial Hypertension Panel; or

2 In-hospital stabilisation in emergency situations.

**ILOPROST**

- **Inj 50 mcg in 0.5 ml ampoule – 1% DV Jan-20 to 2022** ..................305.00 5 Clinect
  - **Nebuliser soln 10 mcg per ml, 2 ml – 1% DV Jan-20 to 2022** ........740.10 30 Ventavis

**Initiation**

Any of the following:

1 For use in patients with a valid Special Authority approval for iloprost by the Pulmonary Arterial Hypertension Panel; or

2 For diagnostic use in catheter laboratories; or

3 For use following mitral or tricuspid valve surgery; or

4 In-hospital stabilisation in emergency situations.

*(Ilomedin Inj 50 mcg in 0.5 ml ampoule to be delisted 1 January 2020)*
## Anti-Infective Preparations

### Antibacterials

<table>
<thead>
<tr>
<th></th>
<th>Brand or Manufacturer</th>
<th>Price (ex man. excl. GST) Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>HYDROGEN PEROXIDE</td>
<td></td>
<td>$8.56 15 g Crystaderm</td>
</tr>
<tr>
<td></td>
<td></td>
<td>$1.40 100 ml Pharmacy Health</td>
</tr>
</tbody>
</table>

*(Pharmacy Health Soln 3% (10 vol) to be delisted 1 July 2020)*

MAFENIDE ACETATE – **Restricted** see terms below

- Powder 50 g sachet
- **Restricted (RS1299)**

Initiation

For the treatment of burns patients.

MUPIROCIN

- Oint 2%
  - **Restricted**

SODIUM FUSIDATE [FUSIDIC ACID]

<table>
<thead>
<tr>
<th></th>
<th>Brand or Manufacturer</th>
<th>Price (ex man. excl. GST) Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Crm 2% – 1% DV May-19 to 2021</td>
<td></td>
<td>$1.59 5 g Foban</td>
</tr>
<tr>
<td>Oint 2% – 1% DV May-19 to 2021</td>
<td></td>
<td>$1.59 5 g Foban</td>
</tr>
</tbody>
</table>

SULFADIAZINE SILVER

<table>
<thead>
<tr>
<th></th>
<th>Brand or Manufacturer</th>
<th>Price (ex man. excl. GST) Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Crm 1% – 1% DV Aug-17 to 2020</td>
<td></td>
<td>$10.80 50 g Flamazine</td>
</tr>
</tbody>
</table>

### Antifungals

<table>
<thead>
<tr>
<th></th>
<th>Brand or Manufacturer</th>
<th>Price (ex man. excl. GST) Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMOROLFINE</td>
<td></td>
<td>$15.95 5 ml MycoNail</td>
</tr>
<tr>
<td></td>
<td></td>
<td>$5 ml</td>
</tr>
</tbody>
</table>

CICLOPIROX OLAMINE

<table>
<thead>
<tr>
<th></th>
<th>Brand or Manufacturer</th>
<th>Price (ex man. excl. GST) Per</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>$5.72 7 ml Apo-Ciclopirox</td>
</tr>
</tbody>
</table>

CLOTRIMAZOLE

<table>
<thead>
<tr>
<th></th>
<th>Brand or Manufacturer</th>
<th>Price (ex man. excl. GST) Per</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>$0.70 20 g Clomazol</td>
</tr>
</tbody>
</table>

ECONAZOLE NITRATE

- **Crm 1%** – **Restricted**: For continuation only
- **Foaming soln 1%**

KETOCONAZOLE

<table>
<thead>
<tr>
<th></th>
<th>Brand or Manufacturer</th>
<th>Price (ex man. excl. GST) Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shampoo 2% – 1% DV Sep-17 to 2020</td>
<td></td>
<td>$2.99 100 ml Sebizole</td>
</tr>
</tbody>
</table>

METRONIDAZOLE

<table>
<thead>
<tr>
<th></th>
<th>Brand or Manufacturer</th>
<th>Price (ex man. excl. GST) Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gel 0.75%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

MICONAZOLE NITRATE

<table>
<thead>
<tr>
<th></th>
<th>Brand or Manufacturer</th>
<th>Price (ex man. excl. GST) Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Crm 2% – 1% DV Jan-18 to 2020</td>
<td></td>
<td>$0.74 15 g Multichem</td>
</tr>
</tbody>
</table>

- **Lotn 2%** – **Restricted**: For continuation only
- **Tinc 2%**

NYSTATIN

<table>
<thead>
<tr>
<th></th>
<th>Brand or Manufacturer</th>
<th>Price (ex man. excl. GST) Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Crm 100,000 u per g</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Antiparasitics

<table>
<thead>
<tr>
<th></th>
<th>Brand or Manufacturer</th>
<th>Price (ex man. excl. GST) Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>DIMETHICONE</td>
<td></td>
<td>$4.98 200 ml healthE Dimethicone 4% Lotion</td>
</tr>
</tbody>
</table>

- **Lotn 4%** – 1% DV Oct-19 to 2022

*Item restricted (see ➥ above); Item restricted (see ➥ below)*

e.g. **Brand** indicates brand example only. It is not a contracted product.
## Antiacne Preparations

### ADAPALENE
- Crm 0.1%
- Gel 0.1%

### BENZOYL PEROXIDE
- Soln 5%

### ISOTRETINOIN
- Cap 5 mg – 1% DV Oct-18 to 2021 ................................................................. 8.14 60 Oratane
- Cap 10 mg – 1% DV Oct-18 to 2021 .............................................................. 13.34 120 Oratane
- Cap 20 mg – 1% DV Oct-18 to 2021 .............................................................. 20.49 120 Oratane

### TRETINOIN
- Crm 0.05% – 1% DV Jun-18 to 2021 .............................................................. 13.90 50 g ReTrieve

## Antipruritic Preparations

### CALAMINE
- Crm, aqueous, BP – 1% DV Nov-18 to 2021 .................................................. 1.26 100 g healthE Calamine Aqueous Cream BP
- Lotn, BP........................................................................................................... 12.94 2,000 ml PSM

(PSM Lotn, BP to be delisted 1 July 2020)

### CROTAMITON
- Crm 10% – 1% DV Sep-18 to 2021 ................................................................. 3.29 20 g Itch-Soothe

## Barrier Creams and Emollients

### Barrier Creams

### DIMETHICONE
- Crm 5% tube – 1% DV Oct-19 to 2022 ............................................................ 1.53 100 g healthE Dimethicone 5%
- Crm 5% pump bottle ....................................................................................... 4.48 500 ml healthE Dimethicone 5%
- Crm 10% pump bottle – 1% DV Sep-18 to 2021 .............................................. 4.52 500 ml healthE Dimethicone 10%

### ZINC
- Crm
  - e.g. Zinc Cream (Orion-)
- Oint
  - e.g. Zinc oxide (PSM)
- Paste

---

**DERMATOLOGICALS**

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) $ Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>MALATHION [MALDISON]</td>
</tr>
<tr>
<td>Lotn 0.5%</td>
</tr>
<tr>
<td>Shampoo 1%</td>
</tr>
<tr>
<td>PERMETHRIN</td>
</tr>
<tr>
<td>Crm 5% – 1% DV Dec-17 to 2020 ........................................... 4.95 30 g Lyderm</td>
</tr>
<tr>
<td>Lotn 5% – 1% DV Oct-17 to 2020 ............................................ 3.69 30 ml A-Scabies</td>
</tr>
<tr>
<td>PHENOTHIRIN</td>
</tr>
<tr>
<td>Shampoo 0.5%</td>
</tr>
</tbody>
</table>

**Antiacne Preparations**

**ADAPALENE**
- Crm 0.1%
- Gel 0.1%

**BENZOYL PEROXIDE**
- Soln 5%

**ISOTRETINOIN**
- Cap 5 mg – 1% DV Oct-18 to 2021 ....................................................... 8.14 60 Oratane
- Cap 10 mg – 1% DV Oct-18 to 2021 ....................................................... 13.34 120 Oratane
- Cap 20 mg – 1% DV Oct-18 to 2021 ....................................................... 20.49 120 Oratane

**TRETINOIN**
- Crm 0.05% – 1% DV Jun-18 to 2021 ....................................................... 13.90 50 g ReTrieve

**Antipruritic Preparations**

**CALAMINE**
- Crm, aqueous, BP – 1% DV Nov-18 to 2021 ........................................... 1.26 100 g healthE Calamine Aqueous Cream BP
- Lotn, BP.......................................................................................................... 12.94 2,000 ml PSM

(PSM Lotn, BP to be delisted 1 July 2020)

**CROTAMITON**
- Crm 10% – 1% DV Sep-18 to 2021 ............................................................. 3.29 20 g Itch-Soothe

**Barrier Creams and Emollients**

**Barrier Creams**

**DIMETHICONE**
- Crm 5% tube – 1% DV Oct-19 to 2022 ...................................................... 1.53 100 g healthE Dimethicone 5%
- Crm 5% pump bottle ................................................................................... 4.48 500 ml healthE Dimethicone 5%
- Crm 10% pump bottle – 1% DV Sep-18 to 2021 ........................................... 4.52 500 ml healthE Dimethicone 10%

**ZINC**
- Crm
  - e.g. Zinc Cream (Orion-)
- Oint
  - e.g. Zinc oxide (PSM)
- Paste
## DERMATOLOGICALS

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
</table>

### ZINC AND CASTOR OIL

<table>
<thead>
<tr>
<th>Description</th>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Crm</td>
<td>$1.63 20 g</td>
<td>Orion</td>
</tr>
<tr>
<td>Oint – 1% DV Jul-18 to 2020</td>
<td>$4.25 500 g</td>
<td>Boucher</td>
</tr>
<tr>
<td>Note: DV limit applies to the pack sizes of greater than 30 g.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oint, BP – 1% DV Nov-17 to 2020</td>
<td>$1.26 20 g</td>
<td>healthE</td>
</tr>
<tr>
<td>Note: DV limit applies to the pack sizes of 30 g or less.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### ZINC WITH WOOL FAT

<table>
<thead>
<tr>
<th>Description</th>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Crm zinc 15.25% with wool fat 4%</td>
<td>e.g. Sudocrem</td>
<td></td>
</tr>
</tbody>
</table>

### Emollients

#### AQUEOUS CREAM

<table>
<thead>
<tr>
<th>Description</th>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Crm 100 g – 1% DV Oct-18 to 2021</td>
<td>$1.05 100 g</td>
<td>Pharmacy Health SLS-free</td>
</tr>
<tr>
<td>Note: DV limit applies to the pack sizes of 100 g or less.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Crm 500 g – 1% DV Dec-18 to 2021</td>
<td>$1.92 500 g</td>
<td>Boucher</td>
</tr>
<tr>
<td>Note: DV limit applies to the pack sizes of greater than 100 g.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### CETOMACROGOL

<table>
<thead>
<tr>
<th>Description</th>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Crm BP, 500 g – 1% DV Sep-18 to 2021</td>
<td>$2.48 500 g</td>
<td>healthE</td>
</tr>
<tr>
<td>Crm BP, 100 g – 1% DV Sep-18 to 2021</td>
<td>$1.42 1</td>
<td>healthE</td>
</tr>
</tbody>
</table>

#### CETOMACROGOL WITH GLYCEROL

<table>
<thead>
<tr>
<th>Description</th>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Crm 90% with glycerol 10%, – 1% DV Dec-19 to 2022</td>
<td>$1.65 100 g</td>
<td>healthE</td>
</tr>
<tr>
<td>Note: DV limit applies to the pack sizes of 100 g or less.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Crm 90% with glycerol 10% – 1% DV Mar-20 to 2022</td>
<td>$3.59 500 ml</td>
<td>Boucher</td>
</tr>
<tr>
<td>$3.10 1,000 ml</td>
<td>Boucher</td>
<td></td>
</tr>
<tr>
<td>$2.82 500 ml</td>
<td>Pharmacy Health Sorbolene with Glycerin</td>
<td></td>
</tr>
<tr>
<td>$3.87 1,000 ml</td>
<td>Pharmacy Health Sorbolene with Glycerin</td>
<td></td>
</tr>
</tbody>
</table>

*(Pharmacy Health Sorbolene with Glycerin Crm 90% with glycerol 10% to be delisted 1 March 2020)*

#### EMULSIFYING OINTMENT

<table>
<thead>
<tr>
<th>Description</th>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oint BP – 1% DV Oct-17 to 2020</td>
<td>$1.84 100 g</td>
<td>Jaychem</td>
</tr>
<tr>
<td>Note: DV limit applies to pack sizes of less than 200 g.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oint BP, 500 g – 1% DV Oct-17 to 2020</td>
<td>$3.59 500 g</td>
<td>AFT</td>
</tr>
<tr>
<td>Note: DV limit applies to pack sizes of greater than 200 g.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### GLYCEROL WITH PARAFFIN

<table>
<thead>
<tr>
<th>Description</th>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Crm glycerol 10% with white soft paraffin 5% and liquid paraffin 10%</td>
<td>e.g. QV cream</td>
<td></td>
</tr>
</tbody>
</table>

#### OIL IN WATER EMULSION

<table>
<thead>
<tr>
<th>Description</th>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Crm, 500 g – 1% DV Jan-19 to 2021</td>
<td>$2.19 500 g</td>
<td>O/W Fatty Emulsion Cream</td>
</tr>
<tr>
<td>Note: DV limit applies to the pack sizes of greater than 100 g.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Crm, 100 g – 1% DV Dec-18 to 2021</td>
<td>$1.44 1</td>
<td>healthE Fatty Cream</td>
</tr>
</tbody>
</table>

### PARAFIN

<table>
<thead>
<tr>
<th>Description</th>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oint liquid paraffin 50% with white soft paraffin 50% – 1% DV Jan-19 to 2021</td>
<td>$1.97 100 g</td>
<td>healthE</td>
</tr>
<tr>
<td>Note: DV limit applies to the pack sizes of 100 g or greater.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>White soft – 1% DV Sep-18 to 2021</td>
<td>$0.79 10 g</td>
<td>healthE</td>
</tr>
<tr>
<td>Note: DV limit applies to pack sizes of 30 g or less, and to both white soft paraffin and yellow soft paraffin.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>White soft, – 1% DV Apr-20 to 2022</td>
<td>$4.99 450 g</td>
<td>healthE</td>
</tr>
<tr>
<td>Yellow soft</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

1 Item restricted (see above); 2 Item restricted (see below)

*e.g. Brand* indicates brand example only. It is not a contracted product.
## DERMATOLOGICALS

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PARAFFIN WITH WOOL FAT</strong></td>
<td>$ Per Brand or Generic Manufacturer</td>
<td>e.g. AlphaKeri; BK; DP; Hydroderm Lotn</td>
</tr>
<tr>
<td>Lotn liquid paraffin 15.9% with wool fat 0.6%</td>
<td></td>
<td>e.g. AlphaKeri Bath Oil</td>
</tr>
<tr>
<td>Lotn liquid paraffin 91.7% with wool fat 3%</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>UREA</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Crm 10%</td>
<td>1.37</td>
<td>100 g healthE Urea Cream</td>
</tr>
<tr>
<td><strong>WOOL FAT</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Crm</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Corticosteroids

#### BETAMETHASONE DIPROPIONATE
- **Crm 0.05%**
- **Oint 0.05%**
- **Crm 0.1% – 1% DV Oct-18 to 2021**
- **Oint 0.1% – 1% DV Oct-18 to 2021**
- **Lotn 0.1% – 1% DV Dec-18 to 2021**
- **BETAMETHASONE VALERATE**
  - **Crm 0.05% – 1% DV Nov-19 to 2022**
  - **Oint 0.05% – 1% DV Nov-19 to 2022**
- **CLOBETASOL PROPIONATE**
  - **Crm 0.05% – 1% DV Dec-18 to 2021**
  - **Crm 0.1% – 1% DV Dec-18 to 2021**
  - **Beta Cream**
  - **Beta Ointment**
  - **Betnovate**
- **CLOBETASONE BUTYRATE**
  - **Crm 0.05%**
  - **DIFLUCORTOLONE VALERATE – Restricted: For continuation only**
    - **Crm 0.1%**
    - **Fatty oint 0.1%**
  - **HYDROCORTISONE**
    - **Crm 1%, 30 g**
    - **Note: DV limit applies to the pack sizes of less than or equal to 100 g.**
    - **Crm 1%, 500 g**
    - **HYDROCORTISONE ACETATE**
      - **Crm 1%**
      - **HYDROCORTISONE AND PARAFFIN LIQUID AND LANOLIN**
        - **Lotn 1% with paraffin liquid 15.9% and lanolin 0.6% – 1% DV Sep-17 to 2020**
        - **HYDROCORTISONE BUTYRATE**
          - **Crm 0.1%**
          - **Oint 0.1% – 1% DV Mar-19 to 2021**
          - **Milky emul 0.1% – 1% DV Mar-19 to 2021**
          - **METHYLPREDNISOLONE ACEPONATE**
            - **Crm 0.1%**
            - **Oint 0.1%**
          - **MOMETASONE FUROATE**
            - **Crm 0.1% – 1% DV Nov-18 to 2021**
            - **Oint 0.1% – 1% DV Nov-18 to 2021**
            - **Lotn 0.1% – 1% DV Nov-18 to 2021**

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Formulation</th>
<th>Dosage</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>TRIAMCINOLONE ACETONIDE</td>
<td>Crm 0.02% – 1% DV Sep-17 to 2020</td>
<td>100 g</td>
<td>6.30</td>
<td>Aristocort</td>
</tr>
<tr>
<td></td>
<td>Oint 0.02% – 1% DV Sep-17 to 2020</td>
<td>100 g</td>
<td>6.35</td>
<td>Aristocort</td>
</tr>
</tbody>
</table>

### Corticosteroids with Anti-Infective Agents

**BETAMETHASONE VALERATE WITH CLIOQUINOL** – Restricted see terms below

- Crm 0.1% with clioquinol 3%
- Restricted (RS1125)

**Initiation**

Either:

1. For the treatment of intertrigo; or
2. For continuation use.

- HYDROCORTISONE WITH MICONAZOLE
  - Crm 1% with miconazole nitrate 2% – 1% DV Sep-18 to 2021
  - 15 g | Micreme H |

- HYDROCORTISONE WITH NATAMYCIN AND NEOMYCIN
  - Crm 1% with natamycin 1% and neomycin sulphate 0.5%
  - Oint 1% with natamycin 1% and neomycin sulphate 0.5%
  - 15 g | Pimafucort |

- TRIAMCINOLONE ACETONIDE WITH NEOMYCIN SULPHATE, GRAMICIDIN AND NYSTATIN
  - Crm 1 mg with nystatin 100,000 u, neomycin sulphate 2.5 mg and gramicidin 250 mcg per g

### Psoriasis and Eczema Preparations

**ACITRETIN**

- Cap 10 mg – 1% DV Sep-17 to 2020
  - 60 | Novatretin |
- Cap 25 mg – 1% DV Sep-17 to 2020
  - 60 | Novatretin |

**BETAMETHASONE DIPROPIONATE WITH CALCIPOTRIOL**

- Gel 500 mcg with calcipotriol 50 mcg per g – 1% DV Dec-18 to 2021
  - 60 g | Daivobet |
- Oint 500 mcg with calcipotriol 50 mcg per g – 1% DV Dec-18 to 2021
  - 30 g | Daivobet |

**CALCIPOTRIOL**

- Oint 50 mcg per g – 1% DV Jul-17 to 2020
  - 100 g | Daivonex |

**COAL TAR WITH SALICYLIC ACID AND SULPHUR**

- Oint 12% with salicylic acid 2% and sulphur 4%

**METHOXSALEN [8-METHOXYPSORALEN]**

- Tab 10 mg
- Lotn 1.2%

**PINE TAR WITH TROLAMINE LAURILSULFATE AND FLUORESCINE**

- Soln 2.3% with trolamine laurilsulfate and fluorescein sodium – 1% DV Oct-17 to 2020
  - 500 ml | Pinetarsol |

**POTASSIUM PERMANGANATE**

- Tab 400 mg
- Crystals

### Scalp Preparations

**BETAMETHASONE VALERATE**

- Scalp app 0.1% – 1% DV Oct-18 to 2021
  - 100 ml | Beta Scalp |
## Wart Preparations

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Brand or Manufacturer</th>
<th>Expiry Date</th>
<th>Price Per</th>
<th>Expiry Date</th>
<th>Price Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>CLOBETASOL PROPIONATE</td>
<td>Dermol</td>
<td>Scalp app 0.05% – 1% DV Nov-19 to 2022</td>
<td>$5.69 30 ml</td>
<td>HYDROCORTISONE BUTYRATE</td>
<td>Locoid 100 ml</td>
</tr>
<tr>
<td>Scalp app 0.05% – 1% DV Nov-19 to 2022</td>
<td>Dermol</td>
<td>$7.30 100 ml</td>
<td>HYDROCORTISONE BUTYRATE</td>
<td>Locoid 100 ml</td>
<td></td>
</tr>
<tr>
<td>Scalp lotn 0.1% – 1% DV Mar-19 to 2021</td>
<td>Locoid</td>
<td>$21.72 24</td>
<td>IMIQUIMOD</td>
<td>Perrigo</td>
<td></td>
</tr>
<tr>
<td>IMIQUIMOD</td>
<td>Perrigo</td>
<td>Crm 5%, 250 mg sachet – 1% DV Aug-18 to 2020</td>
<td>$21.72 24</td>
<td>PODOPHYLLOTOXIN</td>
<td>Condyline</td>
</tr>
<tr>
<td>PODOPHYLLOTOXIN</td>
<td>Condyline</td>
<td>Soln 0.5% – 1% DV Aug-18 to 2020</td>
<td>$33.60 3.5 ml</td>
<td>SILVER NITRATE</td>
<td>Condyline</td>
</tr>
<tr>
<td>SILVER NITRATE</td>
<td>Condyline</td>
<td>Sticks with applicator</td>
<td>$33.60 3.5 ml</td>
<td>Other Skin Preparations</td>
<td>Marine Blue Lotion SPF 50+</td>
</tr>
<tr>
<td>DIPHEMANIL METILSULFATE</td>
<td>Marine Blue Lotion SPF 50+</td>
<td>Powder 2%</td>
<td>SUNSCREEN, PROPRIETARY</td>
<td>Marine Blue Lotion SPF 50+</td>
<td></td>
</tr>
<tr>
<td>SUNSCREEN, PROPRIETARY</td>
<td>Marine Blue Lotion SPF 50+</td>
<td>Crm</td>
<td>Marine Blue Lotion SPF 50+</td>
<td>Marine Blue Lotion SPF 50+</td>
<td></td>
</tr>
<tr>
<td>Calcium Gluconate</td>
<td>Marine Blue Lotion SPF 50+</td>
<td>Gel 2.5%</td>
<td>Marine Blue Lotion SPF 50+</td>
<td>Marine Blue Lotion SPF 50+</td>
<td></td>
</tr>
</tbody>
</table>

## Other Skin Preparations

Antineoplastics

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Brand or Manufacturer</th>
<th>Expiry Date</th>
<th>Price Per</th>
<th>Expiry Date</th>
<th>Price Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>FLUOROURACIL SODIUM</td>
<td>Efudix</td>
<td>Crm 5% – 1% DV Sep-18 to 2021</td>
<td>$7.95 20 g</td>
<td>Methyl Aminolevulinate Hydrochloride Restricted see terms below</td>
<td>Marine Blue Lotion SPF 50+</td>
</tr>
<tr>
<td>Methyl Aminolevulinate Hydrochloride Restricted see terms below</td>
<td>Efudix</td>
<td>Crm 16% Dermatologist or plastic surgeon</td>
<td>Marine Blue Lotion SPF 50+</td>
<td>Wound Management Products</td>
<td>Marine Blue Lotion SPF 50+</td>
</tr>
<tr>
<td>Wound Management Products</td>
<td>Marine Blue Lotion SPF 50+</td>
<td>Marine Blue Lotion SPF 50+</td>
<td>Marine Blue Lotion SPF 50+</td>
<td>Marine Blue Lotion SPF 50+</td>
<td>Marine Blue Lotion SPF 50+</td>
</tr>
<tr>
<td>Calcium Gluconate</td>
<td>Marine Blue Lotion SPF 50+</td>
<td>Marine Blue Lotion SPF 50+</td>
<td>Marine Blue Lotion SPF 50+</td>
<td>Marine Blue Lotion SPF 50+</td>
<td>Marine Blue Lotion SPF 50+</td>
</tr>
</tbody>
</table>

Products with Hospital Supply Status (HSS) are in bold

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
### Anti-Infective Agents

<table>
<thead>
<tr>
<th>ACETIC ACID</th>
<th>Soln 3%</th>
<th>Soln 5%</th>
</tr>
</thead>
</table>

| ACETIC ACID WITH HYDROXYQUINOLINE, GLYCEROL AND RICINOLEIC ACID | Jelly 0.94% with hydroxyquinoline sulphate 0.025%, glycerol 5% and ricinoleic acid 0.75% with applicator |

<table>
<thead>
<tr>
<th>CHLORHEXIDINE GLUCONATE</th>
<th>Crm 1%</th>
<th>Crm 1%, 200 ml</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1.21</td>
<td>2.98</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CLOTRIMAZOLE</th>
<th>Vaginal crm 1% with applicator – 1% DV Jan-20 to 2022</th>
<th>Vaginal crm 2% with applicator – 1% DV Jan-20 to 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2.50</td>
<td>3.00</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>MICONAZOLE NITRATE</th>
<th>Vaginal crm 2% with applicator – 1% DV Sep-17 to 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>3.88</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>NYSTATIN</th>
<th>Vaginal crm 100,000 u per 5 g with applicator(s) – 1% DV Aug-17 to 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>4.45</td>
</tr>
</tbody>
</table>

### Contraceptives

#### Antiandrogen Oral Contraceptives

<table>
<thead>
<tr>
<th>CYPROTERONE ACETATE WITH ETHINYLLOESTRADIOL</th>
<th>Tab 2 mg with ethinylloestradiol 35 mcg and 7 inert tablets – 1% DV Sep-17 to 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>4.67</td>
</tr>
</tbody>
</table>

#### Combined Oral Contraceptives

<table>
<thead>
<tr>
<th>ETHINYLLOESTRADIOL WITH DESOGESTREL</th>
<th>Tab 20 mcg with desogestrel 150 mcg</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2.18</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ETHINYLLOESTRADIOL WITH LEVONORGESTREL</th>
<th>Tab 20 mcg with levonorgestrel 100 mcg and 7 inert tablets – 1% DV Jan-18 to 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1.77</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ETHINYLLOESTRADIOL WITH NORETHISTERONE</th>
<th>Tab 35 mcg with norethisterone 1 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>6.95</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>NORETHISTERONE WITH MESTRANOL</th>
<th>Tab 1 mg with mestranol 50 mcg</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>9.45</td>
</tr>
</tbody>
</table>
### Contraceptive Devices

**INTRA-UTERINE DEVICE**
- IUD 29.1 mm length x 23.2 mm width – 1% DV Nov-19 to 2022 ............... 18.45 1 Choice TT380 Short
- IUD 33.6 mm length x 29.9 mm width – 1% DV Nov-19 to 2022 ............... 18.45 1 Choice TT380 Standard
- IUD 35.5 mm length x 19.6 mm width – 1% DV Nov-19 to 2022 ............... 15.50 1 Choice Load 375

### Emergency Contraception

**LEVONORGESTREL**
- Tab 1.5 mg ........................................................................................................ 4.95 1 Postinor-1

### Progestogen-Only Contraceptives

**LEVONORGESTREL**
- Tab 30 mcg
  - Subdermal implant (2 x 75 mg rods) – 1% DV Mar-18 to 2020............... 106.92 1 Jadelle
  - Intra-uterine device 52 mg – 1% DV Nov-19 to 31 Oct 2022 ............... 269.50 1 Mirena
  - Intra-uterine device 13.5 mg – 1% DV Nov-19 to 31 Oct 2022 ............... 215.60 1 Jaydess

**MEDROXYPROGESTERONE ACETATE**
- Inj 150 mg per ml, 1 ml syringe – 1% DV Dec-19 to 2022 ..................... 7.98 1 Depo-Provera

**NORETHISTERONE**
- Tab 350 mcg – 1% DV Sep-18 to 2021 .................................................. 6.25 84 Noriday 28

### Obstetric Preparations

#### Antiprogestogens

**MIFEPRISTONE**
- Tab 200 mg

#### Oxytocics

**CARBOPROST TROMETAMOL**
- Inj 250 mcg per ml, 1 ml ampoule

**DINOPROSTONE**
- Pessaries 10 mg
- Vaginal gel 1 mg in 3 g................................................................. 52.65 1 Prostin E2
- Vaginal gel 2 mg in 3 g................................................................. 64.60 1 Prostin E2

**ERGOMETRINE MALEATE**
- Inj 500 mcg per ml, 1 ml ampoule – 1% DV Nov-17 to 2020 ............... 105.00 5 DBL Ergometrine

**OXYTOCIN**
- Inj 5 iu per ml, 1 ml ampoule – 1% DV Nov-18 to 2021 ....................... 3.98 5 Oxytocin BNM
- Inj 10 iu per ml, 1 ml ampoule – 1% DV Nov-18 to 2021 ....................... 4.98 5 Oxytocin BNM

**OXYTOCIN WITH ERGOMETRINE MALEATE**
- Inj 5 iu with ergometrine maleate 500 mcg per ml, 1 ml ampoule – 1% DV Oct-18 to 2021 ....................... 15.00 5 Syntometrine

### Tocolytics

**PROGESTERONE – Restricted** see terms on the next page
- Cap 100 mg .................................................................................. 16.50 30 Utrogestan

---

*Products with Hospital Supply Status (HSS) are in **bold**

*Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.*
## GENITO-URINARY SYSTEM

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per</td>
<td></td>
</tr>
</tbody>
</table>

### Restricted (RS1533)

**Initiation**

Gynaecologist or obstetrician

*Re-assessment required after 12 months*

**Both:**

1. For the prevention of pre-term labour*; and
2. Either:
   1. The patient has a short cervix on ultrasound (defined as < 25mm at 16 to 28 weeks); or
   2. The patient has a history of pre-term birth at less than 28 weeks.

**Continuation**

Gynaecologist or obstetrician

*Re-assessment required after 12 months*

**All of the following:**

1. For the prevention of pre-term labour*; and
2. Treatment is required for second or subsequent pregnancy; and
3. Either:
   1. The patient has a short cervix on ultrasound (defined as < 25mm at 16 to 28 weeks); or
   2. The patient has a history of pre-term birth at less than 28 weeks.

*Note: Indications marked with * are unapproved indications.*

**TERBUTALINE** – **Restricted** see terms below

- **Inj 500 mcg ampoule**

**Oestrogens**

**OESTRIOL**

- Crm 1 mg per g with applicator – 1% DV Oct-17 to 2020………………………………..6.62 15 g Ovestin
- Pessaries 500 mcg – 1% DV Oct-17 to 2020………………………………..6.86 15 Ovestin

**Urologicals**

### 5-Alpha Reductase Inhibitors

**FINASTERIDE** – **Restricted** see terms below

- **Tab 5 mg – 1% DV Dec-17 to 2020………………………………..4.81 100 Ricit**

**Alpha-1A Adrenoceptor Blockers**

**TAMSULOSIN HYDROCHLORIDE** – **Restricted** see terms below

- **Cap 400 mcg – 1% DV Jan-20 to 2022………………………………..17.73 100 Tamsulosin-Rex**

*Item restricted (see ➡ above); Item restricted (see ➡ below)*

e.g. *Brand* indicates brand example only. It is not a contracted product.
continued...

1 Patient has symptomatic benign prostatic hyperplasia; and
2 The patient is intolerant of non-selective alpha blockers or these are contraindicated.

### Urinary Alkalisers

**POTASSIUM CITRATE** – Restricted see terms below
- Oral liq 3 mmol per ml – 1% DV Oct-18 to 2021.................................31.80 200 ml Biomed

**Initiation**

Both:

1 The patient has recurrent calcium oxalate urolithiasis; and
2 The patient has had more than two renal calculi in the two years prior to the application.

**SODIUM CITRO-TARTRATE**
- Grans eff 4 g sachets – 1% DV Sep-17 to 2020.................................2.34 28 Ural

### Urinary Antispasmodics

**OXYBUTYNIN**
- Tab 5 mg .................................................................................................8.85 500 Apo-Oxybutynin
- Oral liq 5 mg per 5 ml ...............................................................................60.40 473 ml Apo-Oxybutynin

**SOLIFENACIN SUCCINATE** – Some items restricted see terms below
- Tab 5 mg – 1% DV Dec-18 to 2021.........................................................3.00 30 Solifenacin Mylan
- Tab 10 mg – 1% DV Dec-18 to 2021.......................................................5.50 30 Solifenacin Mylan

**Initiation**

Patient has overactive bladder and a documented intolerance of, or is non-responsive to, oxybutynin.

**TOLTERODINE TARTRATE** – Restricted see terms below
- Tab 1 mg ..................................................................................................14.56 56 Arrow-Tolterodine
- Tab 2 mg ..................................................................................................14.56 56 Arrow-Tolterodine

(Arrow-Tolterodine Tab 1 mg to be delisted 1 March 2020)

**Initiation**

Patient has overactive bladder and a documented intolerance of, or is non-responsive to, oxybutynin.
Anabolic Agents

OXANDROLONE
   ☑ Tab 2.5 mg
   → Restricted (RS1302)

Initiation
For the treatment of burns patients.

Androgen Agonists and Antagonists

CYPROTERONE ACETATE
   Tab 50 mg – 1% DV Dec-18 to 2021.................................13.17 50 Siterone
   Tab 100 mg – 1% DV Dec-18 to 2021.............................26.75 50 Siterone

TESTOSTERONE
   Patch 5 mg per day ....................................................90.00 30 Androderm

TESTOSTERONE CIPIONATE
   Inj 100 mg per ml, 10 ml vial – 1% DV Sep-17 to 2020..........................76.50 1 Depo-Testosterone

TESTOSTERONE ESTERS
   Inj testosterone decanoate 100 mg, testosterone isocaproate 60 mg, testosterone phenylpropionate 60 mg and testosterone propionate 30 mg per ml, 1 ml ampoule

TESTOSTERONE UNDECANOATE
   Cap 40 mg – 1% DV Nov-18 to 2021.................................21.00 60 Andriol Testocaps
   Inj 250 mg per ml, 4 ml vial..........................................86.00 1 Reandron 1000

Calcium Homeostasis

CALCITONIN
   Inj 100 iu per ml, 1 ml ampoule ...........................................121.00 5 Miacalcic

CINACALCET – Restricted see terms below
   ☑ Tab 30 mg – 1% DV Sep-18 to 2021.............................210.30 28 Sensipar
   → Restricted (RS1540)

Initiation
Nephrologist or endocrinologist
Re-assessment required after 6 months

Either:

1 All of the following:
   1.1 The patient has been diagnosed with a parathyroid carcinoma (see Note); and
   1.2 The patient has persistent hypercalcaemia (serum calcium greater than or equal to 3 mmol/L) despite previous first-line treatments including sodium thiosulfate (where appropriate) and bisphosphonates; and
   1.3 The patient is symptomatic; or

2 All of the following:
   2.1 The patient has been diagnosed with calciphylaxis (calcific uraemic arteriolopathy); and
   2.2 The patient has symptomatic (e.g. painful skin ulcers) hypercalcaemia (serum calcium greater than or equal to 3 mmol/L); and
   2.3 The patient's condition has not responded to previous first-line treatments including bisphosphonates and sodium thiosulfate.

continued…
continued...

**Continuation**

Nephrologist or endocrinologist

Both:

1. The patient’s serum calcium level has fallen to < 3mmol/L; and
2. The patient has experienced clinically significant symptom improvement.

Note: This does not include parathyroid adenomas unless these have become malignant.

**ZOLEDRONIC ACID**

Injectable solution (IV) 4 mg per 5 ml, vial – 1% Daily Value (DV) May-19 to 2021…………………………………………..38.03

- **Restricted (RS1602)**

**Initiation – bone metastases**

Oncologist, haematologist or palliative care specialist

Any of the following:

1. Patient has hypercalcaemia of malignancy; or
2. Both:
   2.1 Patient has bone metastases or involvement; and
   2.2 Patient has severe bone pain resistant to standard first-line treatments; or
3. Both:
   3.1 Patient has bone metastases or involvement; and
   3.2 Patient is at risk of skeletal-related events (pathological fracture, spinal cord compression, radiation to bone or surgery to bone).

**Initiation – early breast cancer**

Oncologist

All of the following:

1. Treatment to be used as adjuvant therapy for early breast cancer; and
2. Patient has been amenorrheic for 12 months or greater, either naturally or induced, with endocrine levels consistent with a postmenopausal state; and
3. Treatment to be administered at a minimum interval of 6-monthly for a maximum of 2 years.

**Corticosteroids**

**BETAMETHASONE**

- Tab 500 mcg
- Inj 4 mg per ml, 1 ml ampoule

**BETAMETHASONE SODIUM PHOSPHATE WITH BETAMETHASONE ACETATE**

- Inj 3.9 mg with betamethasone acetate 3 mg per ml, 1 ml ampoule

**DEXAMETHASONE**

- Tab 0.5 mg – 1% DV Oct-18 to 2021…………………………………………………………0.99
- Tab 4 mg – 1% DV Oct-18 to 2021………………………………………………………………1.90
- Oral liq 1 mg per ml .................................................................................................45.00

**DEXAMETHASONE PHOSPHATE**

- Inj 4 mg per ml, 1 ml ampoule ..............................................................................14.19
- Inj 4 mg per ml, 2 ml ampoule .............................................................................25.18

**FLUDROCORTISONE ACETATE**

- Tab 100 mcg...........................................................................................................14.32

**HYDROCORTISONE**

- Tab 5 mg – 1% DV Sep-18 to 2021 ......................................................................8.10
- Tab 20 mg – 1% DV Sep-18 to 2021 .....................................................................20.32
- Inj 100 mg vial ........................................................................................................5.30

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
### HORMONE PREPARATIONS

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) $</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Per</td>
<td></td>
</tr>
</tbody>
</table>

#### METHYL PREDNISOLONE (AS SODIUM SUCCINATE)
- Tab 4 mg – 1% DV Dec-18 to 2021 .................................................. 112.00 100 Medrol
- Tab 100 mg – 1% DV Dec-18 to 2021 .................................................. 194.00 20 Medrol
- Inj 40 mg vial – 1% DV Dec-18 to 2021 ............................................. 18.90 1 Solu-Medrol Act-O-Vial
- Inj 125 mg vial – 1% DV Dec-18 to 2021 .......................................... 29.80 1 Solu-Medrol Act-O-Vial
- Inj 500 mg vial – 1% DV Dec-18 to 2021 .......................................... 22.78 1 Solu-Medrol Act-O-Vial
- Inj 1 g vial – 1% DV Dec-18 to 2021 ............................................... 27.83 1 Solu-Medrol

#### METHYL PREDNISOLONE ACETATE
- Inj 40 mg per ml, 1 ml vial – 1% DV Dec-18 to 2021 .......................... 44.40 5 Depo-Medrol

#### PREDNISOLONE
- Oral liq 5 mg per ml – 1% DV Jun-18 to 2021 .................................. 6.00 30 ml Redipred
- Enema 200 mcg per ml, 100 ml

#### PREDNISONE
- Tab 1 mg – 1% DV Jun-17 to 2020 .................................................. 10.68 500 Apo-Prednisone
- Tab 2.5 mg – 1% DV Jun-17 to 2020 ................................................ 12.09 500 Apo-Prednisone
- Tab 5 mg – 1% DV Jun-17 to 2020 .................................................. 11.09 500 Apo-Prednisone
- Tab 20 mg – 1% DV Jun-17 to 2020 ................................................. 29.03 500 Apo-Prednisone

#### TRIAMCINOLONE ACETONIDE
- Inj 10 mg per ml, 1 ml ampoule – 1% DV Sep-17 to 2020 .................... 20.80 5 Kenacort-A 10
- Inj 40 mg per ml, 1 ml ampoule – 1% DV Sep-17 to 2020 ................. 51.10 5 Kenacort-A 40

#### TRIAMCINOLONE HEXACETONIDE
- Inj 20 mg per ml, 1 ml vial

### Hormone Replacement Therapy

#### Oestrogens

##### OESTRADIOD
- Tab 1 mg
- Tab 2 mg
- Patch 25 mcg per day ............................................................... 6.12 8 Estradot
- Patch 50 mcg per day ............................................................... 7.04 8 Estradot
- Patch 75 mcg per day ............................................................... 7.91 8 Estradot
- Patch 100 mcg per day ......................................................... 7.91 8 Estradot

##### OESTRA DIOL VALERATE
- Tab 1 mg – 1% DV Sep-18 to 2021 .............................................. 12.36 84 Progynova
- Tab 2 mg – 1% DV Sep-18 to 2021 .............................................. 12.36 84 Progynova

##### OESTROGENS (CONJUGATED EQUINE)
- Tab 300 mcg
- Tab 625 mcg

### Progestogen and Oestrogen Combined Preparations

##### OESTRADIOD WITH NORETHISTERONE ACETATE
- Tab 1 mg with 0.5 mg norethisterone acetate
- Tab 2 mg with 1 mg norethisterone acetate
- Tab 2 mg with 1 mg norethisterone acetate (10), and tab 2 mg oestradiol (12) and tab 1 mg oestradiol (6)
HORMONE PREPARATIONS

OESTROGENS WITH MEDROXYPROGESTERONE ACETATE
Tab 625 mcg conjugated equine with 2.5 mg medroxyprogesterone acetate
Tab 625 mcg conjugated equine with 5 mg medroxyprogesterone acetate

Progestogens

MEDROXYPROGESTERONE ACETATE
Tab 2.5 mg ................................................................. 3.75 30 Provera
Tab 5 mg ................................................................. 14.00 100 Provera
Tab 10 mg ................................................................. 7.15 30 Provera

Other Endocrine Agents

CABERGOLINE – Restricted see terms below
Tab 0.5 mg – 1% DV Sep-18 to 2021 ........................................ 3.75 2 Dostinex
15.20 8 Dostinex

CLOMIFENE CITRATE
Tab 50 mg ................................................................. 29.84 10 Mylan Clomiphen

DANAZOL
Cap 100 mg ................................................................. 68.33 100 Azol
19.13 28 Mylan
Cap 200 mg ................................................................. 97.83 100 Azol
(Azol Cap 100 mg to be delisted 1 June 2020)

GESTRINONE
Cap 2.5 mg

METYRAPONE
Cap 250 mg

PENTAGASTRIN
Inj 250 mcg per ml, 2 ml ampoule

Other Oestrogen Preparations

ETHINYLDESTRADIOL
Tab 10 mcg – 1% DV Sep-18 to 2021 ........................................ 17.60 100 NZ Medical and Scientific

OESTRADIOL
Implant 50 mg

OESTRIOL
Tab 2 mg

Other Progestogen Preparations

MEDROXYPROGESTERONE
Tab 100 mg ................................................................. 101.00 100 Provera HD

Products with Hospital Supply Status (HSS) are in bold
Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
### Pituitary and Hypothalamic Hormones and Analogues

<table>
<thead>
<tr>
<th>Name</th>
<th>Type</th>
<th>Price (ex man. excl. GST) $ Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>CORTICOTREOLIN (OVINE)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 100 mcg vial</td>
<td></td>
<td></td>
</tr>
<tr>
<td>THYROTROPIN ALFA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 900 mcg vial</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TETRACOSACTIDE [TETRACOSACTRIN]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 250 mcg per ml, 1 ml ampoule</td>
<td>75.00 1 Synacthen</td>
<td></td>
</tr>
<tr>
<td>Inj 1 mg per ml, 1 ml ampoule</td>
<td>690.00 1 Synacthen Depot</td>
<td></td>
</tr>
</tbody>
</table>

### Adrenocorticotropic Hormones

<table>
<thead>
<tr>
<th>Name</th>
<th>Type</th>
<th>Price (ex man. excl. GST) $ Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>TETRACOSACTIDE [TETRACOSACTRIN]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 1 mg per ml, 5.5 ml vial</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GONADORELIN</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 100 mcg vial</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GOSERELIN</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Implant 3.6 mg, syringe</td>
<td>66.48 1 Zoladex</td>
<td></td>
</tr>
<tr>
<td>Implant 10.8 mg, syringe</td>
<td>177.50 1 Zoladex</td>
<td></td>
</tr>
<tr>
<td>LEUPRORELIN ACETATE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 3.75 mg prefilled dual chamber syringe</td>
<td>221.60 1 Lucrin Depot 1-month</td>
<td></td>
</tr>
<tr>
<td>Inj 11.25 mg prefilled dual chamber syringe</td>
<td>591.68 1 Lucrin Depot 3-month</td>
<td></td>
</tr>
</tbody>
</table>

### GnRH Agonists and Antagonists

<table>
<thead>
<tr>
<th>Name</th>
<th>Type</th>
<th>Price (ex man. excl. GST) $ Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>BUSERELIN</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 1 mg per ml, 5.5 ml vial</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GONADORELIN</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 100 mcg vial</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GOSERELIN</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Implant 3.6 mg, syringe</td>
<td>66.48 1 Zoladex</td>
<td></td>
</tr>
<tr>
<td>Implant 10.8 mg, syringe</td>
<td>177.50 1 Zoladex</td>
<td></td>
</tr>
</tbody>
</table>

### Gonadotrophins

<table>
<thead>
<tr>
<th>Name</th>
<th>Type</th>
<th>Price (ex man. excl. GST) $ Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>CHORIOGONADOTROPIN ALFA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 250 mcg in 0.5 ml syringe</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Growth Hormone

<table>
<thead>
<tr>
<th>Name</th>
<th>Type</th>
<th>Price (ex man. excl. GST) $ Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>SOMATROPIN – Restricted see terms below</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 5 mg cartridge – 1% DV Oct-18 to 2021</td>
<td>34.88 1 Omnitrope</td>
<td></td>
</tr>
<tr>
<td>Inj 10 mg cartridge – 1% DV Oct-18 to 2021</td>
<td>69.75 1 Omnitrope</td>
<td></td>
</tr>
<tr>
<td>Inj 15 mg cartridge – 1% DV Oct-18 to 2021</td>
<td>104.63 1 Omnitrope</td>
<td></td>
</tr>
<tr>
<td>Restricted (RS1549)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Initiation – growth hormone deficiency in children**

Endocrinologist or paediatric endocrinologist

*Re-assessment required after 12 months*

Either:

1. Growth hormone deficiency causing symptomatic hypoglycaemia, or with other significant growth hormone deficient sequelae (e.g. cardiomyopathy, hepatic dysfunction) and diagnosed with GH < 5 mcg/l on at least two random blood samples in the first 2 weeks of life, or from samples during established hypoglycaemia (whole blood glucose < 2 mmol/l using a laboratory device); or

continued…

Item restricted (see ➸ above); Item restricted (see ➸ below)

*E.g. Brand indicates brand example only. It is not a contracted product.*
continued…

2 All of the following:
   2.1 Height velocity < 25th percentile for age; and adjusted for bone age/pubertal status if appropriate over 6 or 12 months using the standards of Tanner and Davies (1985); and
   2.2 A current bone age is < 14 years (female patients) or < 16 years (male patients); and
   2.3 Peak growth hormone value of < 5.0 mcg per litre in response to two different growth hormone stimulation tests. In children who are 5 years or older, GH testing with sex steroid priming is required; and
   2.4 If the patient has been treated for a malignancy, they should be disease free for at least one year based upon follow-up laboratory and radiological imaging appropriate for the malignancy, unless there are strong medical reasons why this is either not necessary or appropriate; and
   2.5 Appropriate imaging of the pituitary gland has been obtained.

Continuation – growth hormone deficiency in children
Endocrinologist or paediatric endocrinologist

Re-assessment required after 12 months

All of the following:
1 A current bone age is 14 years or under (female patients) or 16 years or under (male patients); and
2 Height velocity is greater than or equal to 25th percentile for age (adjusted for bone age/pubertal status if appropriate) while on growth hormone treatment, as calculated over six months using the standards of Tanner and Davis (1985); and
3 Height velocity is greater than or equal to 2.0 cm per year, as calculated over 6 months; and
4 No serious adverse effect that the patients specialist considers is likely to be attributable to growth hormone treatment has occurred; and
5 No malignancy has developed since starting growth hormone.

Initiation – Turner syndrome
Endocrinologist or paediatric endocrinologist

Re-assessment required after 12 months

All of the following:
1 The patient has a post-natal genotype confirming Turner Syndrome; and
2 Height velocity is < 25th percentile over 6-12 months using the standards of Tanner and Davies (1985); and
3 A current bone age is < 14 years.

Continuation – Turner syndrome
Endocrinologist or paediatric endocrinologist

Re-assessment required after 12 months

All of the following:
1 Height velocity greater than or equal to 50th percentile for age (while on growth hormone calculated over 6 to 12 months using the Ranke’s Turner Syndrome growth velocity charts); and
2 Height velocity is greater than or equal to 2 cm per year, calculated over six months; and
3 A current bone age is 14 years or under; and
4 No serious adverse effect that the specialist considers is likely to be attributable to growth hormone treatment has occurred; and
5 No malignancy has developed since starting growth hormone.

Initiation – short stature without growth hormone deficiency
Endocrinologist or paediatric endocrinologist

Re-assessment required after 12 months

All of the following:
1 The patient’s height is more than 3 standard deviations below the mean for age or for bone age if there is marked growth acceleration or delay; and
2 Height velocity is < 25th percentile for age (adjusted for bone age/pubertal status if appropriate), as calculated over 6 to 12 months using the standards of Tanner and Davies(1985); and

continued…
### HORMONE PREPARATIONS

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Per Brand or Generic Manufacturer</th>
</tr>
</thead>
</table>

continued…

3 A current bone age is < 14 years (female patients) or < 16 years (male patients); and
4 The patient does not have severe chronic disease (including malignancy or recognized severe skeletal dysplasia) and is not receiving medications known to impair height velocity.

**Continuation – short stature without growth hormone deficiency**

Endocrinologist or paediatric endocrinologist

*Re-assessment required after 12 months*

All of the following:

1. Height velocity is greater than or equal to 50th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
2. Height velocity is greater than or equal to 2 cm per year as calculated over six months; and
3. Current bone age is 14 years or under (female patients) or 16 years or under (male patients); and
4. No serious adverse effect that the patient’s specialist considers is likely to be attributable to growth hormone treatment has occurred.

**Initiation – short stature due to chronic renal insufficiency**

Endocrinologist, paediatric endocrinologist or renal physician on the recommendation of a endocrinologist or paediatric endocrinologist

*Re-assessment required after 12 months*

All of the following:

1. The patient’s height is more than 2 standard deviations below the mean; and
2. Height velocity is < 25th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
3. A current bone age is to 14 years or under (female patients) or to 16 years or under (male patients); and
4. The patient is metabolically stable, has no evidence of metabolic bone disease and absence of any other severe chronic disease; and
5. The patient is under the supervision of a specialist with expertise in renal medicine; and
6. Either:
   6.1 The patient has a GFR less than or equal to 30 ml/min/1.73 m$^2$ as measured by the Schwartz method (Height(cm)/plasma creatinine (umol/l × 40 = corrected GFR (ml/min/1.73 m$^2$) in a child who may or may not be receiving dialysis; or
   6.2 The patient has received a renal transplant and has received < 5mg/ m$^2$/day of prednisone or equivalent for at least 6 months.

**Continuation – short stature due to chronic renal insufficiency**

Endocrinologist, paediatric endocrinologist or renal physician on the recommendation of a endocrinologist or paediatric endocrinologist

*Re-assessment required after 12 months*

All of the following:

1. Height velocity is greater than or equal to 50th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
2. Height velocity is greater than or equal to 2 cm per year as calculated over six months; and
3. A current bone age is 14 years or under (female patients) or 16 years or under (male patients); and
4. No serious adverse effect that the patients specialist considers is likely to be attributable to growth hormone has occurred; and
5. No malignancy has developed after growth hormone therapy was commenced; and
6. The patient has not experienced significant biochemical or metabolic deterioration confirmed by diagnostic results; and
7. The patient has not received renal transplantation since starting growth hormone treatment; and
8. If the patient requires transplantation, growth hormone prescription should cease before transplantation and a new application should be made after transplantation based on the above criteria.

continued…
HORMONE PREPARATIONS

Price
(ex man. excl. GST) $ Per
Brand or Generic Manufacturer

continued...

Initiation – Prader-Willi syndrome
Endocrinologist or paediatric endocrinologist
Re-assessment required after 12 months
All of the following:
1 The patient has a diagnosis of Prader-Willi syndrome that has been confirmed by genetic testing or clinical scoring criteria; and
2 The patient is aged six months or older; and
3 A current bone age is < 14 years (female patients) or < 16 years (male patients); and
4 Sleep studies or overnight oximetry have been performed and there is no obstructive sleep disorder requiring treatment, or if an obstructive sleep disorder is found, it has been adequately treated under the care of a paediatric respiratory physician and/or ENT surgeon; and
5 Either:
   5.1 Both:
      5.1.1 The patient is aged two years or older; and
      5.1.2 There is no evidence of type II diabetes or uncontrolled obesity defined by BMI that has increased by greater than or equal to 0.5 standard deviations in the preceding 12 months; or
   5.2 The patient is aged between six months and two years and a thorough upper airway assessment is planned to be undertaken prior to treatment commencement and at six to 12 weeks following treatment initiation.

Continuation – Prader-Willi syndrome
Endocrinologist or paediatric endocrinologist
Re-assessment required after 12 months
All of the following:
1 Height velocity is greater than or equal to 50th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
2 Height velocity is greater than or equal to 2 cm per year as calculated over six months; and
3 A current bone age is 14 years or under (female patients) or 16 years or under (male patients); and
4 No serious adverse effect that the patient’s specialist considers is likely to be attributable to growth hormone treatment has occurred; and
5 No malignancy has developed after growth hormone therapy was commenced; and
6 The patient has not developed type II diabetes or uncontrolled obesity as defined by BMI that has increased by greater than or equal to 0.5 standard deviations in the preceding 12 months.

Initiation – adults and adolescents
Endocrinologist or paediatric endocrinologist
Re-assessment required after 12 months
All of the following:
1 The patient has a medical condition that is known to cause growth hormone deficiency (e.g. surgical removal of the pituitary for treatment of a pituitary tumour); and
2 The patient has undergone appropriate treatment of other hormonal deficiencies and psychological illnesses; and
3 The patient has severe growth hormone deficiency (see notes); and
4 The patient’s serum IGF-I is more than 1 standard deviation below the mean for age and sex; and
5 The patient has poor quality of life, as defined by a score of 16 or more using the disease-specific quality of life questionnaire for adult growth hormone deficiency (QoL-AGHDA®).

Notes: For the purposes of adults and adolescents, severe growth hormone deficiency is defined as a peak serum growth hormone level of less than or equal to 3 mcg per litre during an adequately performed insulin tolerance test (ITT) or glucagon stimulation test. Patients with one or more additional anterior pituitary hormone deficiencies and a known structural pituitary lesion only require one test. Patients with isolated growth hormone deficiency require two growth hormone stimulation tests, of which, one should be ITT unless otherwise contraindicated. Where an additional test is required, an arginine provocation test can be used with a peak

continued…
continued...

serum growth hormone level of less than or equal to 0.4 mcg per litre.
The dose of somatropin should be started at 0.2 mg daily and be titrated by 0.1 mg monthly until it is within 1 standard deviation of
the mean normal value for age and sex; and
The dose of somatropin not to exceed 0.7 mg per day for male patients, or 1 mg per day for female patients.
At the commencement of treatment for hypopituitarism, patients must be monitored for any required adjustment in replacement
doses of corticosteroid and levothyroxine.

**Continuation – adults and adolescents**
Endocrinologist or paediatric endocrinologist

*Re-assessment required after 12 months*

Either:

1. All of the following:
   1.1 The patient has been treated with somatropin for < 12 months; and
   1.2 There has been an improvement in the Quality of Life Assessment defined as a reduction of at least 8 points on the
   Quality of Life Assessment of Growth Hormone Deficiency in Adults (QoL-AGHDA®) score from baseline; and
   1.3 Serum IGF-I levels have increased to within ±1SD of the mean of the normal range for age and sex; and
   1.4 The dose of somatropin does not exceed 0.7 mg per day for male patients, or 1 mg per day for female patients; or

2. All of the following:
   2.1 The patient has been treated with somatropin for more than 12 months; and
   2.2 The patient has not had a deterioration in Quality of Life defined as a 6 point or greater increase from their lowest
   QoL-AGHDA® score on treatment (other than due to obvious external factors such as external stressors); and
   2.3 Serum IGF-I levels have continued to be maintained within ±1SD of the mean of the normal range for age and sex
   (other than for obvious external factors); and
   2.4 The dose of somatropin has not exceeded 0.7 mg per day for male patients or 1 mg per day for female patients.

---

### Thyroid and Antithyroid Preparations

<table>
<thead>
<tr>
<th>Item</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>CARBIMAZOLE Tab 5 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IODINE Soln BP 50 mg per ml</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LEVOthyroxine Tab 25 mcg</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Tab 50 mcg</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Tab 100 mcg</td>
<td></td>
</tr>
<tr>
<td>LIOthyronine Sodium Tab 20 mcg</td>
<td></td>
<td>Restricted (RS1301)</td>
</tr>
</tbody>
</table>

**Initiation**

For a maximum of 14 days' treatment in patients with thyroid cancer who are due to receive radioiodine therapy.

Inj 20 mcg vial

<table>
<thead>
<tr>
<th>Item</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>POTASSIUM IODATE Tab 170 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>POTASSIUM PERCHLORATE Cap 200 mg</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**PROPylTHioURACIL – Restricted** see terms [on the next page]

<table>
<thead>
<tr>
<th>Item</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Tab 50 mg</td>
<td>35.00</td>
</tr>
<tr>
<td></td>
<td></td>
<td>100</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PTU</td>
</tr>
</tbody>
</table>
HORMONE PREPARATIONS

Price
(ex man. excl. GST) $ Per
Brand or Generic Manufacturer

→ Restricted (RS1276)

Initiation
Both:
1. The patient has hyperthyroidism; and
2. The patient is intolerant of carbimazole or carbimazole is contraindicated.

Note: Propylthiouracil is not recommended for patients under the age of 18 years unless the patient is pregnant and other treatments are contraindicated.

PROTIRELIN

Inj 100 mcg per ml, 2 ml ampoule

Vasopressin Agents

ARGIPRESSIN [VASOPRESSIN]

Inj 20 u per ml, 1 ml ampoule

DESMOPRESSIN ACETATE – Some items restricted see terms below

<table>
<thead>
<tr>
<th>Item</th>
<th>Description</th>
<th>Price</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 100 mcg</td>
<td>.................................................................25.00</td>
<td>30 Minirin</td>
<td></td>
</tr>
<tr>
<td>Tab 200 mcg</td>
<td>.................................................................54.45</td>
<td>30 Minirin</td>
<td></td>
</tr>
<tr>
<td>Nasal spray 10 mcg per dose – 1% DV Oct-17 to 2020</td>
<td>...........................................23.95</td>
<td>6 ml Desmopressin-PH&amp;T</td>
<td></td>
</tr>
<tr>
<td>Inj 4 mcg per ml, 1 ml ampoule</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 15 mcg per ml, 1 ml ampoule</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nasal drops 100 mcg per ml</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

→ Restricted (RS1339)

Initiation – Nocturnal enuresis

Either:
1. The nasal forms of desmopressin are contraindicated; or
2. An enuresis alarm is contraindicated.

Note: Cranial diabetes insipidus and the nasal forms of desmopressin are contraindicated.

TERLIPRESSIN

<table>
<thead>
<tr>
<th>Item</th>
<th>Description</th>
<th>Price</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 0.1 mg per ml, 8.5 ml ampoule</td>
<td>.................................................................450.00</td>
<td>5 Glypressin</td>
<td></td>
</tr>
<tr>
<td>Inj 1 mg per 8.5 ml ampoule</td>
<td>.................................................................215.00</td>
<td>5 Glypressin</td>
<td></td>
</tr>
</tbody>
</table>
## INFECTIONS

### Antibacterials

#### Aminoglycosides

**AMIKACIN** – *Restricted* see terms below
- **Injectable Solution**
  - **Inj 5 mg per ml, 10 ml syringe**
    - 18.50
  - **Inj 5 mg per ml, 5 ml syringe**
    - 18.50
  - **Inj 15 mg per ml, 5 ml syringe**
    - 18.50
  - **Inj 250 mg per ml, 2 ml vial – 1% DV Aug-18 to 2021**
    - 265.00

- **Restricted (RS1041)**
  - Clinical microbiologist, infectious disease specialist or respiratory specialist

**GENTAMICIN SULPHATE**
- **Injectable Solution**
  - **Inj 10 mg per ml, 1 ml ampoule**
    - 25.00
  - **Inj 40 mg per ml, 2 ml ampoule**
    - 17.50

**PAROMOMYCIN** – *Restricted* see terms below
- **Capsule**
  - 126.00

- **Restricted (RS1603)**
  - Clinical microbiologist, infectious disease specialist or gastroenterologist

**STREPTOMYCIN SULPHATE** – *Restricted* see terms below
- **Injectable Solution**
  - **Inj 400 mg per ml, 2.5 ml ampoule**

- **Restricted (RS1043)**
  - Clinical microbiologist, infectious disease specialist or respiratory specialist

**TOBRAMYCIN**
- **Powder**
  - **Restricted (RS1475)**
    - Clinical microbiologist or infectious disease specialist

  **Initiation**
  - For addition to orthopaedic bone cement.
  - **Inj 40 mg per ml, 2 ml vial – 1% DV Sep-18 to 2021**
    - 15.00

- **Restricted (RS1044)**
  - Clinical microbiologist, infectious disease specialist or respiratory specialist
  - **Inj 100 mg per ml, 5 ml vial**

- **Restricted (RS1044)**
  - Clinical microbiologist, infectious disease specialist or respiratory specialist
  - **Solution for inhalation 60 mg per ml, 5 ml**
    - 2,200.00

- **Restricted (RS1435)**
  - **Initiation**
    - Patient has cystic fibrosis.

#### Carbapenems

**ERTAPENEM** – *Restricted* see terms below
- **Injectable Solution**
  - **Inj 1 g vial – 1% DV Aug-19 to 2022**
    - 70.00

- **Restricted (RS1045)**
  - Clinical microbiologist or infectious disease specialist

**IMIPENEM WITH CILASTATIN** – *Restricted* see terms below
- **Injectable Solution**
  - **Inj 500 mg with 500 mg cilastatin vial – 1% DV Jul-19 to 2022**
    - 60.00

- **Restricted (RS1046)**
  - Clinical microbiologist or infectious disease specialist
## Infections

### Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

### Cephalosporins and Cephamycins - 1st Generation

**CEFLEXIN**
- Cap 250 mg – 1% DV Nov-19 to 2022 .......................................................... 3.33 20 Cephalexin ABM
- Cap 500 mg .................................................................................................. 3.95 20 Cephalexin ABM
- Grans for oral liq 25 mg per ml – 1% DV Oct-18 to 2021 ....................... 8.75 100 ml Cefalexin Sandoz
- Grans for oral liq 50 mg per ml – 1% DV Oct-18 to 2021 ....................... 11.75 100 ml Cefalexin Sandoz

**CEFAZOLIN**
- Inj 500 mg vial – 1% DV Sep-17 to 2020 .................................................. 3.39 5 AFT
- Inj 1 g vial – 1% DV Sep-17 to 2020 .................................................. 3.29 5 AFT

### Cephalosporins and Cephamycins - 2nd Generation

**CEFACLOR**
- Cap 250 mg – 1% DV Oct-19 to 2022 .................................................. 24.70 100 Ranbaxy-Cefaclor
- Grans for oral liq 25 mg per ml – 1% DV Oct-19 to 2022 ....................... 3.53 100 ml Ranbaxy-Cefaclor

**CEFFOXITIN**
- Inj 1 g vial .................................................................................................. 58.00 10 Cefoxitin Actavis

**CEFUROXIME**
- Tab 250 mg – 1% DV Feb-20 to 2022 .................................................. 45.93 50 Zinnat
- Inj 750 mg vial – 1% DV Feb-18 to 2020 .............................................. 9.85 10 Cefuroxime Actavis
- Inj 1.5 g vial – 1% DV Feb-18 to 2020 .................................................. 14.36 10 Cefuroxime Actavis

### Cephalosporins and Cephamycins - 3rd Generation

**CEFOTAXIME**
- Inj 500 mg vial ............................................................................................ 1.90 1 Cefotaxime Sandoz
- Inj 1 g vial – 1% DV Sep-17 to 2020 .................................................. 14.60 10 DBL Cefotaxime

**CEFTAZIDIME** — **Restricted** see terms **below**
- Inj 1 g vial ............................................................................................... 34.00 5 Ceftazidime Mylan

**CEFTRIAXONE**
- Inj 500 mg vial – 1% DV Jan-20 to 2022 .................................................. 0.89 1 Ceftriaxone-AFT
- Inj 1 g vial – 1% DV Jan-20 to 2022 .................................................. 3.99 5 Ceftriaxone-AFT
- Inj 2 g vial – 1% DV Jan-20 to 2022 .................................................. 1.98 1 Ceftriaxone-AFT

*DEVA Inj 500 mg vial to be delisted 1 January 2020*
*DEVA Inj 1 g vial to be delisted 1 January 2020*

### Cephalosporins and Cephamycins - 4th Generation

**CEFEPIIME** — **Restricted** see terms on the next page
- Inj 1 g vial – 1% DV Sep-18 to 2021 .................................................. 3.75 1 Cefepime-AFT
- Inj 2 g vial – 1% DV Sep-18 to 2021 .................................................. 5.69 1 Cefepime-AFT
INFECTIONS

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per Brand or Generic</td>
<td>Manufacturer</td>
</tr>
</tbody>
</table>

**Restricted (RS1049)**
Clinical microbiologist or infectious disease specialist

**Cephalosporins and Cephamycins - 5th Generation**

CEFTAROLINE FOSAMIL – Restricted see terms below

* Inj 600 mg vial ............................................................................................1,450.00 10 Zinforo

**Restricted (RS1446)**
Initiation – multi-resistant organism salvage therapy
Clinical microbiologist or infectious disease specialist
Either:
1. for patients where alternative therapies have failed; or
2. for patients who have a contraindication or hypersensitivity to standard current therapies.

**Macrolides**

AZITHROMYCIN – Restricted see terms below

* Tab 250 mg – 1% DV Sep-18 to 2021 ................................................................8.19 30 Apo-Azithromycin

* Tab 500 mg – 1% DV Sep-18 to 2021 ................................................................0.93 2 Apo-Azithromycin

* Grans for oral liq 200 mg per 5 ml (40 mg per ml) – 1% DV Dec-18 to 2021 ...........................................................................14.38 15 ml Zithromax

**Restricted (RS1598)**
Initiation – bronchiolitis obliterans syndrome, cystic fibrosis and atypical Mycobacterium infections
Any of the following:
1. Patient has received a lung transplant, stem cell transplant or bone marrow transplant and requires treatment for bronchiolitis obliterans syndrome*; or
2. Patient has received a lung transplant and requires prophylaxis for bronchiolitis obliterans syndrome*; or
3. Patient has cystic fibrosis and has chronic infection with Pseudomonas aeruginosa or Pseudomonas related gram negative organisms*; or
4. Patient has an atypical Mycobacterium infection.

Note: Indications marked with * are unapproved indications

**Initiation – non-cystic fibrosis bronchiectasis**
Respiratory specialist or paediatrician
Re-assessment required after 12 months
All of the following:
1. For prophylaxis of exacerbations of non-cystic fibrosis bronchiectasis*; and
2. Patient is aged 18 and under; and
3. Either:
   3.1 Patient has had 3 or more exacerbations of their bronchiectasis, within a 12 month period; or
   3.2 Patient has had 3 acute admissions to hospital for treatment of infective respiratory exacerbations within a 12 month period.

Note: Indications marked with * are unapproved indications. A maximum of 24 months of azithromycin treatment for non-cystic fibrosis will be subsidised in the community.

**Continuation – non-cystic fibrosis bronchiectasis**
Respiratory specialist or paediatrician
Re-assessment required after 12 months
All of the following:
1. The patient has completed 12 months of azithromycin treatment for non-cystic fibrosis bronchiectasis; and
2. Following initial 12 months of treatment, the patient has not received any further azithromycin treatment for non-cystic fibrosis bronchiectasis.

Note: Indications marked with * are unapproved indications. A maximum of 24 months of azithromycin treatment for non-cystic fibrosis will be subsidised in the community.

continued…
continued...

1 fibrosis bronchiectasis for a further 12 months, unless considered clinically inappropriate to stop treatment; and
2 The patient will not receive more than a total of 24 months’ azithromycin cumulative treatment (see note).

Note: Indications marked with * are unapproved indications. A maximum of 24 months of azithromycin treatment for non-cystic fibrosis will be subsidised in the community.

**Initiation – other indications**

*Re-assessment required after 5 days*

For any other condition.

**Continuation – other indications**

*Re-assessment required after 5 days*

For any other condition.

**CLARITHROMYCIN – Restricted** see terms below

1 Tab 250 mg – 1% DV Sep-17 to 2020 ...................................................... 3.98  14  Apo-Clarithromycin
2 Tab 500 mg – 1% DV Sep-17 to 2020 ...................................................... 10.40 14  Apo-Clarithromycin
3 Grans for oral liq 50 mg per ml ............................................................... 192.00  50 ml  Klacid
4 Inj 500 mg vial – 1% DV Dec-17 to 31 Aug 2020 ................................. 12.04  1  Martindale

**Restricted (RS1709)**

**Initiation – Tab 250 mg and oral liquid**

Any of the following:

1 Atypical mycobacterial infection; or
2 Mycobacterium tuberculosis infection where there is drug resistance or intolerance to standard pharmaceutical agents; or
3 Helicobacter pylori eradication; or
4 Prophylaxis of infective endocarditis associated with surgical or dental procedures if amoxicillin is contra-indicated.

**Initiation – Tab 500 mg**

Helicobacter pylori eradication.

**Initiation – Infusion**

Any of the following:

1 Atypical mycobacterial infection; or
2 Mycobacterium tuberculosis infection where there is drug resistance or intolerance to standard pharmaceutical agents; or
3 Community-acquired pneumonia.

**ERYTHROMYCIN (AS ETHYLSUCCINATE)**

Tab 400 mg ................................................................. 16.95  100  E-Mycin
Grans for oral liq 200 mg per 5 ml ...................................................... 5.00  100 ml  E-Mycin
Grans for oral liq 400 mg per 5 ml ...................................................... 6.77  100 ml  E-Mycin

**ERYTHROMYCIN (AS LACTOBIONATE)**

Inj 1 g vial – 1% DV Dec-19 to 2022 ............................................. 10.00  1  Erythrocin IV

**ERYTHROMYCIN (AS STEARATE) – Restricted:** For continuation only

1 Tab 250 mg
2 Tab 500 mg

**ROXITHROMYCIN – Some items restricted** see terms below

1 Tab dispersible 50 mg ............................................................ 8.29  10  Rulide D
2 Tab 150 mg – 1% DV Sep-19 to 2022 ........................................... 8.28  50  Arrow-Roxithromycin
3 Tab 300 mg – 1% DV Sep-19 to 2022 ........................................... 16.33  50  Arrow-Roxithromycin

**Restricted (RS1569)**

**Initiation**

Only for use in patients under 12 years of age.
## Penicillins

<table>
<thead>
<tr>
<th><strong>AMOXICILLIN</strong></th>
<th><strong>AMOXICILLIN WITH CLAVULANIC ACID</strong></th>
<th><strong>BENZATHINE BENZYL-PENICILLIN</strong></th>
<th><strong>BENZYL-PENICILLIN SODIUM [PENICILLIN G]</strong></th>
<th><strong>FLUCLOXACILLIN</strong></th>
<th><strong>PHENOXYMETHYLPENICILLIN [PENICILLIN V]</strong></th>
<th><strong>PIPERACILLIN WITH TAZOBACTAM</strong></th>
<th><strong>PROCAINE PENICILLIN</strong></th>
<th><strong>TICARCILLIN WITH CLAVULANIC ACID</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cap 250 mg – 1% DV Apr-20 to 2022</strong></td>
<td>25 0</td>
<td><strong>Tab 500 mg with clavulanic acid 125 mg – 1% DV Oct-17 to 2020</strong></td>
<td>1.88 20</td>
<td><strong>Inj 900 mg (1.2 million units) in 2.3 ml syringe – 1% DV Dec-18 to 2021</strong></td>
<td>344.93 10</td>
<td></td>
<td><strong>Cilicaine VK</strong></td>
<td>5 Pl</td>
</tr>
<tr>
<td><strong>Cap 500 mg – 1% DV Apr-20 to 2022</strong></td>
<td>14.97</td>
<td><strong>Grans for oral liq 25 mg with clavulanic acid 6.25 mg per ml</strong></td>
<td>3.83 100 ml</td>
<td><strong>Inj 600 mg (1 million units) vial – 1% DV Sep-17 to 2020</strong></td>
<td>25.88 25</td>
<td></td>
<td><strong>Pan-Penicillin G Sodium</strong></td>
<td>10</td>
</tr>
<tr>
<td><strong>Grans for oral liq 125 mg per 5 ml – 1% DV Feb-18 to 2020</strong></td>
<td>16.75</td>
<td><strong>Grans for oral liq 50 mg with clavulanic acid 12.5 mg per ml</strong></td>
<td>2.20 100 ml</td>
<td><strong>Flucloxin</strong></td>
<td>10</td>
<td></td>
<td><strong>Cilicaine VK</strong></td>
<td>5</td>
</tr>
<tr>
<td><strong>Inj 250 mg vial – 1% DV Sep-17 to 2020</strong></td>
<td>10.67 10</td>
<td><strong>Inj 500 mg vial – 1% DV Oct-18 to 2021</strong></td>
<td>28.18 10</td>
<td><strong>Flucloxin</strong></td>
<td>10</td>
<td></td>
<td><strong>AFT</strong></td>
<td>10</td>
</tr>
</tbody>
</table>
### Quinolones

<table>
<thead>
<tr>
<th>Product</th>
<th>Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>CIPROFLOXACIN – Restricted</td>
<td>see terms below</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Tab 250 mg – 1% DV Sep-17 to 2020</td>
<td>1.45</td>
<td>Cipflox</td>
</tr>
<tr>
<td></td>
<td>Tab 500 mg – 1% DV Sep-17 to 2020</td>
<td>1.99</td>
<td>Cipflox</td>
</tr>
<tr>
<td></td>
<td>Tab 750 mg – 1% DV Sep-17 to 2020</td>
<td>3.15</td>
<td>Cipflox</td>
</tr>
<tr>
<td></td>
<td>Oral liq 50 mg per ml</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Oral liq 100 mg per ml</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inj 2 mg per ml, 100 ml bag – 1% DV Oct-18 to 2021</td>
<td>68.20</td>
<td>Cipflox</td>
</tr>
<tr>
<td>MOXIFLOXACIN – Restricted</td>
<td>see terms below</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Tab 400 mg</td>
<td>52.00</td>
<td>Avelox</td>
</tr>
<tr>
<td></td>
<td>Inj 1.6 mg per ml, 250 ml bottle – 1% DV Apr-20 to 2022</td>
<td>70.00</td>
<td>Avelox IV 400</td>
</tr>
<tr>
<td></td>
<td>Oral liq 50 mg per ml</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Oral liq 100 mg per ml</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inj 2 mg per ml, 100 ml bag – 1% DV Oct-18 to 2021</td>
<td>68.20</td>
<td>Cipflox</td>
</tr>
</tbody>
</table>

(Oral liq 50 mg per ml, 100 ml bottle to be delisted 1 April 2020)

### Clinical indications

#### MOXIFLOXACIN

- **Clinical microbiologist or infectious disease specialist**

<table>
<thead>
<tr>
<th>Product</th>
<th>Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>MOXIFLOXACIN – Restricted</td>
<td>see terms below</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Tab 400 mg</td>
<td>52.00</td>
<td>Avelox</td>
</tr>
<tr>
<td></td>
<td>Inj 1.6 mg per ml, 250 ml bottle – 1% DV Apr-20 to 2022</td>
<td>70.00</td>
<td>Avelox IV 400</td>
</tr>
<tr>
<td></td>
<td>Oral liq 50 mg per ml</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Oral liq 100 mg per ml</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inj 2 mg per ml, 100 ml bag – 1% DV Oct-18 to 2021</td>
<td>68.20</td>
<td>Cipflox</td>
</tr>
</tbody>
</table>

(Oral liq 50 mg per ml, 100 ml bottle to be delisted 1 April 2020)

### Clinical indications

- **Clinical microbiologist or infectious disease specialist**

#### NORTHERN WHOLESALE PRICES

- **Moxifloxacin Kabi**

### Clinical indications

#### MOXIFLOXACIN – Restricted (RS1644)

- **Mycobacterium avium-intracellulare complex not responding to other therapy or where such therapy is contraindicated**

#### Initiation – Mycobacterium infection

- **Infectious disease specialist or clinical microbiologist**

- **Infectious disease specialist or clinical microbiologist**

- **Infectious disease specialist or clinical microbiologist**

- **Mycobacterium avium-intracellulare complex not responding to other therapy or where such therapy is contraindicated; or**

- **Patient is under five years of age and has had close contact with a confirmed multi-drug resistant tuberculosis case.**

### Clinical indications

#### Initiation – Pneumonia

- **Infectious disease specialist or clinical microbiologist**

- **Infectious disease specialist or clinical microbiologist**

### Clinical indications

#### Initiation – Penetrating eye injury

- **Ophthalmologist**

- **Five days treatment for patients requiring prophylaxis following a penetrating eye injury.**

### Clinical indications

#### Initiation – Mycoplasma genitalium

- **All of the following:**

- **Has nucleic acid amplification test (NAAT) confirmed Mycoplasma genitalium and is symptomatic; and**

- **Either:**

- **Has tried and failed to clear infection using azithromycin; or**

- **Has laboratory confirmed azithromycin resistance; and**

- **Treatment is only for 7 days.**

### Clinical indications

#### Initiation – Mycoplasma genitalium

- **All of the following:**

- **Has nucleic acid amplification test (NAAT) confirmed Mycoplasma genitalium and is symptomatic; and**

- **Either:**

- **Has tried and failed to clear infection using azithromycin; or**

- **Has laboratory confirmed azithromycin resistance; and**

- **Treatment is only for 7 days.**

### Clinical indications

#### Initiation – Mycoplasma genitalium

- **All of the following:**

- **Has nucleic acid amplification test (NAAT) confirmed Mycoplasma genitalium and is symptomatic; and**

- **Either:**

- **Has tried and failed to clear infection using azithromycin; or**

- **Has laboratory confirmed azithromycin resistance; and**

- **Treatment is only for 7 days.**

### Clinical indications

#### Nortefloxacin

- **Tab 400 mg** | 135.00 | Arrow-Norfloxacin |
<table>
<thead>
<tr>
<th>Tetracyclines</th>
</tr>
</thead>
</table>

**DEMECLOCYCLINE HYDROCHLORIDE**
- Tab 150 mg
- Cap 150 mg
- Cap 300 mg

**DOXYCYCLINE**
- Tab 50 mg – **Restricted**: For continuation only
  - Tab 100 mg
  - Inj 5 mg per ml, 20 ml vial

**MINOCYCLINE**
- Tab 50 mg
  - Cap 100 mg – **Restricted**: For continuation only

**TETRACYCLINE**
- Tab 250 mg
  - Cap 500 mg

**TIGECYCLINE** – **Restricted** see terms below
- Inj 50 mg vial

**Other Antibacterials**

**AZTREONAM** – **Restricted** see terms below
- Inj 1 g vial

**CHLORAMPHENICOL** – **Restricted** see terms below
- Inj 1 g vial

**CLINDAMYCIN** – **Restricted** see terms below
- Cap 150 mg
  - 1% DV Apr-20 to 2022
- Oral liq 15 mg per ml
  - Inj 150 mg per ml, 4 ml ampoule

**COLISTIN SULPHOMETHATE [COLESTIMETHATE]** – **Restricted** see terms below
- Inj 150 mg per ml, 1 ml vial

**DAPTOMYCIN** – **Restricted** see terms below
- Inj 500 mg vial

**FOSFOMYCIN** – **Restricted** see terms on the next page
- Powder for oral solution, 3 g sachet
**INFECTIONS**

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) $ Per Brand or Generic Manufacturer</th>
</tr>
</thead>
</table>

**Restricted (RS1315)**
Clinical microbiologist or infectious disease specialist

LINCOMYCIN – *Restricted* see terms below

- Inj 300 mg per ml, 2 ml vial

**Restricted (RS1065)**
Clinical microbiologist or infectious disease specialist

LINEZOLID – *Restricted* see terms below

- Tab 600 mg – 1% DV Oct-18 to 2021 ........................................... 553.77 10 Zyvox
- Oral liq 20 mg per ml – 1% DV Dec-18 to 2021 ................................... 1,879.00 150 ml Zyvox
- Inj 2 mg per ml, 300 ml bottle – 1% DV Feb-19 to 2021 .................. 18.50 1 Linezolid Kabi

**Restricted (RS1066)**
Clinical microbiologist or infectious disease specialist

METHENAMINE (HEXAMINE) HIPPURATE

- Tab 1 g ................................................................. 40.01 100 Hiprex

NITROFURANTOIN

- Tab 50 mg – 1% DV Apr-19 to 2021 ............................................. 22.20 100 Nifuran
- Tab 100 mg – 1% DV Apr-19 to 2021 ....................................... 37.50 100 Nifuran

PIVMECILLINAM – *Restricted* see terms below

- Tab 200 mg

**Restricted (RS1322)**
Clinical microbiologist or infectious disease specialist

SODIUM FUSIDATE [FUSIDIC ACID] – *Restricted* see terms below

- Tab 250 mg – 1% DV Jun-17 to 2020 .......................................... 34.50 12 Fucidin

**Restricted (RS1064)**
Clinical microbiologist or infectious disease specialist

SULPHADIAZINE – *Restricted* see terms below

- Tab 500 mg

**Restricted (RS1067)**
Clinical microbiologist, infectious disease specialist or maternal-foetal medicine specialist

TEICOPLANIN – *Restricted* see terms below

- Inj 400 mg vial

**Restricted (RS1068)**
Clinical microbiologist or infectious disease specialist

TRIMETHOPRIM

- Tab 100 mg
- Tab 300 mg – 1% DV Oct-18 to 2021 ....................................... 16.50 50 TMP

TRIMETHOPRIM WITH SULPHAMETHOXAZOLE [CO-TRIMOXAZOLE]

- Tab 80 mg with sulphamethoxazole 400 mg
- Oral liq 8 mg with sulphamethoxazole 40 mg per ml – 1% DV Oct-17 to 2020 .................................................. 2.97 100 ml Deprim
- Inj 16 mg with sulphamethoxazole 80 mg per ml, 5 ml ampoule

VANCOMYCIN – *Restricted* see terms below

- Inj 500 mg vial – 1% DV Sep-17 to 2020 ..................................... 2.37 1 Mylan

**Restricted (RS1069)**
Clinical microbiologist or infectious disease specialist

---

*Products with Hospital Supply Status (HSS) are in bold*

*Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.*
## INFECTIONS

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per</td>
<td></td>
</tr>
</tbody>
</table>

### Antifungals

#### Imidazoles

**KETOCONAZOLE**
- Tab 200 mg
- **Restricted (RS1410)**

Oncologist

#### Polyene Antimycotics

**AMPHOTERICIN B**
- Inj (liposomal) 50 mg vial
  - **Restricted (RS1071)**

Initiation
Clinical microbiologist, haematologist, infectious disease specialist, oncologist, respiratory specialist or transplant specialist

Either:
1. Proven or probable invasive fungal infection, to be prescribed under an established protocol; or
2. Both:
   2.1 Possible invasive fungal infection; and
   2.2 A multidisciplinary team (including an infectious disease physician or a clinical microbiologist) considers the treatment to be appropriate.

**NYSTATIN**
- Tab 500,000 u
- Cap 500,000 u

Consultant
Clinical immunologist, clinical microbiologist, dermatologist or infectious disease specialist

#### Triazoles

**FLUCONAZOLE** – **Restricted** see terms below

- Cap 50 mg – 1% DV Feb-18 to 2020
- Cap 150 mg – 1% DV Feb-18 to 2020
- Cap 200 mg – 1% DV Feb-18 to 2020
- Oral liquid 50 mg per 5 ml
- Inj 2 mg per ml, 50 ml vial – 1% DV Oct-19 to 2022
- Inj 2 mg per ml, 100 ml vial – 1% DV Oct-19 to 2022

Consultant
Clinical immunologist, clinical microbiologist, dermatologist or infectious disease specialist

**ITRACONAZOLE** – **Restricted** see terms below
- Cap 100 mg – 1% DV Nov-19 to 2022
- Oral liquid 10 mg per ml

**POSACONAZOLE** – **Restricted** see terms on the next page
- Tab modified-release 100 mg
- Oral liq 40 mg per ml

*e.g. Brand indicates brand example only. It is not a contracted product.*
**INFECTIONS**

**Price (ex man. excl. GST)**

<table>
<thead>
<tr>
<th>Brand or Manufacturer</th>
<th>Per</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Restricted (RS1074)</strong></td>
<td></td>
</tr>
</tbody>
</table>

**Initiation**

Haematologist or infectious disease specialist

*Re-assessment required after 6 weeks*

Both:

1. Either:
   1.1 Patient has acute myeloid leukaemia; or
   1.2 Patient is planned to receive a stem cell transplant and is at high risk for aspergillus infection; and

2. Patient is to be treated with high dose remission induction therapy or re-induction therapy.

**Continuation**

Haematologist or infectious disease specialist

*Re-assessment required after 6 weeks*

Both:

1. Patient has previously received posaconazole prophylaxis during remission induction therapy; and
2. Any of the following:
   2.1 Patient is to be treated with high dose remission re-induction therapy; or
   2.2 Patient is to be treated with high dose consolidation therapy; or
   2.3 Patient is receiving a high risk stem cell transplant.

**VORICONAZOLE – Restricted** see terms below

| Tab 50 mg – 1% DV Sep-18 to 2021 | $91.00 | 56 Vttack |
| Tab 200 mg – 1% DV Sep-18 to 2021 | $350.00 | 56 Vttack |
| Powder for oral suspension 40 mg per ml – 1% DV Dec-18 to 2021 | $1,437.00 | 70 ml Vfend |
| Inj 200 mg vial – 1% DV Oct-19 to 2022 | $44.00 | 1 Neo Health |

**Restricted (RS1075)**

**Initiation – Proven or probable aspergillus infection**

Clinical microbiologist, haematologist or infectious disease specialist

Both:

1. Patient is immunocompromised; and
2. Patient has proven or probable invasive aspergillus infection.

**Initiation – Possible aspergillus infection**

Clinical microbiologist, haematologist or infectious disease specialist

All of the following:

1. Patient is immunocompromised; and
2. Patient has possible invasive aspergillus infection; and
3. A multidisciplinary team (including an infectious disease physician) considers the treatment to be appropriate.

**Initiation – Resistant candidiasis infections and other moulds**

Clinical microbiologist, haematologist or infectious disease specialist

All of the following:

1. Patient is immunocompromised; and
2. Either:
   2.1 Patient has fluconazole resistant candidiasis; or
   2.2 Patient has mould strain such as Fusarium spp. and Scedosporium spp; and
3. A multidisciplinary team (including an infectious disease physician or clinical microbiologist) considers the treatment to be appropriate.

**Other Antifungals**

**CASPOFUNGIN – Restricted** see terms on the next page

| Inj 50 mg vial – 1% DV Dec-19 to 2022 | $220.28 | 1 Max Health |
| Inj 70 mg vial – 1% DV Dec-19 to 2022 | $284.63 | 1 Max Health |

Products with Hospital Supply Status (HSS) are in **bold**

Expire date of HSS period is 30 June of the year indicated unless otherwise stated.
### INFECTIONS

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per Brand or Generic Manufacturer</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>→ Restricted (RS1076)</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Initiation</strong></td>
</tr>
<tr>
<td>Clinical microbiologist, haematologist, infectious disease specialist, oncologist, respiratory specialist or transplant specialist</td>
</tr>
<tr>
<td>Either:</td>
</tr>
<tr>
<td>1 Proven or probable invasive fungal infection, to be prescribed under an established protocol; or</td>
</tr>
<tr>
<td>2 Both:</td>
</tr>
<tr>
<td>2.1 Possible invasive fungal infection; and</td>
</tr>
<tr>
<td>2.2 A multidisciplinary team (including an infectious disease physician or a clinical microbiologist) considers the treatment to be appropriate.</td>
</tr>
</tbody>
</table>

| **FLUCYTOSINE – Restricted see terms below** |
| Cap 500 mg |

| **→ Restricted (RS1279)** |
| Clinical microbiologist or infectious disease specialist |

| **TERBINAFINE** |
| Tab 250 mg – 1% DV Jan-18 to 2020 | 1.33 | 14 | Deolate |

### Antimycobacterials

#### Antileprotics

| **CLOFAZIMINE – Restricted see terms below** |
| Cap 50 mg |

| **→ Restricted (RS1077)** |
| Clinical microbiologist, dermatologist or infectious disease specialist |

| **DAPSONE – Restricted see terms below** |
| Tab 25 mg | 268.50 | 100 | Dapsone |
| Tab 100 mg | 329.50 | 100 | Dapsone |

| **→ Restricted (RS1078)** |
| Clinical microbiologist, dermatologist or infectious disease specialist |

| **Antituberculotics** |

| **CYCLOSERINE – Restricted see terms below** |
| Cap 250 mg |

| **→ Restricted (RS1079)** |
| Clinical microbiologist, infectious disease specialist or respiratory specialist |

| **ETHAMBUTOL HYDROCHLORIDE – Restricted see terms below** |
| Tab 100 mg |
| Tab 400 mg | 49.34 | 56 | Myambutol |

| **→ Restricted (RS1080)** |
| Clinical microbiologist, infectious disease specialist or respiratory specialist |

| **ISONIAZID – Restricted see terms below** |
| Tab 100 mg – 1% DV Oct-18 to 2021 | 22.00 | 100 | PSM |

| **→ Restricted (RS1281)** |
| Clinical microbiologist, dermatologist, paediatrician, public health physician or internal medicine physician |

| **ISONIAZID WITH RIFAMPICIN – Restricted see terms below** |
| Tab 100 mg with rifampicin 150 mg – 1% DV Sep-18 to 2021 | 85.54 | 100 | Rifinah |
| Tab 150 mg with rifampicin 300 mg – 1% DV Sep-18 to 2021 | 170.60 | 100 | Rifinah |

| **→ Restricted (RS1282)** |
| Clinical microbiologist, dermatologist, paediatrician, public health physician or internal medicine physician |

---

*Item restricted (see above); Item restricted (see below)*

e.g. *Brand* indicates brand example only. It is not a contracted product.
INFECTIONS

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per</td>
<td></td>
</tr>
</tbody>
</table>

PARA-AMINOSALICYLIC ACID – **Restricted** see terms below

- **Grans for oral liq 4 g.** .......................................................... 280.00 30 Paser

**→ Restricted (RS1083)**
Clinical microbiologist, infectious disease specialist or respiratory specialist

PROTIONAMIDE – **Restricted** see terms below

- **Tab 250 mg.** ........................................................................... 305.00 100 Peteha

**→ Restricted (RS1084)**
Clinical microbiologist, infectious disease specialist or respiratory specialist

PYRAZINAMIDE – **Restricted** see terms below

- **Tab 500 mg**

**→ Restricted (RS1085)**
Clinical microbiologist, infectious disease specialist or respiratory specialist

RIFABUTIN – **Restricted** see terms below

- **Cap 150 mg.** ........................................................................... 275.00 30 Mycobutin

**→ Restricted (RS1086)**
Clinical microbiologist, gastroenterologist, infectious disease specialist or respiratory specialist

RIFAMPICIN – **Restricted** see terms below

- **Cap 150 mg – 1% DV Sep-17 to 2020** ........................................ 55.75 100 Rifadin
- **Cap 300 mg – 1% DV Sep-17 to 2020** ....................................... 116.25 100 Rifadin
- **Oral liq 100 mg per 5 ml – 1% DV Sep-17 to 2020** .................. 12.00 60 ml Rifadin
- **Inj 600 mg vial – 1% DV Sep-17 to 2020** .................................. 128.85 1 Rifadin

**→ Restricted (RS1087)**
Clinical microbiologist, dermatologist, internal medicine physician, paediatrician or public health physician

**Antiparasitics**

**Anthelmintics**

ALBENDAZOLE – **Restricted** see terms below

- **Tab 200 mg**
- **Tab 400 mg**

**→ Restricted (RS1088)**
Clinical microbiologist or infectious disease specialist

IVERMECTIN – **Restricted** see terms below

- **Tab 3 mg** ............................................................................... 17.20 4 Stromectol

**→ Restricted (RS1283)**
Clinical microbiologist, dermatologist or infectious disease specialist

MEBENDAZOLE

- **Tab 100 mg** ........................................................................... 24.19 24 De-Worm
- **Oral liq 100 mg per 5 ml**

PRAZIQUANTEL

- **Tab 600 mg**

**Antiprotozoals**

ARTEMETHER WITH LUMEFANTRINE – **Restricted** see terms below

- **Tab 20 mg with lumefantrine 120 mg**

**→ Restricted (RS1090)**
Clinical microbiologist or infectious disease specialist

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price</th>
<th>Per</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per</td>
<td>ex man. excl. GST</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**INFECTIONS**

<table>
<thead>
<tr>
<th>Product</th>
<th>Brand or Generic Manufacturer</th>
<th>Price</th>
<th>Per</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>ARTESSUNATE – <strong>Restricted</strong> see terms below</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 60 mg vial</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Restricted (RS1091)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical microbiologist or infectious disease specialist</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ATOVACONazole WITH PROGUANIL HYDROCHLORIDE – <strong>Restricted</strong> see terms below</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 62.5 mg with proguanil hydrochloride 25 mg</td>
<td>25.00</td>
<td>12</td>
<td>Malarone Junior</td>
<td></td>
</tr>
<tr>
<td>Tab 250 mg with proguanil hydrochloride 100 mg</td>
<td>64.00</td>
<td>12</td>
<td>Malarone</td>
<td></td>
</tr>
<tr>
<td><strong>Restricted (RS1092)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical microbiologist or infectious disease specialist</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CHLOROQUINE PHOSPHATE – <strong>Restricted</strong> see terms below</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 250 mg</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Restricted (RS1093)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical microbiologist, dermatologist, infectious disease specialist or rheumatologist</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MEFLOQUINE – <strong>Restricted</strong> see terms below</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 250 mg</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Restricted (RS1094)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical microbiologist, dermatologist, infectious disease specialist or rheumatologist</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>METRONIDAZOLE</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 200 mg</td>
<td>10.45</td>
<td>100</td>
<td>Trichozole</td>
<td></td>
</tr>
<tr>
<td>Tab 400 mg</td>
<td>18.15</td>
<td>100</td>
<td>Trichozole</td>
<td></td>
</tr>
<tr>
<td>Oral liq benzoate 200 mg per 5 ml</td>
<td>25.00</td>
<td>100 ml</td>
<td>Flagyl-S</td>
<td></td>
</tr>
<tr>
<td>Inj 5 mg per ml, 100 ml bottle</td>
<td>1.39</td>
<td>100 ml</td>
<td>AFT</td>
<td></td>
</tr>
<tr>
<td>Inj 5 mg per ml, 100 ml bag</td>
<td>264.00</td>
<td>48</td>
<td>Baxter</td>
<td></td>
</tr>
<tr>
<td>Suppos 500 mg</td>
<td>24.48</td>
<td>10</td>
<td>Flagyl</td>
<td></td>
</tr>
<tr>
<td>NITAZOXANIDE – <strong>Restricted</strong> see terms below</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 500 mg</td>
<td>1,680.00</td>
<td>30</td>
<td>Alinia</td>
<td></td>
</tr>
<tr>
<td>Oral liq 100 mg per 5 ml</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Restricted (RS1095)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical microbiologist or infectious disease specialist</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ORNIDAZOLE</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 500 mg</td>
<td>23.00</td>
<td>10</td>
<td>Arrow-Ornidazole</td>
<td></td>
</tr>
<tr>
<td>PENTAMIDINE ISETHIONATE – <strong>Restricted</strong> see terms below</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 300 mg vial – 1% DV Nov-19 to 2022</td>
<td>216.00</td>
<td>5</td>
<td>Pentacarinat</td>
<td></td>
</tr>
<tr>
<td><strong>Restricted (RS1096)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical microbiologist or infectious disease specialist</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PRIMAQUINE PHOSPHATE – <strong>Restricted</strong> see terms below</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 7.5 mg</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Restricted (RS1097)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical microbiologist or infectious disease specialist</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PYRIMETHAMINE – <strong>Restricted</strong> see terms below</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 25 mg</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Restricted (RS1098)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical microbiologist, infectious disease specialist or maternal-foetal medicine specialist</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>QUININE DIHYDROCHLORIDE – <strong>Restricted</strong> see terms below</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 60 mg per ml, 10 ml ampoule</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 300 mg per ml, 2 ml vial</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Restricted (RS1099)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical microbiologist or infectious disease specialist</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Item restricted (see ➥ above); Item restricted (see ➥ below)*

*e.g. Brand indicates brand example only. It is not a contracted product.*
INFECTIONS

<table>
<thead>
<tr>
<th>Brand or</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Generic</td>
<td>(ex man. excl. GST) Per</td>
</tr>
<tr>
<td>Manufacturer</td>
<td></td>
</tr>
</tbody>
</table>

QUININE SULPHATE
Tab 300 mg .................................................. $61.91 500 Q 300

SODIUM STIBOGLUCONATE – Restricted see terms below

- Inj 100 mg per ml, 1 ml vial
- Restricted (RS1100)
Clinical microbiologist or infectious disease specialist

SPIRAMYCIN – Restricted see terms below

- Tab 500 mg
- Restricted (RS1101)
Maternal-foetal medicine specialist

Antiretrovirals

Non-Nucleoside Reverse Transcriptase Inhibitors

- Restricted (RS1571)

Initiation – Confirmed HIV
Patient has confirmed HIV infection.

Initiation – Prevention of maternal transmission
Either:
1. Prevention of maternal foetal transmission; or
2. Treatment of the newborn for up to eight weeks.

Initiation – Post-exposure prophylaxis following non-occupational exposure to HIV
Both:
1. Treatment course to be initiated within 72 hours post exposure; and
2. Any of the following:
   2.1 Patient has had unprotected receptive anal intercourse with a known HIV positive person; or
   2.2 Patient has shared intravenous injecting equipment with a known HIV positive person; or
   2.3 Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required.

Initiation – Percutaneous exposure
Patient has percutaneous exposure to blood known to be HIV positive.

EFAVIRENZ – Restricted see terms above

- Tab 200 mg .................................................. $190.15 90 Stocrin
- Tab 600 mg .................................................. $63.38 30 Stocrin
- Oral liq 30 mg per ml

ETRAVIRINE – Restricted see terms above

- Tab 200 mg .................................................. $770.00 60 Intelex

NEVIRAPINE – Restricted see terms above

- Tab 200 mg – 1% DV Sep-18 to 2021 .................................................. $60.00 60 Nevirapine Alphapharm
- Oral suspension 10 mg per ml .................................................. $203.55 240 ml Viramune Suspension

Nucleoside Reverse Transcriptase Inhibitors

- Restricted (RS1572)

Initiation – Confirmed HIV
Patient has confirmed HIV infection.

continued…

Products with Hospital Supply Status (HSS) are in bold
Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
continued

### Initiation – Prevention of maternal transmission

Either:

1. Prevention of maternal foetal transmission; or
2. Treatment of the newborn for up to eight weeks.

### Initiation – Post-exposure prophylaxis following non-occupational exposure to HIV

Both:

1. Treatment course to be initiated within 72 hours post exposure; and
2. Any of the following:
   1. Patient has had unprotected receptive anal intercourse with a known HIV positive person; or
   2. Patient has shared intravenous injecting equipment with a known HIV positive person; or
   3. Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required.

### Initiation – Percutaneous exposure

Patient has percutaneous exposure to blood known to be HIV positive.

<table>
<thead>
<tr>
<th>Drug Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ABACAVIR SULPHATE</strong></td>
<td>Tab 300 mg – 1% DV Jul-19 to 2022</td>
<td>180.00 60 Ziangen</td>
</tr>
<tr>
<td></td>
<td>Oral liq 20 mg per ml</td>
<td>256.31 240 ml Ziangen</td>
</tr>
<tr>
<td><strong>ABACAVIR SULPHATE WITH LAMIVUDINE</strong></td>
<td>Tab 600 mg with lamivudine 300 mg – 1% DV Jul-19 to 2022</td>
<td>63.00 30 Kivexa</td>
</tr>
<tr>
<td></td>
<td>Tab 600 mg with emtricitabine 200 mg and tenofovir disoproxil 245 mg</td>
<td>106.88 30 Mylan</td>
</tr>
<tr>
<td><strong>EMTRICITABINE</strong></td>
<td>Cap 200 mg – 1% DV Jul-19 to 2022</td>
<td>307.20 30 Emtriva</td>
</tr>
<tr>
<td><strong>LAMIVUDINE</strong></td>
<td>Oral liq 10 mg per ml</td>
<td>see terms on the previous page</td>
</tr>
<tr>
<td><strong>STAVUDINE</strong></td>
<td>Cap 30 mg</td>
<td>see terms on the previous page</td>
</tr>
<tr>
<td></td>
<td>Cap 40 mg</td>
<td>see terms on the previous page</td>
</tr>
<tr>
<td></td>
<td>Powder for oral soln 1 mg per ml</td>
<td>see terms on the previous page</td>
</tr>
<tr>
<td><strong>ZIDOVUDINE [AZT]</strong></td>
<td>Cap 100 mg</td>
<td>152.25 100 Retrovir</td>
</tr>
<tr>
<td></td>
<td>Oral liq 10 mg per ml</td>
<td>30.45 200 ml Retrovir</td>
</tr>
<tr>
<td></td>
<td>Inj 10 mg per ml, 20 ml vial</td>
<td>750.00 5 Retrovir IV</td>
</tr>
<tr>
<td><strong>ZIDOVUDINE [AZT] WITH LAMIVUDINE</strong></td>
<td>Tab 300 mg with lamivudine 150 mg – 1% DV Sep-17 to 2020</td>
<td>33.00 60 Alphapharm</td>
</tr>
</tbody>
</table>

### Protease Inhibitors

**RS1573**

### Initiation – Confirmed HIV

Patient has confirmed HIV infection.

### Initiation – Prevention of maternal transmission

Either:

continued...
## Strand Transfer Inhibitors

### ATAZANAVIR SULPHATE — Restricted

- **Cap 150 mg — 1% DV Jun-19 to 2022**
  - Price: $141.68 60
  - Manufacturer: Teva

- **Cap 200 mg — 1% DV Jun-19 to 2022**
  - Price: $188.91 60
  - Manufacturer: Teva

### DARUNAVIR — Restricted

- **Tab 400 mg — 1% DV Jun-17 to 2020**
  - Price: $335.00 60
  - Manufacturer: Prezista

- **Tab 600 mg — 1% DV Jun-17 to 2020**
  - Price: $476.00 60
  - Manufacturer: Prezista

### INDINAVIR — Restricted

- **Cap 200 mg**

- **Cap 400 mg**

### LOPINAVIR WITH RITONAVIR — Restricted

- **Tab 100 mg with ritonavir 25 mg**
  - Price: $183.75 60
  - Manufacturer: Kaletra

- **Tab 200 mg with ritonavir 50 mg — 1% DV Sep-17 to 2020**
  - Price: $463.00 120
  - Manufacturer: Kaletra

- **Oral liq 80 mg with ritonavir 20 mg per ml**
  - Price: $735.00 300 ml
  - Manufacturer: Kaletra

### RITONAVIR — Restricted

- **Tab 100 mg — 1% DV Jul-19 to 2022**
  - Price: $43.31 30
  - Manufacturer: Norvir

### Strand Transfer Inhibitors (RS1574)

**Initiation — Confirmed HIV**

Patient has confirmed HIV infection.

**Initiation — Prevention of maternal transmission**

Either:

1. Prevention of maternal foetal transmission; or
2. Treatment of the newborn for up to eight weeks.

**Initiation — Post-exposure prophylaxis following non-occupational exposure to HIV**

Both:

1. Treatment course to be initiated within 72 hours post exposure; and
2. Any of the following:
   1.1 Patient has had unprotected receptive anal intercourse with a known HIV positive person; or
   1.2 Patient has shared intravenous injecting equipment with a known HIV positive person; or
   1.3 Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required.

**Initiation — Percutaneous exposure**

Patient has percutaneous exposure to blood known to be HIV positive.
INFECTIONS

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Price (ex man. excl. GST) $ Per</td>
</tr>
</tbody>
</table>

**Antivirals**

### Hepatitis B

**ADEFOVIR DIPIVOXIL – Restricted** see terms below

- **Tab 10 mg** ......................................................... 670.00 30 Hepsera

**Note:** Restricted (RS1104)

**Initiation**

Gastroenterologist or infectious disease specialist

All of the following:

1. Patient has confirmed Hepatitis B infection (HBsAg+); and
2. Patient has raised serum ALT (> 1 x ULN); and
3. Patient has HBV DNA greater than 100,000 copies per mL, or viral load greater than or equal to 10-fold over nadir; and
4. Detection of M204I or M204V mutation; and
5. Either:
   5.1 Both:
      5.1.1 Patient is cirrhotic; and
      5.1.2 Adefovir dipivoxil to be used in combination with lamivudine; or
   5.2 Both:
      5.2.1 Patient is not cirrhotic; and
      5.2.2 Adefovir dipivoxil to be used as monotherapy.

**ENTECAVIR**

- **Tab 0.5 mg – 1% DV Nov-18 to 2021** ........................................ 52.00 30 Entecavir Sandoz

**LAMIVUDINE**

- **Tab 100 mg – 1% DV Aug-18 to 2020** ........................................ 4.20 28 Zetlim
- **Oral liq 5 mg per ml** .......................................................... 270.00 240 ml Zeffix

**TENOFOVIR DISOPROXIL**

- **Tab 245 mg (300.6 mg as a succinate) – 1% DV Sep-18 to 2021** ...... 38.10 30 Tenofovir Disoproxil Teva

### Hepatitis C

**GLECAPREVIR WITH PIBRENTASVIR**

Note: the supply of treatment is via PHARMAC’s approved direct distribution supply. Further details can be found on PHARMAC’s website https://www.pharmac.govt.nz/hepatitis-c-treatments/.

- **Tab 100 mg with pibrentasvir 40 mg** ....................................... 24,750.00 84 Maviret

**LEDIPASVIR WITH SOFOSBUVIR – Restricted** see terms below

- **Tab 90 mg with sofosbuvir 400 mg** ....................................... 24,363.46 28 Harvoni

**Note:** Only for use in patients with approval by the Hepatitis C Treatment Panel (HepCTP). Applications will be considered by HepCTP at its regular meetings and approved subject to eligibility according to the Access Criteria (set out in Section B of the Pharmaceutical Schedule).
## INFECTIONS

### Herpesviridae

<table>
<thead>
<tr>
<th>Product</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ACICLOVIR</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab dispersible 200 mg – 1% DV Oct-19 to 2022</td>
<td>1.60</td>
<td>25 Lovir</td>
</tr>
<tr>
<td>Tab dispersible 400 mg – 1% DV Oct-19 to 2022</td>
<td>5.38</td>
<td>56 Lovir</td>
</tr>
<tr>
<td>Tab dispersible 800 mg – 1% DV Oct-19 to 2022</td>
<td>5.98</td>
<td>35 Lovir</td>
</tr>
<tr>
<td>Inj 250 mg vial – 1% DV Sep-18 to 2021</td>
<td>9.60</td>
<td>5 Aciclovir-Claris</td>
</tr>
</tbody>
</table>

**CIDOFOVIR** – Restricted see terms below

- Inj 75 mg per ml, 5 ml vial
- Restricted (RS1108)
  
  Clinical microbiologist, infectious disease specialist, otolaryngologist or oral surgeon

**FOSCARNET SODIUM** – Restricted see terms below

- Inj 24 mg per ml, 250 ml bottle
- Restricted (RS1109)
  
  Clinical microbiologist or infectious disease specialist

**GANCICLOVIR** – Restricted see terms below

- Inj 500 mg vial
- Restricted (RS1110)
  
  Clinical microbiologist or infectious disease specialist

**VALACLOVIR**

- Tab 500 mg – 1% DV Sep-18 to 2021
- Tab 1,000 mg – 1% DV Sep-18 to 2021
  
  Clinical microbiologist or infectious disease specialist

**VALGANCLOVIR** – Restricted see terms below

- Tab 450 mg – 1% DV May-19 to 2021
- Restricted (RS1112)
  
  Clinical microbiologist, infectious disease specialist, otolaryngologist or oral surgeon

### HIV Prophylaxis and Treatment

**EMTRICITABINE WITH TENOFOVIR DISOPROXIL** – Restricted see terms on the next page

- Tab 200 mg with tenofovir disoproxil 245 mg (300.6 mg as a succinate)
  
  – 1% DV Jun-19 to 2022
  
  61.15 | 30 | Teva
INFECTIONS

Price
(ex man. excl. GST)
$ Per
Brand or
Generic
Manufacturer

⇒ Restricted (RS1700)

Initiation – Confirmed HIV
Patient has confirmed HIV infection.

Initiation – Prevention of maternal transmission
Either:
1 Prevention of maternal foetal transmission; or
2 Treatment of the newborn for up to eight weeks.

Initiation – Post-exposure prophylaxis following non-occupational exposure to HIV
Both:
1 Treatment course to be initiated within 72 hours post exposure; and
2 Any of the following:
   2.1 Patient has had unprotected receptive anal intercourse with a known HIV positive person; or
   2.2 Patient has shared intravenous injecting equipment with a known HIV positive person; or
   2.3 Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required.

Initiation – Percutaneous exposure
Patient has percutaneous exposure to blood known to be HIV positive.

Initiation – Pre-exposure prophylaxis
Re-assessment required after 3 months
All of the following:
1 Applicant has an up to date knowledge of the safety issues and is competent to prescribe pre-exposure prophylaxis (refer to local health pathways or https://ashm.org.au/HIV/PrEP/ for training materials); and
2 Patient has undergone testing for HIV, syphilis, Hep B if not immune and a full STI screen in the previous two weeks; and
3 Patient has had renal function testing (creatinine, phosphate and urine protein/creatinine ratio) within the last 3 months and is not contraindicated for treatment; and
4 Patient has received advice regarding the reduction of risk of HIV and sexually transmitted infections and how to reduce those risks; and
5 Patient has tested HIV negative and is not at risk of HIV seroconversion; and
6 Either:
   6.1 All of the following:
      6.1.1 Patient is male or transgender; and
      6.1.2 Patient has sex with men; and
      6.1.3 Patient is likely to have multiple episodes of condomless anal intercourse in the next 3 months; and
      6.1.4 Any of the following:
         6.1.4.1 Patient has had at least one episode of condomless receptive anal intercourse with one or more casual male partners in the last 3 months; or
         6.1.4.2 A diagnosis of rectal chlamydia, rectal gonorrhoea, or infectious syphilis within the last 3 months; or
         6.1.4.3 Patient has used methamphetamine in the last three months; or
   6.2 All of the following:
      6.2.1 Patient has a regular partner who has HIV infection; and
      6.2.2 Partner is either not on treatment or has a detectable viral load; and
      6.2.3 Condoms have not been consistently used.

Continuation – Pre-exposure prophylaxis
Re-assessment required after 3 months
All of the following:
1 Applicant has an up to date knowledge of the safety issues and is competent to prescribe pre-exposure prophylaxis (refer to local health pathways or https://ashm.org.au/HIV/PrEP/ for training materials); and

continued…

continued…

Item restricted (see ⇒ above); Item restricted (see ⇒ below)
e.g. Brand indicates brand example only. It is not a contracted product.
continued...

2 Patient has undergone testing for HIV, syphilis, Hep B if not immune and a full STI screen in the previous two weeks; and
3 Patient has had renal function testing (creatinine, phosphate and urine protein/creatinine ratio) within the last 12 months and is not contraindicated for treatment; and
4 Patient has received advice regarding the reduction of risk of HIV and sexually transmitted infections and how to reduce those risks; and
5 Patient has tested HIV negative and is not at risk of HIV seroconversion; and
6 Either:
   6.1 All of the following:
      6.1.1 Patient is male or transgender; and
      6.1.2 Patient has sex with men; and
      6.1.3 Patient is likely to have multiple episodes of condomless anal intercourse in the next 3 months; and
      6.1.4 Any of the following:
         6.1.4.1 Patient has had at least one episode of condomless receptive anal intercourse with one or more casual male partners in the last 3 months; or
         6.1.4.2 A diagnosis of rectal chlamydia, rectal gonorrhoea, or infectious syphilis within the last 3 months; or
         6.1.4.3 Patient has used methamphetamine in the last three months; or
   6.2 All of the following:
      6.2.1 Patient has a regular partner who has HIV infection; and
      6.2.2 Partner is either not on treatment or has a detectable viral load; and
      6.2.3 Condoms have not been consistently used.

### Influenza

**OSELTMIVIR** – **Restricted** see terms below

Note: The restriction on the use of oseltamivir to hospitalised patients means that supply into the community for a new course is not permitted. Supply of a part original pack on discharge where initiated as a hospital inpatient is permitted.

- Tab 75 mg
- Powder for oral suspension 6 mg per ml
- **Restricted** (RS1307)

**Initiation**

Either:

1. Only for hospitalised patient with known or suspected influenza; or
2. For prophylaxis of influenza in hospitalised patients as part of a DHB hospital approved infections control plan.

**ZANAMIVIR**

Note: The restriction on the use of zanamivir to hospitalised patients means that supply into the community for a new course is not permitted. Supply of a part original pack on discharge where initiated as a hospital inpatient is permitted.

- Powder for inhalation 5 mg

**Restricted** (RS1369)

**Initiation**

Either:

1. Only for hospitalised patient with known or suspected influenza; or
2. For prophylaxis of influenza in hospitalised patients as part of a DHB hospital approved infections control plan.

### Immune Modulators

**INTERFERON ALFA-2A**

- Inj 3 m iu prefilled syringe
- Inj 6 m iu prefilled syringe
- Inj 9 m iu prefilled syringe
INFECTIONS

INTERFERON ALFA-2B

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per</td>
<td></td>
</tr>
</tbody>
</table>

- Inj 18 m iu, 1.2 ml multidose pen
- Inj 30 m iu, 1.2 ml multidose pen
- Inj 60 m iu, 1.2 ml multidose pen

INTERFERON GAMMA – Restricted see terms below

- Inj 100 mcg in 0.5 ml vial
  - Restricted (RS1113)

Initiation

- Patient has chronic granulomatous disease and requires interferon gamma.

PEGYLATED INTERFERON ALFA-2A – Restricted see terms below

- Inj 180 mcg prefilled syringe – 1% DV Oct-17 to 2020

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per</td>
<td></td>
</tr>
<tr>
<td>500.00 4</td>
<td>Pegasys</td>
</tr>
</tbody>
</table>
  - Restricted (RS1340)

Initiation – Chronic hepatitis C - genotype 1, 4, 5 or 6 infection or co-infection with HIV or genotype 2 or 3 post liver transplant

Limited to 48 weeks treatment

Any of the following:

1. Patient has chronic hepatitis C, genotype 1, 4, 5 or 6 infection; or
2. Patient has chronic hepatitis C and is co-infected with HIV; or
3. Patient has chronic hepatitis C genotype 2 or 3 and has received a liver transplant.

Notes: Consider stopping treatment if there is absence of a virological response (defined as at least a 2-log reduction in viral load) following 12 weeks of treatment since this is predictive of treatment failure.

Consider reducing treatment to 24 weeks if serum HCV RNA level at Week 4 is undetectable by sensitive PCR assay (less than 50IU/ml) AND Baseline serum HCV RNA is less than 400,000IU/ml.

Continuation – Chronic hepatitis C - genotype 1 infection

Gastroenterologist, infectious disease specialist or general physician

Re-assessment required after 48 weeks

All of the following:

1. Patient has chronic hepatitis C, genotype 1; and
2. Patient has had previous treatment with pegylated interferon and ribavirin; and
3. Either:
   - 3.1 Patient has responder relapsed; or
   - 3.2 Patient was a partial responder; and
4. Patient is to be treated in combination with boceprevir.

Initiation – Chronic Hepatitis C - genotype 1 infection treatment more than 4 years prior

Gastroenterologist, infectious disease specialist or general physician

Limited to 48 weeks treatment

All of the following:

1. Patient has chronic hepatitis C, genotype 1; and
2. Patient has had previous treatment with pegylated interferon and ribavirin; and
3. Any of the following:
   - 3.1 Patient has responder relapsed; or
   - 3.2 Patient was a partial responder; or
   - 3.3 Patient received interferon treatment prior to 2004; and
4. Patient is to be treated in combination with boceprevir.

Initiation – Chronic hepatitis C - genotype 2 or 3 infection without co-infection with HIV

Limited to 6 months treatment

Patient has chronic hepatitis C, genotype 2 or 3 infection.

continued…
Initiation – Hepatitis B
Gastroenterologist, infectious disease specialist or general physician
Limited to 48 weeks treatment
All of the following:
1. Patient has confirmed Hepatitis B infection (HBsAg positive for more than 6 months); and
2. Patient is Hepatitis B treatment-naive; and
3. ALT > 2 times Upper Limit of Normal; and
4. HBV DNA < 10 log10 IU/ml; and
5. Either:
   5.1 HBeAg positive; or
   5.2 Serum HBV DNA greater than or equal to 2,000 units/ml and significant fibrosis (greater than or equal to Metavir Stage F2 or moderate fibrosis); and
6. Compensated liver disease; and
7. No continuing alcohol abuse or intravenous drug use; and
8. Not co-infected with HCV, HIV or HDV; and
9. Neither ALT nor AST > 10 times upper limit of normal; and
10. No history of hypersensitivity or contraindications to pegylated interferon.

Notes: Approved dose is 180 mcg once weekly.
The recommended dose of Pegylated Interferon alfa-2a is 180 mcg once weekly.
In patients with renal insufficiency (calculated creatinine clearance less than 50ml/min), Pegylated Interferon alfa-2a dose should be reduced to 135 mcg once weekly.
In patients with neutropaenia and thrombocytopenia, dose should be reduced in accordance with the datasheet guidelines. Pegylated Interferon alfa-2a is not approved for use in children.
### MUSCULOSKELETAL SYSTEM

#### Price (ex man. excl. GST)

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Per</th>
</tr>
</thead>
</table>

#### Anticholinesterases

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EDROPHONIUM CHLORIDE</strong> – Restricted see terms below</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 10 mg per ml, 15 ml vial</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 10 mg per ml, 1 ml ampoule</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>NEOSTIGMINE METILSULFATE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 2.5 mg per ml, 1 ml ampoule – 1% DV Nov-17 to 2020</td>
<td>98.00</td>
<td>AstraZeneca</td>
</tr>
<tr>
<td><strong>NEOSTIGMINE METILSULFATE WITH GLYCOPYRRONIUM BROMIDE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 2.5 mg with glycopyrronium bromide 0.5 mg per ml, 1 ml ampoule</td>
<td>20.90</td>
<td>Max Health</td>
</tr>
<tr>
<td><strong>PYRIDOSTIGMINE BROMIDE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 60 mg – 1% DV Nov-19 to 2022</td>
<td>45.79</td>
<td>Mestinon</td>
</tr>
</tbody>
</table>

#### Antirheumatoid Agents

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>HYDROXYCHLOROQUINE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 200 mg – 1% DV Sep-18 to 2021</td>
<td>7.98</td>
<td>Plaquenil</td>
</tr>
<tr>
<td><strong>LEFLUNOMIDE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 10 mg – 1% DV Jun-17 to 2020</td>
<td>2.90</td>
<td>Apo-Leflunomide</td>
</tr>
<tr>
<td>Tab 20 mg – 1% DV Jun-17 to 2020</td>
<td>2.90</td>
<td>Apo-Leflunomide</td>
</tr>
<tr>
<td><strong>PENICILLAMINE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 125 mg</td>
<td>67.23</td>
<td>D-Penamine</td>
</tr>
<tr>
<td>Tab 250 mg</td>
<td>110.12</td>
<td>D-Penamine</td>
</tr>
<tr>
<td><strong>SODIUM AUROTHIOMALATE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 10 mg in 0.5 ml ampoule</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 20 mg in 0.5 ml ampoule</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 50 mg in 0.5 ml ampoule</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Drugs Affecting Bone Metabolism

##### Bisphosphonates

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ALENDRONATE SODIUM</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 70 mg – 1% DV Apr-19 to 2022</td>
<td>2.44</td>
<td>Fosamax</td>
</tr>
<tr>
<td><strong>ALENDRONATE SODIUM WITH COLECALCIFEROL</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 70 mg with colecalciferol 5,600 lu – 1% DV Apr-19 to 2022</td>
<td>1.51</td>
<td>Fosamax Plus</td>
</tr>
<tr>
<td><strong>PAMIDRONATE DISODIUM</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 3 mg per ml, 10 ml vial – 1% DV Sep-17 to 2020</td>
<td>5.98</td>
<td>Pamisol</td>
</tr>
<tr>
<td>Inj 6 mg per ml, 10 ml vial – 1% DV Sep-17 to 2020</td>
<td>15.02</td>
<td>Pamisol</td>
</tr>
<tr>
<td>Inj 9 mg per ml, 10 ml vial – 1% DV Sep-17 to 2020</td>
<td>17.05</td>
<td>Pamisol</td>
</tr>
<tr>
<td><strong>RISEDRONATE SODIUM</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 35 mg – 1% DV Oct-19 to 2022</td>
<td>3.10</td>
<td>Risedronate Sandoz</td>
</tr>
<tr>
<td><strong>ZOLEDRONIC ACID</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 5 mg per 100 ml, vial – 1% DV Oct-19 to 2022</td>
<td>60.00</td>
<td>Aclasta</td>
</tr>
</tbody>
</table>

---

*Item restricted (see ➥ above); Item restricted (see ➥ below)*  
*e.g. Brand indicates brand example only. It is not a contracted product.*
MUSCULOSKELETAL SYSTEM

Price
(ex man. excl. GST)
$ Per
Brand or
Generic
Manufacturer

→ Restricted (RS1663)

Initiation – Inherited bone fragility disorders
Any specialist
Patient has been diagnosed with an inherited bone fragility disorder (e.g. osteogenesis imperfecta).

Initiation – Osteoporosis
Any specialist
Therapy limited to 3 doses
Both:

1. Any of the following:
   1.1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) greater than or equal to 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score less than or equal to -2.5) (see Note); or
   1.2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or
   1.3 History of two significant osteoporotic fractures demonstrated radiologically; or
   1.4 Documented T-Score greater than or equal to -3.0 (see Note); or
   1.5 A 10-year risk of hip fracture greater than or equal to 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Note); or
   1.6 Patient has had a Special Authority approval for alendronate (Underlying cause - Osteoporosis) prior to 1 February 2019 or has had a Special Authority approval for raloxifene; and

2. The patient will not be prescribed more than 5 mg of zoledronic acid in a 12-month period.

Initiation – glucocorticosteroid therapy
Any specialist
Re-assessment required after 12 months
All of the following:

1. The patient is receiving systemic glucocorticosteroid therapy (greater than or equal to 5 mg per day prednisone equivalents) and has already received or is expected to receive therapy for at least three months; and

2. Any of the following:
   2.1 The patient has documented BMD greater than or equal to 1.5 standard deviations below the mean normal value in young adults (i.e. T-Score less than or equal to -1.5) (see Note); or
   2.2 The patient has a history of one significant osteoporotic fracture demonstrated radiologically; or
   2.3 The patient has had a Special Authority approval for alendronate (Underlying cause - glucocorticosteroid therapy) prior to 1 February 2019 or has had a Special Authority approval for raloxifene; and

3. The patient will not be prescribed more than 5 mg of zoledronic acid in the 12-month approval period.

Continuation – glucocorticosteroid therapy
Any specialist
Re-assessment required after 12 months
Both:

1. The patient is continuing systemic glucocorticosteroid therapy (greater than or equal to 5 mg per day prednisone equivalents); and

2. The patient will not be prescribed more than 5 mg of zoledronic acid in the 12-month approval period.

Initiation – Paget’s disease
Any specialist
Re-assessment required after 12 months
All of the following:

1. Paget’s disease; and

continued…
continued…

2 Any of the following:
   2.1 Bone or articular pain; or
   2.2 Bone deformity; or
   2.3 Bone, articular or neurological complications; or
   2.4 Asymptomatic disease, but risk of complications; or
   2.5 Preparation for orthopaedic surgery; and

3 The patient will not be prescribed more than 5 mg of zoledronic acid in the 12-month approval period.

Continuation – Paget’s disease

Any specialist

Re-assessment required after 12 months

Both:

1 Any of the following:
   1.1 The patient has relapsed (based on increases in serum alkaline phosphatase); or
   1.2 The patient’s serum alkaline phosphatase has not normalised following previous treatment with zoledronic acid; or
   1.3 Symptomatic disease (prescriber determined); and

2 The patient will not be prescribed more than 5 mg of zoledronic acid in the 12-month approval period.

Notes:

1 BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA).
   Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable.

2 Evidence suggests that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score less than or equal to -2.5 and, therefore, do not require BMD measurement for treatment with bisphosphonates.

3 Osteoporotic fractures are the incident events for severe (established) osteoporosis and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less.

4 A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

Other Drugs Affecting Bone Metabolism

DENOSUMAB – Restricted see terms below

Inject 60 mg prefilled syringe..............................................................................................................326.00 1 Prolia

Restricted (RS1665)

Initiation

All of the following:

1 The patient has severe, established osteoporosis; and

2 Either:
   2.1 The patient is female and postmenopausal; or
   2.2 The patient is male or non-binary; and

3 Any of the following:
   3.1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) greater than or equal to 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score less than or equal to -2.5) (see Note); or

continued…
continued...

3.2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons; or

3.3 History of two significant osteoporotic fractures demonstrated radiologically; or

3.4 Documented T-Score less than or equal to -3.0 (see Note); or

3.5 A 10-year risk of hip fracture greater than or equal to 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Note); or

3.6 Patient has had a Special Authority approval for alendronate (Underlying cause - Osteoporosis) prior to 1 February 2019 or has had a Special Authority approval for raloxifene; and

4 Zoledronic acid is contraindicated because the patient’s creatinine clearance is less than 35 mL/min; and

5 The patient has experienced at least one symptomatic new fracture after at least 12 months’ continuous therapy with a funded antiresorptive agent at adequate doses (see Notes); and

6 The patient must not receive concomitant treatment with any other funded antiresorptive agent for this condition or teriparatide.

Notes:

1 BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable.

2 Evidence suggests that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score less than or equal to -2.5 and, therefore, do not require BMD measurement for treatment with denosumab.

3 Osteoporotic fractures are the incident events for severe (established) osteoporosis and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less.

4 A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

5 Antiresorptive agents and their adequate doses for the purposes of this Special Authority are defined as: risedronate sodium tab 35 mg once weekly; alendronate sodium tab 70 mg or tab 70 mg with cholecalciferol 5,600 iu once weekly; raloxifene hydrochloride tab 60 mg once daily. If an intolerance of a severity necessitating permanent treatment withdrawal develops during the use of one antiresorptive agent, an alternate antiresorptive agent must be trialled so that the patient achieves the minimum requirement of 12 months’ continuous therapy.

RALOXIFENE – Restricted see terms below

Tab 60 mg .................................................................53.76 28 Evista

Initiation

Any of the following:

1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) greater than or equal to 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score less than or equal to -2.5) (see Notes); or

2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or

3 History of two significant osteoporotic fractures demonstrated radiologically; or

4 Documented T-Score greater than or equal to -3.0 (see Notes); or

5 A 10-year risk of hip fracture greater than or equal to 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Notes); or

continued…

Products with Hospital Supply Status (HSS) are in bold

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
continued...

6 Patient has had a Special Authority approval for zoledronic acid (Underlying cause - Osteoporosis) or has had a Special Authority approval for alendronate (Underlying cause - Osteoporosis) prior to 1 February 2019.

Notes:
1 BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable.
2 Evidence suggests that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score less than or equal to -2.5 and, therefore, do not require BMD measurement for raloxifene funding.
3 Osteoporotic fractures are the incident events for severe (established) osteoporosis, and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less.
4 A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

TERIPARATIDE – Restricted see terms below

Inj 250 mcg per ml, 2.4 ml cartridge ..............................................................490.00 1 Forteo

Initiation
Limited to 18 months treatment

All of the following:
1 The patient has severe, established osteoporosis; and
2 The patient has a documented T-score less than or equal to -3.0 (see Notes); and
3 The patient has had two or more fractures due to minimal trauma; and
4 The patient has experienced at least one symptomatic new fracture after at least 12 months' continuous therapy with a funded antiresorptive agent at adequate doses (see Notes).

Notes:
1 The bone mineral density (BMD) measurement used to derive the T-score must be made using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable.
2 Antiresorptive agents and their adequate doses for the purposes of this restriction are defined as: alendronate sodium tab 70 mg or tab 70 mg with colecalciferol 5,600 iu once weekly; raloxifene hydrochloride tab 60 mg once daily; zoledronic acid 5 mg per year. If an intolerance of a severity necessitating permanent treatment withdrawal develops during the use of one antiresorptive agent, an alternate antiresorptive agent must be trialled so that the patient achieves the minimum requirement of 12 months' continuous therapy.
3 A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

Enzymes

HYALURONIDASE
Inj 1,500 iu ampoule

Hyperuricaemia and Antigout

ALLOPURINOL
Tab 100 mg – 1% DV Jan-18 to 2020 ..............................................................4.54 500 DP-Allopurinol
Tab 300 mg – 1% DV Jan-18 to 2020 ...........................................................10.35 500 DP-Allopurinol
MUSCULOSKELETAL SYSTEM

BENZBROMARONE – **Restricted** see terms below

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) $</th>
<th>Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 100 mg</td>
<td>45.00</td>
<td>100</td>
</tr>
</tbody>
</table>

**Initiation**

Any specialist

All of the following:

1. Patient has been diagnosed with gout; and
2. Any of the following:
   1. The patient has a serum urate level greater than 0.36 mmol/l despite treatment with allopurinol at doses of at least 600 mg/day and addition of probenecid at doses of up to 2 g per day or maximum tolerated dose; or
   2. The patient has experienced intolerable side effects from allopurinol such that treatment discontinuation is required and serum urate remains greater than 0.36 mmol/l despite use of probenecid at doses of up to 2 g per day or maximum tolerated dose; or

3. Both:
   1. The patient has renal impairment such that probenecid is contraindicated or likely to be ineffective and serum urate remains greater than 0.36 mmol/l despite optimal treatment with allopurinol (see Note); and
   2. The patient has a rate of creatinine clearance greater than or equal to 20 ml/min; or

4. All of the following:
   1. The patient is taking azathioprine and requires urate-lowering therapy; and
   2. Allopurinol is contraindicated; and
   3. Appropriate doses of probenecid are ineffective or probenecid cannot be used due to reduced renal function; and
   4. The patient is receiving monthly liver function tests.

**Notes:** Benzbromarone has been associated with potentially fatal hepatotoxicity. In chronic renal insufficiency, particularly when the glomerular filtration rate is 30 ml/minute or less, probenecid may not be effective. Optimal treatment with allopurinol in patients with renal impairment is defined as treatment to the creatinine clearance-adjusted dose of allopurinol then, if serum urate remains greater than 0.36 mmol/l, a gradual increase of the dose of allopurinol to 600 mg or the maximum tolerated dose. The New Zealand Rheumatology Association has developed information for prescribers which can be accessed from its website at [www.rheumatology.org.nz/home/resources-2/](http://www.rheumatology.org.nz/home/resources-2/)

COLCHICINE

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) $</th>
<th>Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 500 mcg</td>
<td>9.58</td>
<td>100</td>
</tr>
</tbody>
</table>

FEBUXOSTAT – **Restricted** see terms below

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) $</th>
<th>Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 80 mg</td>
<td>39.50</td>
<td>28</td>
</tr>
<tr>
<td>Tab 120 mg</td>
<td>39.50</td>
<td>28</td>
</tr>
</tbody>
</table>

**Initiation**

Any specialist

Both:

1. Patient has been diagnosed with gout; and
2. Any of the following:
   1. The patient has a serum urate level greater than 0.36 mmol/l despite treatment with allopurinol at doses of at least 600 mg/day and addition of probenecid at doses of up to 2 g per day or maximum tolerated dose; or
   2. The patient has experienced intolerable side effects from allopurinol such that treatment discontinuation is required and serum urate remains greater than 0.36 mmol/l despite use of probenecid at doses of up to 2 g per day or maximum tolerated dose; or

3. The patient has renal impairment such that probenecid is contraindicated or likely to be ineffective and serum urate remains greater than 0.36 mmol/l despite optimal treatment with allopurinol (see Note).

**Note:** In chronic renal insufficiency, particularly when the glomerular filtration rate is 30 ml/minute or less, probenecid may not be effective.
effective. The efficacy and safety of febuxostat have not been fully evaluated in patients with severe renal impairment (creatinine clearance less than 30 ml/minute). No dosage adjustment of febuxostat is necessary in patients with mild or moderate renal impairment. Optimal treatment with allopurinol in patients with renal impairment is defined as treatment to the creatinine clearance-adjusted dose of allopurinol then, if serum urate remains greater than 0.36 mmol/l, a gradual increase of the dose of allopurinol to 600 mg or the maximum tolerated dose.

PROBENECID
Tab 500 mg

RASBURICASE – Restricted see terms below
$ Inj 1.5 mg vial
– Restricted (RS1016)
Haematologist

Muscle Relaxants and Related Agents

ATRACURIUM BESYLATE
Inj 10 mg per ml, 2.5 ml ampoule – 1% DV Jun-18 to 2021 ......................... 10.00 5 Tracrium
Inj 10 mg per ml, 5 ml ampoule – 1% DV Jun-18 to 2021 ......................... 12.50 5 Tracrium

BACLOFEN
Tab 10 mg – 1% DV Oct-18 to 2021 ............................................................... 4.20 100 Pacifen
Oral liq 1 mg per ml
Inj 0.05 mg per ml, 1 ml ampoule ................................................................. 11.55 1 Lioresal Intrathecal
Inj 2 mg per ml, 5 ml ampoule – 1% DV Apr-19 to 2021 ......................... 372.98 5 Medsurge

CLOSTRIDIUM BOTULINUM TYPE A TOXIN
Inj 100 u vial .................................................................................................. 467.50 1 Botox
Inj 300 u vial .................................................................................................. 388.50 1 Dysport
Inj 500 u vial .................................................................................................. 1295.00 2 Dysport

DANTROLENE
Cap 25 mg ..................................................................................................... 65.00 100 Dantrium
Cap 50 mg ..................................................................................................... 77.00 100 Dantrium
Inj 20 mg vial ................................................................................................ 800.00 6 Dantrium IV

MIVACURIUM CHLORIDE
Inj 2 mg per ml, 5 ml ampoule .................................................................... 33.92 5 Mivacron
Inj 2 mg per ml, 10 ml ampoule .................................................................. 67.17 5 Mivacron

ORPHENADRINE CITRATE
Tab 100 mg – 1% DV Jun-18 to 2021 ............................................................ 18.54 100 Norflex

PANCURONIUM BROMIDE
Inj 2 mg per ml, 2 ml ampoule ..................................................................... 260.00 50 AstraZeneca
(AstraZeneca Inj 2 mg per ml, 2 ml ampoule to be delisted 1 January 2020)

ROCURONIUM BROMIDE
Inj 10 mg per ml, 5 ml vial .......................................................................... 25.95 10 DBL Rocuronium Bromide

SUXAMETHONIUM CHLORIDE
Inj 50 mg per ml, 2 ml ampoule – 1% DV Nov-17 to 2020 ......................... 78.00 50 AstraZeneca

VECURONIUM BROMIDE
Inj 10 mg vial
Reversers of Neuromuscular Blockade

SUGAMMADEX – Restricted see terms below
- Inj 100 mg per ml, 2 ml vial .............................................................. 1,200.00 10 Bridion
- Inj 100 mg per ml, 5 ml vial .............................................................. 3,000.00 10 Bridion

Initiation
Any of the following:
1. Patient requires reversal of profound neuromuscular blockade following rapid sequence induction that has been undertaken using rocuronium (i.e. suxamethonium is contraindicated or undesirable); or
2. Severe neuromuscular degenerative disease where the use of neuromuscular blockade is required; or
3. Patient has an unexpectedly difficult airway that cannot be intubated and requires a rapid reversal of anaesthesia and neuromuscular blockade; or
4. The duration of the patient’s surgery is unexpectedly short; or
5. Neostigmine or a neostigmine/anticholinergic combination is contraindicated (for example the patient has ischaemic heart disease, morbid obesity or COPD); or
6. Patient has a partial residual block after conventional reversal.

Non-Steroidal Anti-Inflammatory Drugs

CELECOXIB
Note - The DV limit of 1% applies to the celecoxib chemical rather than each individual line item.
- Cap 100 mg ......................................................................................... 3.63 60 Celecoxib Pfizer
- Cap 200 mg – 1% DV Aug-17 to 2020 ..................................................... 2.30 30 Celecoxib Pfizer

DICLOFENAC SODIUM
- Tab EC 25 mg – 1% DV Oct-18 to 2021 .................................................. 1.23 50 Diclofenac Sandoz
- Tab 50 mg dispersible ......................................................................... 1.50 20 Voltaren D
- Tab EC 50 mg – 1% DV Oct-18 to 2021 .................................................. 1.23 50 Diclofenac Sandoz
- Tab long-acting 75 mg – 1% DV Oct-18 to 2021 ..................................... 22.80 500 Apo-Diclo SR
- Tab long-acting 100 mg – 1% DV Oct-18 to 2021 .................................... 25.15 500 Apo-Diclo SR
- Inj 25 mg per ml, 3 ml ampoule .......................................................... 13.20 5 Voltaren
- Suppos 12.5 mg ..................................................................................... 2.04 10 Voltaren
- Suppos 25 mg ....................................................................................... 2.44 10 Voltaren
- Suppos 50 mg ....................................................................................... 4.22 10 Voltaren
- Suppos 100 mg ..................................................................................... 7.00 10 Voltaren

ETORICOXIB – Restricted see terms below
- Tab 30 mg
- Tab 60 mg
- Tab 90 mg
- Tab 120 mg

Initiation
For in-vivo investigation of allergy only.

IBUPROFEN
- Tab 200 mg – 1% DV Feb-18 to 2020 .................................................... 11.71 1,000 Relieve
- Tab 400 mg – Restricted: For continuation only
- Tab 600 mg – Restricted: For continuation only
- Tab long-acting 800 mg ................................................................. 7.99 30 Brufen SR
- Oral liq 20 mg per ml – 1% DV May-19 to 2021 ..................................... 1.88 200 ml Ethics
- Inj 5 mg per ml, 2 ml ampoule
- Inj 10 mg per ml, 2 ml vial

Products with Hospital Supply Status (HSS) are in bold
Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
## MUSCULOSKELETAL SYSTEM

<table>
<thead>
<tr>
<th>Drug</th>
<th>Formulations</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>INDOMETHACIN</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cap 25 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cap 50 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cap long-acting 75 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 1 mg vial</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Suppos 100 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>KETOPROFEN</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cap long-acting 200 mg</td>
<td></td>
<td>12.07</td>
<td>28 Oruvail SR</td>
</tr>
<tr>
<td><strong>MEFENAMIC ACID – Restricted:</strong> For continuation only</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cap 250 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>NAPROXEN</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 250 mg – 1% DV Dec-18 to 2021</td>
<td></td>
<td>32.69</td>
<td>500 Noflam 250</td>
</tr>
<tr>
<td>Tab 500 mg – 1% DV Dec-18 to 2021</td>
<td></td>
<td>22.19</td>
<td>250 Noflam 500</td>
</tr>
<tr>
<td>Tab long-acting 750 mg – 1% DV Oct-18 to 2021</td>
<td></td>
<td>6.16</td>
<td>28 Naprosyn SR 750</td>
</tr>
<tr>
<td>Tab long-acting 1 g – 1% DV Oct-18 to 2021</td>
<td></td>
<td>8.21</td>
<td>28 Naprosyn SR 1000</td>
</tr>
<tr>
<td><strong>PARECOXIB</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 40 mg vial</td>
<td></td>
<td>100.00</td>
<td>10 Dynat</td>
</tr>
<tr>
<td><strong>SULINDAC</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 100 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 200 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>TENOXICAM</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 20 mg – 1% DV Oct-19 to 2022</td>
<td></td>
<td>9.15</td>
<td>100 Tilcotil</td>
</tr>
<tr>
<td>Inj 20 mg vial</td>
<td></td>
<td>9.95</td>
<td>1 AFT</td>
</tr>
</tbody>
</table>

### Topical Products for Joint and Muscular Pain

<table>
<thead>
<tr>
<th>Drug</th>
<th>Formulations</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CAPSAICIN – Restricted</strong> see terms below</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Crm 0.025%</td>
<td></td>
<td>9.95</td>
<td>45 g Zostrix</td>
</tr>
<tr>
<td><strong>Restricted (RS1309)</strong> Initiation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patient has osteoarthritis that is not responsive to paracetamol and oral non-steroidal anti-inflammatories are contraindicated.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Agents for Parkinsonism and Related Disorders

RILUZOLE – Restricted see terms below

Tab 50 mg – 1% DV Aug-18 to 2021 ........................................................................ 130.00 56 Rilutek

Restricted (RS1351)

Initiation

Neurologist or respiratory specialist

Re-assessment required after 6 months

All of the following:

1. The patient has amyotrophic lateral sclerosis with disease duration of 5 years or less; and
2. The patient has at least 60 percent of predicted forced vital capacity within 2 months prior to the initial application; and
3. The patient has not undergone a tracheostomy; and
4. The patient has not experienced respiratory failure; and
5. Any of the following:
   5.1 The patient is ambulatory; or
   5.2 The patient is able to use upper limbs; or
   5.3 The patient is able to swallow.

Continuation

Re-assessment required after 18 months

All of the following:

1. The patient has not undergone a tracheostomy; and
2. The patient has not experienced respiratory failure; and
3. Any of the following:
   3.1 The patient is ambulatory; or
   3.2 The patient is able to use upper limbs; or
   3.3 The patient is able to swallow.

TETRABENAZINE

Tab 25 mg – 1% DV Oct-19 to 2022 ........................................................................ 91.10 112 Motetis

Anticholinergics

BENZATROPINE MESYLATE

Tab 2 mg ........................................................................................................... 7.99 60 Benztrop
Inj 1 mg per ml, 2 ml ampoule .......................................................................... 95.00 5 Cogentin

PROCYCLIDINE HYDROCHLORIDE

Tab 5 mg

Dopamine Agonists and Related Agents

AMANTADINE HYDROCHLORIDE

Cap 100 mg ...................................................................................................... 38.24 60 Symmetrel

APOMORPHINE HYDROCHLORIDE

Inj 10 mg per ml, 2 ml ampoule ...................................................................... 119.00 5 Movapo

BROMOCRIPTINE

Tab 2.5 mg
Cap 5 mg

ENTACAPONE

Tab 200 mg – 1% DV Sep-18 to 2021 ................................................................... 22.00 100 Entapone
<table>
<thead>
<tr>
<th>NERVOUS SYSTEM</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>LEVODOPA WITH BENSERAZIDE</strong></td>
</tr>
<tr>
<td>Tab dispersible 50 mg with benserazide 12.5 mg</td>
</tr>
<tr>
<td>Cap 50 mg with benserazide 12.5 mg</td>
</tr>
<tr>
<td>Cap 100 mg with benserazide 25 mg</td>
</tr>
<tr>
<td>Cap long-acting 100 mg with benserazide 25 mg</td>
</tr>
<tr>
<td>Cap 200 mg with benserazide 50 mg</td>
</tr>
</tbody>
</table>

| **LEVODOPA WITH CARBIDOPA** |
| Tab 100 mg with carbidopa 25 mg – 1% DV Feb-18 to 2020 | 17.97 | 100 Sinemet |
| Tab long-acting 100 mg with carbidopa 25 mg | 37.15 | 100 Sinemet CR |
| Tab long-acting 200 mg with carbidopa 50 mg – 1% DV Feb-18 to 2020 | 32.67 | 100 Sinemet |
| Tab 250 mg with carbidopa 25 mg – 1% DV Feb-18 to 2020 | 32.67 | 100 Sinemet |

| **PRAMIPEXOLE HYDROCHLORIDE** |
| Tab 0.25 mg – 1% DV Oct-19 to 2022 | 6.12 | 100 Ramipex |
| Tab 1 mg – 1% DV Oct-19 to 2022 | 20.73 | 100 Ramipex |

| **ROPINIROLE HYDROCHLORIDE** |
| Tab 0.25 mg – 1% DV Mar-20 to 2022 | 2.78 | 100 Apo-Ropinirole |
| Tab 1 mg – 1% DV Mar-20 to 2022 | 5.00 | 100 Apo-Ropinirole |
| Tab 2 mg – 1% DV Mar-20 to 2022 | 7.72 | 100 Apo-Ropinirole |
| Tab 5 mg – 1% DV Mar-20 to 2022 | 16.51 | 100 Apo-Ropinirole |

(Apo-Ropinirole Tab 0.25 mg to be delisted 1 March 2020)
(Apo-Ropinirole Tab 1 mg to be delisted 1 March 2020)
(Apo-Ropinirole Tab 2 mg to be delisted 1 March 2020)
(Apo-Ropinirole Tab 5 mg to be delisted 1 March 2020)

| **SELEGILINE HYDROCHLORIDE** |
| Tab 5 mg |
| Tab 100 mg | 132.50 | 100 Tasmar |

<table>
<thead>
<tr>
<th><strong>Anaesthetics</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>General Anaesthetics</strong></td>
</tr>
<tr>
<td><strong>DESFLURANE</strong></td>
</tr>
<tr>
<td>Soln for inhalation 100%, 240 ml bottle – 1% DV Sep-16 to 2020</td>
</tr>
<tr>
<td><strong>DEXMEDETOMIDINE</strong></td>
</tr>
<tr>
<td>Inj 100 mcg per ml, 2 ml vial – 1% DV Sep-17 to 2020</td>
</tr>
<tr>
<td><strong>ETOMIDATE</strong></td>
</tr>
<tr>
<td>Inj 2 mg per ml, 10 ml ampoule</td>
</tr>
<tr>
<td><strong>ISOFLURANE</strong></td>
</tr>
<tr>
<td>Soln for inhalation 100%, 250 ml bottle – 1% DV Sep-16 to 2020</td>
</tr>
<tr>
<td><strong>KETAMINE</strong></td>
</tr>
<tr>
<td>Inj 1 mg per ml, 100 ml bag – 1% DV Feb-20 to 2022</td>
</tr>
<tr>
<td>Inj 10 mg per ml, 10 ml syringe – 1% DV Feb-20 to 2022</td>
</tr>
<tr>
<td>Inj 100 mg per ml, 2 ml vial – 1% DV Jan-19 to 2021</td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>
NERVOUS SYSTEM

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
</tr>
</thead>
</table>

### METHOHEXITAL SODIUM
- Inj 10 mg per ml, 50 ml vial

### PROPOFOL
- Inj 10 mg per ml, 20 ml ampoule – 10% DV Dec-19 to 2022: $4.35 5
- Inj 10 mg per ml, 50 ml vial – 10% DV Oct-19 to 2022: $19.50 10
- Inj 10 mg per ml, 100 ml vial – 10% DV Oct-19 to 2022: $39.00 10

### SEVOFLURANE
- Soln for inhalation 100%, 250 ml bottle – 1% DV Sep-16 to 2020: $840.00 6
- Baxter

### THIOPENTAL [THIOPENTONE] SODIUM
- Inj 500 mg ampoule

### Local Anaesthetics

#### ARTICAIN HYDROCHLORIDE
- Inj 1%

#### ARTICAIN HYDROCHLORIDE WITH ADRENALINE
- Inj 4% with adrenaline 1:100,000, 1.7 ml dental cartridge
- Inj 4% with adrenaline 1:100,000, 2.2 ml dental cartridge
- Inj 4% with adrenaline 1:200,000, 1.7 ml dental cartridge
- Inj 4% with adrenaline 1:200,000, 2.2 ml dental cartridge

#### BENZOCAINE
- Gel 20%

#### BENZOCAINE WITH TETRACAINE HYDROCHLORIDE
- Gel 18% with tetracaine hydrochloride 2%
  - e.g. ZAP Topical Anaesthetic Gel

#### BUPIVACAINE HYDROCHLORIDE
- Inj 5 mg per ml, 4 ml ampoule – 1% DV Sep-17 to 2020: $50.00 5
- Inj 2.5 mg per ml, 20 ml ampoule
- Inj 2.5 mg per ml, 20 ml ampoule sterile pack: $29.20 5
- Inj 5 mg per ml, 10 ml ampoule sterile pack: $20.25 5
- Inj 5 mg per ml, 20 ml ampoule
- Inj 5 mg per ml, 20 ml ampoule sterile pack: $20.70 5
- Inj 1.25 mg per ml, 100 ml bag
- Inj 1.25 mg per ml, 200 ml bag
- Inj 2.5 mg per ml, 100 ml bag – 1% DV Sep-17 to 2020: $150.00 5
- Inj 2.5 mg per ml, 200 ml bag
- Inj 1.25 mg per ml, 500 ml bag

#### BUPIVACAINE HYDROCHLORIDE WITH ADRENALINE
- Inj 2.5 mg per ml with adrenaline 1:400,000, 20 ml vial – 1% DV Aug-19 to 2022: $94.50 5
- Inj 5 mg per ml with adrenaline 1:200,000, 20 ml vial – 1% DV Aug-19 to 2022: $80.50 5
<table>
<thead>
<tr>
<th><strong>NERVOUS SYSTEM</strong></th>
</tr>
</thead>
</table>

| **BUPIVACAINE HYDROCHLORIDE WITH FENTANYL** |
| Inj 0.625 mg with fentanyl 2 mcg per ml, 100 ml bag |
| Inj 0.625 mg with fentanyl 2 mcg per ml, 200 ml bag – 1% DV Apr-20 to 2022 | 305.00 | 10 | Biomed |
| Inj 1.25 mg with fentanyl 2 mcg per ml, 100 ml syringe |
| Inj 1.25 mg with fentanyl 2 mcg per ml, 100 ml bag – 1% DV Nov-19 to 2022 | 225.00 | 10 | Bupafen |
| Inj 1.25 mg with fentanyl 2 mcg per ml, 200 ml bag – 1% DV Nov-19 to 2022 | 235.00 | 10 | Bupafen |
| Inj 1.25 mg with fentanyl 2 mcg per ml, 50 ml syringe |
| Inj 1.25 mg with fentanyl 2 mcg per ml, 15 ml syringe | 72.00 | 10 | Biomed |
| BuPINAC and fentanyl 2 mcg per ml, 20 ml syringe | 92.00 | 10 | Biomed |

| **BUPIVACAINE HYDROCHLORIDE WITH GLUCOSE** |
| Inj 0.5% with glucose 8%, 4 ml ampoule | 38.00 | 5 | Marcin Heavy |

| **COCAINE HYDROCHLORIDE** |
| Paste 5% |
| Soln 15%, 2 ml syringe |
| Soln 4%, 2 ml syringe | 25.46 | 1 | Biomed |

| **COCAINE HYDROCHLORIDE WITH ADRENALINE** |
| Paste 15% with adrenaline 0.06% |
| Paste 25% with adrenaline 0.06% |

| **ETHYL CHLORIDE** |
| Spray 100% |

| **LIDOCAINE [LIGNOCAINE]** |
| Crm 4% | 5.40 | 5 g | LMX4 |
| Soln 4% | 27.00 | 30 g | LMX4 |

| **LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE** |
| Gel 2% – 1% DV Nov-18 to 2021 | 4.87 | 20 g | Orion |
| Soln 4% |
| Spray 10% – 1% DV Jul-19 to 2022 | 75.00 | 50 ml | Xylocaine |
| Oral (gel) soln 2% – 1% DV Oct-17 to 2020 | 38.00 | 200 ml | Mucosoothe |
| Inj 1%, 20 ml ampoule, sterile pack |
| Inj 2%, 20 ml ampoule, sterile pack |
| Inj 1%, 5 ml ampoule | 8.75 | 25 | Lidocaine-Claris |
| Inj 1%, 20 ml vial – 1% DV Jul-19 to 2022 | 6.20 | 5 | Lidocaine-Claris |
| Inj 2%, 5 ml ampoule – 1% DV Nov-19 to 2022 | 8.25 | 25 | Lidocaine-Claris |
| Inj 2%, 20 ml vial – 1% DV Jul-19 to 2022 | 6.45 | 5 | Lidocaine-Claris |
| Gel 2%, 10 ml urethral syringe – 1% DV Nov-19 to 2022 | 105.00 | 25 | Cathejell |

| **LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE WITH ADRENALINE** |
| Inj 1% with adrenaline 1:100,000, 5 ml ampoule – 1% DV Nov-19 to 2022 | 29.00 | 10 | Xylocaine |
| Inj 1% with adrenaline 1:200,000, 20 ml vial | 50.00 | 5 | Xylocaine |
| Inj 2% with adrenaline 1:80,000, 1.7 ml dental cartridge |
| Inj 2% with adrenaline 1:80,000, 1.8 ml dental cartridge |
| Inj 2% with adrenaline 1:80,000, 2.2 ml dental cartridge |
| Inj 2% with adrenaline 1:200,000, 20 ml vial | 60.00 | 5 | Xylocaine |

| **LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE WITH ADRENALINE AND TETRACAINE HYDROCHLORIDE** |
| Soln 4% with adrenaline 0.1% and tetracaine hydrochloride 0.5%, 5 ml syringe – 1% DV Sep-17 to 2020 | 17.50 | 1 | Topicaene |

---

- Item restricted (see ➩ above); Item restricted (see ➩ below)
- e.g. Brand indicates brand example only. It is not a contracted product.
## NERVOUS SYSTEM

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) $</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE WITH CHLORHEXIDINE</strong></td>
<td></td>
</tr>
<tr>
<td>Gel 2% with chlorhexidine 0.05%, 10 ml urethral syringe</td>
<td>$81.50</td>
</tr>
</tbody>
</table>

| **LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE WITH PHENYLEPHRINE HYDROCHLORIDE** |
| Nasal spray 5% with phenylephrine hydrochloride 0.5% |

| **LIDOCAINE [LIGNOCAINE] WITH PRILOCAINE** |
| Crm 2.5% with prilocaine 2.5% | $45.00 | 30 g EMLA |
| Patch 25 mcg with prilocaine 25 mcg | $115.00 | 20 EMLA |
| Crm 2.5% with prilocaine 2.5%, 5 g | $45.00 | 5 EMLA |

| **MEPIVACAINE HYDROCHLORIDE** |
| Inj 3%, 1.8 ml dental cartridge | $43.60 | 50 Scandonest 3% |
| Inj 3%, 2.2 ml dental cartridge | $43.60 | 50 Scandonest 3% |

| **PRILOCAINE HYDROCHLORIDE** |
| Inj 0.5%, 50 ml vial | $100.00 | 5 Citanest |
| Inj 2%, 5 ml ampoule |

| **PRILOCAINE HYDROCHLORIDE WITH FELYPRESSIN** |
| Inj 3% with felypressin 0.03 iu per ml, 1.8 ml dental cartridge |
| Inj 3% with felypressin 0.03 iu per ml, 2.2 ml dental cartridge |

| **ROPIVACAINE HYDROCHLORIDE** |
| Inj 2 mg per ml, 10 ml ampoule – 1% DV Sep-17 to 2020 | $8.80 | 5 Ropivacaine Kabi |
| Inj 2 mg per ml, 20 ml ampoule – 1% DV Sep-17 to 2020 | $9.20 | 5 Ropivacaine Kabi |
| Inj 2 mg per ml, 100 ml bag – 1% DV Sep-17 to 2020 | $29.50 | 5 Ropivacaine Kabi |
| Inj 2 mg per ml, 200 ml bag – 1% DV Sep-17 to 2020 | $39.00 | 5 Ropivacaine Kabi |
| Inj 7.5 mg per ml, 10 ml ampoule – 1% DV Sep-17 to 2020 | $9.90 | 5 Ropivacaine Kabi |
| Inj 7.5 mg per ml, 20 ml ampoule – 1% DV Sep-17 to 2020 | $12.15 | 5 Ropivacaine Kabi |
| Inj 10 mg per ml, 10 ml ampoule – 1% DV Sep-17 to 2020 | $10.55 | 5 Ropivacaine Kabi |
| Inj 10 mg per ml, 20 ml ampoule – 1% DV Sep-17 to 2020 | $15.80 | 5 Ropivacaine Kabi |

| **ROPIVACAINE HYDROCHLORIDE WITH FENTANYL** |
| Inj 2 mg with fentanyl 2 mcg per ml, 100 ml bag | $198.50 | 5 Naropin |
| Inj 2 mg with fentanyl 2 mcg per ml, 200 ml bag | $270.00 | 5 Naropin |

| **TETRACAINE [AMETHOCAINE] HYDROCHLORIDE** |
| Gel 4% |

### Analgesics

#### Non-Opioid Analgesics

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) $</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ASPIRIN</strong></td>
<td></td>
</tr>
<tr>
<td>Tab dispersible 300 mg – 1% DV Oct-19 to 2022</td>
<td>$4.50</td>
</tr>
</tbody>
</table>

| **CAPSAICIN** – **Restricted** see terms below |
| Crm 0.075% | $12.50 | 45 g Zostrix HP |

- **Restricted (RS1145)**

**Initiation**

For post-herpetic neuralgia or diabetic peripheral neuropathy.

| ** METHOXYFLURANE** – **Restricted** see terms below |
| Soln for inhalation 99.9%, 3 ml bottle | |

- **Restricted (RS1292)**

**Initiation**

Both:

---

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
continued…

1. Patient is undergoing a painful procedure with an expected duration of less than one hour; and
2. Only to be used under supervision by a medical practitioner or nurse who is trained in the use of methoxyflurane.

NEFOPAM HYDROCHLORIDE
Tab 30 mg

PARACETAMOL – Some items restricted see terms below
Tab soluble 500 mg
Tab 500 mg
Oral liq 120 mg per 5 ml – 1% DV Dec-17 to 2020
Oral liq 250 mg per 5 ml – 20% DV Aug-18 to 2020

Inj 10 mg per ml, 100 ml vial – 1% DV Sep-17 to 2020
Suppos 25 mg – 1% DV Nov-19 to 2022
Suppos 50 mg – 1% DV Nov-19 to 2022
Suppos 125 mg – 1% DV Nov-18 to 2021
Suppos 250 mg – 1% DV Nov-18 to 2021
Suppos 500 mg – 1% DV Feb-19 to 2021

Opioid Analgesics

ALFENTANIL
Inj 0.5 mg per ml, 2 ml ampoule – 1% DV Sep-17 to 2020

CODEINE PHOSPHATE
Tab 15 mg
Tab 30 mg
Tab 60 mg

DIHYDROCODEINE TARTRATE
Tab long-acting 60 mg – 1% DV Oct-19 to 2022

FENTANYL
Inj 10 mcg per ml, 10 ml syringe
Inj 50 mcg per ml, 2 ml ampoule – 1% DV Nov-18 to 2021
Inj 10 mcg per ml, 50 ml bag
Inj 10 mcg per ml, 50 ml syringe
Inj 50 mcg per ml, 10 ml ampoule – 1% DV Nov-18 to 2021
Inj 10 mcg per ml, 100 ml bag – 1% DV Nov-19 to 2022
Inj 20 mcg per ml, 100 ml syringe – 1% DV Oct-18 to 2021
Inj 20 mcg per ml, 100 ml bag
Patch 12.5 mcg per hour – 1% DV Oct-17 to 2020
Patch 25 mcg per hour – 1% DV Oct-17 to 2020
Patch 50 mcg per hour – 1% DV Oct-17 to 2020
Patch 75 mcg per hour – 1% DV Oct-17 to 2020
Patch 100 mcg per hour – 1% DV Oct-17 to 2020
<table>
<thead>
<tr>
<th>Product Description</th>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST) $</th>
<th>Per</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>METHADONE HYDROCHLORIDE</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 5 mg – 1% DV Sep-19 to 2022</td>
<td></td>
<td></td>
<td>10</td>
</tr>
<tr>
<td>Oral liq 2 mg per ml – 1% DV Oct-18 to 2021</td>
<td></td>
<td></td>
<td>200 ml</td>
</tr>
<tr>
<td>Oral liq 5 mg per ml – 1% DV Oct-18 to 2021</td>
<td></td>
<td></td>
<td>200 ml</td>
</tr>
<tr>
<td>Oral liq 10 mg per ml – 1% DV Oct-18 to 2021</td>
<td></td>
<td></td>
<td>200 ml</td>
</tr>
<tr>
<td>Inj 10 mg per ml, 1 ml vial</td>
<td></td>
<td></td>
<td>10</td>
</tr>
<tr>
<td><strong>MORPHINE HYDROCHLORIDE</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oral liq 1 mg per ml – 1% DV Dec-18 to 2021</td>
<td></td>
<td></td>
<td>200 ml</td>
</tr>
<tr>
<td>Oral liq 2 mg per ml – 1% DV Dec-18 to 2021</td>
<td></td>
<td></td>
<td>200 ml</td>
</tr>
<tr>
<td>Oral liq 5 mg per ml – 1% DV Dec-18 to 2021</td>
<td></td>
<td></td>
<td>200 ml</td>
</tr>
<tr>
<td>Oral liq 10 mg per ml – 1% DV Dec-18 to 2021</td>
<td></td>
<td></td>
<td>200 ml</td>
</tr>
<tr>
<td><strong>MORPHINE SULPHATE</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab long-acting 10 mg</td>
<td></td>
<td></td>
<td>10</td>
</tr>
<tr>
<td>Tab immediate-release 10 mg – 1% DV Sep-17 to 2020</td>
<td></td>
<td></td>
<td>10</td>
</tr>
<tr>
<td>Tab immediate-release 20 mg – 1% DV Sep-17 to 2020</td>
<td></td>
<td></td>
<td>10</td>
</tr>
<tr>
<td>Tab long-acting 30 mg</td>
<td></td>
<td></td>
<td>10</td>
</tr>
<tr>
<td>Tab long-acting 60 mg</td>
<td></td>
<td></td>
<td>10</td>
</tr>
<tr>
<td>Tab long-acting 100 mg</td>
<td></td>
<td></td>
<td>10</td>
</tr>
<tr>
<td>Cap long-acting 10 mg – 1% DV Jan-20 to 2022</td>
<td></td>
<td></td>
<td>10</td>
</tr>
<tr>
<td>Cap long-acting 30 mg – 1% DV Jan-20 to 2022</td>
<td></td>
<td></td>
<td>10</td>
</tr>
<tr>
<td>Cap long-acting 60 mg – 1% DV Jan-20 to 2022</td>
<td></td>
<td></td>
<td>10</td>
</tr>
<tr>
<td>Cap long-acting 100 mg – 1% DV Jan-20 to 2022</td>
<td></td>
<td></td>
<td>10</td>
</tr>
<tr>
<td>Inj 1 mg per ml, 100 ml bag – 1% DV Oct-17 to 2020</td>
<td></td>
<td></td>
<td>5</td>
</tr>
<tr>
<td>Inj 1 mg per ml, 10 ml syringe – 1% DV Oct-17 to 2020</td>
<td></td>
<td></td>
<td>5</td>
</tr>
<tr>
<td>Inj 1 mg per ml, 50 ml syringe – 1% DV Oct-17 to 2020</td>
<td></td>
<td></td>
<td>5</td>
</tr>
<tr>
<td>Inj 1 mg per ml, 2 ml syringe</td>
<td></td>
<td></td>
<td>10</td>
</tr>
<tr>
<td>Inj 2 mg per ml, 30 ml syringe</td>
<td></td>
<td></td>
<td>10</td>
</tr>
<tr>
<td>Inj 5 mg per ml, 1 ml ampoule – 1% DV Sep-17 to 2020</td>
<td></td>
<td></td>
<td>5</td>
</tr>
<tr>
<td>Inj 10 mg per ml, 1 ml ampoule – 1% DV Sep-17 to 2020</td>
<td></td>
<td></td>
<td>5</td>
</tr>
<tr>
<td>Inj 10 mg per ml, 100 mg cassette</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 10 mg per ml, 100 ml bag</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 15 mg per ml, 1 ml ampoule – 1% DV Sep-17 to 2020</td>
<td></td>
<td></td>
<td>5</td>
</tr>
<tr>
<td>Inj 30 mg per ml, 1 ml ampoule – 1% DV Sep-17 to 2020</td>
<td></td>
<td></td>
<td>5</td>
</tr>
<tr>
<td>Inj 200 mcg in 0.4 ml syringe</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 300 mcg in 0.3 ml syringe</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>MORPHINE TARTRATE</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 80 mg per ml, 1.5 ml ampoule</td>
<td></td>
<td></td>
<td>5</td>
</tr>
</tbody>
</table>

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
## NERVOUS SYSTEM

### OXYCODONE HYDROCHLORIDE

<table>
<thead>
<tr>
<th>Price Per Brand or Generic Manufacturer</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>$2.15 20 Oxycodon Sandoz</td>
<td>Tab controlled-release 5 mg – 1% DV May-19 to 2021</td>
</tr>
<tr>
<td>$2.15 20 Oxycodon Sandoz</td>
<td>Tab controlled-release 10 mg – 1% DV May-19 to 2021</td>
</tr>
<tr>
<td>$2.15 20 Oxycodon Sandoz</td>
<td>Tab controlled-release 20 mg – 1% DV May-19 to 2021</td>
</tr>
<tr>
<td>$3.20 20 Oxycodon Sandoz</td>
<td>Tab controlled-release 40 mg – 1% DV May-19 to 2021</td>
</tr>
<tr>
<td>$10.98 20 OxyNorm</td>
<td>Tab controlled-release 80 mg – 1% DV May-19 to 2021</td>
</tr>
<tr>
<td>$1.88 20 OxyNorm</td>
<td>Cap immediate-release 5 mg – 1% DV Sep-18 to 2021</td>
</tr>
<tr>
<td>$3.32 20 OxyNorm</td>
<td>Cap immediate-release 10 mg – 1% DV Sep-18 to 2021</td>
</tr>
<tr>
<td>$5.81 20 OxyNorm</td>
<td>Cap immediate-release 20 mg – 1% DV Sep-18 to 2021</td>
</tr>
<tr>
<td>$11.20 200 ml OxyNorm</td>
<td>Oral liq 5 mg per 5 ml – 1% DV Sep-17 to 2020</td>
</tr>
<tr>
<td>$1.88 100 ml bag</td>
<td>Cap immediate-release 5 mg – 1% DV Sep-18 to 2021</td>
</tr>
<tr>
<td>$1.88 200 ml bag</td>
<td>Cap immediate-release 10 mg – 1% DV Sep-18 to 2021</td>
</tr>
<tr>
<td>$5.81 200 ml bag</td>
<td>Cap immediate-release 20 mg – 1% DV Sep-18 to 2021</td>
</tr>
</tbody>
</table>

### PARACETAMOL WITH CODEINE

<table>
<thead>
<tr>
<th>Price Per Brand or Generic Manufacturer</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>$18.21 1,000 Paracetamol + Codeine (Relieve)</td>
<td>Tab paracetamol 500 mg with codeine phosphate 8 mg – 1% DV Sep-17 to 2020</td>
</tr>
</tbody>
</table>

### PETHIDINE HYDROCHLORIDE

<table>
<thead>
<tr>
<th>Price Per Brand or Generic Manufacturer</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>$4.46 10 PSM</td>
<td>Tab 50 mg – 1% DV Sep-18 to 2021</td>
</tr>
<tr>
<td>$7.28 5 OxyNorm</td>
<td>Inj 1 mg per ml, 100 ml bag</td>
</tr>
<tr>
<td>$14.36 5 OxyNorm</td>
<td>Inj 10 mg per ml, 2 ml ampoule – 1% DV Sep-18 to 2021</td>
</tr>
<tr>
<td>$30.60 5 OxyNorm</td>
<td>Inj 50 mg per ml, 1 ml ampoule – 1% DV Sep-18 to 2021</td>
</tr>
</tbody>
</table>

### REMIFENTANIL

<table>
<thead>
<tr>
<th>Price Per Brand or Generic Manufacturer</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>$13.95 5 Remifentanil-AFT</td>
<td>Inj 1 mg vial – 1% DV Oct-17 to 2020</td>
</tr>
<tr>
<td>$19.95 5 Remifentanil-AFT</td>
<td>Inj 2 mg vial – 1% DV Oct-17 to 2020</td>
</tr>
</tbody>
</table>

### TRAMADOL HYDROCHLORIDE

<table>
<thead>
<tr>
<th>Price Per Brand or Generic Manufacturer</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>$1.55 20 Tramal SR 100</td>
<td>Tab sustained-release 100 mg – 1% DV Sep-17 to 2020</td>
</tr>
<tr>
<td>$2.10 20 Tramal SR 150</td>
<td>Tab sustained-release 150 mg – 1% DV Sep-17 to 2020</td>
</tr>
<tr>
<td>$2.75 20 Tramal SR 200</td>
<td>Tab sustained-release 200 mg – 1% DV Sep-17 to 2020</td>
</tr>
<tr>
<td>$4.50 5 Tramal 50</td>
<td>Cap 50 mg – 1% DV Sep-17 to 2020</td>
</tr>
<tr>
<td>$4.50 5 Tramal 100</td>
<td>Oral soln 10 mg per ml</td>
</tr>
</tbody>
</table>

### Antidepressants

#### Cyclic and Related Agents

### AMITRIPTYLINE

<table>
<thead>
<tr>
<th>Price Per Brand or Generic Manufacturer</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>$1.96 100 Arrow-Amitriptyline</td>
<td>Tab 10 mg – 1% DV Apr-18 to 2020</td>
</tr>
<tr>
<td>$1.52 100 Arrow-Amitriptyline</td>
<td>Tab 25 mg – 1% DV Apr-18 to 2020</td>
</tr>
<tr>
<td>$2.51 100 Arrow-Amitriptyline</td>
<td>Tab 50 mg – 1% DV Apr-18 to 2020</td>
</tr>
</tbody>
</table>

### CLOMIPRAMINE HYDROCHLORIDE

<table>
<thead>
<tr>
<th>Price Per Brand or Generic Manufacturer</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>$13.99 100 Apo-Clomipramine</td>
<td>Tab 10 mg – 1% DV Oct-18 to 2021</td>
</tr>
<tr>
<td>$9.46 100 Apo-Clomipramine</td>
<td>Tab 25 mg – 1% DV Oct-18 to 2021</td>
</tr>
</tbody>
</table>

---

*Item restricted (see ➔ above); Item restricted (see ➔ below)*

*e.g. Brand indicates brand example only. It is not a contracted product.*
### NERVOUS SYSTEM

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>DOSULEPIN [DOTHIEPIN] HYDROCHLORIDE</strong> – <em>Restricted:</em> For continuation only</td>
<td></td>
<td></td>
</tr>
<tr>
<td>→ Tab 75 mg</td>
<td>11.19</td>
<td>100</td>
</tr>
<tr>
<td>→ Cap 25 mg</td>
<td>6.45</td>
<td>100</td>
</tr>
<tr>
<td></td>
<td>7.83</td>
<td>50</td>
</tr>
</tbody>
</table>

*(Dopress Tab 75 mg to be delisted 1 August 2020)  
(Dopress Cap 25 mg to be delisted 1 January 2020)*

### DOXEPIN HYDROCHLORIDE – *Restricted:* For continuation only

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>→ Cap 10 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>→ Cap 25 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>→ Cap 50 mg</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### IMPATRIAMINE HYDROCHLORIDE

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>→ Tab 10 mg</td>
<td>5.48</td>
<td>50</td>
</tr>
<tr>
<td>→ Tab 25 mg</td>
<td>6.58</td>
<td>60</td>
</tr>
<tr>
<td>→ Tab 50 mg</td>
<td>8.80</td>
<td>50</td>
</tr>
</tbody>
</table>

### MAPROTILINE HYDROCHLORIDE

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>→ Tab 25 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>→ Tab 75 mg</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### MIANSERIN HYDROCHLORIDE – *Restricted:* For continuation only

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>→ Tab 30 mg</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### NORTRIPTYLINE HYDROCHLORIDE

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>→ Tab 10 mg – 1% DV Oct-19 to 2022</td>
<td>2.44</td>
<td>100</td>
</tr>
<tr>
<td>→ Tab 25 mg – 1% DV Oct-19 to 2022</td>
<td>5.98</td>
<td>180</td>
</tr>
</tbody>
</table>

### Monoamine-Oxidase Inhibitors - Non-Selective

### PHENELZINE SULPHATE

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>→ Tab 15 mg</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### TRANYLCYPROMINE SULPHATE

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>→ Tab 10 mg</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Monoamine-Oxidase Type A Inhibitors

### MOCLOBEMIDE

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>→ Tab 150 mg – 1% DV Apr-19 to 2021</td>
<td>6.40</td>
<td>60</td>
</tr>
<tr>
<td>→ Tab 300 mg – 1% DV Apr-19 to 2021</td>
<td>9.80</td>
<td>60</td>
</tr>
</tbody>
</table>

### Other Antidepressants

### MIRTAZAPINE

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>→ Tab 30 mg – 1% DV Oct-18 to 2021</td>
<td>2.63</td>
<td>30</td>
</tr>
<tr>
<td>→ Tab 45 mg – 1% DV Oct-18 to 2021</td>
<td>3.48</td>
<td>30</td>
</tr>
</tbody>
</table>

### VENLAFAXINE

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>→ Cap 37.5 mg – 1% DV Jun-17 to 2020</td>
<td>6.38</td>
<td>84</td>
</tr>
<tr>
<td>→ Cap 75 mg – 1% DV Jun-17 to 2020</td>
<td>8.11</td>
<td>84</td>
</tr>
<tr>
<td>→ Cap 150 mg – 1% DV Jun-17 to 2020</td>
<td>11.16</td>
<td>84</td>
</tr>
</tbody>
</table>

### Selective Serotonin Reuptake Inhibitors

### CITALOPRAM HYDROBROMIDE

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>→ Tab 20 mg – 1% DV Sep-18 to 2021</td>
<td>1.52</td>
<td>84</td>
</tr>
</tbody>
</table>

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
## NERVOUS SYSTEM

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$</td>
<td></td>
</tr>
</tbody>
</table>

### ESCITALOPRAM
- Tab 10 mg – 1% DV Dec-17 to 2020
- Tab 20 mg – 1% DV Dec-17 to 2020

### FLUOXETINE HYDROCHLORIDE
- Tab dispersible 20 mg, scored
- Cap 20 mg

(Arrow-Fluoxetine Tab dispersible 20 mg, scored to be delisted 1 August 2020)
(Arrow-Fluoxetine Cap 20 mg to be delisted 1 August 2020)

### PAROXETINE
- Tab 20 mg – 1% DV Mar-20 to 2022
- Tab 10 mg – 1% DV Mar-20 to 2022

(Apo-Paroxetine Tab 20 mg to be delisted 1 March 2020)
(Apo-Paroxetine Tab 10 mg to be delisted 1 March 2020)

### SERTRALINE
- Tab 50 mg – 1% DV Mar-20 to 2022
- Tab 100 mg – 1% DV Mar-20 to 2022

(Arrow-Sertraline Tab 50 mg to be delisted 1 March 2020)
(Arrow-Sertraline Tab 100 mg to be delisted 1 March 2020)

### Antiepilepsy Drugs

### Agents for the Control of Status Epilepticus

#### CLONAZEPAM
- Inj 1 mg per ml, 1 ml ampoule

#### DIAZEPAM
- Inj 5 mg per ml, 2 ml ampoule
- Rectal tubes 5 mg
- Rectal tubes 10 mg

#### LORAZEPAM
- Inj 2 mg vial
- Inj 4 mg per ml, 1 ml vial

#### PARALDEHYDE
- Inj 5 ml ampoule

#### PHENYTOIN SODIUM
- Inj 50 mg per ml, 2 ml ampoule
- Inj 50 mg per ml, 5 ml ampoule

### Control of Epilepsy

#### CARBAMAZEPINE
- Tab 200 mg
- Tab long-acting 200 mg
- Tab 400 mg
- Tab long-acting 400 mg
- Oral liq 20 mg per ml

#### CLOBAZAM
- Tab 10 mg

#### CLONAZEPAM
- Oral drops 2.5 mg per ml

---

1. Item restricted (see above);
2. Item restricted (see below); 
3. e.g. Brand indicates brand example only. It is not a contracted product.
### NERVOUS SYSTEM

#### ETHOSUXIMIDE
- Cap 250 mg: $140.88 100 Zarontin
- Oral liq 50 mg per ml: $56.35 200 ml Zarontin

#### GABAPENTIN
Note: Gabapentin not to be given in combination with pregabalin
- Cap 100 mg – 1% DV Aug-18 to 2021: $2.65 100 Apo-Gabapentin
- Cap 300 mg – 1% DV Aug-18 to 2021: $4.07 100 Apo-Gabapentin
- Cap 400 mg – 1% DV Aug-18 to 2021: $5.64 100 Apo-Gabapentin

#### LACOSAMIDE – Restricted see terms below
- Tab 50 mg: $25.04 14 Vimpat
- Tab 100 mg: $50.06 14 Vimpat
- Tab 150 mg: $75.10 14 Vimpat
- Tab 200 mg: $100.24 56 Vimpat
- Tab 250 mg: $120.24 56 Vimpat
- Tab 300 mg: $150.24 56 Vimpat
- Tab 350 mg: $180.24 56 Vimpat
- Tab 400 mg: $200.24 56 Vimpat
- Inj 10 mg per ml, 20 ml vial
  - Restricted (RS1151)

**Initiation**
Re-assessment required after 15 months

Both:
1. Patient has partial-onset epilepsy; and
2. Seizures are not adequately controlled by, or patient has experienced unacceptable side effects from, optimal treatment with all of the following: sodium valproate, topiramate, levetiracetam and any two of carbamazepine, lamotrigine and phenytoin sodium (see Note).

Note: “Optimal treatment” is defined as treatment which is indicated and clinically appropriate for the patient, given in adequate doses for the patient’s age, weight and other features affecting the pharmacokinetics of the drug with good evidence of compliance. Women of childbearing age are not required to have a trial of sodium valproate.

**Continuation**
Patient has demonstrated a significant and sustained improvement in seizure rate or severity and/or quality of life compared with that prior to starting lacosamide treatment (see Note).

Note: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed quality of life from the patient’s perspective

#### LAMOTRIGINE
- Tab dispersible 2 mg: $6.74 30 Lamictal
- Tab dispersible 5 mg: $15.00 56 Arrow-Lamotrigine
- Tab dispersible 25 mg – 5% DV Oct-19 to 2022: $2.76 56 Logem
- Tab dispersible 50 mg – 5% DV Oct-19 to 2022: $3.31 56 Logem
- Tab dispersible 100 mg – 5% DV Oct-19 to 2022: $4.40 56 Logem

#### LEVETIRACETAM
- Tab 250 mg – 1% DV Aug-19 to 2022: $4.99 60 Everet
- Tab 500 mg – 1% DV Aug-19 to 2022: $8.79 60 Everet
- Tab 750 mg – 1% DV Aug-19 to 2022: $14.39 60 Everet
- Tab 1,000 mg – 1% DV Aug-19 to 2022: $18.59 60 Everet
- Oral liq 100 mg per ml – 1% DV Apr-18 to 2020: $44.78 300 ml Levetiracetam-AFT
- Inj 100 mg per ml, 5 ml vial – 1% DV Oct-19 to 2022: $38.95 10 Levetiracetam-AFT

#### PHENOBARBITONE
- Tab 15 mg – 1% DV Oct-18 to 2021: $40.00 500 PSM
- Tab 30 mg – 1% DV Oct-18 to 2021: $40.00 500 PSM

#### PHENYTOIN
- Tab 50 mg

---

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
NERVOUS SYSTEM

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) $ Per Brand or Generic Manufacturer</th>
</tr>
</thead>
</table>

PHENYTOIN SODIUM
- Cap 30 mg
- Cap 100 mg
- Oral liq 6 mg per ml

PREGABALIN
Note: Pregabalin not to be given in combination with gabapentin
- Cap 25 mg – 1% DV Jul-18 to 2021 ............................................. 2.25 56 Pregabalin Pfizer
- Cap 75 mg – 1% DV Jul-18 to 2021 ............................................. 2.65 56 Pregabalin Pfizer
- Cap 150 mg – 1% DV Jul-18 to 2021 ......................................... 4.01 56 Pregabalin Pfizer
- Cap 300 mg – 1% DV Jul-18 to 2021 ......................................... 7.38 56 Pregabalin Pfizer

PRIMIDONE
- Tab 250 mg

SODIUM VALPROATE
- Tab 100 mg
- Tab EC 200 mg
- Tab EC 500 mg
- Oral liq 40 mg per ml
- Inj 100 mg per ml, 4 ml vial – 1% DV Sep-18 to 2021 ........................ 9.98 1 Epilim IV

STIRIPENTOL – Restricted see terms below
- Cap 250 mg ............................................................................. 509.29 60 Diacomit
- Powder for oral liq 250 mg sachet ................................................ 509.29 60 Diacomit

- Restricted (RS1152)

Initiation
Paediatric neurologist
Re-assessment required after 6 months
Both:
1. Patient has confirmed diagnosis of Dravet syndrome; and
2. Seizures have been inadequately controlled by appropriate courses of sodium valproate, clobazam and at least two of the following: topiramate, levetiracetam, ketogenic diet.

Continuation
Paediatric neurologist
Patient continues to benefit from treatment as measured by reduced seizure frequency from baseline.

TOPIRAMATE
- Tab 25 mg ............................................................................. 11.07 60 Arrow-Topiramate
- Tab 25 mg ............................................................................. 26.04 Topamax
- Tab 50 mg ............................................................................. 11.07 Topiramate Actavis
- Tab 50 mg ............................................................................. 44.26 Topamax
- Tab 100 mg .......................................................................... 18.81 Topiramate Actavis
- Tab 100 mg .......................................................................... 75.25 Topamax
- Tab 200 mg .......................................................................... 31.99 Topiramate Actavis
- Tab 200 mg .......................................................................... 129.85 Topamax
- Cap sprinkle 15 mg ............................................................. 20.84 60 Topamax
- Cap sprinkle 25 mg ............................................................. 26.04 60 Topamax

VIGABATRIN – Restricted see terms on the next page
- Tab 500 mg

**e.g. Brand indicates brand example only. It is not a contracted product.**
**Restricted (RS1153)**

**Initiation**

*Re-assessment required after 15 months*

Both:

1. Either:
   1.1 Patient has infantile spasms; or
   1.2 Both:
      1.2.1 Patient has epilepsy; and
      1.2.2 Either:
         1.2.2.1 Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents; or
         1.2.2.2 Seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatment with other antiepilepsy agents; and

2. Either:
   2.1 Patient is, or will be, receiving regular automated visual field testing (ideally before starting therapy and on a 6-monthly basis thereafter); or
   2.2 It is impractical or impossible (due to comorbid conditions) to monitor the patient's visual fields.

Notes: "Optimal treatment with other antiepilepsy agents" is defined as treatment with other antiepilepsy agents which are indicated and clinically appropriate for the patient, given in adequate doses for the patient's age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of compliance.

Vigabatrin is associated with a risk of irreversible visual field defects, which may be asymptomatic in the early stages.

**Continuation**

Both:

1. The patient has demonstrated a significant and sustained improvement in seizure rate or severity and or quality of life; and
2. Either:
   2.1 Patient is receiving regular automated visual field testing (ideally every 6 months) on an ongoing basis for duration of treatment with vigabatrin; or
   2.2 It is impractical or impossible (due to comorbid conditions) to monitor the patient's visual fields.

Notes: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed quality of life from the patient's perspective.

Vigabatrin is associated with a risk of irreversible visual field defects, which may be asymptomatic in the early stages.

**Antimigraine Preparations**

**Acute Migraine Treatment**

**DIHYDROERGOTAMINE MESYLATE**

Inj 1 mg per ml, 1 ml ampoule

**ERGOTAMINE TARTRATE WITH CAFFEINE**

Tab 1 mg with caffeine 100 mg

**METOCLOPRAMIDE HYDROCHLORIDE WITH PARACETAMOL**

Tab 5 mg with paracetamol 500 mg

**RIZATRIPTAN**

Tab orodispersible 10 mg – 1% DV Sep-17 to 2020................................................. 5.26 30 Rizamelt

**SUMATRIPTAN**

Tab 50 mg – 1% DV Oct-19 to 2022................................................................. 24.44 100 Apo-Sumatriptan

Tab 100 mg – 1% DV Oct-19 to 2022............................................................. 46.23 100 Apo-Sumatriptan

Inj 12 mg per ml, 0.5 ml prefilled pen .......................................................... 81.15 2 Clustran

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
### Prophylaxis of Migraine

**PIZOTIFEN**  
Tab 500 mcg.................................................................23.21 100 Sandomigran

### Antinausea and Vertigo Agents

**APREPIRANT**  
– Restricted see terms below  
† Cap 2 x 80 mg and 1 x 125 mg – 1% DV Jul-18 to 2021.................................84.00 3 Emend Tri-Pack  
⇒ Restricted (RS1154)

**BETAHISTINE DIHYDROCHLORIDE**  
Tab 16 mg – 1% DV Sep-17 to 2020..............................................2.89 84 Vergo 16

**CYCLIZINE HYDROCHLORIDE**  
Tab 50 mg – 1% DV Jan-19 to 2021 ..............................................0.55 10 Nausicalm

**CYCLIZINE LACTATE**  
Inj 50 mg per ml, 1 ml ampoule ..............................................14.95 5 Nausicalm

**DOMPERIDONE**  
Tab 10 mg – 1% DV Mar-19 to 2021.........................................2.25 100 Pharmacy Health

**DROPERIDOL**  
Inj 2.5 mg per ml, 1 ml ampoule – 1% DV May-20 to 2022 ................30.95 10 Droleptan  
35.00 Droperidol Panpharma

*(Droperidol Panpharma Inj 2.5 mg per ml, 1 ml ampoule to be delisted 1 May 2020)*

**GRANISETRON**  
Inj 1 mg per ml, 3 ml ampoule – 1% DV Dec-18 to 2020....................0.40 1 Deva

**HYOSCINE HYDROBROMIDE**  
Inj 400 mcg per ml, 1 ml ampoule ..............................................46.50 5 Hospira  
† Patch 1.5 mg .........................................................14.11 2 Scopoderm TTS  
⇒ Restricted (RS1155)

**METOCLOPRAMIDE HYDROCHLORIDE**  
Tab 10 mg – 1% DV Jan-18 to 2020.................................1.30 100 Metoclopramide  
10  Actavis 10

Oral liq 5 mg per 5 ml  
Inj 5 mg per ml, 2 ml ampoule – 1% DV Jan-20 to 2022 ................9.50 10 Pfizer
### NERVOUS SYSTEM

#### ONDANSETRON

<table>
<thead>
<tr>
<th>Product</th>
<th>Formulation</th>
<th>Expiry</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 4 mg – 1% DV Apr-20 to 2022</td>
<td></td>
<td></td>
<td>3.36</td>
<td>Apo-Ondansetron</td>
</tr>
<tr>
<td>Tab dispersible 4 mg – 1% DV Apr-18 to 2020</td>
<td></td>
<td></td>
<td>0.95</td>
<td>Ondansetron</td>
</tr>
<tr>
<td>Tab 8 mg – 1% DV Apr-20 to 2022</td>
<td></td>
<td></td>
<td>4.77</td>
<td>Apo-Ondansetron</td>
</tr>
<tr>
<td>Tab dispersible 8 mg – 1% DV Apr-18 to 2020</td>
<td></td>
<td></td>
<td>1.43</td>
<td>Ondansetron</td>
</tr>
<tr>
<td>Inj 2 mg per ml, 2 ml ampoule</td>
<td></td>
<td></td>
<td>1.50</td>
<td>Ondansetron-Claris</td>
</tr>
<tr>
<td>Inj 2 mg per ml, 4 ml ampoule</td>
<td></td>
<td></td>
<td>2.20</td>
<td>Ondansetron Kabi</td>
</tr>
</tbody>
</table>

(Apo-Ondansetron Tab 4 mg to be delisted 1 April 2020)

(Apo-Ondansetron Tab 8 mg to be delisted 1 April 2020)

#### PROCHLORPERAZINE

<table>
<thead>
<tr>
<th>Product</th>
<th>Formulation</th>
<th>Expiry</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab buccal 3 mg</td>
<td></td>
<td></td>
<td>6.35</td>
<td>Nausafix</td>
</tr>
<tr>
<td>Tab 5 mg – 1% DV Mar-18 to 2020</td>
<td></td>
<td></td>
<td>6.35</td>
<td>Nausafix</td>
</tr>
<tr>
<td>Inj 12.5 mg per ml, 1 ml ampoule</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Suppos 25 mg</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### TROPISETRON

<table>
<thead>
<tr>
<th>Product</th>
<th>Formulation</th>
<th>Expiry</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 1 mg per ml, 2 ml ampoule – 1% DV Sep-18 to 2021</td>
<td></td>
<td></td>
<td>8.95</td>
<td>Tropisetron-AFT</td>
</tr>
<tr>
<td>Inj 1 mg per ml, 5 ml ampoule</td>
<td></td>
<td></td>
<td>13.95</td>
<td>Tropisetron-AFT</td>
</tr>
</tbody>
</table>

#### Antipsychotic Agents

**General**

#### AMISULPRIDE

<table>
<thead>
<tr>
<th>Product</th>
<th>Formulation</th>
<th>Expiry</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 100 mg – 1% DV Nov-19 to 2022</td>
<td></td>
<td></td>
<td>5.15</td>
<td>Sulpriz</td>
</tr>
<tr>
<td>Tab 200 mg – 1% DV Nov-19 to 2022</td>
<td></td>
<td></td>
<td>14.96</td>
<td>Sulpriz</td>
</tr>
<tr>
<td>Tab 400 mg – 1% DV Feb-20 to 2022</td>
<td></td>
<td></td>
<td>29.78</td>
<td>Sulpriz</td>
</tr>
<tr>
<td>Oral liq 100 mg per ml</td>
<td></td>
<td></td>
<td>65.53</td>
<td>Solian</td>
</tr>
</tbody>
</table>

(Solian Oral liq 100 mg per ml to be delisted 1 July 2020)

#### ARIPIPRAZOLE

<table>
<thead>
<tr>
<th>Product</th>
<th>Formulation</th>
<th>Expiry</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 5 mg – 1% DV Aug-18 to 2021</td>
<td></td>
<td></td>
<td>17.50</td>
<td>Aripiprazole Sandoz</td>
</tr>
<tr>
<td>Tab 10 mg – 1% DV Aug-18 to 2021</td>
<td></td>
<td></td>
<td>17.50</td>
<td>Aripiprazole Sandoz</td>
</tr>
<tr>
<td>Tab 15 mg – 1% DV Aug-18 to 2021</td>
<td></td>
<td></td>
<td>17.50</td>
<td>Aripiprazole Sandoz</td>
</tr>
<tr>
<td>Tab 20 mg – 1% DV Aug-18 to 2021</td>
<td></td>
<td></td>
<td>17.50</td>
<td>Aripiprazole Sandoz</td>
</tr>
<tr>
<td>Tab 30 mg – 1% DV Aug-18 to 2021</td>
<td></td>
<td></td>
<td>17.50</td>
<td>Aripiprazole Sandoz</td>
</tr>
</tbody>
</table>

#### CHLORPROMAZINE HYDROCHLORIDE

<table>
<thead>
<tr>
<th>Product</th>
<th>Formulation</th>
<th>Expiry</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 10 mg – 1% DV Jan-20 to 2022</td>
<td></td>
<td></td>
<td>14.83</td>
<td>Largactil</td>
</tr>
<tr>
<td>Tab 25 mg – 1% DV Jan-20 to 2022</td>
<td></td>
<td></td>
<td>15.62</td>
<td>Largactil</td>
</tr>
<tr>
<td>Tab 100 mg – 1% DV Jan-20 to 2022</td>
<td></td>
<td></td>
<td>36.73</td>
<td>Largactil</td>
</tr>
<tr>
<td>Oral liq 10 mg per ml</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oral liq 20 mg per ml</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 25 mg per ml, 2 ml ampoule – 1% DV Jan-20 to 2022</td>
<td></td>
<td></td>
<td>30.79</td>
<td>Largactil</td>
</tr>
<tr>
<td>NERVOUS SYSTEM</td>
<td>Price (ex man. excl. GST)</td>
<td>Brand or Generic Manufacturer</td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------------</td>
<td>--------------------------</td>
<td>-------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>CLOZAPINE</strong></td>
<td>Per</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 25 mg</td>
<td>..................................................</td>
<td>6.69</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>..................................................</td>
<td>13.37</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>..................................................</td>
<td>5.69</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>..................................................</td>
<td>11.36</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 50 mg</td>
<td>..................................................</td>
<td>8.67</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>..................................................</td>
<td>17.33</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 100 mg</td>
<td>..................................................</td>
<td>17.33</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>..................................................</td>
<td>34.65</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>..................................................</td>
<td>14.73</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>..................................................</td>
<td>29.45</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 200 mg</td>
<td>..................................................</td>
<td>34.65</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oral liq 50 mg per ml</td>
<td>..................................................</td>
<td>69.30</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**HALOPERIDOL**

| Tab 500 mcg - 1% DV Oct-19 to 2022 | .................................................. | 6.23 |
| Tab 1.5 mg - 1% DV Oct-19 to 2022  | .................................................. | 9.43 |
| Tab 5 mg - 1% DV Oct-19 to 2022    | .................................................. | 29.72 |
| Oral liq 2 mg per ml - 1% DV Oct-19 to 2022 | .................................................. | 23.84 |
| Inj 5 mg per ml, 1ml ampoule - 1% DV Oct-19 to 2022 | .................................................. | 21.55 |

**LEVOMEPROMAZINE**

| Tab 25 mg - 1% DV Sep-19 to 2022 | .................................................. | 16.10 |
| Tab 100 mg - 1% DV Sep-19 to 2022 | .................................................. | 41.75 |

**LEVOMEPROMAZINE HYDROCHLORIDE**

Inj 25 mg per ml, 1 ml ampoule - 1% DV Apr-20 to 2022 | .................................................. | 33.50 |

(Nozinan Inj 25 mg per ml, 1 ml ampoule to be delisted 1 April 2020)

**LITHIUM CARBONATE**

| Tab long-acting 400 mg | .................................................. | 34.30 |
| Tab 250 mg            | .................................................. | 9.42  |
| Cap 250 mg            | .................................................. | 34.30 |

**OLANZAPINE**

| Tab 2.5 mg - 1% DV Sep-17 to 2020 | .................................................. | 0.64  |
| Tab 5 mg - 1% DV Sep-17 to 2020   | .................................................. | 1.15  |
| Tab orodispersible 5 mg - 1% DV Sep-17 to 2020 | .................................................. | 1.25  |
| Tab 10 mg - 1% DV Sep-17 to 2020  | .................................................. | 1.65  |
| Tab orodispersible 10 mg - 1% DV Sep-17 to 2020 | .................................................. | 2.05  |
| Inj 10 mg vial          | .................................................. | 2.05  |

**PERICYZINE**

| Tab 2.5 mg | .................................................. | 0.64  |
| Tab 10 mg  | .................................................. | 1.15  |

**QUETIAPINE**

| Tab 25 mg - 1% DV Sep-17 to 2020 | .................................................. | 1.79  |
| Tab 100 mg - 1% DV Sep-17 to 2020 | .................................................. | 3.45  |
| Tab 200 mg - 1% DV Sep-17 to 2020 | .................................................. | 5.75  |
| Tab 300 mg - 1% DV Sep-17 to 2020 | .................................................. | 9.60  |

1 Item restricted (see ➔ above); 2 Item restricted (see ➔ below)
e.g. Brand indicates brand example only. It is not a contracted product.
NERVOUS SYSTEM

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Strength/Package</th>
<th>Expiry Date</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Risperidone</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 0.5 mg</td>
<td>1% DV Dec-17 to 2020</td>
<td></td>
<td>1.86</td>
<td>Actavis</td>
</tr>
<tr>
<td>Tab 1 mg</td>
<td>1% DV Dec-17 to 2020</td>
<td></td>
<td>2.06</td>
<td>Actavis</td>
</tr>
<tr>
<td>Tab 2 mg</td>
<td>1% DV Dec-17 to 2020</td>
<td></td>
<td>2.29</td>
<td>Actavis</td>
</tr>
<tr>
<td>Tab 3 mg</td>
<td>1% DV Dec-17 to 2020</td>
<td></td>
<td>2.50</td>
<td>Actavis</td>
</tr>
<tr>
<td>Oral liq 1 mg per ml</td>
<td>1% DV Sep-17 to 2020</td>
<td></td>
<td>7.66</td>
<td>Risperon</td>
</tr>
<tr>
<td>Ziprasidone</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cap 20 mg</td>
<td>1% DV Dec-18 to 2021</td>
<td></td>
<td>14.50</td>
<td>Zusdone</td>
</tr>
<tr>
<td>Cap 40 mg</td>
<td>1% DV Sep-18 to 2021</td>
<td></td>
<td>24.70</td>
<td>Zusdone</td>
</tr>
<tr>
<td>Cap 60 mg</td>
<td>1% DV Sep-18 to 2021</td>
<td></td>
<td>33.80</td>
<td>Zusdone</td>
</tr>
<tr>
<td>Cap 80 mg</td>
<td>1% DV Sep-18 to 2021</td>
<td></td>
<td>39.70</td>
<td>Zusdone</td>
</tr>
<tr>
<td>Zuclopenthixol Acetate</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 50 mg per ml, 1 ml ampoule</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 50 mg per ml, 2 ml ampoule</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zuclopenthixol Hydrochloride</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 10 mg</td>
<td></td>
<td></td>
<td>31.45</td>
<td>Clopixol</td>
</tr>
</tbody>
</table>

**Depot Injections**

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Strength/Package</th>
<th>Expiry Date</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Flupenthixol Decanoate</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 20 mg per ml, 1 ml ampoule</td>
<td></td>
<td></td>
<td>13.14</td>
<td>Fluanxol</td>
</tr>
<tr>
<td>Inj 20 mg per ml, 2 ml ampoule</td>
<td></td>
<td></td>
<td>20.90</td>
<td>Fluanxol</td>
</tr>
<tr>
<td>Inj 100 mg per ml, 1 ml ampoule</td>
<td></td>
<td></td>
<td>40.87</td>
<td>Fluanxol</td>
</tr>
<tr>
<td>Haloperidol Decanoate</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 50 mg per ml, 1 ml ampoule</td>
<td></td>
<td></td>
<td>28.39</td>
<td>Haldol</td>
</tr>
<tr>
<td>Inj 100 mg per ml, 1 ml ampoule</td>
<td></td>
<td></td>
<td>55.90</td>
<td>Haldol Concentrate</td>
</tr>
<tr>
<td>Olanzapine – Restricted</td>
<td>see terms below</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 210 mg vial</td>
<td>1% DV Oct-18 to 2021</td>
<td></td>
<td>252.00</td>
<td>Zyprexa Relprevv</td>
</tr>
<tr>
<td>Inj 300 mg vial</td>
<td>1% DV Oct-18 to 2021</td>
<td></td>
<td>414.00</td>
<td>Zyprexa Relprevv</td>
</tr>
<tr>
<td>Inj 405 mg vial</td>
<td>1% DV Oct-18 to 2021</td>
<td></td>
<td>504.00</td>
<td>Zyprexa Relprevv</td>
</tr>
<tr>
<td>Paliperidone – Restricted</td>
<td>(RS1379)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Initiation</td>
<td>Re-assessment required after 12 months</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Either:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 The patient has had an initial Special Authority approval for risperidone depot injection or paliperidone depot injection; or</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 All of the following:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.1 The patient has schizophrenia; and</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.2 The patient has tried but failed to comply with treatment using oral atypical antipsychotic agents; and</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.3 The patient has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in the last 12 months.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Continuation</td>
<td>Re-assessment required after 12 months</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>The initiation of olanzapine depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of an atypical antipsychotic depot injection.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Paliperidone – Restricted</td>
<td>see terms on the next page</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 25 mg syringe</td>
<td></td>
<td></td>
<td>194.25</td>
<td>Invega Sustenna</td>
</tr>
<tr>
<td>Inj 50 mg syringe</td>
<td></td>
<td></td>
<td>271.95</td>
<td>Invega Sustenna</td>
</tr>
<tr>
<td>Inj 75 mg syringe</td>
<td></td>
<td></td>
<td>357.42</td>
<td>Invega Sustenna</td>
</tr>
<tr>
<td>Inj 100 mg syringe</td>
<td></td>
<td></td>
<td>435.12</td>
<td>Invega Sustenna</td>
</tr>
<tr>
<td>Inj 150 mg syringe</td>
<td></td>
<td></td>
<td>435.12</td>
<td>Invega Sustenna</td>
</tr>
</tbody>
</table>

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
**NERVOUS SYSTEM**

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per Manufacturer</td>
<td></td>
</tr>
</tbody>
</table>

**Risperidone** – **Restricted** (RS1381)

**Initiation**

*Re-assessment required after 12 months*

Either:

1. The patient has had an initial Special Authority approval for risperidone depot injection or olanzapine depot injection; or
2. All of the following:
   1. The patient has schizophrenia or other psychotic disorder; and
   2. The patient has tried but failed to comply with treatment using oral atypical antipsychotic agents; and
   3. The patient has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in the last 12 months.

**Continuation**

*Re-assessment required after 12 months*

The initiation of paliperidone depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of an atypical antipsychotic depot injection.

**Zuclopenthixol Decanoate**

- **Inj 200 mg per ml, 1 ml ampoule** ......................................................... 19.80 5 Clopixol
- **Inj 500 mg per ml, 1 ml ampoule** ......................................................... e.g. Clopixol Conc

**Anxiolytics**

**Buspirone Hydrochloride**

- **Tab 5 mg – 1% DV Sep-18 to 2021** ........................................................... 20.23 100 Orion
- **Tab 10 mg – 1% DV Sep-18 to 2021** .......................................................... 13.16 100 Orion

**Clonazepam**

- **Tab 2 mg – 1% DV Jun-18 to 2020** .......................................................... 5.64 100 Paxam
- **Tab 5 mg – 1% DV Jun-18 to 2020** ........................................................... 10.78 100 Paxam

**Diazepam**

- **Tab 2 mg – 1% DV Mar-18 to 2020** .......................................................... 15.05 500 Arrow-Diazepam
- **Tab 5 mg – 1% DV Mar-18 to 2020** ........................................................... 16.18 500 Arrow-Diazepam

---

*Item restricted (see ➤ above); ➤ Item restricted (see ➤ below)*

*E.g. Brand indicates brand example only. It is not a contracted product.*
### NERVOUS SYSTEM

#### LORAZEPAM

<table>
<thead>
<tr>
<th>Brand or Manufacturer</th>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 1 mg – 1% DV Sep-18 to 2021</td>
<td>$9.72</td>
<td>250 Ativan</td>
</tr>
<tr>
<td>Tab 2.5 mg – 1% DV Sep-18 to 2021</td>
<td>$12.50</td>
<td>100 Ativan</td>
</tr>
</tbody>
</table>

#### OXAZEPAM

<table>
<thead>
<tr>
<th>Manufacturer</th>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 10 mg – 1% DV Sep-17 to 2020</td>
<td>$6.17</td>
<td>100 Ox-Pam</td>
</tr>
<tr>
<td>Tab 15 mg – 1% DV Sep-17 to 2020</td>
<td>$8.53</td>
<td>100 Ox-Pam</td>
</tr>
</tbody>
</table>

### Multiple Sclerosis Treatments

#### DIMETHYL FUMARATE

- **Restricted** see terms below

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cap 120 mg</td>
<td>$520.00</td>
</tr>
<tr>
<td>Cap 240 mg</td>
<td>$2,000.00</td>
</tr>
</tbody>
</table>

#### FINGOLIMOD

- **Restricted** see terms below

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cap 0.5 mg</td>
<td>$2,200.00</td>
</tr>
</tbody>
</table>

#### NATALIZUMAB

- **Restricted** see terms below

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 20 mg per ml, 15 ml vial</td>
<td>$1,750.00</td>
</tr>
</tbody>
</table>

#### OCRELIZUMAB

- **Restricted** see terms below

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 30 mg per ml, 10 ml vial</td>
<td>$9,346.00</td>
</tr>
</tbody>
</table>

#### TERIFLUNOMIDE

- **Restricted** see terms below

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 14 mg</td>
<td>$1,582.62</td>
</tr>
</tbody>
</table>
NERVOUS SYSTEM

Other Multiple Sclerosis Treatments

**Restricted (RS1434)**

Initiation

Only for use in patients with approval by the Multiple Sclerosis Treatment Assessment Committee (MSTAC). Applications will be considered by MSTAC at its regular meetings and approved subject to eligibility according to the Entry and Stopping criteria (set out in Section B of the Pharmaceutical Schedule).

- **GLATIRAMER ACETATE** – **Restricted** see terms above
  - Inj 40 mg prefilled syringe................................................................. 2,275.00 12 Copaxone

- **INTERFERON BETA-1-ALPHA** – **Restricted** see terms above
  - Inj 6 million iu in 0.5 ml pen injector................................................ 1,170.00 4 Avonex Pen
  - Inj 6 million iu in 0.5 ml syringe.......................................................... 1,170.00 4 Avonex

- **INTERFERON BETA-1-BETA** – **Restricted** see terms above
  - Inj 8 million iu per ml, 1 ml vial

**Sedatives and Hypnotics**

- **CHLORAL HYDRATE**
  - Oral liq 100 mg per ml
  - Oral liq 200 mg per ml

- **LORMETAZEPAM** – **Restricted**: For continuation only
  - Tab 1 mg

- **MELATONIN** – **Restricted** see terms below
  - Tab modified-release 2 mg............................................................... 28.22 30 Circadin
  - Tab 3 mg
    - Note: Only for use in compounding an oral liquid formulation, for in-hospital use only.

**Restricted (RS1576)**

Initiation – insomnia secondary to neurodevelopmental disorder

Psychiatrist, paediatrician, neurologist or respiratory specialist

*Re-assessment required after 12 months*

All of the following:

1. Patient has been diagnosed with persistent and distressing insomnia secondary to a neurodevelopmental disorder (including, but not limited to, autism spectrum disorder or attention deficit hyperactivity disorder); and
2. Behavioural and environmental approaches have been tried or are inappropriate; and
3. Funded modified-release melatonin is to be given at doses no greater than 10 mg per day; and
4. Patient is aged 18 years or under.

Continuation – insomnia secondary to neurodevelopmental disorder

Psychiatrist, paediatrician, neurologist or respiratory specialist

*Re-assessment required after 12 months*

All of the following:

1. Patient is aged 18 years or under; and
2. Patient has demonstrated clinically meaningful benefit from funded modified-release melatonin (clinician determined); and
3. Patient has had a trial of funded modified-release melatonin discontinuation within the past 12 months and has had a recurrence of persistent and distressing insomnia; and
4. Funded modified-release melatonin is to be given at doses no greater than 10 mg per day.

Initiation – insomnia where benzodiazepines and zopiclone are contraindicated

Both:

1. Patient has insomnia and benzodiazepines and zopiclone are contraindicated; and
2. For in-hospital use only.

---

*Item restricted (see ➡ above); Item restricted (see ➡ below)*

e.g. *Brand* indicates brand example only. It is not a contracted product.
NERVOUS SYSTEM

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per</td>
<td></td>
</tr>
</tbody>
</table>

**MIDAZOLAM**
Tab 7.5 mg
Oral liq 2 mg per ml
Inj 1 mg per ml, 5 ml ampoule – 1% DV Jan-19 to 2021 ................. 2.98 10 Mylan Midazolam
Inj 5 mg per ml, 3 ml ampoule – 1% DV Jan-19 to 2021 ................. 2.36 5 Mylan Midazolam

**NITRAZEPAM** – Restricted: For continuation only
- Tab 5 mg .......................................................... 5.22 100 Nitrados

*(Nitrados Tab 5 mg to be delisted 1 September 2020)*

**PHENOBARBITONE**
Inj 200 mg per ml, 1 ml ampoule

**TEMAZEPAM**
Tab 10 mg – 1% DV Sep-17 to 2020 ........................................... 1.27 25 Normison

**TRIAZOLAM** – Restricted: For continuation only
- Tab 125 mcg
- Tab 250 mcg

**ZOPICLONE**
Tab 7.5 mg ........................................................................... 0.98 30 Zopiclone Actavis

**Stimulants / ADHD Treatments**

**ATOMOXETINE** – Restricted see terms below
- Cap 10 mg .................................................. 107.03 28 Strattera
- Cap 18 mg .................................................. 107.03 28 Strattera
- Cap 25 mg .................................................. 107.03 28 Strattera
- Cap 40 mg .................................................. 107.03 28 Strattera
- Cap 60 mg .................................................. 107.03 28 Strattera
- Cap 80 mg .................................................. 139.11 28 Strattera
- Cap 100 mg .................................................. 139.11 28 Strattera

- Restricted (RS1371)

**Initiation**
All of the following:
1. Patient has ADHD (Attention Deficit and Hyperactivity Disorder) diagnosed according to DSM-IV or ICD 10 criteria; and
2. Once-daily dosing; and
3. Any of the following:
   3.1 Treatment with a subsidised formulation of a stimulant has resulted in the development or worsening of serious adverse reactions or where the combination of subsidised stimulant treatment with another agent would pose an unacceptable medical risk; or
   3.2 Treatment with a subsidised formulation of a stimulant has resulted in worsening of co-morbid substance abuse or there is a significant risk of diversion with subsidised stimulant therapy; or
   3.3 An effective dose of a subsidised formulation of a stimulant has been trialled and has been discontinued because of inadequate clinical response; or
   3.4 Treatment with a subsidised formulation of a stimulant is considered inappropriate because the patient has a history of psychoses or has a first-degree relative with schizophrenia; and
4. The patient will not be receiving treatment with atomoxetine in combination with a subsidised formulation of a stimulant, except for the purposes of transitioning from subsidised stimulant therapy to atomoxetine.

Note: A "subsidised formulation of a stimulant" refers to currently listed methylphenidate hydrochloride tablet formulations (immediate-release, sustained-release and extended-release) or dexamphetamine sulphate tablets.

**CAFFEINE**
Tab 100 mg

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
NERVOUS SYSTEM

Price (ex man. excl. GST) $ Per Brand or Generic Manufacturer

DEXAMFETAMINE SULFATE – Restricted see terms below

- Restricted (RS1169)
Initiation – ADHD
Paediatrician or psychiatrist
Patient has ADHD (Attention Deficit and Hyperactivity Disorder), diagnosed according to DSM-IV or ICD 10 criteria.

Initiation – Narcolepsy
Neurologist or respiratory specialist
Re-assessment required after 24 months
Patient suffers from narcolepsy.

Continuation – Narcolepsy
Neurologist or respiratory specialist
Re-assessment required after 24 months
The treatment remains appropriate and the patient is benefiting from treatment.

METHYLPHENIDATE HYDROCHLORIDE – Restricted see terms below

- Restricted (RS1294)
Initiation – ADHD (immediate-release and sustained-release formulations)
Paediatrician or psychiatrist
Patient has ADHD (Attention Deficit and Hyperactivity Disorder), diagnosed according to DSM-IV or ICD 10 criteria.

Initiation – Narcolepsy (immediate-release and sustained-release formulations)
Neurologist or respiratory specialist
Re-assessment required after 24 months
Patient suffers from narcolepsy.

Continuation – Narcolepsy (immediate-release and sustained-release formulations)
Neurologist or respiratory specialist
Re-assessment required after 24 months
The treatment remains appropriate and the patient is benefiting from treatment.

continued…
continued...

**Initiation – Extended-release and modified-release formulations**

**Paediatrician or psychiatrist**

**Both:**

1. Patient has ADHD (Attention Deficit and Hyperactivity Disorder), diagnosed according to DSM-IV or ICD 10 criteria; and
2. Either:
   1. Patient is taking a currently listed formulation of methylphenidate hydrochloride (immediate-release or sustained-release) which has not been effective due to significant administration and/or compliance difficulties; or
   2. There is significant concern regarding the risk of diversion or abuse of immediate-release methylphenidate hydrochloride.

**MODAFINIL – Restricted** see terms below

<table>
<thead>
<tr>
<th>Product</th>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 100 mg</td>
<td>64.00</td>
<td>Modavigil</td>
</tr>
</tbody>
</table>

**Initiation – Narcolepsy**

**Neurologist or respiratory specialist**

**Re-assessment required after 24 months**

All of the following:

1. The patient has a diagnosis of narcolepsy and has excessive daytime sleepiness associated with narcolepsy occurring almost daily for three months or more; and
2. Either:
   1. The patient has a multiple sleep latency test with a mean sleep latency of less than or equal to 10 minutes and 2 or more sleep onset rapid eye movement periods; or
   2. The patient has at least one of: cataplexy, sleep paralysis or hypnagogic hallucinations; and
3. Either:
   1. An effective dose of a listed formulation of methylphenidate or dexamphetamine has been trialled and discontinued because of intolerable side effects; or
   2. Methylphenidate and dexamphetamine are contraindicated.

**Continuation – Narcolepsy**

**Neurologist or respiratory specialist**

**Re-assessment required after 24 months**

The treatment remains appropriate and the patient is benefiting from treatment.

**Treatments for Dementia**

**DONEPEZIL HYDROCHLORIDE**

<table>
<thead>
<tr>
<th>Product</th>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 5 mg</td>
<td>4.34</td>
<td>Donepezil-Rex</td>
</tr>
<tr>
<td>Tab 10 mg</td>
<td>6.64</td>
<td>Donepezil-Rex</td>
</tr>
</tbody>
</table>

**RIVASTIGMINE – Restricted** see terms below

<table>
<thead>
<tr>
<th>Product</th>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patch 4.6 mg per 24 hour</td>
<td>90.00</td>
<td>Exelon</td>
</tr>
<tr>
<td>Patch 9.5 mg per 24 hour</td>
<td>90.00</td>
<td>Exelon</td>
</tr>
</tbody>
</table>

**Initiation**

**Re-assessment required after 6 months**

Both:

1. The patient has been diagnosed with dementia; and
2. The patient has experienced intolerable nausea and/or vomiting from donepezil tablets.

continued…

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
NERVOUS SYSTEM

Price
(ex man. excl. GST) $ Per
Brand or Generic Manufacturer

continued…

Continuation
Re-assessment required after 12 months
Both:
1 The treatment remains appropriate; and
2 The patient has demonstrated a significant and sustained benefit from treatment.

Treatments for Substance Dependence

BUPRENORPHINE WITH NALOXONE – Restricted see terms below

↓ Tab 2 mg with naloxone 0.5 mg – 1% DV Apr-20 to 2022 ......................... 18.37 28  Buprenorphine Naloxone BNM Suboxone
57.40

↓ Tab 8 mg with naloxone 2 mg – 1% DV Apr-20 to 2022 ......................... 53.12 28  Buprenorphine Naloxone BNM Suboxone
166.00

(Suboxone Tab 2 mg with naloxone 0.5 mg to be delisted 1 April 2020)
(Suboxone Tab 8 mg with naloxone 2 mg to be delisted 1 April 2020)

Initiation – Detoxification
All of the following:
1 Patient is opioid dependent; and
2 Patient is currently engaged with an opioid treatment service approved by the Ministry of Health; and
3 Prescriber works in an opioid treatment service approved by the Ministry of Health.

Initiation – Maintenance treatment
All of the following:
1 Patient is opioid dependent; and
2 Patient will not be receiving methadone; and
3 Patient is currently enrolled in an opioid substitution treatment program in a service approved by the Ministry of Health; and
4 Prescriber works in an opioid treatment service approved by the Ministry of Health.

BUPROPION HYDROCHLORIDE
Tab modified-release 150 mg – 1% DV Jun-17 to 2020 ......................... 11.00 30  Zyban

DISULFIRAM
Tab 200 mg ................................................................. 153.00 100 Antabuse

NALTREXONE HYDROCHLORIDE – Restricted see terms below

↓ Tab 50 mg – 1% DV Sep-17 to 2020 ........................................... 112.55 30  Naltraccord

Initiation – Alcohol dependence
Both:
1 Patient is currently enrolled, or is planned to be enrolled, in a recognised comprehensive treatment programme for alcohol dependence; and
2 Naltrexone is to be prescribed by, or on the recommendation of, a physician working in an Alcohol and Drug Service.

Initiation – Constipation
For the treatment of opioid-induced constipation.
### NICOTINE – Some items restricted see terms below

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patch 7 mg per 24 hours – 1% DV Apr-18 to 2020</td>
<td>$17.28</td>
<td>Habitrol</td>
</tr>
<tr>
<td>Patch 14 mg per 24 hours – 1% DV Apr-18 to 2020</td>
<td>$19.00</td>
<td>Habitrol</td>
</tr>
<tr>
<td>Patch 21 mg per 24 hours – 1% DV Apr-18 to 2020</td>
<td>$21.77</td>
<td>Habitrol</td>
</tr>
<tr>
<td>Oral spray 1 mg per dose</td>
<td></td>
<td>e.g. Nicorette QuickMist</td>
</tr>
<tr>
<td>Lozenge 1 mg – 1% DV Apr-18 to 2020</td>
<td>$18.27</td>
<td>Habitrol</td>
</tr>
<tr>
<td>Lozenge 2 mg – 1% DV Apr-18 to 2020</td>
<td>$20.02</td>
<td>Habitrol</td>
</tr>
<tr>
<td>Soln for inhalation 15 mg cartridge</td>
<td></td>
<td>e.g. Nicorette Inhalator</td>
</tr>
<tr>
<td>Gum 2 mg – 1% DV Apr-18 to 2020</td>
<td>$36.39</td>
<td>Habitrol (Fruit)</td>
</tr>
<tr>
<td>Gum 4 mg – 1% DV Apr-18 to 2020</td>
<td>$42.07</td>
<td>Habitrol (Mint)</td>
</tr>
</tbody>
</table>

**⇒ Restricted (RS1310)**

**Initiation**

Any of the following:

1. For perioperative use in patients who have a 'nil by mouth' instruction; or
2. For use within mental health inpatient units; or
3. For acute use in agitated patients who are unable to leave the hospital facilities.

### VARENICLINE – Restricted see terms below

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 0.5 mg x 11 and 1 mg x 42 – 1% DV Mar-19 to 2021</td>
<td>$25.64</td>
<td>Varenicline Pfizer</td>
</tr>
<tr>
<td>Tab 1 mg – 1% DV Mar-19 to 2021</td>
<td>$27.10</td>
<td>Varenicline Pfizer</td>
</tr>
</tbody>
</table>

**⇒ Restricted (RS1702)**

**Initiation**

All of the following:

1. Short-term therapy as an aid to achieving abstinence in a patient who has indicated that they are ready to cease smoking; and
2. The patient is part of, or is about to enrol in, a comprehensive support and counselling smoking cessation programme, which includes prescriber or nurse monitoring; and
3. Either:
   3.1 The patient has tried but failed to quit smoking after at least two separate trials of nicotine replacement therapy, at least one of which included the patient receiving comprehensive advice on the optimal use of nicotine replacement therapy; or
   3.2 The patient has tried but failed to quit smoking using bupropion or nortriptyline; and
4. The patient has not had a Special Authority for varenicline approved in the last 6 months; and
5. Varenicline is not to be used in combination with other pharmacological smoking cessation treatments and the patient has agreed to this; and
6. The patient is not pregnant; and
7. The patient will not be prescribed more than 12 weeks' funded varenicline in a 12 month period.
Chemotherapeutic Agents

Alkylating Agents

BENDAMUSTINE HYDROCHLORIDE – **Restricted** see terms below

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST) $ Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Ribomustin</td>
<td>271.35</td>
</tr>
<tr>
<td>1 Ribomustin</td>
<td>1,085.38</td>
</tr>
</tbody>
</table>

**Restricted** (RS1578)

**Initiation – treatment naive CLL**

All of the following:

1. The patient has Binet stage B or C, or progressive stage A chronic lymphocytic leukaemia requiring treatment; and
2. The patient is chemotherapy treatment naive; and
3. The patient is unable to tolerate toxicity of full-dose FCR; and
4. Patient has ECOG performance status 0-2; and
5. Patient has a Cumulative Illness Rating Scale (CIRS) score of < 6; and
6. Bendamustine is to be administered at a maximum dose of 100 mg/m² on days 1 and 2 every 4 weeks for a maximum of 6 cycles.

Note: ‘Chronic lymphocytic leukaemia (CLL)’ includes small lymphocytic lymphoma (SLL). Chemotherapy treatment is considered to comprise a known standard therapeutic chemotherapy regimen and supportive treatments.

**Initiation – Indolent, Low-grade lymphomas**

*Re-assessment required after 9 months*

All of the following:

1. The patient has indolent low grade NHL requiring treatment; and
2. Patient has a WHO performance status of 0-2; and
3. Either:
   3.1 Both:
      3.1.1 Patient is treatment naive; and
      3.1.2 Bendamustine is to be administered for a maximum of 6 cycles (in combination with rituximab when CD20+); or
   3.2 All of the following:
      3.2.1 Patient has relapsed refractory disease following prior chemotherapy; and
      3.2.2 The patient has not received prior bendamustine therapy; and
      3.2.3 Either:
         3.2.3.1 Both:
            3.2.3.1.1 Bendamustine is to be administered for a maximum of 6 cycles in relapsed patients (in combination with rituximab when CD20+); and
            3.2.3.1.2 Patient has had a rituximab treatment-free interval of 12 months or more; or
         3.2.3.2 Bendamustine is to be administered as a monotherapy for a maximum of 6 cycles in rituximab refractory patients.

**Continuation – Indolent, Low-grade lymphomas**

*Re-assessment required after 9 months*

Both:

1. Patients have not received a bendamustine regimen within the last 12 months; and
2. Either:
   2.1 Both:
      2.1.1 Bendamustine is to be administered for a maximum of 6 cycles in relapsed patients (in combination with rituximab when CD20+); and
      2.1.2 Patient has had a rituximab treatment-free interval of 12 months or more; or

continued…

---

1 Item restricted (see ➥ above); 2 Item restricted (see ➥ below) 

*e.g. Brand* indicates brand example only. It is not a contracted product.
continued...

2.2 Bendamustine is to be administered as a monotherapy for a maximum of 6 cycles in rituximab refractory patients. Note: 'indolent, low-grade lymphomas' includes follicular, mantle cell, marginal zone and lymphoplasmacytic/Waldenström’s macroglobulinaemia.

<table>
<thead>
<tr>
<th>Product</th>
<th>Dose</th>
<th>Price</th>
<th>Brand or Generic</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>BUSULFAN</td>
<td>Tab 2 mg</td>
<td>89.25</td>
<td>100</td>
<td>Myleran</td>
</tr>
<tr>
<td></td>
<td>Inj 6 mg per ml, 10 ml ampoule</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CARMUSTINE</td>
<td>Inj 100 mg vial</td>
<td>1,387.00</td>
<td>1</td>
<td>BiCNU</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Bicnu Heritage</td>
</tr>
<tr>
<td>CHLORAMBUCIL</td>
<td>Tab 2 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CYCLOPHOSPHAMIDE</td>
<td>Tab 50 mg</td>
<td>79.00</td>
<td>50</td>
<td>Endoxan</td>
</tr>
<tr>
<td></td>
<td></td>
<td>158.00</td>
<td>100</td>
<td>Procysix</td>
</tr>
<tr>
<td></td>
<td>Inj 1 g vial – 1% DV Oct-18 to 2021</td>
<td>35.65</td>
<td>1</td>
<td>Endoxan</td>
</tr>
<tr>
<td></td>
<td>Inj 2 g vial – 1% DV Oct-18 to 2021</td>
<td>71.25</td>
<td>1</td>
<td>Endoxan</td>
</tr>
<tr>
<td>IFOSFAMIDE</td>
<td>Inj 1 g vial</td>
<td>96.00</td>
<td>1</td>
<td>Holoxan</td>
</tr>
<tr>
<td></td>
<td>Inj 2 g vial</td>
<td>180.00</td>
<td>1</td>
<td>Holoxan</td>
</tr>
<tr>
<td>LOMUSTINE</td>
<td>Cap 10 mg</td>
<td>132.59</td>
<td>20</td>
<td>Ceenu</td>
</tr>
<tr>
<td></td>
<td>Cap 40 mg</td>
<td>399.15</td>
<td>20</td>
<td>Ceenu</td>
</tr>
<tr>
<td>MELPHALAN</td>
<td>Tab 2 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inj 50 mg vial</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>THIOTEPA</td>
<td>Inj 15 mg vial</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inj 100 mg vial</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Anthracyclines and Other Cytotoxic Antibiotics

<table>
<thead>
<tr>
<th>Product</th>
<th>Dose</th>
<th>Price</th>
<th>Brand or Generic</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>BLEOMYCIN SULPHATE</td>
<td>Inj 15,000 iu vial – 1% DV Dec-18 to 2021</td>
<td>161.01</td>
<td>1</td>
<td>DBL Bleomycin Sulfate</td>
</tr>
<tr>
<td>DACTINOMYCIN [ACTINOMYCIN D]</td>
<td>Inj 0.5 mg vial</td>
<td>166.75</td>
<td>1</td>
<td>Cosmegen</td>
</tr>
<tr>
<td>DAUNORUBICIN</td>
<td>Inj 2 mg per ml, 10 ml vial</td>
<td>130.00</td>
<td>1</td>
<td>Pfizer</td>
</tr>
<tr>
<td>DOXORUBICIN HYDROCHLORIDE</td>
<td>Inj 2 mg per ml, 5 ml vial</td>
<td>11.50</td>
<td>1</td>
<td>Doxorubicin Ebewe</td>
</tr>
<tr>
<td></td>
<td>Inj 2 mg per ml, 25 ml vial</td>
<td></td>
<td></td>
<td>Doxorubicin Ebewe</td>
</tr>
<tr>
<td></td>
<td>Note: DV limit applies to all 50 mg presentations of doxorubicin hydrochloride.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inj 50 mg vial</td>
<td></td>
<td></td>
<td>Doxorubicin Ebewe</td>
</tr>
<tr>
<td></td>
<td>Inj 2 mg per ml, 50 ml vial – 1% DV Jan-19 to 2021</td>
<td>23.00</td>
<td>1</td>
<td>Doxorubicin Ebewe</td>
</tr>
<tr>
<td></td>
<td>Inj 2 mg per ml, 100 ml vial – 1% DV Jan-19 to 2021</td>
<td>56.15</td>
<td>1</td>
<td>Doxorubicin Ebewe</td>
</tr>
<tr>
<td>EPIRUBICIN HYDROCHLORIDE</td>
<td>Inj 2 mg per ml, 5 ml vial</td>
<td>25.00</td>
<td>1</td>
<td>Epirubicin Ebewe</td>
</tr>
<tr>
<td></td>
<td>Inj 2 mg per ml, 25 ml vial</td>
<td>30.00</td>
<td>1</td>
<td>Epirubicin Ebewe</td>
</tr>
<tr>
<td></td>
<td>Inj 2 mg per ml, 100 ml vial – 1% DV Apr-19 to 2021</td>
<td>85.00</td>
<td>1</td>
<td>Epirubicin Ebewe</td>
</tr>
</tbody>
</table>

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
<table>
<thead>
<tr>
<th>IDARUBICIN HYDROCHLORIDE</th>
<th>Price (ex man. excl. GST) $ Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 5 mg vial – 1% DV Sep-18 to 2021</td>
<td>93.00 1 Zavedos</td>
</tr>
<tr>
<td>Inj 10 mg vial – 1% DV Sep-18 to 2021</td>
<td>198.00 1 Zavedos</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>MITOMYCIN C</th>
<th>Price (ex man. excl. GST) $ Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 5 mg vial</td>
<td>204.08 1 Arrow</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>MITOZANTRONE</th>
<th>Price (ex man. excl. GST) $ Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 2 mg per ml, 10 ml vial</td>
<td>97.50 1 Mitozantrone Ebewe</td>
</tr>
</tbody>
</table>

### Antimetabolites

<table>
<thead>
<tr>
<th>AZACITIDINE – Restricted see terms below</th>
<th>Price (ex man. excl. GST) $ Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 100 mg vial – 1% DV Dec-18 to 2021</td>
<td>139.00 1 Azacitidine Dr Reddy’s</td>
</tr>
</tbody>
</table>

**Initiation**

Haematologist

*Re-assessment required after 12 months*

All of the following:

1. Any of the following:
   1.1 The patient has International Prognostic Scoring System (IPSS) intermediate-2 or high risk myelodysplastic syndrome; or
   1.2 The patient has chronic myelomonocytic leukaemia (10%-29% marrow blasts without myeloproliferative disorder); or
   1.3 The patient has acute myeloid leukaemia with 20-30% blasts and multi-lineage dysplasia, according to World Health Organisation Classification (WHO); and

2. The patient has performance status (WHO/ECOG) grade 0-2; and

3. The patient does not have secondary myelodysplastic syndrome resulting from chemical injury or prior treatment with chemotherapy and/or radiation for other diseases; and

4. The patient has an estimated life expectancy of at least 3 months.

**Continuation**

Haematologist

*Re-assessment required after 12 months*

Both:

1. No evidence of disease progression, and; and

2. The treatment remains appropriate and patient is benefitting from treatment.

<table>
<thead>
<tr>
<th>CAPECITABINE</th>
<th>Price (ex man. excl. GST) $ Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 150 mg</td>
<td>11.15 60 Brinov</td>
</tr>
<tr>
<td>Tab 500 mg</td>
<td>62.28 120 Brinov</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CLADRIBINE</th>
<th>Price (ex man. excl. GST) $ Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 2 mg per ml, 5 ml vial</td>
<td>5,249.72 7 Leustatin</td>
</tr>
<tr>
<td>Inj 1 mg per ml, 10 ml vial</td>
<td>5,249.72 7 Leustatin</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CYTARABINE</th>
<th>Price (ex man. excl. GST) $ Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 20 mg per ml, 5 ml vial</td>
<td>400.00 5 Pfizer</td>
</tr>
<tr>
<td>Inj 100 mg per ml, 20 ml vial – 1% DV Dec-18 to 2021</td>
<td>41.36 1 Pfizer</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>FLUDARABINE PHOSPHATE</th>
<th>Price (ex man. excl. GST) $ Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 10 mg – 1% DV Sep-18 to 2021</td>
<td>412.00 20 Fludara Oral</td>
</tr>
<tr>
<td>Inj 50 mg vial – 1% DV Nov-19 to 2022</td>
<td>576.45 5 Fludarabine Ebewe</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>FLUOROURACIL</th>
<th>Price (ex man. excl. GST) $ Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 50 mg per ml, 20 ml vial – 1% DV Oct-18 to 2021</td>
<td>12.00 1 Fluorouracil Ebewe</td>
</tr>
<tr>
<td>Inj 50 mg per ml, 100 ml vial – 1% DV Oct-18 to 2021</td>
<td>30.00 1 Fluorouracil Ebewe</td>
</tr>
</tbody>
</table>
### GEMCITABINE

<table>
<thead>
<tr>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$15.89</td>
<td>Gemcitabine Ebewe</td>
</tr>
</tbody>
</table>

### MERCAPTOPURINE

**Restricted (RS1635)**

**Initiation**
Paediatric haematologist or paediatric oncologist

*Re-assessment required after 12 months*

The patient requires a total dose of less than one full 50 mg tablet per day.

**Continuation**
Paediatric haematologist or paediatric oncologist

*Re-assessment required after 12 months*

The patient requires a total dose of less than one full 50 mg tablet per day.

### METHOTREXATE

<table>
<thead>
<tr>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$8.05</td>
<td>Trexate Sandoz</td>
</tr>
<tr>
<td>$31.75</td>
<td>Trexate</td>
</tr>
<tr>
<td>$14.61</td>
<td>Methotrexate Sandoz</td>
</tr>
<tr>
<td>$14.66</td>
<td>Methotrexate Sandoz</td>
</tr>
<tr>
<td>$14.77</td>
<td>Methotrexate Sandoz</td>
</tr>
<tr>
<td>$14.88</td>
<td>Methotrexate Sandoz</td>
</tr>
<tr>
<td>$14.99</td>
<td>Methotrexate Sandoz</td>
</tr>
<tr>
<td>$15.09</td>
<td>Methotrexate Sandoz</td>
</tr>
<tr>
<td>$30.00</td>
<td>DBL Methotrexate Onco-Vial</td>
</tr>
<tr>
<td>$45.00</td>
<td>DBL Methotrexate Onco-Vial</td>
</tr>
</tbody>
</table>

### PEMETREXED – Restricted see terms below

**Initiation – Mesothelioma**

*Re-assessment required after 8 months*

Both:

1. Patient has been diagnosed with mesothelioma; and
2. Pemetrexed to be administered at a dose of 500 mg/m² every 21 days in combination with cisplatin or carboplatin for a maximum of 6 cycles.

**Continuation – Mesothelioma**

*Re-assessment required after 8 months*

All of the following:

1. No evidence of disease progression; and
2. The treatment remains appropriate and the patient is benefitting from treatment; and
3. Pemetrexed to be administered at a dose of 500mg/m² every 21 days for a maximum of 6 cycles.
continued...

Initiation – Non small cell lung cancer
_re-assessment required after 8 months_

Both:
1. Patient has locally advanced or metastatic non-squamous non-small cell lung carcinoma; and
2. Either:
   2.1 Both:
      2.1.1 Patient has chemotherapy-naive disease; and
      2.1.2 Pemetrexed is to be administered at a dose of 500 mg/m² every 21 days in combination with cisplatin or carboplatin for a maximum of 6 cycles; or
   2.2 All of the following:
      2.2.1 Patient has had first-line treatment with platinum based chemotherapy; and
      2.2.2 Patient has not received prior funded treatment with pemetrexed; and
      2.2.3 Pemetrexed is to be administered at a dose of 500 mg/m² every 21 days for a maximum of 6 cycles.

Continuation – Non small cell lung cancer
_re-assessment required after 8 months_

All of the following:
1. No evidence of disease progression; and
2. The treatment remains appropriate and the patient is benefitting from treatment; and
3. Pemetrexed is to be administered at a dose of 500 mg/m² every 21 days.

THIOGUANINE
Tab 40 mg

_Other Cytotoxic Agents_

AMSACRINE
Inj 50 mg per ml, 1.5 ml ampoule
Inj 75 mg

ANAGRELI DE HYDROCHLORIDE
Cap 0.5 mg

ARSENC TRIOXIDE
Inj 1 mg per ml, 10 ml vial.................................................................4,817.00 10 Phenasen

BORTEZOMIB – Restricted see terms below
Inj 3.5 mg vial.................................................................1,892.50 1 Velcade

Initiation – treatment naive multiple myeloma/amyloidosis
_Limited to 15 months_ treatment

Both:
1. Either:
   1.1 The patient has treatment-naive symptomatic multiple myeloma; or
   1.2 The patient has treatment-naive symptomatic systemic AL amyloidosis; and

Initiation – relapsed/refractory multiple myeloma/amyloidosis
_re-assessment required after 8 months_

All of the following:
1. Either:
   1.1 The patient has relapsed or refractory multiple myeloma; or

continued…
1.2 The patient has relapsed or refractory systemic AL amyloidosis; and
2 The patient has received only one prior front line chemotherapy for multiple myeloma or amyloidosis; and
3 The patient has not had prior publicly funded treatment with bortezomib; and
4 Maximum of 4 treatment cycles.

Continuation – relapsed/refractory multiple myeloma/amyloidosis

Re-assessment required after 8 months

Both:
1 The patient's disease obtained at least a partial response from treatment with bortezomib at the completion of cycle 4; and
2 Maximum of 4 further treatment cycles (making a total maximum of 8 consecutive treatment cycles).

Notes: Responding relapsed/refractory multiple myeloma patients should receive no more than 2 additional cycles of treatment beyond the cycle at which a confirmed complete response was first achieved. A line of therapy is considered to comprise either:
1 A known therapeutic chemotherapy regimen and supportive treatments; or
2 A transplant induction chemotherapy regimen, stem cell transplantation and supportive treatments.

Refer to datasheet for recommended dosage and number of doses of bortezomib per treatment cycle.

COLASPASE [L-ASPARAGINASE]

Inj 10,000 iu vial.............................................................................................102.32 1 Leunase

(Dacarbazine Inj 10,000 iu vial to be delisted 1 December 2020)

DACARBAZINE

Inj 200 mg vial.................................................................................................58.06 1 DBL Dacarbazine

ETOPOSIDE

Cap 50 mg – 1% DV Jul-19 to 2022.................................................................340.73 20 Vepesid
Cap 100 mg – 1% DV Jul-19 to 2022.................................................................340.73 10 Vepesid
Inj 20 mg per ml, 5 ml vial............................................................................7.90 1 Rex Medical

ETOPOSIDE (AS PHOSPHATE)

Inj 100 mg vial..................................................................................................40.00 1 Etopophos

HYDROXYUREA

Cap 500 mg......................................................................................................31.76 100 Hydrea

IRINOTECAN HYDROCHLORIDE

Inj 20 mg per ml, 5 ml vial – 1% DV Apr-19 to 2021.................................71.44 1 Irinotecan Actavis 100

LENALIDOMIDE – Restricted see terms below

Cap 10 mg.......................................................................................................6,207.00 21 Revlimid
Cap 15 mg.......................................................................................................7,239.18 21 Revlimid
Cap 25 mg.......................................................................................................7,627.00 21 Revlimid

→ Restricted (RS1419)

Initiation

Haematologist

Re-assessment required after 6 months

All of the following:
1 Patient has relapsed or refractory multiple myeloma with progressive disease; and
2 Either:
   2.1 Lenalidomide to be used as third line* treatment for multiple myeloma; or
   2.2 Both:
      2.2.1 Lenalidomide to be used as second line treatment for multiple myeloma; and
      2.2.2 The patient has experienced severe (grade 3 or higher), dose limiting, peripheral neuropathy with either bortezomib or thalidomide that precludes further treatment with either of these treatments; and

continued…
### ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST) Per</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Continued...

3. Lenalidomide to be administered at a maximum dose of 25 mg/day in combination with dexamethasone.

**Continuation**

Haematologist

*Re-assessment required after 6 months*

Both:

1. No evidence of disease progression; and
2. The treatment remains appropriate and patient is benefitting from treatment.

Note: Indication marked with * is an unapproved indication. A line of treatment is considered to comprise either: a) a known therapeutic chemotherapy regimen and supportive treatments or b) a transplant induction chemotherapy regimen, stem cell transplantation and supportive treatments. Prescriptions must be written by a registered prescriber in the lenalidomide risk management programme operated by the supplier.

**PEGASPARGASE – Restricted** see terms below

- **Inj 750 iu per ml, 5 ml vial**

  - $3,005.00  1 Oncaspar
  - Oncaspar LYO

*(Oncaspar Inj 750 iu per ml, 5 ml vial to be delisted 1 May 2020)*

**Initiation – Newly diagnosed ALL**

*Limited to 12 months treatment*

All of the following:

1. The patient has newly diagnosed acute lymphoblastic leukaemia; and
2. Pegaspargase to be used with a contemporary intensive multi-agent chemotherapy treatment protocol; and
3. Treatment is with curative intent.

**Initiation – Relapsed ALL**

*Limited to 12 months treatment*

All of the following:

1. The patient has relapsed acute lymphoblastic leukaemia; and
2. Pegaspargase to be used with a contemporary intensive multi-agent chemotherapy treatment protocol; and
3. Treatment is with curative intent.

**PENTOSTATIN [DEOXYCOFORMYCIN]**

- Inj 10 mg vial

**PROCARBAZINE HYDROCHLORIDE**

- Cap 50 mg

  - $980.00  50 Natulan

**TEMOZOLOMIDE – Restricted** see terms on the next page

- Cap 5 mg – 1% DV May-20 to 2022
  - $10.20  5 Orion Temozolomide
  - Temaccord

- Cap 20 mg – 1% DV May-20 to 2022
  - $18.30  5 Orion Temozolomide
  - Temaccord

- Cap 100 mg – 1% DV May-20 to 2022
  - $40.20  5 Orion Temozolomide
  - Temaccord

- Cap 140 mg – 1% DV May-20 to 2022
  - $50.12  5 Orion Temozolomide

- Cap 250 mg – 1% DV May-20 to 2022
  - $96.80  5 Orion Temozolomide

*(Orion Temozolomide Cap 5 mg to be delisted 1 May 2020)*

*(Orion Temozolomide Cap 20 mg to be delisted 1 May 2020)*

*(Orion Temozolomide Cap 100 mg to be delisted 1 May 2020)*

*(Orion Temozolomide Cap 250 mg to be delisted 1 May 2020)*

---

*Item restricted (see ➕ above); Item restricted (see ➕ below)*

*e.g. Brand* indicates brand example only. It is not a contracted product.
ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

Price
(ex man. excl. GST)
$ Per
Brand or
Generic
Manufacturer

Restricted (RS1645)

Initiation – High grade gliomas
Re-assessment required after 12 months
All of the following:

1 Either:
   1.1 Patient has newly diagnosed glioblastoma multiforme; or
   1.2 Patient has newly diagnosed anaplastic astrocytoma*; and
2 Temozolomide is to be (or has been) given concomitantly with radiotherapy; and
3 Following concomitant treatment temozolomide is to be used for a maximum of 5 days treatment per cycle at a maximum dose of 200 mg/m² per day.

Continuation – High grade gliomas
Re-assessment required after 12 months
Either:

1 Both:
   1.1 Patient has glioblastoma multiforme; and
   1.2 The treatment remains appropriate and the patient is benefitting from treatment; or
2 All of the following:
   2.1 Patient has anaplastic astrocytoma*; and
   2.2 The treatment remains appropriate and the patient is benefitting from treatment; and
   2.3 Adjuvant temozolomide is to be used for a maximum of 24 months.

Initiation – Neuroendocrine tumours
Re-assessment required after 9 months
All of the following:

1 Patient has been diagnosed with metastatic or unresectable well-differentiated neuroendocrine tumour*; and
2 Temozolomide is to be given in combination with capecitabine; and
3 Temozolomide is to be used in 28 day treatment cycles for a maximum of 5 days treatment per cycle at a maximum dose of 200 mg/m² per day; and
4 Temozolomide to be discontinued at disease progression.

Continuation – Neuroendocrine tumours
Re-assessment required after 6 months
Both:

1 No evidence of disease progression; and
2 The treatment remains appropriate and the patient is benefitting from treatment.

Initiation – ewing's sarcoma
Re-assessment required after 9 months
Patient has relapse or refractory Ewing’s sarcoma.

Continuation – ewing's sarcoma
Re-assessment required after 6 months
Both:

1 No evidence of disease progression; and
2 The treatment remains appropriate and the patient is benefitting from treatment.

Note: Indication marked with a * is an unapproved indication. Temozolomide is not funded for the treatment of relapsed high grade glioma.

THALIDOMIDE – Restricted see terms below

Cap 50 mg.................................................378.00 28 Thalomid
Cap 100 mg....................................................756.00 28 Thalomid

Restricted (RS1192)

Initiation
Re-assessment required after 12 months
Any of the following:

continued…
continued…

1 The patient has multiple myeloma; or
2 The patient has systemic AL amyloidosis*; or
3 The patient has erythema nodosum leprosum.

Continuation
Patient has obtained a response from treatment during the initial approval period.
Notes: Prescription must be written by a registered prescriber in the thalidomide risk management programme operated by the supplier
Maximum dose of 400 mg daily as monotherapy or in a combination therapy regimen

Indication marked with * is an unapproved indication

TRETINOIN
Cap 10 mg.....................................................................................................479.50 100 Vesanoid

VENETOCLAX – Restricted see terms below
 endorse
Tab 14 x 10 mg, 7 x 50 mg, 21 x 100 mg..................................................1,771.86 42 Venclexta
 endorse
Tab 10 mg .....................................................................................................95.78 14 Venclexta
 endorse
Tab 50 mg .....................................................................................................239.44 7 Venclexta
 endorse
Tab 100 mg .................................................................................................8,209.41 120 Venclexta

 ← Restricted (RS1713)
Initiation – relapsed/refractory chronic lymphocytic leukaemia
Haematologist
Re-assessment required after 7 months
All of the following:
1 Patient has chronic lymphocytic leukaemia requiring treatment; and
2 Patient has received at least one prior therapy for chronic lymphocytic leukaemia; and
3 Patient has not previously received funded venetoclax; and
4 The patient’s disease has relapsed within 36 months of previous treatment; and
5 Venetoclax to be used in combination with six 28-day cycles of rituximab commencing after the 5-week dose titration schedule with venetoclax; and
6 Patient has an ECOG performance status of 0-2.

Continuation – relapsed/refractory chronic lymphocytic leukaemia
Haematologist
Re-assessment required after 6 months
Both:
1 Treatment remains clinically appropriate and the patient is benefitting from and tolerating treatment; and
2 Venetoclax is to be discontinued after a maximum of 24 months of treatment following the titration schedule unless earlier discontinuation is required due to disease progression or unacceptable toxicity.

Initiation – previously untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation*
Haematologist
Re-assessment required after 6 months
All of the following:
1 Patient has previously untreated chronic lymphocytic leukaemia; and
2 There is documentation confirming that patient has 17p deletion by FISH testing or TP53 mutation by sequencing; and
3 Patient has an ECOG performance status of 0-2.

Continuation – previously untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation*
Haematologist
Re-assessment required after 6 months
The treatment remains clinically appropriate and the patient is benefitting from and tolerating treatment.
Note: ‘Chronic lymphocytic leukaemia (CLL)” includes small lymphocytic lymphoma (SLL)” and B-cell prolymphocytic leukaemia (B-PLL)”. Indications marked with * are unapproved indications.
Platinum Compounds

CARBOPLATIN
Inj 10 mg per ml, 45 ml vial – 1% DV Jun-19 to 2021 ............................................... 45.20 1 Carboplatin Ebewe

CISPLATIN
Inj 1 mg per ml, 50 ml vial ................................................................................ 12.29 1 DBL Cisplatin
Inj 1 mg per ml, 100 ml vial – 1% DV Sep-18 to 2021 ........................................ 19.70 1 DBL Cisplatin

OXALIPLATIN
Inj 5 mg per ml, 20 ml vial – 1% DV Feb-20 to 2021 ....................................... 46.32 1 Oxaliccord

(Oxaliccord Inj 5 mg per ml, 20 ml vial to be delisted 1 February 2020)

Protein-Tyrosine Kinase Inhibitors

ALECTINIB – Restricted see terms below
Cap 150 mg .................................................................................................. 7,935.00 224 Alecensa

Initiation
Re-assessment required after 6 months
All of the following:
1 Patient has locally advanced, or metastatic, unresectable, non-small cell lung cancer; and
2 There is documentation confirming that the patient has an ALK tyrosine kinase gene rearrangement using an appropriate ALK test; and
3 Patient has an ECOG performance score of 0-2.

Continuation
Re-assessment required after 6 months
Both:
1 No evidence of progressive disease according to RECIST criteria; and
2 The patient is benefitting from and tolerating treatment.

DASATINIB – Restricted see terms below
Tab 20 mg .................................................................................................. 3,774.06 60 Sprycel
Tab 50 mg .................................................................................................. 6,214.20 60 Sprycel
Tab 70 mg .................................................................................................. 7,692.58 60 Sprycel

Initiation
Haematologist or any relevant practitioner on the recommendation of a haematologist
Re-assessment required after 6 months
Any of the following:
1 Both:
   1.1 The patient has a diagnosis of chronic myeloid leukaemia (CML) in blast crisis or accelerated phase; and
   1.2 Maximum dose of 140 mg/day; or
2 Both:
   2.1 The patient has a diagnosis of Philadelphia chromosome-positive acute lymphoid leukaemia (Ph+ ALL); and
   2.2 Maximum dose of 140 mg/day; or
3 All of the following:
   3.1 The patient has a diagnosis of CML in chronic phase; and
   3.2 Maximum dose of 100 mg/day; and

continued…
continued...

3.3 Any of the following:
   3.3.1 Patient has documented treatment failure* with imatinib; or
   3.3.2 Patient has experienced treatment-limiting toxicity with imatinib precluding further treatment with imatinib; or
   3.3.3 Patient has high-risk chronic-phase CML defined by the Sokal or EURO scoring system; or
   3.3.4 Patients is enrolled in the KISS study** and requires dasatinib treatment according to the study protocol.

Continuation
Haematologist or any relevant practitioner on the recommendation of a haematologist
* Re-assessment required after 6 months

All of the following:
1. Lack of treatment failure while on dasatinib*; and
2. Dasatinib treatment remains appropriate and the patient is benefiting from treatment; and
3. Maximum dasatinib dose of 140 mg/day for accelerated or blast phase CML and Ph+ ALL, and 100 mg/day for chronic phase CML.

Note: *treatment failure for CML as defined by Leukaemia Net Guidelines. **Kinase-Inhibition Study with Sprycel Start-up
https://www.cancertrialsnz.ac.nz/kiss/

ERLOTINIB – Restricted see terms below

◆ Tab 100 mg ................................................................. 764.00 30 Tarceva
◆ Tab 150 mg ................................................................. 1,146.00 30 Tarceva

→ Restricted (RS1579)

Initiation
* Re-assessment required after 4 months

All of the following:
1. Patient has locally advanced or metastatic, unresectable, non-squamous Non Small Cell Lung Cancer (NSCLC); and
2. There is documentation confirming that the disease expresses activating mutations of EGFR tyrosine kinase; and
3. Either:
   3.1 Patient is treatment naive; or
   3.2 Both:
      3.2.1 The patient has discontinued getitinib due to intolerance; and
      3.2.2 The cancer did not progress while on gefitinib; and
4. Erlotinib is to be given for a maximum of 3 months.

Continuation
* Re-assessment required after 6 months

Both:
1. Radiological assessment (preferably including CT scan) indicates NSCLC has not progressed; and
2. Erlotinib is to be given for a maximum of 3 months.

GEFITINIB – Restricted see terms below

◆ Tab 250 mg ................................................................. 1,700.00 30 Iressa

→ Restricted (RS1580)

Initiation
* Re-assessment required after 4 months

All of the following:
1. Patient has locally advanced, or metastatic, unresectable, non-squamous Non Small Cell Lung Cancer (NSCLC); and
2. Either:
   2.1 Patient is treatment naive; or
   2.2 Both:
      2.2.1 The patient has discontinued erlotinib due to intolerance; and
continued…
continued...

2.2.2 The cancer did not progress whilst on erlotinib; and
3. There is documentation confirming that disease expresses activating mutations of EGFR tyrosine kinase; and
4. Gefitinib is to be given for a maximum of 3 months.

Continuation

*Re-assessment required after 6 months*

Both:

1. Radiological assessment (preferably including CT scan) indicates NSCLC has not progressed; and
2. Gefitinib is to be given for a maximum of 3 months.

**IMATINIB MESILATE**

Imatinib-AFT is not a registered for the treatment of Gastro Intestinal Stromal Tumours (GIST). The Glivec brand of imatinib mesilate (supplied by Novartis) remains fully subsidised under Special Authority for patients with unresectable and/or metastatic malignant GIST, see SA1460 in Section B of the Pharmaceutical Schedule.

<table>
<thead>
<tr>
<th>Tab</th>
<th>Price (ex man. excl. GST) Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>100 mg</td>
<td>2,400.00 60 Glivec</td>
</tr>
</tbody>
</table>

**Initiation**

*Re-assessment required after 12 months*

Both:

1. Patient has diagnosis (confirmed by an oncologist) of unresectable and/or metastatic malignant gastrointestinal stromal tumour (GIST); and
2. Maximum dose of 400 mg/day.

**Continuation**

*Re-assessment required after 12 months*

Adequate clinical response to treatment with imatinib (prescriber determined).

Note: The Glivec brand of imatinib mesilate (supplied by Novartis) remains fully subsidised under Special Authority for patients with unresectable and/or metastatic malignant GIST, see SA1460 in Section B of the Pharmaceutical Schedule.

<table>
<thead>
<tr>
<th>Cap 100 mg – 1% DV Oct-17 to 2020</th>
<th>Price (ex man. excl. GST) Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>98.00</td>
<td>60 Imatinib-AFT</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Cap 400 mg – 1% DV Oct-17 to 2020</th>
<th>Price (ex man. excl. GST) Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>197.50</td>
<td>30 Imatinib-AFT</td>
</tr>
</tbody>
</table>

**LAPATINIB** – Restricted see terms below

<table>
<thead>
<tr>
<th>Tab 250 mg</th>
<th>Price (ex man. excl. GST) Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>1,899.00</td>
<td>70 Tykerb</td>
</tr>
</tbody>
</table>

**Initiation**

*Re-assessment required after 12 months*

Either:

1. All of the following:
   1.1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
   1.2 The patient has not previously received trastuzumab treatment for HER 2 positive metastatic breast cancer; and
   1.3 Lapatinib not to be given in combination with trastuzumab; and
   1.4 Lapatinib to be discontinued at disease progression; or

2. All of the following:
   2.1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
   2.2 The patient started trastuzumab for metastatic breast cancer but discontinued trastuzumab within 3 months of starting treatment due to intolerance; and
   2.3 The cancer did not progress whilst on trastuzumab; and
   2.4 Lapatinib not to be given in combination with trastuzumab; and

continued…
continued...

2.5 Lapatinib to be discontinued at disease progression.

**Continuation**

*Re-assessment required after 12 months*

All of the following:

1. The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
2. The cancer has not progressed at any time point during the previous 12 months whilst on lapatinib; and
3. Lapatinib not to be given in combination with trastuzumab; and
4. Lapatinib to be discontinued at disease progression.

**NILOTINIB – Restricted** see terms below

<table>
<thead>
<tr>
<th>Cap 150 mg</th>
<th>4,680.00</th>
<th>120</th>
<th>Tasigna</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cap 200 mg</td>
<td>6,532.00</td>
<td>120</td>
<td>Tasigna</td>
</tr>
</tbody>
</table>

**Initiation**

Haematologist

*Re-assessment required after 6 months*

All of the following:

1. Patient has a diagnosis of chronic myeloid leukaemia (CML) in blast crisis, accelerated phase, or in chronic phase; and
2. Either:
   1. Patient has documented CML treatment failure* with imatinib; or
   2. Patient has experienced treatment limiting toxicity with imatinib precluding further treatment with imatinib; and
3. Maximum nilotinib dose of 800 mg/day; and
4. Subsidised for use as monotherapy only.

Note: *treatment failure as defined by Leukaemia Net Guidelines.

**Continuation**

Haematologist

*Re-assessment required after 6 months*

All of the following:

1. Lack of treatment failure while on nilotinib as defined by Leukaemia Net Guidelines; and
2. Nilotinib treatment remains appropriate and the patient is benefiting from treatment; and
3. Maximum nilotinib dose of 800 mg/day; and
4. Subsidised for use as monotherapy only.

**PAZOPANIB – Restricted** see terms below

<table>
<thead>
<tr>
<th>Tab 200 mg</th>
<th>1,334.70</th>
<th>30</th>
<th>Votrient</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 400 mg</td>
<td>2,669.40</td>
<td>30</td>
<td>Votrient</td>
</tr>
</tbody>
</table>

**Initiation**

*Re-assessment required after 3 months*

All of the following:

1. The patient has metastatic renal cell carcinoma; and
2. Any of the following:
   1. The patient is treatment naive; or
   2. The patient has only received prior cytokine treatment; or
   3. Both:
      1. The patient has discontinued sunitinib within 3 months of starting treatment due to intolerance; and
      2. The cancer did not progress whilst on sunitinib; and

continued…
continued...

3 The patient has good performance status (WHO/ECOG grade 0-2); and
4 The disease is of predominant clear cell histology; and
5 All of the following:
   5.1 Lactate dehydrogenase level > 1.5 times upper limit of normal; and
   5.2 Haemoglobin level < lower limit of normal; and
   5.3 Corrected serum calcium level > 10 mg/dL (2.5 mmol/L); and
   5.4 Interval of < 1 year from original diagnosis to the start of systemic therapy; and
   5.5 Karnofsky performance score of less than or equal to 70; and
   5.6 2 or more sites of organ metastasis.

Continuation
Re-assessment required after 3 months
Both:
   1 No evidence of disease progression; and
   2 The treatment remains appropriate and the patient is benefiting from treatment.

Notes: Pazopanib treatment should be stopped if disease progresses.
Poor prognosis patients are defined as having at least 3 of criteria 5.1-5.6. Intermediate prognosis patients are defined as having 1 or 2 of criteria 5.1-5.6.

RUXOLITINIB – Restricted see terms below
Initiation
Haematologist
Re-assessment required after 12 months
All of the following:
   1 The patient has primary myelofibrosis or post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis; and
   2 A classification of risk of intermediate-2 or high-risk myelofibrosis according to either the International Prognostic Scoring System (IPSS), Dynamic International Prognostic Scoring System (DIPSS), or the Age-Adjusted DIPSS; and
   3 A maximum dose of 20 mg twice daily is to be given.

Continuation
Haematologist
Re-assessment required after 12 months
Both:
   1 The treatment remains appropriate and the patient is benefiting from treatment; and
   2 A maximum dose of 20 mg twice daily is to be given.

SUNITINIB – Restricted see terms below
Initiation – RCC
Re-assessment required after 3 months
All of the following:
   1 The patient has metastatic renal cell carcinoma; and
continued...

2 Any of the following:
   2.1 The patient is treatment naive; or
   2.2 The patient has only received prior cytokine treatment; or
   2.3 The patient has only received prior treatment with an investigational agent within the confines of a bona fide clinical trial which has Ethics Committee approval; or
   2.4 Both:
      2.4.1 The patient has discontinued pazopanib within 3 months of starting treatment due to intolerance; and
      2.4.2 The cancer did not progress whilst on pazopanib; and

3 The patient has good performance status (WHO/ECOG grade 0-2); and

4 The disease is of predominant clear cell histology; and

5 All of the following:
   5.1 Lactate dehydrogenase level > 1.5 times upper limit of normal; and
   5.2 Haemoglobin level < lower limit of normal; and
   5.3 Corrected serum calcium level > 10 mg/dL (2.5 mmol/L); and
   5.4 Interval of < 1 year from original diagnosis to the start of systemic therapy; and
   5.5 Karnofsky performance score of less than or equal to 70; and
   5.6 2 or more sites of organ metastasis; and

6 Sunitinib to be used for a maximum of 2 cycles.

Notes: RCC - Sunitinib treatment should be stopped if disease progresses. Poor prognosis patients are defined as having at least 3 of criteria 5.1-5.6. Intermediate prognosis patients are defined as having 1 or 2 of criteria 5.1-5.6.

Continuation – RCC
Re-assessment required after 3 months
Both:
   1 No evidence of disease progression; and
   2 The treatment remains appropriate and the patient is benefiting from treatment.

Initiation – GIST
Re-assessment required after 3 months
Both:
   1 The patient has unresectable or metastatic malignant gastrointestinal stromal tumour (GIST); and
   2 Either:
      2.1 The patient's disease has progressed following treatment with imatinib; or
      2.2 The patient has documented treatment-limiting intolerance, or toxicity to, imatinib.

Continuation – GIST
Re-assessment required after 6 months
Both:

The patient has responded to treatment or has stable disease as determined by Choi's modified CT response evaluation criteria as follows:

1 Any of the following:
   1.1 The patient has had a complete response (disappearance of all lesions and no new lesions); or
   1.2 The patient has had a partial response (a decrease in size of 10% or more or decrease in tumour density in Hounsfield Units (HU) of 15% or more on CT and no new lesions and no obvious progression of non-measurable disease); or
   1.3 The patient has stable disease (does not meet criteria the two above) and does not have progressive disease and no symptomatic deterioration attributed to tumour progression; and

2 The treatment remains appropriate and the patient is benefiting from treatment.

Note: GIST - It is recommended that response to treatment be assessed using Choi's modified CT response evaluation criteria (J... continued...
continued...
Clin Oncol, 2007, 25:1753-1759). Progressive disease is defined as either: an increase in tumour size of 10% or more and not meeting criteria of partial response (PR) by tumour density (HU) on CT; or: new lesions, or new intratumoral nodules, or increase in the size of the existing intratumoral nodules.

### Taxanes

**DOCETAXEL**
- Inj 10 mg per ml, 2 ml vial – 1% DV Sep-17 to 2020 ........................................ 12.40 1 DBL Docetaxel
- Inj 10 mg per ml, 8 ml vial – 1% DV Sep-17 to 2020 ..................................... 26.95 1 DBL Docetaxel

**PACLITAXEL**
- Inj 6 mg per ml, 5 ml vial – 1% DV Oct-17 to 2020 ........................................ 47.30 5 Paclitaxel Ebewe
- Inj 6 mg per ml, 16.7 ml vial – 1% DV Oct-17 to 2020 ................................ 20.00 1 Paclitaxel Ebewe
- Inj 6 mg per ml, 25 ml vial ................................................................. 26.69 1 Paclitaxel Ebewe
- Inj 6 mg per ml, 50 ml vial – 1% DV Oct-17 to 2020 ................................ 35.35 1 Paclitaxel Ebewe

### Treatment of Cytotoxic-Induced Side Effects

**CALCIUM FOLINATE**
- Tab 15 mg ................................................................................................ 104.26 10 DBL Leucovorin Calcium
- Inj 3 mg per ml, 1 ml ampoule ............................................................... 18.25 5 Calcium Folate Ebewe
- Inj 10 mg per ml, 5 ml ampoule ............................................................ 7.28 1 Calcium Folate Ebewe
- Inj 10 mg per ml, 10 ml vial – 1% DV Jan-20 to 2022 ................................ 7.33 1 Calcium Folate Ebewe
- Inj 10 mg per ml, 10 ml vial ................................................................. 9.49 1 Calcium Folate Ebewe
- Inj 10 mg per ml, 30 ml vial ................................................................. 22.51 1 Calcium Folate Ebewe
- Inj 10 mg per ml, 35 ml vial – 1% DV Nov-19 to 2022 .......................... 25.14 1 Calcium Folate Ebewe
- Inj 10 mg per ml, 100 ml vial – 1% DV Mar-20 to 2022 ..................... 67.51 1 Calcium Folate Ebewe
- Inj 10 mg per ml, 100 ml vial ............................................................... 72.00 1 Calcium Folate Ebewe

*(Calcium Folate Ebewe Inj 10 mg per ml, 10 ml vial to be delisted 1 January 2020)*
*(Calcium Folate Ebewe Inj 10 mg per ml, 100 ml vial to be delisted 1 March 2020)*

**DEXRAZOXANE** – **Restricted** see terms **below**
- Inj 500 mg ................................................................. e.g. Cardioxane

*Restricted (RS1695)*

**Initiation**
Medical oncologist, paediatric oncologist, haematologist or paediatric haematologist

All of the following:
1. Patient is to receive treatment with high dose anthracycline given with curative intent; and
2. Based on current treatment plan, patient’s cumulative lifetime dose of anthracycline will exceed 250mg/m² doxorubicin equivalent or greater; and
3. Dexrazoxane to be administered only whilst on anthracycline treatment; and
4. Either:
   4.1 Treatment to be used as a cardioprotectant for a child or young adult; or
   4.2 Treatment to be used as a cardioprotectant for secondary malignancy.
## Oncology Agents and Immunosuppressants

<table>
<thead>
<tr>
<th>MESNA</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 400 mg – 1% DV Nov-19 to 2022</td>
<td>$314.00</td>
</tr>
<tr>
<td>Tab 600 mg – 1% DV Nov-19 to 2022</td>
<td>$448.50</td>
</tr>
<tr>
<td>Inj 100 mg per ml, 4 ml ampoule – 1% DV Nov-19 to 2022</td>
<td>$177.45</td>
</tr>
<tr>
<td>Inj 100 mg per ml, 10 ml ampoule – 1% DV Nov-19 to 2022</td>
<td>$407.40</td>
</tr>
</tbody>
</table>

## Vinca Alkaloids

**VINBLASTINE SULPHATE**
- Inj 1 mg per ml, 10 ml vial: $186.46 5 Hospira

**VINCRIStINE SULPHATE**
- Inj 1 mg per ml, 1 ml vial: $74.52 5 DBL Vincristine Sulfate
- Inj 1 mg per ml, 2 ml vial: $85.61 5 DBL Vincristine Sulfate

**VINORELBINE**
- Inj 10 mg per ml, 1 ml vial: $12.00 1 Navelbine
- Inj 10 mg per ml, 5 ml vial: $56.00 1 Navelbine

## Endocrine Therapy

**ABIRATERONE ACETATE** – **Restricted** see terms below
- Tab 250 mg: $4,276.19 120 Zytiga

**Initiation**
- Medical oncologist, radiation oncologist or urologist
- Re-assessment required after 6 months
- All of the following:
  1. Patient has prostate cancer; and
  2. Patient has metastases; and
  3. Patient’s disease is castration resistant; and
  4. Either:
     4.1 All of the following:
        4.1.1 Patient is symptomatic; and
        4.1.2 Patient has disease progression (rising serum PSA) after second line anti-androgen therapy; and
        4.1.3 Patient has ECOG performance score of 0-1; and
        4.1.4 Patient has not had prior treatment with taxane chemotherapy; or
    4.2 All of the following:
      4.2.1 Patient’s disease has progressed following prior chemotherapy containing a taxane; and
      4.2.2 Patient has ECOG performance score of 0-2; and
      4.2.3 Patient has not had prior treatment with abiraterone.

**Continuation**
- Medical oncologist, radiation oncologist or urologist
- Re-assessment required after 6 months
- All of the following:
  1. Significant decrease in serum PSA from baseline; and
  2. No evidence of clinical disease progression; and
  3. No initiation of taxane chemotherapy with abiraterone; and
  4. The treatment remains appropriate and the patient is benefiting from treatment.

**BICALUTAMIDE**
- Tab 50 mg – 1% DV Feb-18 to 2020: $3.80 28 Binarex

**FLUTAMIDE**
- Tab 250 mg: $119.50 100 Flutamin
MEGESTROL ACETATE
Tab 160 mg – 1% DV Oct-18 to 2021 ............................................................ 63.53 30 Apo-Megestrol

OCTREOTIDE – Some items restricted see terms below
Inj 50 mcg per ml, 1 ml ampoule – 1% DV Nov-17 to 2020 ........................................ 30.64 5 DBL Octreotide
Inj 100 mcg per ml, 1 ml ampoule – 1% DV Nov-17 to 2020 .............................. 18.69 5 DBL Octreotide
Inj 500 mcg per ml, 1 ml ampoule – 1% DV Nov-17 to 2020 .............................. 72.50 5 DBL Octreotide
Inj 10 mg vial .............................................................................................. 1,772.50 1 Sandostatin LAR
Inj 20 mg vial .............................................................................................. 2,358.75 1 Sandostatin LAR
Inj 30 mg vial .............................................................................................. 2,951.25 1 Sandostatin LAR

Initiation – Malignant bowel obstruction
All of the following:
1. The patient has nausea* and vomiting* due to malignant bowel obstruction*; and
2. Treatment with antiemetics, rehydration, antimuscarinic agents, corticosteroids and analgesics for at least 48 hours has failed; and
3. Octreotide to be given at a maximum dose 1500 mcg daily for up to 4 weeks.

Note: Indications marked with * are unapproved indications

Initiation – acromegaly
Re-assessment required after 3 months
Both:
1. The patient has acromegaly; and
2. Any of the following:
   2.1 Treatment with surgery, radiotherapy and a dopamine agonist has failed; or
   2.2 Treatment with octreotide is for an interim period while awaiting the effects of radiotherapy and a dopamine agonist has failed; or
   2.3 The patient is unwilling, or unable, to undergo surgery and/or radiotherapy.

Continuation – acromegaly
Both:
1. IGF1 levels have decreased since starting octreotide; and
2. The treatment remains appropriate and the patient is benefiting from treatment.

Note: In patients with acromegaly octreotide treatment should be discontinued if IGF1 levels have not decreased after 3 months treatment. In patients treated with radiotherapy octreotide treatment should be withdrawn every 2 years, for 1 month, for assessment of remission. Octreotide treatment should be stopped where there is biochemical evidence of remission (normal IGF1 levels) following octreotide treatment withdrawal for at least 4 weeks.

Initiation – Other indications
Any of the following:
1. VIPomas and glucagonomas - for patients who are seriously ill in order to improve their clinical state prior to definitive surgery; or
2. Both:
   2.1 Gastrinoma; and
   2.2 Either:
      2.2.1 Patient has failed surgery; or
      2.2.2 Patient in metastatic disease after H2 antagonists (or proton pump inhibitors) have failed; or
3. Both:
   3.1 Insulinomas; and
   3.2 Surgery is contraindicated or has failed; or
4. For pre-operative control of hypoglycaemia and for maintenance therapy; or
5. Both:
   5.1 Carcinoid syndrome (diagnosed by tissue pathology and/or urinary 5HIAA analysis); and
   5.2 Disabling symptoms not controlled by maximal medical therapy.

Note: restriction applies only to the long-acting formulations of octreotide

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
### Oncology Agents and Immunosuppressants

<table>
<thead>
<tr>
<th>ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS</th>
<th>Price (ex man. excl. GST) $</th>
<th>Per Brand or Generic Manufacturer</th>
</tr>
</thead>
</table>

#### TAMOXIFEN CITRATE
- **Tab 10 mg** – 1% DV Jan-19 to 2020 ................................................................. 11.75 60 Tamoxifen Sandoz
- **Tab 20 mg** – 1% DV Jan-19 to 2020 ................................................................. 5.60 60 Tamoxifen Sandoz

#### Aromatase Inhibitors

<table>
<thead>
<tr>
<th>ANASTROZOLE</th>
<th>Price (ex man. excl. GST) $</th>
<th>Per</th>
</tr>
</thead>
</table>
- **Tab 1 mg** – 1% DV Jan-18 to 2020 ................................................................. 5.04 30 Rolin

<table>
<thead>
<tr>
<th>EXEMESTANE</th>
<th>Price (ex man. excl. GST) $</th>
<th>Per</th>
</tr>
</thead>
</table>
- **Tab 25 mg** – 1% DV Sep-17 to 2020 ................................................................. 14.50 30 Pfizer Exemestane

<table>
<thead>
<tr>
<th>LETROZOLE</th>
<th>Price (ex man. excl. GST) $</th>
<th>Per</th>
</tr>
</thead>
</table>
- **Tab 2.5 mg** – 1% DV Nov-18 to 2021 ............................................................... 4.68 30 Letrole

#### Imaging Agents

<table>
<thead>
<tr>
<th>AMINOLEVULINIC ACID HYDROCHLORIDE – <strong>Restricted</strong> see terms below</th>
<th>Price (ex man. excl. GST) $</th>
<th>Per</th>
</tr>
</thead>
</table>
- Powder for oral soln, 30 mg per ml, 1.5 g vial ........................................ 4,400.00 1 Gliolan
  
  44,000.00 10 Gliolan

  **→ Restricted (RS1565)**

  **Initiation – high grade malignant glioma**

  All of the following:
  1. Patient has newly diagnosed, untreated, glioblastoma multiforme; and
  2. Treatment to be used as adjuvant to fluorescence-guided resection; and
  3. Patient's tumour is amenable to complete resection.

#### Immunosuppressants

#### Calcineurin Inhibitors

<table>
<thead>
<tr>
<th>CICLOSPORIN</th>
<th>Price (ex man. excl. GST) $</th>
<th>Per</th>
</tr>
</thead>
</table>
- **Cap 25 mg** ................................................................. 44.63 50 Neoral
- **Cap 50 mg** ................................................................. 88.91 50 Neoral
- **Cap 100 mg** ................................................................. 177.81 50 Neoral
- Oral liq 100 mg per ml ................................................................. 198.13 50 ml Neoral
- Inj 50 mg per ml, 5 ml ampoule ................................................................. 276.30 10 Sandimmun

<table>
<thead>
<tr>
<th>TACROLIMUS – <strong>Restricted</strong> see terms below</th>
<th>Price (ex man. excl. GST) $</th>
<th>Per</th>
</tr>
</thead>
</table>
- **Cap 0.5 mg** ................................................................. 49.60 100 Tacrolimus Sandoz
- **Cap 0.75 mg** ................................................................. 99.30 100 Tacrolimus Sandoz
- **Cap 1 mg** ................................................................. 84.30 100 Tacrolimus Sandoz
- **Cap 5 mg** ................................................................. 248.20 50 Tacrolimus Sandoz
- **Inj 5 mg per ml, 1 ml ampoule** ................................................................. 248.20 50 Tacrolimus Sandoz

  **→ Restricted (RS1651)**

  **Initiation – organ transplant recipients**

  Any specialist

  For use in organ transplant recipients.

  **Initiation – non-transplant indications**

  Any specialist

  Both:
  1. Patient requires long-term systemic immunosuppression; and
  2. Ciclosporin has been trialled and discontinued treatment because of unacceptable side effects or inadequate clinical response.

  Note: Indications marked with * are unapproved indications.
**Fusion Proteins**

**ETANERCEPT** — **Restricted** see terms below

- **Inj 25 mg vial** — 5% DV Sep-19 to 2024.................................799.96 4 Enbrel
- **Inj 50 mg autoinjector** — 5% DV Sep-19 to 2024....................1,599.96 4 Enbrel
- **Inj 50 mg syringe** — 5% DV Sep-19 to 2024.............................1,599.96 4 Enbrel

**Initiation — juvenile idiopathic arthritis**
Rheumatologist or named specialist
*Re-assessment required after 6 months*

Either:

1. Both:
   1.1 The patient has had an initial Special Authority approval for adalimumab for juvenile idiopathic arthritis (JIA); and
   1.2 Either:
      1.2.1 The patient has experienced intolerable side effects from adalimumab; or
      1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for JIA; or

2. All of the following:
   2.1 Patient diagnosed with Juvenile Idiopathic Arthritis (JIA); and
   2.2 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
   2.3 Patient has had severe active polyarticular course JIA for 6 months duration or longer; and
   2.4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate (at a dose of 10-20 mg/m$^2$ weekly or at the maximum tolerated dose) in combination with either oral corticosteroids (prednisone 0.25 mg/kg or at the maximum tolerated dose) or a full trial of serial intra-articular corticosteroid injections; and

2.5 Both:
   2.5.1 Either:
      2.5.1.1 Patient has persistent symptoms of poorly-controlled and active disease in at least 20 swollen, tender joints; or
      2.5.1.2 Patient has persistent symptoms of poorly-controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, shoulder, cervical spine, hip; and
   2.5.2 Physician's global assessment indicating severe disease.

**Continuation — juvenile idiopathic arthritis**
Rheumatologist or named specialist
*Re-assessment required after 6 months*

Both:

1. Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
2. Either:
   2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician's global assessment from baseline; or
   2.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline.

**Initiation — rheumatoid arthritis**
Rheumatologist
*Re-assessment required after 6 months*

Either:

1. Both:

Continued…
continued...

1. The patient has had an initial Special Authority approval for adalimumab for rheumatoid arthritis; and

2. Either:
   1.2.1 The patient has experienced intolerable side effects from adalimumab; or
   1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for rheumatoid arthritis; or

2 All of the following:
   2.1 Patient has had severe and active erosive rheumatoid arthritis (either confirmed by radiology imaging, or the patient is cyclic citrullinated peptide (CCP) antibody positive) for six months duration or longer; and
   2.2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
   2.3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
   2.4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with sulfasalazine and hydroxychloroquine sulphate (at maximum tolerated doses); and
   2.5 Any of the following:
      2.5.1 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with the maximum tolerated dose of ciclosporin; or
      2.5.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with intramuscular gold; or
      2.5.3 Patient has tried and not responded to at least three months of therapy at the maximum tolerated dose of leflunomide alone or in combination with oral or parenteral methotrexate; and
   2.6 Either:
      2.6.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 swollen, tender joints; or
      2.6.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
   2.7 Either:
      2.7.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
      2.7.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Continuation – rheumatoid arthritis
Rheumatologist
Re-assessment required after 6 months
All of the following:

1 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and

2 Either:
   2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
   2.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and

3 Etanercept to be administered at doses no greater than 50 mg every 7 days.

Initiation – ankylosing spondylitis
Rheumatologist
Re-assessment required after 6 months
Either:

continued…
continued...

1 Both:
   1.1 The patient has had an initial Special Authority approval for adalimumab for ankylosing spondylitis; and
   1.2 Either:
      1.2.1 The patient has experienced intolerable side effects from adalimumab; or
      1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab
          for ankylosing spondylitis; or

2 All of the following:
   2.1 Patient has a confirmed diagnosis of ankylosing spondylitis present for more than six months; and
   2.2 Patient has low back pain and stiffness that is relieved by exercise but not by rest; and
   2.3 Patient has bilateral sacroiliitis demonstrated by plain radiographs, CT or MRI scan; and
   2.4 Patient’s ankylosing spondylitis has not responded adequately to treatment with two or more non-steroidal
      anti-inflammatory drugs (NSAIDs), in combination with anti-ulcer therapy if indicated, while patient was undergoing
      at least 3 months of a regular exercise regimen for ankylosing spondylitis; and
   2.5 Either:
      2.5.1 Patient has limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by
          the following Bath Ankylosing Spondylitis Metrology Index (BASMI) measures: a modified Schober’s test of
          less than or equal to 4 cm and lumbar side flexion measurement of less than or equal to 10 cm (mean of left
          and right); or
      2.5.2 Patient has limitation of chest expansion by at least 2.5 cm below the average normal values corrected for
          age and gender (see Notes); and
   2.6 Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 6 on a 0-10 scale.

Notes: The BASDAI must have been determined at the completion of the 3 month exercise trial, but prior to ceasing NSAID
      treatment. The BASDAI measure must be no more than 1 month old at the time of starting treatment.

Average normal chest expansion corrected for age and gender:

<table>
<thead>
<tr>
<th>Age</th>
<th>Male</th>
<th>Female</th>
</tr>
</thead>
<tbody>
<tr>
<td>18-24</td>
<td>7.0 cm</td>
<td>5.5 cm</td>
</tr>
<tr>
<td>25-34</td>
<td>7.5 cm</td>
<td>5.5 cm</td>
</tr>
<tr>
<td>35-44</td>
<td>6.5 cm</td>
<td>4.5 cm</td>
</tr>
<tr>
<td>45-54</td>
<td>6.0 cm</td>
<td>5.0 cm</td>
</tr>
<tr>
<td>55-64</td>
<td>5.5 cm</td>
<td>4.0 cm</td>
</tr>
<tr>
<td>65-74</td>
<td>4.0 cm</td>
<td>4.0 cm</td>
</tr>
<tr>
<td>75+</td>
<td>3.0 cm</td>
<td>2.5 cm</td>
</tr>
</tbody>
</table>

Continuation – ankylosing spondylitis

Rheumatologist

Re-assessment required after 6 months

All of the following:

1 Following 12 weeks’ initial treatment and for subsequent renewals, treatment has resulted in an improvement in BASDAI of
   4 or more points from pre-treatment baseline on a 10 point scale, or an improvement in BASDAI of 50%, whichever is less;
   and
2 Physician considers that the patient has benefited from treatment and that continued treatment is appropriate; and
3 Etanercept to be administered at doses no greater than 50 mg every 7 days.

Initiation – psoriatic arthritis

Rheumatologist

Re-assessment required after 6 months

Either:

continued…
continued...

1 Both:
   1.1 The patient has had an initial Special Authority approval for adalimumab for psoriatic arthritis; and
   1.2 Either:
      1.2.1 The patient has experienced intolerable side effects from adalimumab; or
      1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for psoriatic arthritis; or

2 All of the following:
   2.1 Patient has had severe active psoriatic arthritis for six months duration or longer; and
   2.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
   2.3 Patient has tried and not responded to at least three months of sulfasalazine at a dose of at least 2 g per day or leflunomide at a dose of up to 20 mg daily (or maximum tolerated doses); and
   2.4 Either:
      2.4.1 Patient has persistent symptoms of poorly controlled and active disease in at least 15 swollen, tender joints; or
      2.4.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and

2.5 Any of the following:
   2.5.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
   2.5.2 Patient has an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or
   2.5.3 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Continuation – psoriatic arthritis
Rheumatologist
Re-assessment required after 6 months
Both:
   1 Either:
      1.1 Following 3 to 4 months’ initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
      1.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior etanercept treatment in the opinion of the treating physician; and
   2 Etanercept to be administered at doses no greater than 50 mg every 7 days.

Initiation – severe chronic plaque psoriasis, prior TNF use
Dermatologist
Limited to 4 months treatment
All of the following:
   1 The patient has had an initial Special Authority approval for adalimumab for severe chronic plaque psoriasis; and
   2 Either:
      2.1 The patient has experienced intolerable side effects from adalimumab; or
      2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for severe chronic plaque psoriasis; and
   3 Patient must be reassessed for continuation after 3 doses.

Initiation – severe chronic plaque psoriasis, treatment-naive
Dermatologist
Limited to 4 months treatment
All of the following:

continued…
continued...

1 Either:
   1.1 Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of
greater than 10, where lesions have been present for at least 6 months from the time of initial diagnosis; or
   1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or
plaques have been present for at least 6 months from the time of initial diagnosis; and

2 Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least
three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, ciclosporin, or
acitretin; and

3 A PASI assessment or Dermatology Quality of Life Index (DLQI) assessment has been completed for at least the most
recent prior treatment course (but preferably all prior treatment courses), preferably while still on treatment but no longer
than 1 month following cessation of each prior treatment course; and

4 The most recent PASI or DLQI assessment is no more than 1 month old at the time of initiation.

Note: "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 10, as
assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for
severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom subscores for erythema, thickness and
scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot,
as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment.

Continuation – severe chronic plaque psoriasis
Dermatologist
Re-assessment required after 6 months
Both:

1 Either:
   1.1 Both:
      1.1.1 Patient had "whole body" severe chronic plaque psoriasis at the start of treatment; and
   1.1.2 Either:
      1.1.2.1 Following each prior etanercept treatment course the patient has a PASI score which is reduced by
75% or more, or is sustained at this level, when compared with the pre-etanercept treatment baseline
value; or
      1.1.2.2 Following each prior etanercept treatment course the patient has a Dermatology Quality of Life Index
(DLQI) improvement of 5 or more, when compared with the pre-treatment baseline value; or

1.2 Both:
   1.2.1 Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of
   treatment; and
   1.2.2 Either:
      1.2.2.1 Following each prior etanercept treatment course the patient has a reduction in the PASI symptom
subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as
compared to the treatment course baseline values; or
      1.2.2.2 Following each prior etanercept treatment course the patient has a reduction of 75% or more in the
skin area affected, or sustained at this level, as compared to the pre-etanercept treatment baseline
value; and

2 Etanercept to be administered at doses no greater than 50 mg every 7 days.

Initiation – pyoderma gangrenosum
Dermatologist
All of the following:

1 Patient has pyoderma gangrenosum*; and

2 Patient has received three months of conventional therapy including a minimum of three pharmaceuticals (e.g.
prednisone, ciclosporin, azathioprine, or methotrexate) and not received an adequate response; and

continued…
### Monoclonal Antibodies

#### ABCIXIMAB – Restricted see terms below

<table>
<thead>
<tr>
<th>Item Code</th>
<th>Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>ReoPro</td>
<td>Inj 2 mg per ml, 5 ml vial</td>
<td>$579.53</td>
<td>1</td>
</tr>
</tbody>
</table>

#### ADALIMUMAB – Restricted see terms below

<table>
<thead>
<tr>
<th>Item Code</th>
<th>Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Humira</td>
<td>Inj 20 mg per 0.4 ml syringe</td>
<td>$1,599.96</td>
<td>2</td>
</tr>
<tr>
<td>HumiraPen</td>
<td>Inj 40 mg per 0.8 ml pen</td>
<td>$1,599.96</td>
<td>2</td>
</tr>
<tr>
<td>Humira</td>
<td>Inj 40 mg per 0.8 ml syringe</td>
<td>$1,599.96</td>
<td>2</td>
</tr>
</tbody>
</table>

### Continuation – pyoderma gangrenosum

**Dermatologist**

All of the following:

1. Patient has shown clinical improvement; and
2. Patient continues to require treatment; and
3. A maximum of 4 doses.

### Initiation – adult-onset Still's disease

**Rheumatologist**

*Re-assessment required after 6 months*

Either:

1. Both:
   1.1 Either:
      1.1.1 The patient has had an initial Special Authority approval for etanercept for adult-onset Still's disease (AOSD); or
      1.1.2 The patient has been started on tocilizumab for AOSD in a DHB hospital in accordance with the Section H rules; and
   1.2 Either:
      1.2.1 The patient has experienced intolerable side effects from etanercept and/or tocilizumab; or
      1.2.2 The patient has received insufficient benefit from at least a three-month trial of adalimumab and/or tocilizumab such that they do not meet the renewal criteria for AOSD; or
2. All of the following:
   2.1 Patient diagnosed with AOSD according to the Yamaguchi criteria (J Rheumatol 1992;19:424-430); and
   2.2 Patient has tried and not responded to at least 6 months of glucocorticosteroids at a dose of at least 0.5 mg/kg, non-steroidal antiinflammatory drugs (NSAIDs) and methotrexate; and
   2.3 Patient has persistent symptoms of disabling poorly controlled and active disease.

### Continuation – adult-onset Still's disease

**Rheumatologist**

*Re-assessment required after 6 months*

The patient has a sustained improvement in inflammatory markers and functional status.
continued...

1 Either:
   1.1 Both:
      1.1.1 The patient has had an initial Special Authority approval for etanercept for juvenile idiopathic arthritis (JIA); and
      1.1.2 Either:
         1.1.2.1 The patient has experienced intolerable side effects from etanercept; or
         1.1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for JIA; or

2 All of the following:
   2.1 Patient diagnosed with Juvenile Idiopathic Arthritis (JIA); and
   2.2 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
   2.3 Patient has had severe active polyarticular course JIA for 6 months duration or longer; and
   2.4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate (at a dose of 10-20 mg/m^2 weekly or at the maximum tolerated dose) in combination with either oral corticosteroids (prednisone 0.25 mg/kg or at the maximum tolerated dose) or a full trial of serial intra-articular corticosteroid injections; and
   2.5 Both:
      2.5.1 Either:
         2.5.1.1 Patient has persistent symptoms of poorly-controlled and active disease in at least 20 swollen, tender joints; or
         2.5.1.2 Patient has persistent symptoms of poorly-controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, shoulder, cervical spine, hip; and
      2.5.2 Physician’s global assessment indicating severe disease.

Continuation – juvenile idiopathic arthritis
Rheumatologist or named specialist
Re-assessment required after 6 months
Both:
   1 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
   2 Either:
      2.1 Following 3 to 4 months’ initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician’s global assessment from baseline; or
      2.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician’s global assessment from baseline.

Initiation – fistulising Crohn’s disease
Gastroenterologist
Re-assessment required after 4 months
All of the following:
   1 Patient has confirmed Crohn’s disease; and
   2 Either:
      2.1 Patient has one or more complex externally draining enterocutaneous fistula(e); or
      2.2 Patient has one or more rectovaginal fistula(e); and
   3 A Baseline Fistula Assessment (a copy of which is available at www.pharmac.govt.nz/latest/BaselineFistulaAssessment.pdf) has been completed and is no more than 1 month old at the time of application.

continued…
Continuation – fistulising Crohn’s disease
Gastroenterologist
Re-assessment required after 6 months

Either:
1. The number of open draining fistulae have decreased from baseline by at least 50%; or
2. There has been a marked reduction in drainage of all fistula(e) from baseline as demonstrated by a reduction in the Fistula Assessment score, together with less induration and patient-reported pain.

Initiation – Crohn’s disease - adults
Gastroenterologist
Re-assessment required after 3 months

All of the following:
1. Patient has severe active Crohn’s disease; and
2. Any of the following:
   2.1 Patient has a Crohn’s Disease Activity Index (CDAI) score of greater than or equal to 300; or
   2.2 Patient has extensive small intestine disease affecting more than 50 cm of the small intestine; or
   2.3 Patient has evidence of short gut syndrome or would be at risk of short gut syndrome with further bowel resection; or
   2.4 Patient has an ileostomy or colostomy, and has intestinal inflammation; and
3. Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses (unless contraindicated) and corticosteroids; and
4. Surgery (or further surgery) is considered to be clinically inappropriate.

Continuation – Crohn’s disease - adults
Gastroenterologist
Re-assessment required after 3 months

Both:
1. Either:
   1.1 Either:
      1.1.1 CDAI score has reduced by 100 points from the CDAI score when the patient was initiated on adalimumab; or
      1.1.2 CDAI score is 150 or less; or
   1.2 Both:
      1.2.1 The patient has demonstrated an adequate response to treatment but CDAI score cannot be assessed; and
      1.2.2 Applicant to indicate the reason that CDAI score cannot be assessed; and
2. Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Initiation – Crohn’s disease - children
Gastroenterologist
Re-assessment required after 3 months

All of the following:
1. Paediatric patient has severe active Crohn’s disease; and
2. Either:
   2.1 Patient has a Paediatric Crohn’s Disease Activity Index (PCDAI) score of greater than or equal to 30; or
   2.2 Patient has extensive small intestine disease; and
3. Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses (unless contraindicated) and corticosteroids; and
4. Surgery (or further surgery) is considered to be clinically inappropriate.

continued…
continued...

**Continuation – Crohn’s disease - children**

Gastroenterologist

*Re-assessment required after 3 months*

*Both:*

1. Any of the following:
   1.1. PCDAI score has reduced by 100 points from the PCDAI score when the patient was initiated on adalimumab; or
   1.2. PCDAI score is 150 or less; or
   1.3. The patient has demonstrated an adequate response to treatment but PCDAI score cannot be assessed; and

2. Adalimumab to be administered at doses no greater than 40 mg every 14 days.

**Initiation – rheumatoid arthritis**

Rheumatologist

*Re-assessment required after 6 months*

*Either:*

1. Both:
   1.1. The patient has had an initial Special Authority approval for etanercept for rheumatoid arthritis; and
   1.2. Either:
       1.2.1. The patient has experienced intolerable side effects from etanercept; or
       1.2.2. The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for rheumatoid arthritis; or

2. All of the following:

   2.1. Patient has had severe and active erosive rheumatoid arthritis (either confirmed by radiology imaging, or the patient is cyclic citrullinated peptide (CCP) antibody positive) for six months duration or longer; and
   2.2. Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
   2.3. Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
   2.4. Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with sulfasalazine and hydroxychloroquine sulphate (at maximum tolerated doses); and
   2.5. Any of the following:
       2.5.1. Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with the maximum tolerated dose of ciclosporin; or
       2.5.2. Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with intramuscular gold; or
       2.5.3. Patient has tried and not responded to at least three months of therapy at the maximum tolerated dose of leflunomide alone or in combination with oral or parenteral methotrexate; and
   2.6. Either:
       2.6.1. Patient has persistent symptoms of poorly controlled and active disease in at least 20 swollen, tender joints; or
       2.6.2. Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and

2.7. Either:

   2.7.1. Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
   2.7.2. C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

*continued…*
Continuation – rheumatoid arthritis
Rheumatologist
Re-assessment required after 6 months
All of the following:

1. Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
2. Either:
   2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
   2.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and
3. Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Initiation – ankylosing spondylitis
Rheumatologist
Re-assessment required after 6 months
Either:

1. Both:
   1.1 The patient has had an initial Special Authority approval for etanercept for ankylosing spondylitis; and
   1.2 Either:
      1.2.1 The patient has experienced intolerable side effects from etanercept; or
      1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for ankylosing spondylitis; or
2. All of the following:
   2.1 Patient has a confirmed diagnosis of ankylosing spondylitis present for more than six months; and
   2.2 Patient has low back pain and stiffness that is relieved by exercise but not by rest; and
   2.3 Patient has bilateral sacroiliitis demonstrated by plain radiographs, CT or MRI scan; and
   2.4 Patient's ankylosing spondylitis has not responded adequately to treatment with two or more non-steroidal anti-inflammatory drugs (NSAIDs), in combination with anti-ulcer therapy if indicated, while patient was undergoing at least 3 months of a regular exercise regimen for ankylosing spondylitis; and
   2.5 Either:
      2.5.1 Patient has limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by the following Bath Ankylosing Spondylitis Metrology Index (BASMI) measures: a modified Schober's test of less than or equal to 4 cm and lumbar side flexion measurement of less than or equal to 10 cm (mean of left and right); or
      2.5.2 Patient has limitation of chest expansion by at least 2.5 cm below the average normal values corrected for age and gender (see Notes); and
   2.6 Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 6 on a 0-10 scale.

Notes: The BASDAI must have been determined at the completion of the 3 month exercise trial, but prior to ceasing NSAID treatment. The BASDAI measure must be no more than 1 month old at the time of starting treatment.

Average normal chest expansion measure corrected for age and gender:

continued…
continued…

<table>
<thead>
<tr>
<th>Age</th>
<th>Male</th>
<th>Female</th>
</tr>
</thead>
<tbody>
<tr>
<td>18-24</td>
<td>7.0 cm</td>
<td>5.5 cm</td>
</tr>
<tr>
<td>25-34</td>
<td>7.5 cm</td>
<td>5.5 cm</td>
</tr>
<tr>
<td>35-44</td>
<td>6.5 cm</td>
<td>4.5 cm</td>
</tr>
<tr>
<td>45-54</td>
<td>6.0 cm</td>
<td>5.0 cm</td>
</tr>
<tr>
<td>55-64</td>
<td>5.5 cm</td>
<td>4.0 cm</td>
</tr>
<tr>
<td>65-74</td>
<td>4.0 cm</td>
<td>4.0 cm</td>
</tr>
<tr>
<td>75+</td>
<td>3.0 cm</td>
<td>2.5 cm</td>
</tr>
</tbody>
</table>

**Continuation – ankylosing spondylitis**

Rheumatologist

*Re-assessment required after 6 months*

All of the following:

1. Following 12 weeks’ initial treatment and subsequent renewals, treatment has resulted in an improvement in BASDAI of 4 or more points from pre-treatment baseline on a 10 point scale, or an improvement in BASDAI of 50%, whichever is less; and
2. Physician considers that the patient has benefited from treatment and that continued treatment is appropriate; and
3. Adalimumab to be administered at doses no greater than 40 mg every 14 days.

**Initiation – psoriatic arthritis**

Rheumatologist

*Re-assessment required after 6 months*

Either:

1. Both:
   1.1 The patient has had an initial Special Authority approval for etanercept for psoriatic arthritis; and
   1.2 Either:
      1.2.1 The patient has experienced intolerable side effects from etanercept; or
      1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for psoriatic arthritis; or
2. All of the following:
   2.1 Patient has had severe active psoriatic arthritis for six months duration or longer; and
   2.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
   2.3 Patient has tried and not responded to at least three months of sulfasalazine at a dose of at least 2 g per day or leflunomide at a dose of up to 20 mg daily (or maximum tolerated doses); and
   2.4 Either:
      2.4.1 Patient has persistent symptoms of poorly controlled and active disease in at least 15 swollen, tender joints; or
      2.4.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
   2.5 Any of the following:
      2.5.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
      2.5.2 Patient has an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or
      2.5.3 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

continued…

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
Continuation – psoriatic arthritis
Rheumatologist
Re-assessment required after 6 months
Both:

1. Either:
   1.1 Following 3 to 4 months’ initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
   1.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior adalimumab treatment in the opinion of the treating physician; and

2. Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Initiation – plaque psoriasis, prior TNF use
Dermatologist
Limited to 4 months treatment
Both:

1. The patient has had an initial Special Authority approval for etanercept for severe chronic plaque psoriasis; and
2. Either:
   2.1 The patient has experienced intolerable side effects from etanercept; or
   2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for severe chronic plaque psoriasis.

Initiation – plaque psoriasis, treatment-naive
Dermatologist
Limited to 4 months treatment
All of the following:

1. Either:
   1.1 Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 10, where lesions have been present for at least 6 months from the time of initial diagnosis; or
   1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and

2. Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, ciclosporin, or acitretin; and

3. A PASI assessment or Dermatology Quality of Life Index (DLQI) assessment has been completed for at least the most recent prior treatment course (but preferably all prior treatment courses), preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and

4. The most recent PASI or DLQI assessment is no more than 1 month old at the time of initiation.

Note: "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 10, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom subscores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment.

Continuation – plaque psoriasis
Dermatologist
Re-assessment required after 6 months
Both:

1. Either:
   1.1 Both:
      1.1.1 Patient had "whole body" severe chronic plaque psoriasis at the start of treatment; and
continued...

1.1.2 Either:

1.1.2.1 Following each prior adalimumab treatment course the patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-adalimumab treatment baseline value; or

1.1.2.2 Following each prior adalimumab treatment course the patient has a Dermatology Quality of Life Index (DLQI) improvement of 5 or more, when compared with the pre-treatment baseline value; or

1.2 Both:

1.2.1 Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment; and

1.2.2 Either:

1.2.2.1 Following each prior adalimumab treatment course the patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values; or

1.2.2.2 Following each prior adalimumab treatment course the patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-etanercept treatment baseline value; and

2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

**Initiation – pyoderma gangrenosum**
Dermatologist
All of the following:

1 Patient has pyoderma gangrenosum*; and

2 Patient has received three months of conventional therapy including a minimum of three pharmaceuticals (e.g. prednisone, ciclosporin, azathioprine, or methotrexate) and not received an adequate response; and

3 A maximum of 4 doses.

Note: Indications marked with * are unapproved indications.

**Continuation – pyoderma gangrenosum**
Dermatologist
All of the following:

1 Patient has shown clinical improvement; and

2 Patient continues to require treatment; and

3 A maximum of 4 doses.

**Initiation – adult-onset Still’s disease**
Rheumatologist
*Re-assessment required after 6 months*

Either:

1 Both:

1.1 Either:

1.1.1 The patient has had an initial Special Authority approval for etanercept for adult-onset Still’s disease (AOSD); or

1.1.2 The patient has been started on tocilizumab for AOSD in a DHB hospital in accordance with the Section H rules; and

1.2 Either:

1.2.1 The patient has experienced intolerable side effects from etanercept and/or tocilizumab; or

1.2.2 The patient has received insufficient benefit from at least a three-month trial of etanercept and/or tocilizumab such that they do not meet the renewal criteria for AOSD; or

2 All of the following:

2.1 Patient diagnosed with AOSD according to the Yamaguchi criteria (J Rheumatol 1992;19:424-430); and

continued…
continued...

2.2 Patient has tried and not responded to at least 6 months of glucocorticosteroids at a dose of at least 0.5 mg/kg, non-steroidal antinflammatory drugs (NSAIDs) and methotrexate; and

2.3 Patient has persistent symptoms of disabling poorly controlled and active disease.

Continuation – adult-onset Still’s disease
Rheumatologist
Re-assessment required after 6 months
The patient has a sustained improvement in inflammatory markers and functional status.

Initiation – severe Behcet’s disease
Any relevant practitioner
Re-assessment required after 3 months
All of the following:

1 The patient has severe Behcet’s disease that is significantly impacting the patient’s quality of life (see Notes); and

2 Either:

   2.1 The patient has severe ocular, neurological, gastrointestinal, rheumatological, mucocutaneous and/or vasculitic symptoms and has not responded adequately to treatment with infliximab (see Notes); or

   2.2 The patient has severe ocular, neurological, gastrointestinal, rheumatological, mucocutaneous and/or vasculitic symptoms and has experienced intolerable side effects from treatment with infliximab; and

3 The patient is experiencing significant loss of quality of life; and

4 Adalimumab to be administered at doses no greater than 40 mg every 14 days.


Continuation – severe Behcet’s disease
Any relevant practitioner
Re-assessment required after 6 months
Both:

1 Patient has had a good clinical response to initial treatment with measurably improved quality of life; and

2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Initiation – severe ocular inflammation
Re-assessment required after 4 months
Either:

1 Both:

   1.1 The patient has had an initial Special Authority approval for infliximab for severe ocular inflammation; and

   1.2 Either:

      1.2.1 The patient has experienced intolerable side effects from infliximab; or

      1.2.2 The patient has received insufficient benefit from infliximab to meet the renewal criteria for infliximab for severe ocular inflammation; or

2 Both:

   2.1 Patient has severe, vision-threatening ocular inflammation requiring rapid control; and

   2.2 Any of the following:

      2.2.1 Treatment with high-dose steroids (intravenous methylprednisolone) followed by high dose oral steroids has proven ineffective at controlling symptoms; or

      2.2.2 Patient developed new inflammatory symptoms while receiving high dose steroids; or

      2.2.3 Patient is aged under 8 years and treatment with high dose oral steroids and other immunosuppressants has proven ineffective at controlling symptoms.

continued…
Continuation – severe ocular inflammation
Re-assessment required after 12 months
Both:

1 Any of the following:
   1.1 The patient has had a good clinical response following 3 initial doses; or
   1.2 Following each 12-month treatment period, the patient has had a sustained reduction in inflammation
      (Standardisation of Uveitis Nomenclature (SUN) criteria < ½+ anterior chamber or vitreous cells, absence of active
      vitreous or retinal lesions, or resolution of uveitic cystoid macular oedema); or
   1.3 Following each 12-month treatment period, the patient has a sustained steroid sparing effect, allowing reduction in
      prednisone to < 10mg daily, or steroid drops less than twice daily if under 18 years old; and

2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Note: A trial withdrawal should be considered after every 24 months of stability, unless the patient is deemed to have extremely
high risk of irreversible vision loss if adalimumab is withdrawn.

Initiation – chronic ocular inflammation
Re-assessment required after 4 months
Either:

1 Both:
   1.1 The patient has had an initial Special Authority approval for infliximab for chronic ocular inflammation; and
   1.2 Either:
      1.2.1 The patient has experienced intolerable side effects from infliximab; or
      1.2.2 The patient has received insufficient benefit from infliximab to meet the renewal criteria for infliximab for
      chronic ocular inflammation; or

2 Both:
   2.1 Patient has severe uveitis uncontrolled with treatment of steroids and other immunosuppressants with a severe risk
      of vision loss; and
   2.2 Any of the following:
      2.2.1 Patient is 18 years or older and treatment with at least two other immunomodulatory agents has proven
      ineffective; or
      2.2.2 Patient is under 18 years and treatment with methotrexate has proven ineffective or is not tolerated at a
      therapeutic dose; or
      2.2.3 Patient is under 8 years and treatment with steroids or methotrexate has proven ineffective or is not
      tolerated at a therapeutic dose; or disease requires control to prevent irreversible vision loss prior to
      achieving a therapeutic dose of methotrexate.

Continuation – chronic ocular inflammation
Re-assessment required after 12 months
Both:

1 Any of the following:
   1.1 The patient has had a good clinical response following 12 weeks’ initial treatment; or
   1.2 Following each 12-month treatment period, the patient has had a sustained reduction in inflammation
      (Standardisation of Uveitis Nomenclature (SUN) criteria < ½+ anterior chamber or vitreous cells, absence of active
      vitreous or retinal lesions, or resolution of uveitic cystoid macular oedema); or
   1.3 Following each 12-month treatment period, the patient has a sustained steroid sparing effect, allowing reduction in
      prednisone to < 10mg daily, or steroid drops less than twice daily if under 18 years old; and

2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Note: A trial withdrawal should be considered after every 24 months of stability, unless the patient is deemed to have extremely
high risk of irreversible vision loss if adalimumab is withdrawn.
Initiation – hidradenitis suppurativa
Dermatologist
Re-assessment required after 4 months
All of the following:
1. Patient has hidradenitis suppurativa Hurley Stage II or Hurley Stage III lesions in distinct anatomic areas; and
2. Patient has tried, but had an inadequate response to at least a 90 day trial of systemic antibiotics or patient has demonstrated intolerance to or has contraindications for systemic antibiotics; and
3. The patient has 3 or more active lesions (e.g. inflammatory nodules, abscesses, draining fistulae); and
4. The patient has a Dermatology Quality of Life Index of 10 or more and the assessment is no more than 1 month old at time of application; and
5. Following the initial loading doses, adalimumab is to be administered at doses no greater than 40mg every 7 days.

Continuation – hidradenitis suppurativa
Dermatologist
Re-assessment required after 6 months
All of the following:
1. The patient has a reduction in active lesions (e.g. inflammatory nodules, abscesses, draining fistulae) of 25% or more from baseline; and
2. The patient has a Dermatology Quality of Life Index improvement of 4 or more from baseline; and
3. Adalimumab is to be administered at doses no greater than 40mg every 7 days. Fortnightly dosing has been considered.

AFLIBERCEPT – Restricted see terms below
$ Inj 40 mg per ml, 0.1 ml vial.................................................................$1,250.00 1 Eylea

Initiation – Wet Age Related Macular Degeneration
Ophthalmologist
Re-assessment required after 3 months
Either:
1. All of the following:
   1.1 Any of the following:
      1.1.1 Wet age-related macular degeneration (wet AMD); or
      1.1.2 Polypoidal choroidal vasculopathy; or
      1.1.3 Choroidal neovascular membrane from causes other than wet AMD; and
   1.2 Either:
      1.2.1 The patient has developed severe endophthalmitis or severe posterior uveitis following treatment with bevacizumab; or
      1.2.2 There is worsening of vision or failure of retina to dry despite three intraocular injections of bevacizumab four weeks apart; and
   1.3 There is no structural damage to the central fovea of the treated eye; and
   1.4 Patient has not previously been treated with ranibizumab for longer than 3 months; or
2. Either:
   2.1 Patient has current approval to use ranibizumab for treatment of wAMD and was found to be intolerant to ranibizumab within 3 months; or
   2.2 Patient has previously* (*before June 2018) received treatment with ranibizumab for wAMD and disease was stable while on treatment.

Continuation – Wet Age Related Macular Degeneration
Ophthalmologist
Re-assessment required after 12 months
All of the following:

continued…
continued...

1 Documented benefit must be demonstrated to continue; and
2 Patient's vision is 6/36 or better on the Snellen visual acuity score; and
3 There is no structural damage to the central fovea of the treated eye.

**Initiation – Diabetic Macular Oedema**
Ophthalmologist

*Re-assessment required after 4 months*

All of the following:

1 Patient has centre involving diabetic macular oedema (DMO); and
2 Patient's disease is non-responsive to 4 doses of intravitreal bevacizumab when administered 4-6 weekly; and
3 Patient has reduced visual acuity between 6/9 – 6/36 with functional awareness of reduction in vision; and
4 Patient has DMO within central OCT (ocular coherence tomography) subfield > 350 micrometers; and
5 There is no centre-involving sub-retinal fibrosis or foveal atrophy.

**Continuation – Diabetic Macular Oedema**
Ophthalmologist

*Re-assessment required after 12 months*

All of the following:

1 There is stability or two lines of Snellen visual acuity gain; and
2 There is structural improvement on OCT scan (with reduction in intra-retinal cysts, central retinal thickness, and sub-retinal fluid); and
3 Patient's vision is 6/36 or better on the Snellen visual acuity score; and
4 There is no centre-involving sub-retinal fibrosis or foveal atrophy; and
5 After each consecutive 12 months treatment with aflibercept, patient has retrialled with at least one injection of bevacizumab and had no response.

**BASILIXIMAB – Restricted** see terms below

- Inj 20 mg vial ................................................................. 2,560.00 1 Simulect
- **Restricted (RS1203)**

**Initiation**
For use in solid organ transplants.

**BEVACIZUMAB – Restricted** see terms below

- Inj 25 mg per ml, 4 ml vial
- Inj 25 mg per ml, 16 ml vial
- **Restricted (RS1691)**

**Initiation – Recurrent Respiratory Papillomatosis**
Otolaryngologist

*Re-assessment required after 12 months*

All of the following:

1 Maximum of 6 doses; and
2 The patient has recurrent respiratory papillomatosis; and
3 The treatment is for intra-lesional administration.

**Continuation – Recurrent Respiratory Papillomatosis**
Otolaryngologist

*Re-assessment required after 12 months*

All of the following:

1 Maximum of 6 doses; and
2 The treatment is for intra-lesional administration; and
3 There has been a reduction in surgical treatments or disease regrowth as a result of treatment.
continued…

Initiation – ocular conditions
Either:
1 Ocular neovascularisation; or
2 Exudative ocular angiopathy.

CETUXIMAB – Restricted see terms below

- Inj 5 mg per ml, 20 ml vial..............................................................................364.00 1 Erbitux
- Inj 5 mg per ml, 100 ml vial.........................................................................1,820.00 1 Erbitux

Initiation
Medical oncologist
All of the following:
1 Patient has locally advanced, non-metastatic, squamous cell cancer of the head and neck; and
2 Patient is contraindicated to, or is intolerant of, cisplatin; and
3 Patient has good performance status; and
4 To be administered in combination with radiation therapy.

INFLIXIMAB – Restricted see terms below

- Inj 100 mg – 10% DV Mar-15 to 29 Feb 2020 .............................................806.00 1 Remicade

Initiation – Graft vs host disease
Patient has steroid-refractory acute graft vs. host disease of the gut.
Initiation – rheumatoid arthritis
Rheumatologist

Re-assessment required after 4 months
All of the following:
1 The patient has had an initial Special Authority approval for adalimumab and/or etanercept for rheumatoid arthritis; and
2 Either:
   2.1 The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept; or
   2.2 Following at least a four month trial of adalimumab and/or etanercept, the patient did not meet the renewal criteria for adalimumab and/or etanercept; and
3 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance.

Continuation – rheumatoid arthritis
Rheumatologist

Re-assessment required after 6 months
All of the following:
1 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
2 Either:
   2.1 Following 3 to 4 months’ initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
   2.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and
3 Infliximab to be administered at doses no greater than 3 mg/kg every 8 weeks.

continued…
continued...

**Initiation – ankylosing spondylitis**

Rheumatologist

*Re-assessment required after 3 months*

Both:

1. The patient has had an initial Special Authority approval for adalimumab and/or etanercept for ankylosing spondylitis; and
2. Either:
   1.1 The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept; or
   1.2 Following 12 weeks of adalimumab and/or etanercept treatment, the patient did not meet the renewal criteria for adalimumab and/or etanercept for ankylosing spondylitis.

**Continuation – ankylosing spondylitis**

Rheumatologist

*Re-assessment required after 6 months*

All of the following:

1. Following 12 weeks of infliximab treatment, BASDAI has improved by 4 or more points from pre-infliximab baseline on a 10 point scale, or by 50%, whichever is less; and
2. Physician considers that the patient has benefited from treatment and that continued treatment is appropriate; and
3. Infliximab to be administered at doses no greater than 5 mg/kg every 6-8 weeks.

**Initiation – psoriatic arthritis**

Rheumatologist

*Re-assessment required after 4 months*

Both:

1. The patient has had an initial Special Authority approval for adalimumab and/or etanercept for psoriatic arthritis; and
2. Either:
   1.1 The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept; or
   1.2 Following 3-4 months' initial treatment with adalimumab and/or etanercept, the patient did not meet the renewal criteria for adalimumab and/or etanercept for psoriatic arthritis.

**Continuation – psoriatic arthritis**

Rheumatologist

*Re-assessment required after 6 months*

Both:

1. Either:
   1.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
   1.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior infliximab treatment in the opinion of the treating physician; and
2. Infliximab to be administered at doses no greater than 5 mg/kg every 8 weeks.

**Initiation – severe ocular inflammation**

*Re-assessment required after 3 doses*

Either:

1. Both:
   1.1 The patient has had an initial Special Authority approval for adalimumab for severe ocular inflammation; and
   1.2 Either:
      1.2.1 The patient has experienced intolerable side effects from adalimumab; or
      1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for severe ocular inflammation; or
2. Both:
   2.1 Patient has severe, vision-threatening ocular inflammation requiring rapid control; and
   continued…
continued…

2.2 Any of the following:

2.2.1 Treatment with high-dose steroids (intravenous methylprednisolone) followed by high dose oral steroids has proven ineffective at controlling symptoms; or

2.2.2 Patient developed new inflammatory symptoms while receiving high dose steroids; or

2.2.3 Patient is aged under 8 years and treatment with high dose oral steroids and other immunosuppressants has proven ineffective at controlling symptoms.

**Continuation – severe ocular inflammation**

**Re-assessment required after 12 months**

Any of the following:

1. The patient has had a good clinical response following 3 initial doses; or

2. Following each 12-month treatment period, the patient has had a sustained reduction in inflammation (Standardisation of Uveitis Nomenclature (SUN) criteria < ½+ anterior chamber or vitreous cells, absence of active vitreous or retinal lesions, or resolution of uveitic cystoid macular oedema); or

3. Following each 12-month treatment period, the patient has a sustained steroid sparing effect, allowing reduction in prednisone to < 10mg daily, or steroid drops less than twice daily if under 18 years old.

Note: A trial withdrawal should be considered after every 24 months of stability, unless the patient is deemed to have extremely high risk of irreversible vision loss if infliximab is withdrawn.

**Initiation – chronic ocular inflammation**

**Re-assessment required after 3 doses**

Either:

1. Both:
   
   1.1 The patient has had an initial Special Authority approval for adalimumab for chronic ocular inflammation; and

   1.2 Either:
      
      1.2.1 The patient has experienced intolerable side effects from adalimumab; or

      1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for chronic ocular inflammation; or

2. Both:

   2.1 Patient has severe uveitis uncontrolled with treatment of steroids and other immunosuppressants with a severe risk of vision loss; and

   2.2 Any of the following:

      2.2.1 Patient is 18 years or older and treatment with at least two other immunomodulatory agents has proven ineffective; or

      2.2.2 Patient is under 18 years and treatment with methotrexate has proven ineffective or is not tolerated at therapeutic dose; or

      2.2.3 Patient is under 8 years and treatment with steroids or methotrexate has proven ineffective or is not tolerated at a therapeutic dose; or disease requires control to prevent irreversible vision loss prior to achieving a therapeutic dose of methotrexate.

**Continuation – chronic ocular inflammation**

**Re-assessment required after 12 months**

Any of the following:

1. The patient has had a good clinical response following 3 initial doses; or

2. Following each 12-month treatment period, the patient has had a sustained reduction in inflammation (Standardisation of Uveitis Nomenclature (SUN) criteria < ½+ anterior chamber or vitreous cells, absence of active vitreous or retinal lesions, or resolution of uveitic cystoid macular oedema); or

3. Following each 12-month treatment period, the patient has a sustained steroid sparing effect, allowing reduction in prednisone to < 10mg daily, or steroid drops less than twice daily if under 18 years old.

Note: A trial withdrawal should be considered after every 24 months of stability, unless the patient is deemed to have extremely continued…
Continuation – Crohn's disease (adults)
Gastroenterologist
Re-assessment required after 6 months
Both:
1 Any of the following:
   1.1 CDAI score has reduced by 100 points from the CDAI score when the patient was initiated on infliximab; or
   1.2 CDAI score is 150 or less; or
   1.3 The patient has demonstrated an adequate response to treatment but CDAI score cannot be assessed; and
2 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle.

Initiation – Crohn's disease (children)
Gastroenterologist
Re-assessment required after 3 months
All of the following:
1 Paediatric patient has severe active Crohn's disease; and
2 Either:
   2.1 Patient has a Paediatric Crohn's Disease Activity Index (PCDAI) score of greater than or equal to 30; or
   2.2 Patient has extensive small intestine disease; and
3 Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses (unless contraindicated) and corticosteroids; and
4 Surgery (or further surgery) is considered to be clinically inappropriate; and
5 Patient must be reassessed for continuation after 3 months of therapy.

continued...
Continuation – Crohn’s disease (children)
Gastroenterologist
Re-assessment required after 6 months
Both:

1. Any of the following:
   1.1 PCDAI score has reduced by 10 points from the PCDAI score when the patient was initiated on infliximab; or
   1.2 PCDAI score is 15 or less; or
   1.3 The patient has demonstrated an adequate response to treatment but PCDAI score cannot be assessed; and
2. Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle.

Initiation – fistulising Crohn’s disease
Gastroenterologist
Re-assessment required after 4 months
Both:

1. Patient has confirmed Crohn’s disease; and
2. Either:
   2.1 Patient has one or more complex externally draining enterocutaneous fistula(e); or
   2.2 Patient has one or more rectovaginal fistula(e).

Continuation – fistulising Crohn’s disease
Gastroenterologist
Re-assessment required after 6 months
Both:

1. Either:
   1.1 The number of open draining fistulae have decreased from baseline by at least 50%; or
   1.2 There has been a marked reduction in drainage of all fistula(e) from baseline (in the case of adult patients, as demonstrated by a reduction in the Fistula Assessment score), together with less induration and patient reported pain; and
2. Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle.

Initiation – acute severe fulminant ulcerative colitis
Gastroenterologist
Limited to 6 weeks treatment
Both:

1. Patient has acute, severe fulminant ulcerative colitis; and
2. Treatment with intravenous or high dose oral corticosteroids has not been successful.

Continuation – severe fulminant ulcerative colitis
Gastroenterologist
Re-assessment required after 6 months
Both:

1. Where maintenance treatment is considered appropriate, infliximab should be used in combination with immunomodulators and reassessed every 6 months; and
2. Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle.

continued...
ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

Products with Hospital Supply Status (HSS) are in bold

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

continued...

Initiation – severe ulcerative colitis
Gastroenterologist
Re-assessment required after 3 months
All of the following:

1. Patient has histologically confirmed ulcerative colitis; and
2. Either:
   2.1 Patient is 18 years or older and the Simple Clinical Colitis Activity Index (SCCAI) is greater than or equal to 4; or
   2.2 Patient is under 18 years and the Paediatric Ulcerative Colitis Activity Index (PUCAI) score is greater than or equal to 65; and
3. Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses for an adequate duration (unless contraindicated) and corticosteroids; and
4. Surgery (or further surgery) is considered to be clinically inappropriate.

Continuation – severe ulcerative colitis
Gastroenterologist
Re-assessment required after 6 months
All of the following:

1. Patient is continuing to maintain remission and the benefit of continuing infliximab outweighs the risks; and
2. Either:
   2.1 Patient is 18 years or older and the SCCAI score has reduced by 2 points or more from the SCCAI score when the patient was initiated on infliximab; or
   2.2 Patient is under 18 years and the PUCAI score has reduced by 30 points or more from the PUCAI score when the patient was initiated on infliximab; and
3. Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle.

Initiation – plaque psoriasis
Dermatologist
Re-assessment required after 3 doses
Either:

1. Both:
   1.1 The patient has had an initial Special Authority approval for adalimumab or etanercept for severe chronic plaque psoriasis; and
   1.2 Either:
      1.2.1 The patient has experienced intolerable side effects from adalimumab or etanercept; or
      1.2.2 The patient has received insufficient benefit from adalimumab or etanercept to meet the renewal criteria for adalimumab or etanercept for severe chronic plaque psoriasis; or
2. All of the following:
   2.1 Either:
      2.1.1 Patient has “whole body” severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 15, where lesions have been present for at least 6 months from the time of initial diagnosis; or
      2.1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and
   2.2 Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, cyclosporin, or acitretin; and

continued…
continued...

2.3 A PASI assessment has been completed for at least the most recent prior treatment course (but preferably all prior treatment courses), preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and

2.4 The most recent PASI assessment is no more than 1 month old at the time of initiation.

Note: "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 15, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom subscores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment.

**Continuation – plaque psoriasis**

Dermatologist

Re-assessment required after 3 doses

Both:

1. Either:
   1.1 Both:
      1.1.1 Patient had "whole body" severe chronic plaque psoriasis at the start of treatment; and
      1.1.2 Following each prior infliximab treatment course the patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-infliximab treatment baseline value; or
   1.2 Both:
      1.2.1 Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment; and
      1.2.2 Either:
         1.2.2.1 Following each prior infliximab treatment course the patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values; or
         1.2.2.2 Following each prior infliximab treatment course the patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-infliximab treatment baseline value; and

2. Infliximab to be administered at doses no greater than 5 mg/kg every 8 weeks.

**Initiation – neurosarcoïdosis**

Neurologist

Re-assessment required after 18 months

All of the following:

1. Biopsy consistent with diagnosis of neurosarcoïdosis; and
2. Patient has CNS involvement; and
3. Patient has steroid-refractory disease; and
4. Either:
   4.1 IV cyclophosphamide has been tried; or
   4.2 Treatment with IV cyclophosphamide is clinically inappropriate.

**Continuation – neurosarcoïdosis**

Neurologist

Re-assessment required after 18 months

Either:

1. A withdrawal period has been tried and the patient has relapsed; or
2. All of the following:
   2.1 A withdrawal period has been considered but would not be clinically appropriate; and
   2.2 There has been a marked reduction in prednisone dose; and

continued…
continued...

2.3 Either:

2.3.1 There has been an improvement in MRI appearances; or

2.3.2 Marked improvement in other symptomology.

**Initiation – severe Behcet’s disease**

*Re-assessment required after 4 months*

All of the following:

1. The patient has severe Behcet’s disease which is significantly impacting the patient’s quality of life (see Notes); and

2. Either:

2.1 The patient has severe ocular, neurological and/or vasculitic symptoms and has not responded adequately to one or more treatment(s) appropriate for the particular symptom(s) (see Notes); or

2.2 The patient has severe gastrointestinal, rheumatologic and/or mucocutaneous symptoms and has not responded adequately to two or more treatment appropriate for the particular symptom(s) (see Notes); and

3. The patient is experiencing significant loss of quality of life.

**Notes:**


2. Treatments appropriate for the particular symptoms are those that are considered standard conventional treatments for these symptoms, for example intravenous/oral steroids and other immunosuppressants for ocular symptoms; azathioprine, steroids, thalidomide, interferon alpha and ciclosporin for mucocutaneous symptoms; and colchicine, steroids and methotrexate for rheumatological symptoms.

**Continuation – severe Behcet’s disease**

*Re-assessment required after 6 months*

Both:

1. Patient has had a good clinical response to initial treatment with measurably improved quality of life; and

2. Infliximab to be administered at doses no greater than 5 mg/kg every 8 weeks.

**OBINUTUZUMAB – Restricted see terms below**

Inj 25 mg per ml, 40 ml vial.................................................................5,910.00 1 Gazyva

*Restricted (RS1550)*

**Initiation**

Haematologist

*Limited to 6 months* treatment

All of the following:

1. The patient has progressive Binet stage A, B or C CD20+ chronic lymphocytic leukaemia requiring treatment; and

2. The patient is obinutuzumab treatment naive; and

3. The patient is not eligible for full dose FCR due to comorbidities with a score > 6 on the Cumulative Illness Rating Scale (CIRS) or reduced renal function (creatinine clearance < 70mL/min); and

4. Patient has adequate neutrophil and platelet counts* unless the cytopenias are a consequence of marrow infiltration by CLL; and

5. Patient has good performance status; and

6. Obinutuzumab to be administered at a maximum cumulative dose of 8,000 mg and in combination with chlorambucil for a maximum of 6 cycles.

**Notes:** Chronic lymphocytic leukaemia includes small lymphocytic lymphoma. Comorbidity refers only to illness/impairment other than CLL induced illness/impairment in the patient. ‘Good performance status’ means ECOG score of 0-1, however, in patients temporarily debilitated by their CLL disease symptoms a higher ECOG (2 or 3) is acceptable where treatment with obinutuzumab is expected to improve symptoms and improve ECOG score to < 2.

* greater than or equal to $1.5 \times 10^9$/L and platelets greater than or equal to $75 \times 10^9$/L

---

**Products with Hospital Supply Status (HSS) are in bold**

Expiration date of HSS period is 30 June of the year indicated unless otherwise stated.
OMALIZUMAB – Restricted see terms below

Inj 150 mg prefilled syringe ................................................................. 450.00 1 Xolair
Inj 150 mg vial ......................................................................................... 450.00 1 Xolair

Initiation – severe asthma
Clinical immunologist or respiratory specialist
Re-assessment required after 6 months

All of the following:
1. Patient must be aged 6 years or older; and
2. Patient has a diagnosis of severe asthma; and
3. Past or current evidence of atopy, documented by skin prick testing or RAST; and
4. Total serum human immunoglobulin E (IgE) between 76 IU/mL and 1300 IU/ml at baseline; and
5. Proven adherence with optimal inhaled therapy including high dose inhaled corticosteroid (budesonide 1,600 mcg per day or fluticasone propionate 1,000 mcg per day or equivalent), plus long-acting beta-2 agonist therapy (at least salmeterol 50 mcg bd or eformoterol 12 mcg bd) for at least 12 months, unless contraindicated or not tolerated; and
6. Either:
   6.1 Patient has received courses of systemic corticosteroids equivalent to at least 28 days treatment in the past 12 months, unless contraindicated or not tolerated; or
   6.2 Patient has had at least 4 exacerbations needing systemic corticosteroids in the previous 12 months, where an exacerbation is defined as either documented use of oral corticosteroids for at least 3 days or parenteral steroids; and
7. Patient has an Asthma Control Test (ACT) score of 10 or less; and
8. Baseline measurements of the patient’s asthma control using the ACT and oral corticosteroid dose must be made at the time of application, and again at around 26 weeks after the first dose to assess response to treatment.

Continuation – severe asthma
Respiratory specialist
Re-assessment required after 6 months

Both:
1. An increase in the Asthma Control Test (ACT) score of at least 5 from baseline; and
2. A reduction in the maintenance oral corticosteroid dose or number of exacerbations of at least 50% from baseline.

Initiation – severe chronic spontaneous urticaria
Clinical immunologist or dermatologist
Re-assessment required after 6 months

All of the following:
1. Patient must be aged 12 years or older; and
2. Either:
   2.1 Both:
      2.1.1 Patient is symptomatic with Urticaria Activity Score 7 (UAS7) of 20 or above; and
      2.1.2 Patient has a Dermatology life quality index (DLQI) of 10 or greater; and
3. Any of the following:
   3.1 Patient has been taking high dose antihistamines (e.g. 4 times standard dose) and ciclosporin (> 3 mg/kg day) for at least 6 weeks; or
   3.2 Patient has been taking high dose antihistamines (e.g. 4 times standard dose) and at least 3 courses of systemic corticosteroids (> 20 mg prednisone per day for at least 5 days) in the previous 6 months; or
   3.3 Patient has developed significant adverse effects whilst on corticosteroids or ciclosporin; and
4. Either:
   4.1 Treatment to be stopped if inadequate response* following 4 doses; or
   4.2 Complete response* to 6 doses of omalizumab.

continued…

[172]

e.g. Brand indicates brand example only. It is not a contracted product.
Continuation – severe chronic spontaneous urticaria
Clinical immunologist or dermatologist
Re-assessment required after 6 months
Either:
  1 Patient has previously had a complete response* to 6 doses of omalizumab; or
  2 Both:
     2.1 Patient has previously had a complete response* to 6 doses of omalizumab; and
     2.2 Patient has relapsed after cessation of omalizumab therapy.

Note: *Inadequate response defined as less than 50% reduction in baseline UAS7 and DLQI score, or an increase in Urticaria Control Test (UCT) score of less than 4 from baseline. Patient is to be reassessed for response after 4 doses of omalizumab. Complete response is defined as UAS7 less than or equal to 6 and DLQI less than or equal to 5; or UCT of 16. Relapse of chronic urticaria on stopping prednisone/ciclosporin does not justify the funding of omalizumab.

PERTUZUMAB – Restricted see terms below

- Inj 30 mg per ml, 14 ml vial

Initiation
Re-assessment required after 12 months
All of the following:
  1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
  2 Either:
     2.1 Patient is chemotherapy treatment naive; or
     2.2 Patient has not received prior treatment for their metastatic disease and has had a treatment free interval of at least 12 months between prior (neo)adjuvant chemotherapy treatment and diagnosis of metastatic breast cancer; and
  3 The patient has good performance status (ECOG grade 0-1); and
  4 Pertuzumab to be administered in combination with trastuzumab; and
  5 Pertuzumab maximum first dose of 840 mg, followed by maximum of 420 mg every 3 weeks; and
  6 Pertuzumab to be discontinued at disease progression.

Continuation
Re-assessment required after 12 months
Both:
  1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
  2 The cancer has not progressed at any time point during the previous 12 months whilst on pertuzumab and trastuzumab.

RANIBIZUMAB – Restricted see terms below

- Inj 10 mg per ml, 0.23 ml vial
- Inj 10 mg per ml, 0.3 ml vial

Initiation – Wet Age Related Macular Degeneration
Ophthalmologist
Re-assessment required after 3 months
Either:
  1 All of the following:
     1.1 Any of the following:
        1.1.1 Wet age-related macular degeneration (wet AMD); or
        1.1.2 Polypoidal choroidal vasculopathy; or
  continued…
continued…

1.1.3 Choroidal neovascular membrane from causes other than wet AMD; and

1.2 Either:
   1.2.1 The patient has developed severe endophthalmitis or severe posterior uveitis following treatment with bevacizumab; or
   1.2.2 There is worsening of vision or failure of retina to dry despite three intraocular injections of bevacizumab four weeks apart; and

1.3 There is no structural damage to the central fovea of the treated eye; and

1.4 Patient has not previously been treated with aflibercept for longer than 3 months; or

2 Patient has current approval to use aflibercept for treatment of wAMD and was found to be intolerant to aflibercept within 3 months.

Continuation – Wet Age Related Macular Degeneration

Ophthalmologist

Re-assessment required after 12 months

All of the following:

1 Documented benefit must be demonstrated to continue; and

2 Patient’s vision is 6/36 or better on the Snellen visual acuity score; and

3 There is no structural damage to the central fovea of the treated eye.

RITUXIMAB – Restricted see terms below

Initiation – haemophilia with inhibitors

Haematologist

Any of the following:

1 Patient has mild congenital haemophilia complicated by inhibitors; or

2 Patient has severe congenital haemophilia complicated by inhibitors and has failed immune tolerance therapy; or

3 Patient has acquired haemophilia.

Continuation – haemophilia with inhibitors

Haematologist

All of the following:

1 Patient was previously treated with rituximab for haemophilia with inhibitors; and

2 An initial response lasting at least 12 months was demonstrated; and

3 Patient now requires repeat treatment.

Initiation – post-transplant

Both:

1 The patient has B-cell post-transplant lymphoproliferative disorder*; and

2 To be used for a maximum of 8 treatment cycles.

Note: Indications marked with * are unapproved indications.

Continuation – post-transplant

All of the following:

1 The patient has had a rituximab treatment-free interval of 12 months or more; and

2 The patient has B-cell post-transplant lymphoproliferative disorder*; and

3 To be used for no more than 6 treatment cycles.

Note: Indications marked with * are unapproved indications.

continued…
continued...

**Initiation – indolent, low-grade lymphomas or hairy cell leukaemia***

*Re-assessment required after 9 months*

Either:

1. Both:
   1.1 The patient has indolent low grade NHL or hairy cell leukaemia* with relapsed disease following prior chemotherapy; and
   1.2 To be used for a maximum of 6 treatment cycles; or

2. Both:
   2.1 The patient has indolent, low grade lymphoma or hairy cell leukaemia* requiring first-line systemic chemotherapy; and
   2.2 To be used for a maximum of 6 treatment cycles.

Note: 'Indolent, low-grade lymphomas' includes follicular, mantle, marginal zone and lymphoplasmacytic/Waldenstrom macroglobulinaemia. *Unapproved indication. ‘Hairy cell leukaemia’ also includes hairy cell leukaemia variant.

**Continuation – indolent, low-grade lymphomas or hairy cell leukaemia***

*Re-assessment required after 9 months*

All of the following:

1. The patient has had a rituximab treatment-free interval of 12 months or more; and
2. The patient has indolent, low-grade NHL or hairy cell leukaemia* with relapsed disease following prior chemotherapy; and
3. To be used for no more than 6 treatment cycles.

Note: 'Indolent, low-grade lymphomas' includes follicular, mantle, marginal zone and lymphoplasmacytic/Waldenstrom macroglobulinaemia. *Unapproved indication. ‘Hairy cell leukaemia’ also includes hairy cell leukaemia variant.

**Initiation – aggressive CD20 positive NHL**

Either:

1. All of the following:
   1.1 The patient has treatment naive aggressive CD20 positive NHL; and
   1.2 To be used with a multi-agent chemotherapy regimen given with curative intent; and
   1.3 To be used for a maximum of 8 treatment cycles; or

2. Both:
   2.1 The patient has aggressive CD20 positive NHL with relapsed disease following prior chemotherapy; and
   2.2 To be used for a maximum of 6 treatment cycles.

Note: 'Aggressive CD20 positive NHL' includes large B-cell lymphoma and Burkitt's lymphoma/leukaemia.

**Continuation – aggressive CD20 positive NHL**

All of the following:

1. The patient has had a rituximab treatment-free interval of 12 months or more; and
2. The patient has relapsed refractory/aggressive CD20 positive NHL; and
3. To be used with a multi-agent chemotherapy regimen given with curative intent; and
4. To be used for a maximum of 4 treatment cycles.

Note: 'Aggressive CD20 positive NHL' includes large B-cell lymphoma and Burkitt's lymphoma/leukaemia.

**Initiation – Chronic lymphocytic leukaemia**

*Re-assessment required after 12 months*

All of the following:

1. The patient has progressive Binet stage A, B or C chronic lymphocytic leukaemia (CLL) requiring treatment; and
2. Any of the following:
   2.1 The patient is rituximab treatment naive; or
   2.2 Either:
      2.2.1 The patient is chemotherapy treatment naive; or
      2.2.2 Both:
continued…

2.2.2.1 The patient’s disease has relapsed following no more than three prior lines of chemotherapy treatment; and

2.2.2.2 The patient has had a treatment-free interval of 12 months or more if previously treated with fludarabine and cyclophosphamide chemotherapy; or

2.3 The patient’s disease has relapsed within 36 months of previous treatment and rituximab treatment is to be used in combination with funded venetoclax; and

3 The patient has good performance status; and

4 Either:
   4.1 The patient does not have chromosome 17p deletion CLL; or
   4.2 Rituximab treatment is to be used in combination with funded venetoclax for relapsed/refractory chronic lymphocytic leukaemia; and

5 Rituximab to be administered in combination with fludarabine and cyclophosphamide, bendamustine or venetoclax for a maximum of 6 treatment cycles; and

6 It is planned that the patient receives full dose fludarabine and cyclophosphamide (orally or dose equivalent intravenous administration), bendamustine or venetoclax.

Note: ‘Chronic lymphocytic leukaemia (CLL)’ includes small lymphocytic lymphoma. A line of chemotherapy treatment is considered to comprise a known standard therapeutic chemotherapy regimen and supportive treatments. ‘Good performance status’ means ECOG score of 0-1, however, in patients temporarily debilitated by their CLL disease symptoms a higher ECOG (2 or 3) is acceptable where treatment with rituximab is expected to improve symptoms and improve ECOG score to < 2.

**Continuation – Chronic lymphocytic leukaemia**

**Re-assessment required after 12 months**

Both:

1 Either:
   1.1 The patient’s disease has relapsed within 36 months of previous treatment and rituximab treatment is to be used in combination with funded venetoclax; or

   1.2 All of the following:
      1.2.1 The patient’s disease has relapsed following no more than one prior line of treatment with rituximab for CLL; and
      1.2.2 The patient has had an interval of 36 months or more since commencement of initial rituximab treatment; and
      1.2.3 The patient does not have chromosome 17p deletion CLL; and
      1.2.4 It is planned that the patient receives full dose fludarabine and cyclophosphamide (orally or dose equivalent intravenous administration) or bendamustine; and

2 Rituximab to be administered in combination with fludarabine and cyclophosphamide, bendamustine or venetoclax for a maximum of 6 treatment cycles.

Note: ‘Chronic lymphocytic leukaemia (CLL)’ includes small lymphocytic lymphoma. A line of chemotherapy treatment is considered to comprise a known standard therapeutic chemotherapy regimen and supportive treatments.

**Initiation – Rheumatoid arthritis - prior TNF inhibitor use**

**Rheumatologist**

**Limited to 4 months** treatment

All of the following:

1 Both:
   1.1 The patient has had an initial community Special Authority approval for at least one of etanercept and/or adalimumab for rheumatoid arthritis; and

   1.2 Either:
      1.2.1 The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept; or

continued…
continued...

1.2.2 Following at least a four month trial of adalimumab and/or etanercept, the patient did not meet the renewal criteria for adalimumab and/or etanercept for rheumatoid arthritis; and

2 Either:
   2.1 Rituximab to be used as an adjunct to methotrexate or leflunomide therapy; or
   2.2 Patient is contraindicated to both methotrexate and leflunomide, requiring rituximab monotherapy to be used; and

3 Maximum of two 1,000 mg infusions of rituximab given two weeks apart.

Initiation – rheumatoid arthritis - TNF inhibitors contraindicated

Rheumatologist

Limited to 4 months treatment

All of the following:

1 Treatment with a Tumour Necrosis Factor alpha inhibitor is contraindicated; and

2 Patient has had severe and active erosive rheumatoid arthritis (either confirmed by radiology imaging, or the patient is cyclic citrullinated peptide (CCP) antibody positive) for six months duration or longer; and

3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and

4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with sulfasalazine and hydroxychloroquine sulphate (at maximum tolerated doses); and

5 Any of the following:
   5.1 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with the maximum tolerated dose of cyclosporin; or
   5.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with intramuscular gold; or
   5.3 Patient has tried and not responded to at least three months of therapy at the maximum tolerated dose of leflunomide alone or in combination with oral or parenteral methotrexate; and

6 Either:
   6.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 swollen, tender joints; or
   6.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and

7 Either:
   7.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
   7.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months; and

8 Either:
   8.1 Rituximab to be used as an adjunct to methotrexate or leflunomide therapy; or
   8.2 Patient is contraindicated to both methotrexate and leflunomide, requiring rituximab monotherapy to be used; and

9 Maximum of two 1,000 mg infusions of rituximab given two weeks apart.

Continuation – rheumatoid arthritis - re-treatment in 'partial responders' to rituximab

Rheumatologist

Re-assessment required after 4 months

All of the following:

1 Any of the following:
   1.1 At 4 months following the initial course of rituximab infusions the patient had between a 30% and 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
   1.2 At 4 months following the second course of rituximab infusions the patient had at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or

continued…
continued...

1.3 At 4 months following the third and subsequent courses of rituximab infusions, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and

2 Rituximab re-treatment not to be given within 6 months of the previous course of treatment; and

3 Either:
   3.1 Rituximab to be used as an adjunct to methotrexate or leflunomide therapy; or
   3.2 Patient is contraindicated to both methotrexate and leflunomide, requiring rituximab monotherapy to be used; and

4 Maximum of two 1,000 mg infusions of rituximab given two weeks apart.

Continuation – rheumatoid arthritis - re-treatment in 'responders' to rituximab

Rheumatologist

Re-assessment required after 4 months

All of the following:

1 Either:
   1.1 At 4 months following the initial course of rituximab infusions the patient had at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
   1.2 At 4 months following the second and subsequent courses of rituximab infusions, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and

2 Rituximab re-treatment not to be given within 6 months of the previous course of treatment; and

3 Either:
   3.1 Rituximab to be used as an adjunct to methotrexate or leflunomide therapy; or
   3.2 Patient is contraindicated to both methotrexate and leflunomide, requiring rituximab monotherapy to be used; and

4 Maximum of two 1,000 mg infusions of rituximab given two weeks apart.

Initiation – severe cold haemagglutinin disease (CHAD)

Haematologist

Re-assessment required after 4 weeks

Both:

1 Patient has cold haemagglutinin disease*; and

2 Patient has severe disease which is characterized by symptomatic anaemia, transfusion dependence or disabling circulatory symptoms.

Note: Indications marked with * are unapproved indications.

Continuation – severe cold haemagglutinin disease (CHAD)

Haematologist

Re-assessment required after 4 weeks

Either:

1 Previous treatment with lower doses of rituximab (100 mg weekly for 4 weeks) have proven ineffective and treatment with higher doses (375 mg/m² weekly for 4 weeks) is now planned; or

2 All of the following:
   2.1 Patient was previously treated with rituximab for severe cold haemagglutinin disease*; and
   2.2 An initial response lasting at least 12 months was demonstrated; and
   2.3 Patient now requires repeat treatment.

Note: Indications marked with * are unapproved indications.

Initiation – warm autoimmune haemolytic anaemia (warm AIHA)

Haematologist

Re-assessment required after 4 weeks

Both:

1 Patient has warm autoimmune haemolytic anaemia*; and
continued...

2 One of the following treatments has been ineffective: steroids (including if patient requires ongoing steroids at doses equivalent to > 5 mg prednisone daily), cytotoxic agents (e.g. cyclophosphamide monotherapy or in combination), intravenous immunoglobulin.

Note: Indications marked with * are unapproved indications.

**Continuation – warm autoimmune haemolytic anaemia (warm AIHA)**
Haematologist

*Re-assessment required after 4 weeks*

Either:

1. Previous treatment with lower doses of rituximab (100 mg weekly for 4 weeks) have proven ineffective and treatment with higher doses (375 mg/m² weekly for 4 weeks) is now planned; or

2. All of the following:
   1. Patient was previously treated with rituximab for warm autoimmune haemolytic anaemia*; and
   2. An initial response lasting at least 12 months was demonstrated; and

Note: Indications marked with * are unapproved indications.

**Initiation – immune thrombocytopenic purpura (ITP)**
Haematologist

*Re-assessment required after 4 weeks*

Both:

1. Either:
   1.1 Patient has immune thrombocytopenic purpura* with a platelet count of less than or equal to 20,000 platelets per microlitre; or
   1.2 Patient has immune thrombocytopenic purpura* with a platelet count of 20,000 to 30,000 platelets per microlitre and significant mucocutaneous bleeding; and

2. Any of the following:
   2.1 Treatment with steroids and splenectomy have been ineffective; or
   2.2 Treatment with steroids has been ineffective and splenectomy is an absolute contraindication; or
   2.3 Other treatments including steroids have been ineffective and patient is being prepared for elective surgery (e.g. splenectomy).

Note: Indications marked with * are unapproved indications.

**Continuation – immune thrombocytopenic purpura (ITP)**
Haematologist

*Re-assessment required after 4 weeks*

Either:

1. Previous treatment with lower doses of rituximab (100 mg weekly for 4 weeks) have proven ineffective and treatment with higher doses (375 mg/m² weekly for 4 weeks) is now planned; or

2. All of the following:
   2.1 Patient was previously treated with rituximab for immune thrombocytopenic purpura*; and
   2.2 An initial response lasting at least 12 months was demonstrated; and
   2.3 Patient now requires repeat treatment.

Note: Indications marked with * are unapproved indications.

**Initiation – thrombotic thrombocytopenic purpura (TTP)**
Haematologist

*Re-assessment required after 4 weeks*

Either:

1. Patient has thrombotic thrombocytopenic purpura* and has experienced progression of clinical symptoms or persistent thrombocytopenia despite plasma exchange; or

continued...
2 Patient has acute idiopathic thrombotic thrombocytopenic purpura* with neurological or cardiovascular pathology.

Note: Indications marked with * are unapproved indications.

Continuation – thrombotic thrombocytopenic purpura (TTP)

Haematologist

Re-assessment required after 4 weeks

All of the following:

1 Patient was previously treated with rituximab for thrombotic thrombocytopenic purpura*; and
2 An initial response lasting at least 12 months was demonstrated; and
3 Patient now requires repeat treatment.

Note: Indications marked with * are unapproved indications.

Initiation – pure red cell aplasia (PRCA)

Haematologist

Re-assessment required after 6 weeks

Patient has autoimmune pure red cell aplasia* associated with a demonstrable B-cell lymphoproliferative disorder.

Note: Indications marked with * are unapproved indications.

Continuation – pure red cell aplasia (PRCA)

Haematologist

Re-assessment required after 6 weeks

Patient was previously treated with rituximab for pure red cell aplasia* associated with a demonstrable B-cell lymphoproliferative disorder and demonstrated an initial response lasting at least 12 months.

Note: Indications marked with * are unapproved indications.

Initiation – ANCA associated vasculitis

Re-assessment required after 4 weeks

All of the following:

1 Patient has been diagnosed with ANCA associated vasculitis*; and
2 The total rituximab dose would not exceed the equivalent of 375 mg/m² of body-surface area per week for a total of 4 weeks; and
3 Any of the following:
   3.1 Induction therapy with daily oral or pulse intravenous cyclophosphamide has failed to achieve significant improvement of disease after at least 3 months; or
   3.2 Patient has previously had a cumulative dose of cyclophosphamide > 15 g or a further repeat 3 month induction course of cyclophosphamide would result in a cumulative dose > 15 g; or
   3.3 Cyclophosphamide and methotrexate are contraindicated; or
   3.4 Patient is a female of child-bearing potential; or
   3.5 Patient has a previous history of haemorrhagic cystitis, urological malignancy or haematological malignancy.

Note: Indications marked with * are unapproved indications.

Continuation – ANCA associated vasculitis

Re-assessment required after 4 weeks

All of the following:

1 Patient has been diagnosed with ANCA associated vasculitis*; and
2 Patient has previously responded to treatment with rituximab but is now experiencing an acute flare of vasculitis; and
3 The total rituximab dose would not exceed the equivalent of 375 mg/m² of body-surface area per week for a total of 4 weeks.

Note: Indications marked with * are unapproved indications.

Initiation – treatment refractory systemic lupus erythematosus (SLE)

Rheumatologist or nephrologist

All of the following:

continued…
continued...

1. The patient has severe, immediately life- or organ-threatening SLE*; and
2. The disease has proved refractory to treatment with steroids at a dose of at least 1 mg/kg; and
3. The disease has relapsed following prior treatment for at least 6 months with maximal tolerated doses of azathioprine, mycophenolate mofetil and high dose cyclophosphamide, or cyclophosphamide is contraindicated; and
4. Maximum of four 1000 mg infusions of rituximab.

Note: Indications marked with * are unapproved indications.

Continuation – treatment refractory systemic lupus erythematosus (SLE)
Rheumatologist or nephrologist
All of the following:
1. Patient's SLE* achieved at least a partial response to the previous round of prior rituximab treatment; and
2. The disease has subsequently relapsed; and
3. Maximum of two 1000 mg infusions of rituximab.

Note: Indications marked with * are unapproved indications.

Initiation – Antibody-mediated renal transplant rejection
Nephrologist
Patient has been diagnosed with antibody-mediated renal transplant rejection*.
Note: Indications marked with * are unapproved indications.

Initiation – ABO-incompatible renal transplant
Nephrologist
Patient is to undergo an ABO-incompatible renal transplant*.
Note: Indications marked with * are unapproved indications.

Initiation – Steroid dependent nephrotic syndrome (SDNS) or frequently relapsing nephrotic syndrome (FRNS)
Nephrologist
Re-assessment required after 4 weeks
All of the following:
1. Patient is a child with SDNS* or FRNS*; and
2. Treatment with steroids for at least a period of 3 months has been ineffective or associated with evidence of steroid toxicity; and
3. Treatment with ciclosporin for at least a period of 3 months has been ineffective and/or discontinued due to unacceptable side effects; and
4. Treatment with mycophenolate for at least a period of 3 months with no reduction in disease relapses; and
5. The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks.

Note: Indications marked with a * are unapproved indications.

Continuation – Steroid dependent nephrotic syndrome (SDNS) or frequently relapsing nephrotic syndrome (FRNS)
Nephrologist
Re-assessment required after 4 weeks
All of the following:
1. Patient who was previously treated with rituximab for nephrotic syndrome*; and
2. Treatment with rituximab was previously successful and has demonstrated sustained response for > 6 months, but the condition has relapsed and the patient now requires repeat treatment; and
3. The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks.

Note: Indications marked with a * are unapproved indications.

Initiation – Steroid resistant nephrotic syndrome (SRNS)
Nephrologist
Re-assessment required after 4 weeks
All of the following:
1. Patient who was previously treated with rituximab for nephrotic syndrome*; and
2. Treatment with rituximab was previously successful and has demonstrated sustained response for > 6 months, but the condition has relapsed and the patient now requires repeat treatment; and
3. The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks.

Note: Indications marked with a * are unapproved indications.
Patient is a child with SRNS* where treatment with steroids and ciclosporin for at least 3 months have been ineffective; and  
2 Treatment with tacrolimus for at least 3 months has been ineffective; and  
3 Genetic causes of nephrotic syndrome have been excluded; and  
4 The total rituximab dose used would not exceed the equivalent of 375 mg/m$^2$ of body surface area per week for a total of 4 weeks.

Note: Indications marked with a * are unapproved indications.

Continuation – Steroid resistant nephrotic syndrome (SRNS)
Nephrologist  
Re-assessment required after 4 weeks  
All of the following:  
1 Patient who was previously treated with rituximab for nephrotic syndrome*; and  
2 Treatment with rituximab was previously successful and has demonstrated sustained response for greater than 6 months, but the condition has relapsed and the patient now requires repeat treatment; and  
3 The total rituximab dose used would not exceed the equivalent of 375 mg/m$^2$ of body surface area per week for a total of 4 weeks.

Note: Indications marked with a * are unapproved indications.

Initiation – Neuromyelitis Optica Spectrum Disorder (NMOSD)
Relevant specialist or medical practitioner on the recommendation of a Relevant specialist  
Re-assessment required after 6 months  
Both:  
1 One of the following dose regimens is to be used: 2 doses of 1,000 mg rituximab administered fortnightly, or 4 doses of 375 mg/m$^2$ administered weekly for four weeks; and  
2 Either:  
   2.1 The patient has experienced a severe episode or attack of NMOSD (rapidly progressing symptoms and clinical investigations supportive of a severe attack of NMOSD); or  
   2.2 All of the following:  
      2.2.1 The patient has experienced a breakthrough attack of NMOSD; and  
      2.2.2 The patient is receiving treatment with mycophenolate; and  
      2.2.3 The patients is receiving treatment with corticosteroids.

Continuation – Neuromyelitis Optica Spectrum Disorder (NMOSD)
Relevant specialist or medical practitioner on the recommendation of a Relevant specialist  
Re-assessment required after 2 years  
All of the following:  
1 One of the following dose regimens is to be used: 2 doses of 1,000 mg rituximab administered fortnightly, or 4 doses of 375 mg/m$^2$ administered weekly for four weeks; and  
2 The patients has responded to the most recent course of rituximab; and  
3 The patient has not received rituximab in the previous 6 months.

Initiation – Severe Refractory Myasthenia Gravis
Neurologist or medical practitioner on the recommendation of a Neurologist  
Re-assessment required after 2 years  
Both:  
1 One of the following dose regimens is to be used: 375 mg/m$^2$ of body surface area per week for a total of four weeks, or 500 mg once weekly for four weeks, or two 1,000 mg doses given two weeks apart; and  
2 Either:  
   2.1 Treatment with corticosteroids and at least one other immunosuppressant for at least a period of 12 months has been ineffective; or  

continued…
continued...

2.2 Both:

2.2.1 Treatment with at least one other immunosuppressant for a period of at least 12 months; and

2.2.2 Corticosteroids have been trialed for at least 12 months and have been discontinued due to unacceptable side effects.

Continuation – Severe Refractory Myasthenia Gravis

Neurologist or medical practitioner on the recommendation of a Neurologist

Re-assessment required after 2 years

All of the following:

1 One of the following dose regimens is to be used: 375 mg/m² of body surface area per week for a total of four weeks, or 500 mg once weekly for four weeks, or two 1,000 mg doses given two weeks apart; and

2 An initial response lasting at least 12 months was demonstrated; and

3 Either:

3.1 The patient has relapsed despite treatment with corticosteroids and at least one other immunosuppressant for a period of at least 12 months; or

3.2 Both:

3.2.1 The patient’s myasthenia gravis has relapsed despite treatment with at least one immunosuppressant for a period of at least 12 months; and

3.2.2 Corticosteroids have been trialed for at least 12 months and have been discontinued due to unacceptable side effects.

SECUKINUMAB – Restricted see terms below

Inj 150 mg per ml, 1 ml prefilled syringe.....................................................1,599.00 2 Cosentyx

Initiation – severe chronic plaque psoriasis, second-line biologic

Dermatologist

Re-assessment required after 4 months

All of the following:

1 The patient has had an initial Special Authority approval for adalimumab or etanercept, or has trialled infliximab in a DHB hospital in accordance with the General Rules of the Pharmaceutical Schedule, for severe chronic plaque psoriasis; and

2 Either:

2.1 The patient has experienced intolerable side effects from adalimumab, etanercept or infliximab; or

2.2 The patient has received insufficient benefit from adalimumab, etanercept or infliximab; and

3 A Psoriasis Area and Severity Index (PASI) assessment or Dermatology Quality of Life Index (DLQI) assessment has been completed for at least the most recent prior treatment course, preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and

4 The most recent PASI or DQLI assessment is no more than 1 month old at the time of application.

Continuation – severe chronic plaque psoriasis, second-line biologic

Dermatologist

Re-assessment required after 6 months

Both:

1 Either:

1.1 Patient’s PASI score has reduced by 75% or more (PASI 75) as compared to baseline PASI prior to commencing secukinumab; or

1.2 Patient has a Dermatology Quality of Life Index (DLQI) improvement of 5 or more, as compared to baseline DLQI prior to commencing secukinumab; and

2 Secukinumab to be administered at a maximum dose of 300 mg monthly.

continued…
continued…

**Initiation – severe chronic plaque psoriasis, first-line biologic**

Dermatologist  
*Re-assessment required after 4 months*

All of the following:

1. Either:
   1.1 Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 10, where lesions have been present for at least 6 months from the time of initial diagnosis; or
   1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and

2. Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, ciclosporin, or acitretin; and

3. A PASI assessment or Dermatology Quality of Life Index (DLQI) assessment has been completed for at least the most recent prior treatment course, preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and

4. The most recent PASI or DQLI assessment is no more than 1 month old at the time of application.

Note: A treatment course is defined as a minimum of 12 weeks of treatment. "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 10, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom sub scores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment.

**Continuation – severe chronic plaque psoriasis, first-line biologic**

Dermatologist  
*Re-assessment required after 6 months*

Both:

1. Either:
   1.1 Patient’s PASI score has reduced by 75% or more (PASI 75) as compared to baseline PASI prior to commencing secukinumab; or
   1.2 Patient has a Dermatology Quality of Life Index (DLQI) improvement of 5 or more, as compared to baseline DLQI prior to commencing secukinumab; and

2. Secukinumab to be administered at a maximum dose of 300 mg monthly.

**SILTUXIMAB – Restricted** see terms below

<table>
<thead>
<tr>
<th>Item</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 100 mg vial</td>
<td>770.57</td>
<td>Sylvant</td>
</tr>
<tr>
<td>Inj 400 mg vial</td>
<td>3,082.33</td>
<td>Sylvant</td>
</tr>
</tbody>
</table>

*Restricted (RS1525) *

**Initiation**

Haematologist or rheumatologist  
*Re-assessment required after 6 months*

All of the following:

1. Patient has severe HHV-8 negative idiopathic multicentric Castleman's Disease; and

2. Treatment with an adequate trial of corticosteroids has proven ineffective; and

3. Siltuximab is to be administered at doses no greater than 11 mg/kg every 3 weeks.

**Continuation**

Haematologist or rheumatologist  
*Re-assessment required after 12 months*

The treatment remains appropriate and the patient has sustained improvement in inflammatory markers and functional status.
TOCILIZUMAB – Restricted see terms below

- Inj 20 mg per ml, 4 ml vial.................................................................220.00 1 Actemra
- Inj 20 mg per ml, 10 ml vial..........................................................550.00 1 Actemra
- Inj 20 mg per ml, 20 ml vial.........................................................1,100.00 1 Actemra

Initiation – cytokine release syndrome

Therapy limited to 3 doses

Either:

1. All of the following:
   1.1 The patient is enrolled in the Children’s Oncology Group AALL1731 trial; and
   1.2 The patient has developed grade 3 or 4 cytokine release syndrome associated with the administration of
   blinatumomab for the treatment of acute lymphoblastic leukaemia; and
   1.3 Tocilizumab is to be administered at doses no greater than 8 mg/kg IV for a maximum of 3 doses (if less than 30kg,
   maximum of 12 mg/kg); or

2. All of the following:
   2.1 The patient is enrolled in the Malaghan Institute of Medical Research Phase I ENABLE trial; and
   2.2 The patient has developed CRS or CAR T-Cell Related Encephalopathy Syndrome (CRES) associated with the
   administration of CAR T-cell therapy for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma; and
   2.3 Tocilizumab is to be administered according to the consensus guidelines for CRS and CRES for CAR T-cell therapy
   (Neelapu et al. Nat Rev Clin Oncol 2018;15:47-62) at doses no greater than 8 mg/kg IV for a maximum of 3 doses.

Initiation – previous use

Any relevant practitioner

Limited to 6 months treatment

Both:

1. Patient was being treated with tocilizumab prior to 1 February 2019; and

2. Any of the following:
   2.1 rheumatoid arthritis; or
   2.2 systemic juvenile idiopathic arthritis; or
   2.3 adult-onset Still’s disease; or
   2.4 polyarticular juvenile idiopathic arthritis; or
   2.5 idiopathic multicentric Castleman’s disease.

Initiation – Rheumatoid Arthritis (patients previously treated with adalimumab or etanercept)

Rheumatologist or Practitioner on the recommendation of a rheumatologist

Limited to 6 months treatment

All of the following:

1. The patient has had an initial Special Authority approval for adalimumab and/or etanercept for rheumatoid arthritis; and

2. Either:
   2.1 The patient has experienced intolerable side effects from adalimumab and/or etanercept; or
   2.2 The patient has received insufficient benefit from at least a three-month trial of adalimumab and/or etanercept such
   that they do not meet the renewal criteria for rheumatoid arthritis; and

3. Either:
   3.1 The patient is seronegative for both anti-cyclic citrullinated peptide (CCP) antibodies and rheumatoid factor; or
   3.2 Both:
      3.2.1 The patient has been started on rituximab for rheumatoid arthritis in a DHB hospital in accordance with the
      Section H rules; and
      3.2.2 Either:
         3.2.2.1 The patient has experienced intolerable side effects from rituximab; or

continued…
3.2.2.2 At four months following the initial course of rituximab the patient has received insufficient benefit such that they do not meet the renewal criteria for rheumatoid arthritis.

Initiation – Rheumatoid Arthritis
Rheumatologist or Practitioner on the recommendation of a rheumatologist
Re-assessment required after 6 months
All of the following:

1 Patient has had severe and active erosive rheumatoid arthritis (either confirmed by radiology imaging, or the patient is cyclic citrullinated peptide (CCP) antibody positive) for six months duration or longer; and
2 Tocilizumab is to be used as monotherapy; and
3 Either:
   3.1 Treatment with methotrexate is contraindicated; or
   3.2 Patient has tried and did not tolerate oral and/or parenteral methotrexate; and
4 Either:
   4.1 Patient has tried and not responded to at least three months therapy at the maximum tolerated dose of ciclosporin alone or in combination with another agent; or
   4.2 Patient has tried and not responded to at least three months therapy at the maximum tolerated dose of leflunomide alone or in combination with another agent; and
5 Either:
   5.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 active, swollen, tender joints; or
   5.2 Patient has persistent symptoms of poorly controlled and active disease in at least four active joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
6 Either:
   6.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
   6.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Initiation – systemic juvenile idiopathic arthritis
Rheumatologist or Practitioner on the recommendation of a rheumatologist
Re-assessment required after 6 months
Both:

1 Patient diagnosed with systemic juvenile idiopathic arthritis; and
2 Patient has tried and not responded to a reasonable trial of all of the following, either alone or in combination: oral or parenteral methotrexate; non-steroidal anti-inflammatory drugs (NSAIDs); and systemic corticosteroids.

Initiation – adult-onset Still's disease
Rheumatologist or Practitioner on the recommendation of a rheumatologist
Re-assessment required after 6 months
Either:

1 Both:
   1.1 Either:
      1.1.1 The patient has had an initial Special Authority approval for adalimumab and/or etanercept for adult-onset Still's disease (AOSD); or
      1.1.2 The patient has been started on tocilizumab for AOSD in a DHB hospital in accordance with the General Rules of the Pharmaceutical Schedule; and
   1.2 Either:
      1.2.1 The patient has experienced intolerable side effects from adalimumab and/or etanercept; or

continued…
1.2.2 The patient has received insufficient benefit from at least a three-month trial of adalimumab and/or etanercept such that they do not meet the renewal criteria for AOSD; or

2 All of the following:

2.1 Patient diagnosed with AOSD according to the Yamaguchi criteria (J Rheumatol 1992;19:424-430); and

2.2 Patient has tried and not responded to at least 6 months of glucocorticosteroids at a dose of at least 0.5 mg/kg, non-steroidal antiinflammatory drugs (NSAIDs) and methotrexate; and

2.3 Patient has persistent symptoms of disabling poorly controlled and active disease.

**Initiation – polyarticular juvenile idiopathic arthritis**

Rheumatologist or Practitioner on the recommendation of a rheumatologist

*Re-assessment required after 4 months*

Either:

1 Both:

1.1 The patient has had an initial Special Authority approval for both etanercept and adalimumab for juvenile idiopathic arthritis (JIA); and

1.2 The patient has experienced intolerable side effects, or has received insufficient benefit from, both etanercept and adalimumab; or

2 All of the following:

2.1 Treatment with a tumour necrosis factor alpha inhibitor is contraindicated; and

2.2 Patient has had severe active polyarticular course JIA for 6 months duration or longer; and

2.3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate (at a dose of 10-20 mg/m² weekly or at the maximum tolerated dose) in combination with either oral corticosteroids (prednisone 0.25 mg/kg or at the maximum tolerated dose) or a full trial of serial intra-articular corticosteroid injections; and

2.4 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and

2.5 Both:

2.5.1 Either:

2.5.1.1 Patient has persistent symptoms of poorly-controlled and active disease in at least 20 swollen, tender joints; or

2.5.1.2 Patient has persistent symptoms of poorly-controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, shoulder, cervical spine, hip; and

2.5.2 Physician’s global assessment indicating severe disease.

**Initiation – idiopathic multicentric Castleman’s disease**

Haematologist, rheumatologist or Practitioner on the recommendation of a haematologist or rheumatologist

*Re-assessment required after 6 months*

All of the following:

1 Patient has severe HHV-8 negative idiopathic multicentric Castleman's disease; and

2 Treatment with an adequate trial of corticosteroids has proven ineffective; and

3 Tocilizumab to be administered at doses no greater than 8 mg/kg IV every 3-4 weeks.

**Continuation – Rheumatoid Arthritis**

Rheumatologist or Practitioner on the recommendation of a rheumatologist

*Re-assessment required after 6 months*

Either:

1 Following 6 months’ initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or

2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician.
continued...

**Continuation – systemic juvenile idiopathic arthritis**
Rheumatologist or Practitioner on the recommendation of a rheumatologist
*Re-assessment required after 6 months*
Either:
1. Following up to 6 months' initial treatment, the patient has achieved at least an American College of Rheumatology paediatric 30% improvement criteria (ACR Pedi 30) response from baseline; or
2. On subsequent reapplications, the patient demonstrates at least a continuing ACR Pedi 30 response from baseline.

**Continuation – adult-onset Still's disease**
Rheumatologist or Practitioner on the recommendation of a rheumatologist
*Re-assessment required after 6 months*
the patient has a sustained improvement in inflammatory markers and functional status.

**Continuation – polyarticular juvenile idiopathic arthritis**
Rheumatologist or Practitioner on the recommendation of a rheumatologist
*Re-assessment required after 6 months*
Both:
1. Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
2. Either:
   2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician's global assessment from baseline; or
   2.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline.

**Continuation – idiopathic multicentric Castleman's disease**
Haematologist, rheumatologist or Practitioner on the recommendation of a haematologist or rheumatologist
*Re-assessment required after 12 months*
the treatment remains appropriate and the patient has a sustained improvement in inflammatory markers and functional status.

**TRASTUZUMAB – Restricted** see terms below

<table>
<thead>
<tr>
<th>Item</th>
<th>Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Inj 150 mg vial</td>
<td>$1,350.00</td>
<td>1 Herceptin</td>
</tr>
<tr>
<td>2.</td>
<td>Inj 440 mg vial</td>
<td>$3,875.00</td>
<td>1 Herceptin</td>
</tr>
</tbody>
</table>


**Initiation – Early breast cancer**
*Limited to 12 months treatment*
All of the following:
1. The patient has early breast cancer expressing HER 2 IHC 3+ or ISH+ (including FISH or other current technology); and
2. Maximum cumulative dose of 106 mg/kg (12 months' treatment); and
3. Any of the following:
   3.1 9 weeks' concurrent treatment with adjuvant chemotherapy is planned; or
   3.2 12 months' concurrent treatment with adjuvant chemotherapy is planned; or
   3.3 12 months' sequential treatment following adjuvant chemotherapy is planned; or
   3.4 12 months' treatment with neoadjuvant and adjuvant chemotherapy is planned; or
   3.5 Other treatment regimen, in association with adjuvant chemotherapy, is planned.

**Initiation – metastatic breast cancer (trastuzumab-naive patients)**
*Limited to 12 months treatment*
All of the following:
1. The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
2. Either:
   2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician's global assessment from baseline; or
   2.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline.

continued…
continued...

2.1 The patient has not previously received lapatinib treatment for HER-2 positive metastatic breast cancer; or
2.2 Both:
   2.2.1 The patient started lapatinib treatment for metastatic breast cancer but discontinued lapatinib within
       3 months of starting treatment due to intolerance; and
   2.2.2 The cancer did not progress whilst on lapatinib; and

3 Either:
   3.1 Trastuzumab will not be given in combination with pertuzumab; or
   3.2 All of the following:
      3.2.1 Trastuzumab to be administered in combination with pertuzumab; and
      3.2.2 Patient has not received prior treatment for their metastatic disease and has had a treatment-free interval of
           at least 12 months between prior (neo)adjuvant chemotherapy treatment and diagnosis of metastatic breast
           cancer; and
      3.2.3 The patient has good performance status (ECOG grade 0-1); and

4 Trastuzumab not to be given in combination with lapatinib; and
5 Trastuzumab to be discontinued at disease progression.

Initiation – metastatic breast cancer (patients previously treated with trastuzumab)

Limited to 12 months treatment

All of the following:
1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
2 Either:
   2.1 The patient has not previously received lapatinib treatment for HER-2 positive metastatic breast cancer; or
   2.2 Both:
      2.2.1 The patient started lapatinib treatment for metastatic breast cancer but discontinued lapatinib within
           3 months of starting treatment due to intolerance; and
      2.2.2 The cancer did not progress whilst on lapatinib; and

3 Either:
   3.1 Trastuzumab will not be given in combination with pertuzumab; or
   3.2 All of the following:
      3.2.1 Trastuzumab to be administered in combination with pertuzumab; and
      3.2.2 Patient has not received prior treatment for their metastatic disease and has had a treatment-free interval of
           at least 12 months between prior (neo)adjuvant chemotherapy treatment and diagnosis of metastatic breast
           cancer; and
      3.2.3 The patient has good performance status (ECOG grade 0-1); and

4 Trastuzumab not to be given in combination with lapatinib; and
5 Trastuzumab to be discontinued at disease progression.

Continuation – metastatic breast cancer

Re-assessment required after 12 months

All of the following:
1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
2 The cancer has not progressed at any time point during the previous 12 months whilst on trastuzumab; and
3 Trastuzumab not to be given in combination with lapatinib; and
4 Trastuzumab to be discontinued at disease progression.

TRASTUZUMAB EMTANSINE – Restricted see terms on the next page

<table>
<thead>
<tr>
<th></th>
<th>Description</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Inj 100 mg vial</td>
<td>$2,320.00</td>
</tr>
<tr>
<td></td>
<td>Inj 160 mg vial</td>
<td>$3,712.00</td>
</tr>
</tbody>
</table>

Products with Hospital Supply Status (HSS) are in bold

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
## Programmed Cell Death-1 (PD-1) Inhibitors

**NIVOLUMAB** – **Restricted** see terms below

<table>
<thead>
<tr>
<th>Item</th>
<th>Price</th>
<th>Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 10 mg per ml, 4 ml vial</td>
<td>$1,051.98</td>
<td>1 Opdivo</td>
</tr>
<tr>
<td>Inj 10 mg per ml, 10 ml vial</td>
<td>$2,629.96</td>
<td>1 Opdivo</td>
</tr>
</tbody>
</table>

### Initiation

**Medical oncologist**

**Re-assessment required after 4 months**

All of the following:

1. Patient has metastatic or unresectable melanoma (excluding uveal) stage III or IV; and
2. Patient has measurable disease as defined by RECIST version 1.1; and
3. The patient has ECOG performance score of 0-2; and
4. Either:
   4.1 Patient has not received funded pembrolizumab; or
   4.2 Both:
      4.2.1 Patient has received an initial Special Authority approval for pembrolizumab and has discontinued pembrolizumab within 12 weeks of starting treatment due to intolerance; and
      4.2.2 The cancer did not progress while the patient was on pembrolizumab; and
5. Nivolumab is to be used at a maximum dose of no greater than the equivalent of 3 mg/kg every 2 weeks; and
6. Baseline measurement of overall tumour burden is documented (see Note); and
7. Documentation confirming that the patient has been informed and acknowledges that the initial funded treatment period of nivolumab will not be continued beyond 12 weeks (6 cycles) if their disease progresses during this time.

continued…
Continuation

Medical oncologist

Re-assessment required after 4 months

Either:

1 All of the following:

1.1 Any of the following:

1.1.1 Patient's disease has had a complete response to treatment according to RECIST criteria (see Note); or
1.1.2 Patient's disease has had a partial response to treatment according to RECIST criteria (see Note); or
1.1.3 Patient has stable disease according to RECIST criteria (see Note); and

1.2 Either:

1.2.1 Response to treatment in target lesions has been determined by radiologic assessment (CT or MRI scan) following the most recent treatment period; or
1.2.2 Both:

1.2.2.1 Patient has measurable disease as defined by RECIST version 1.1; and
1.2.2.2 Patient's disease has not progressed clinically and disease response to treatment has been clearly documented in patient notes; and

1.3 No evidence of progressive disease according to RECIST criteria (see Note); and

1.4 The treatment remains clinically appropriate and the patient is benefitting from the treatment; and

1.5 Nivolumab will be used at a maximum dose of no greater than the equivalent of 3 mg/kg every 2 weeks; or

2 All of the following:

2.1 Patient has previously discontinued treatment with nivolumab for reasons other than severe toxicity or disease progression; and

2.2 Patient has signs of disease progression; and

2.3 Disease has not progressed during previous treatment with nivolumab; and

2.4 Nivolumab will be used at a maximum dose of no greater than the equivalent of 3 mg/kg every 2 weeks.

Notes: Baseline assessment and disease responses to be assessed according to the Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 (Eisenhauer EA, et al. Eur J Cancer 2009;45:228-47). Assessments of overall tumour burden and measurable disease to be undertaken on a minimum of one lesion and maximum of 5 target lesions (maximum two lesions per organ). Target lesions should be selected on the basis of their size (lesions with the longest diameter), be representative of all involved organs, and suitable for reproducible repeated measurements. Measurable disease includes by CT or MRI imaging or caliper measurement by clinical exam. Target lesion measurements should be assessed using the same method of assessment and the same technique used to characterise each identified and reported lesion at baseline and every 12 weeks. Response definitions as follows:

- Complete Response: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm.
- Partial Response: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
- Progressive Disease: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).
- Stable Disease: Neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease.

PEMBROLIZUMAB – Restricted see terms below

<table>
<thead>
<tr>
<th>Inj 25 mg per ml, 4 ml vial</th>
<th>4,680.00</th>
</tr>
</thead>
</table>

Keytruda

Initiation

Medical oncologist

Re-assessment required after 4 months

All of the following: continued…
continued...

1 Patient has metastatic or unresectable melanoma (excluding uveal) stage III or IV; and
2 Patient has measurable disease as defined by RECIST version 1.1; and
3 The patient has ECOG performance score of 0-2; and
4 Either:
   4.1 Patient has not received funded nivolumab; or
   4.2 Both:
      4.2.1 Patient has received an initial Special Authority approval for nivolumab and has discontinued nivolumab
           within 12 weeks of starting treatment due to intolerance; and
      4.2.2 The cancer did not progress while the patient was on nivolumab; and
5 Pembrolizumab is to be used at a maximum dose of no greater than the equivalent of 2 mg/kg every 3 weeks; and
6 Baseline measurement of overall tumour burden is documented (see Note); and
7 Documentation confirming that the patient has been informed and acknowledges that the initial funded treatment period of
   pembrolizumab will not be continued beyond 12 weeks (4 cycles) if their disease progresses during this time.

Continuation
Medical oncologist
Re-assessment required after 4 months
Either:

1 All of the following:
   1.1 Any of the following:
      1.1.1 Patient's disease has had a complete response to treatment according to RECIST criteria (see Note); or
      1.1.2 Patient's disease has had a partial response to treatment according to RECIST criteria (see Note); or
      1.1.3 Patient has stable disease according to RECIST criteria (see Note); and
   1.2 Either:
      1.2.1 Response to treatment in target lesions has been determined by radiologic assessment (CT or MRI scan)
           following the most recent treatment period; or
      1.2.2 Both:
         1.2.2.1 Patient has measurable disease as defined by RECIST version 1.1; and
         1.2.2.2 Patient's disease has not progressed clinically and disease response to treatment has been clearly
           documented in patient notes; and
   1.3 No evidence of progressive disease according to RECIST criteria (see Note); and
   1.4 The treatment remains clinically appropriate and the patient is benefitting from the treatment; and
   1.5 Pembrolizumab will be used at a maximum dose of no greater than the equivalent of 2 mg/kg every 3 weeks; or

2 All of the following:
   2.1 Patient has previously discontinued treatment with pembrolizumab for reasons other than severe toxicity or disease
       progression; and
   2.2 Patient has signs of disease progression; and
   2.3 Disease has not progressed during previous treatment with pembrolizumab; and
   2.4 Pembrolizumab will be used at a maximum dose of no greater than the equivalent of 2 mg/kg every 3 weeks.

Notes: Baseline assessment and disease responses to be assessed according to the Response Evaluation Criteria in Solid
and measurable disease to be undertaken on a minimum of one lesion and maximum of 5 target lesions (maximum two lesions
per organ). Target lesions should be selected on the basis of their size (lesions with the longest diameter), be representative of
all involved organs, and suitable for reproducible repeated measurements. Measurable disease includes by CT or MRI imaging
or caliper measurement by clinical exam. Target lesion measurements should be assessed using the same method of
assessment and the same technique used to characterise each identified and reported lesion at baseline and every 12 weeks.
Response definitions as follows:
continued...

- **Complete Response**: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm.
- **Partial Response**: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
- **Progressive Disease**: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).
- **Stable Disease**: Neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease.

### Other Immunosuppressants

**ANTITHYMOCYTE GLOBULIN (EQUINE)**

<table>
<thead>
<tr>
<th>Package</th>
<th>Price (excl. GST)</th>
<th>Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 50 mg per ml, 5 ml ampoule</td>
<td>$2,351.25</td>
<td>5 ATGAM</td>
</tr>
</tbody>
</table>

**ANTITHYMOCYTE GLOBULIN (RABBIT)**

<table>
<thead>
<tr>
<th>Package</th>
<th>Price (excl. GST)</th>
<th>Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 25 mg vial</td>
<td>$7.35</td>
<td>60 Azamun</td>
</tr>
<tr>
<td>Tab 25 mg – 1% DV Jan-20 to 2022</td>
<td>$9.66</td>
<td>100 Imuran</td>
</tr>
<tr>
<td>Tab 50 mg – 1% DV Jan-20 to 2022</td>
<td>$7.60</td>
<td>100 Azamun</td>
</tr>
<tr>
<td>Inj 50 mg vial – 1% DV Nov-19 to 2022</td>
<td>$199.00</td>
<td>1 Imuran</td>
</tr>
</tbody>
</table>

**AZATHIOPRINE**

<table>
<thead>
<tr>
<th>Package</th>
<th>Price (excl. GST)</th>
<th>Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 25 mg – 1% DV Jan-20 to 2022</td>
<td>$7.35</td>
<td>60 Azamun</td>
</tr>
<tr>
<td>Tab 50 mg – 1% DV Jan-20 to 2022</td>
<td>$9.66</td>
<td>100 Imuran</td>
</tr>
<tr>
<td>Inj 50 mg vial – 1% DV Nov-19 to 2022</td>
<td>$199.00</td>
<td>1 Imuran</td>
</tr>
</tbody>
</table>

*(Imuran Tab 25 mg to be delisted 1 January 2020)*

*(Imuran Tab 50 mg to be delisted 1 January 2020)*

**BACILLUS CALMETTE-GUERIN (BCG)** – **Restricted** see terms below

<table>
<thead>
<tr>
<th>Package</th>
<th>Price (excl. GST)</th>
<th>Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 2-8 x 10^8 CFU vial</td>
<td>$149.37</td>
<td>1 OncoTICE</td>
</tr>
</tbody>
</table>

*Restricted (RS1206)*

**Initiation**

For use in bladder cancer.

**EVEROLIMUS** – **Restricted** see terms below

<table>
<thead>
<tr>
<th>Package</th>
<th>Price (excl. GST)</th>
<th>Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 5 mg</td>
<td>$4,555.76</td>
<td>30 Afinitor</td>
</tr>
<tr>
<td>Tab 10 mg</td>
<td>$6,512.29</td>
<td>30 Afinitor</td>
</tr>
</tbody>
</table>

*Restricted (RS1440)*

**Initiation**

Neurologist or oncologist

Re-assessment required after 3 months

Both:

1. Patient has tuberous sclerosis; and
2. Patient has progressively enlarging sub-ependymal giant cell astrocytomas (SEGAs) that require treatment.

**Continuation**

Neurologist or oncologist

Re-assessment required after 12 months

All of the following:

1. Documented evidence of SEGA reduction or stabilisation by MRI within the last 3 months; and
2. The treatment remains appropriate and the patient is benefiting from treatment; and
3. Everolimus to be discontinued at progression of SEGAs.

Note: MRI should be performed at minimum once every 12 months, more frequent scanning should be performed with new onset of symptoms such as headaches, visual complaints, nausea or vomiting, or increase in seizure activity.
ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) $</th>
<th>Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
</table>

**MYCOPHENOLATE MOFETIL**

- Tab 500 mg ................................................................. 25.00 50 CellCept
- Cap 250 mg ................................................................. 25.00 100 CellCept
- Powder for oral liq 1 g per 5 ml .................................. 187.25 165 ml CellCept
- Inj 500 mg vial ............................................................ 133.33 4 CellCept

**PICIBANIL**

- Inj 100 mg vial

**SIROLIMUS – Restricted see terms below**

- Tab 1 mg ........................................................................ 749.99 100 Rapamune
- Tab 2 mg ........................................................................ 1,499.99 100 Rapamune
- Oral liq 1 mg per ml ....................................................... 449.99 60 ml Rapamune

**Restricted (RS1208)**

**Initiation**

For rescue therapy for an organ transplant recipient.

Notes: Rescue therapy defined as unresponsive to calcineurin inhibitor treatment as defined by refractory rejection; or intolerant to calcineurin inhibitor treatment due to any of the following:

- GFR < 30 ml/min; or
- Rapidly progressive transplant vasculopathy; or
- Rapidly progressive obstructive bronchiolitis; or
- HUS or TTP; or
- Leukoencephalopathy; or
- Significant malignant disease
Antiallergy Preparations

Allergic Emergencies

ICATIBANT – **Restricted** see terms [below](#)
- Inj 10 mg per ml, 3 ml prefilled syringe.......................................................2,668.00 1 Firazyr

**Restricted (RS1501)**

**Initiation**
Clinical immunologist or relevant specialist

**Re-assessment required after 12 months**

**Both:**
1. Supply for anticipated emergency treatment of laryngeal/oro-pharyngeal or severe abdominal attacks of acute hereditary angioedema (HAE) for patients with confirmed diagnosis of C1-esterase inhibitor deficiency; and
2. The patient has undergone product training and has agreed upon an action plan for self-administration.

**Continuation**
**Re-assessment required after 12 months**
The treatment remains appropriate and the patient is benefiting from treatment.

Allergy Desensitisation

BEE VENOM – **Restricted** see terms [below](#)
- Maintenance kit - 6 vials 120 mcg freeze dried venom, with diluent
- Inj 550 mcg vial with diluent

**Restricted (RS1117)**

**Initiation**

Both:
1. RAST or skin test positive; and
2. Patient has had severe generalised reaction to the sensitising agent.

PAPER WASP VENOM – **Restricted** see terms [below](#)
- Treatment kit - 6 vials 120 mcg freeze dried venom, with diluent
- Inj 550 mcg vial with diluent

**Restricted (RS1118)**

**Initiation**

Both:
1. RAST or skin test positive; and
2. Patient has had severe generalised reaction to the sensitising agent.

YELLOW JACKET WASP VENOM – **Restricted** see terms [below](#)
- Treatment kit - 6 vials 120 mcg freeze dried venom, with diluent
- Inj 550 mcg vial with diluent

**Restricted (RS1119)**

**Initiation**

Both:
1. RAST or skin test positive; and
2. Patient has had severe generalised reaction to the sensitising agent.

Allergy Prophylactics

BECLOMETHASONE DIPROPIONATE
- Nasal spray 50 mcg per dose.................................................................5.26 200 dose Alanase
- Nasal spray 100 mcg per dose..............................................................6.00 200 dose Alanase

---

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
# RESPIRATORY SYSTEM AND ALLERGIES

<table>
<thead>
<tr>
<th>Drug</th>
<th>Formulation</th>
<th>Brand or Manufacturer</th>
<th>Price (ex man. excl. GST $ Per)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>BUDESONIDE</strong></td>
<td>Nasal spray 50 mcg per dose – 1% DV Oct-18 to 2020</td>
<td>SteroClear</td>
<td>2.59 200 dose</td>
</tr>
<tr>
<td></td>
<td>Nasal spray 100 mcg per dose – 1% DV Oct-18 to 2020</td>
<td>SteroClear</td>
<td>2.87 200 dose</td>
</tr>
<tr>
<td><strong>FLUTICASONE PROPIONATE</strong></td>
<td>Nasal spray 50 mcg per dose – 1% DV Nov-18 to 2021</td>
<td>Flixonase Hayfever &amp; Allergy</td>
<td>1.98 120 dose</td>
</tr>
<tr>
<td><strong>IPRATROPİUM BROMİDE</strong></td>
<td>Aqueous nasal spray 0.03% – 1% DV Oct-17 to 2020</td>
<td>Univent</td>
<td>4.61 15 ml</td>
</tr>
<tr>
<td><strong>SODIUM CROMOGLICATE</strong></td>
<td>Nasal spray 4%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

## Antihistamines

<table>
<thead>
<tr>
<th>Drug</th>
<th>Formulation</th>
<th>Brand or Manufacturer</th>
<th>Price (ex man. excl. GST $ Per)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CETIRIZINE HYDROCHLORIDE</strong></td>
<td>Tab 10 mg – 1% DV Nov-19 to 2022</td>
<td>Zista</td>
<td>1.12 100</td>
</tr>
<tr>
<td></td>
<td>Oral liq 1 mg per ml</td>
<td></td>
<td>2.99 200 ml Histaclear</td>
</tr>
<tr>
<td><strong>CHLORPHENIRAMINE MALEATE</strong></td>
<td>Oral liq 0.4 mg per ml</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inj 10 mg per ml, 1 ml ampoule</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>CYPROHEPTADINE HYDROCHLORIDE</strong></td>
<td>Tab 4 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>FEXOFENADINE HYDROCHLORIDE</strong></td>
<td>Tab 60 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Tab 120 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Tab 180 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>LORATADINE</strong></td>
<td>Tab 10 mg – 1% DV Feb-20 to 2022</td>
<td>Lorafix</td>
<td>1.69 100</td>
</tr>
<tr>
<td></td>
<td>Oral liq 1 mg per ml</td>
<td></td>
<td>2.15 120 ml Lorfast</td>
</tr>
<tr>
<td><strong>PROMETHAZINE HYDROCHLORIDE</strong></td>
<td>Tab 10 mg – 1% DV Sep-18 to 2021</td>
<td>Allersoothe</td>
<td>1.68 50</td>
</tr>
<tr>
<td></td>
<td>Tab 25 mg – 1% DV Sep-18 to 2021</td>
<td></td>
<td>1.89 50</td>
</tr>
<tr>
<td></td>
<td>Oral liq 1 mg per ml – 1% DV Sep-18 to 2021</td>
<td>Allersoothe</td>
<td>2.69 100 ml</td>
</tr>
<tr>
<td></td>
<td>Inj 25 mg per ml, 2 ml ampoule</td>
<td></td>
<td>15.54 5 Hospira</td>
</tr>
</tbody>
</table>

## Anticholinergic Agents

<table>
<thead>
<tr>
<th>Drug</th>
<th>Formulation</th>
<th>Brand or Manufacturer</th>
<th>Price (ex man. excl. GST $ Per)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>IPRATROPİUM BROMİDE</strong></td>
<td>Aerosol inhaler 20 mcg per dose</td>
<td>Univent</td>
<td>3.35 20</td>
</tr>
<tr>
<td></td>
<td>Nebuliser soln 250 mcg per ml, 1 ml ampoule</td>
<td></td>
<td>11.73 20</td>
</tr>
<tr>
<td><strong>Anticholinergic Agents with Beta-Adrenoceptor Agonists</strong></td>
<td>Aerosol inhaler 100 mcg with ipratropium bromide 20 mcg per dose</td>
<td>Duolin</td>
<td>5.20 20</td>
</tr>
</tbody>
</table>
Long-Acting Muscarinic Agents

GLYCOPPYRONIUM
Note: inhaled glycopyrronium treatment must not be used if the patient is also receiving treatment with subsidised tiotropium or umeclidinium.
Powder for inhalation 50 mcg per dose...........................................................61.00 30 dose Seebri Breezhaler

TIOTROPIUM BROMIDE
Note: tiotropium treatment must not be used if the patient is also receiving treatment with subsidised inhaled glycopyrronium or umeclidinium.
Soln for inhalation 2.5 mcg per dose...............................................................50.37 60 dose Spiriva Respimat
Powder for inhalation 18 mcg per dose...........................................................50.37 30 dose Spiriva

UMECLIDINIUM
Note: Umeclidinium must not be used if the patient is also receiving treatment with subsidised inhaled glycopyrronium or tiotropium bromide.
Powder for inhalation 62.5 mcg per dose........................................................61.50 30 dose Incruse Ellipta

Long-Acting Muscarinic Antagonists with Long-Acting Beta-Adrenoceptor Agonists

→ Restricted (RS1518)
Initiation
Re-assessment required after 2 years
Both:
1 Patient has been stabilised on a long acting muscarinic antagonist; and
2 The prescriber considers that the patient would receive additional benefit from switching to a combination product.

Continuation
Re-assessment required after 2 years
Both:
1 Patient is compliant with the medication; and
2 Patient has experienced improved COPD symptom control (prescriber determined).

Note: Combination long acting muscarinic antagonist and long acting beta-2 agonist must not be used if the patient is also receiving treatment with a combination inhaled corticosteroid and long acting beta-2 agonist.

GLYCOPPYRONIUM WITH INDACATEROL – Restricted see terms above
 Powder for Inhalation 50 mcg with indacaterol 110 mcg........................................81.00 30 dose Ultibro Breezhaler

TIOTROPIUM BROMIDE WITH OLODATEROL – Restricted see terms above
 Soln for inhalation 2.5 mcg with olodaterol 2.5 mcg........................................81.00 60 dose Spiolto Respimat

UMECLIDINIUM WITH VILANDEROL – Restricted see terms above
 Powder for inhalation 62.5 mcg with vilanterol 25 mcg...................................77.00 30 dose Anoro Ellipta

Antifibrotics

NINTEDANIB – Restricted see terms below
 Cap 100 mg................................................................................................2,554.00 60 Ofev
 Cap 150 mg................................................................................................3,870.00 60 Ofev

→ Restricted (RS1654)
Initiation – idiopathic pulmonary fibrosis
Respiratory specialist
Re-assessment required after 12 months
All of the following:
continued…

1. Patient has been diagnosed with idiopathic pulmonary fibrosis by a multidisciplinary team including a radiologist; and
2. Forced vital capacity is between 50% and 90% predicted; and
3. Nintedanib is to be discontinued at disease progression (See Note); and
4. Nintedanib is not to be used in combination with subsidised pirfenidone; and
5. Any of the following:
   5.1. The patient has not previously received treatment with pirfenidone; or
   5.2. Patient has previously received pirfenidone, but discontinued pirfenidone within 12 weeks due to intolerance; or
   5.3. Patient has previously received pirfenidone, but the patient’s disease has not progressed (disease progression defined as 10% or more decline in predicted FVC within any 12 month period since starting treatment with pirfenidone).

Continuation – idiopathic pulmonary fibrosis
Respiratory specialist
Re-assessment required after 12 months
All of the following:
1. Treatment remains clinically appropriate and patient is benefitting from and tolerating treatment; and
2. Nintedanib is not to be used in combination with subsidised pirfenidone; and
3. Nintedanib is to be discontinued at disease progression (See Note).

Note: disease progression is defined as a decline in percent predicted FVC of 10% or more within any 12 month period.

PIRFENIDONE – Restricted see terms below

- Tab 801 mg..........................................................$3,645.00 90 Esbriet
- Cap 267 mg..........................................................$3,645.00 270 Esbriet

Initiation – idiopathic pulmonary fibrosis
Respiratory specialist
Re-assessment required after 12 months
All of the following:
1. Patient has been diagnosed with idiopathic pulmonary fibrosis by a multidisciplinary team including a radiologist; and
2. Forced vital capacity is between 50% and 90% predicted; and
3. Pirfenidone is to be discontinued at disease progression (See Notes); and
4. Pirfenidone is not to be used in combination with subsidised nintedanib; and
5. Any of the following:
   5.1. The patient has not previously received treatment with nintedanib; or
   5.2. Patient has previously received nintedanib, but discontinued nintedanib within 12 weeks due to intolerance; or
   5.3. Patient has previously received nintedanib, but the patient’s disease has not progressed (disease progression defined as 10% or more decline in predicted FVC within any 12 month period since starting treatment with nintedanib).

Continuation – idiopathic pulmonary fibrosis
Respiratory specialist
Re-assessment required after 12 months
All of the following:
1. Treatment remains clinically appropriate and patient is benefitting from and tolerating treatment; and
2. Pirfenidone is not to be used in combination with subsidised nintedanib; and
3. Pirfenidone is to be discontinued at disease progression (See Note).

Note: disease progression is defined as a decline in percent predicted FVC of 10% or more within any 12 month period.
# RESPIRATORY SYSTEM AND ALLERGIES

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per Brand or Generic Manufacturer</td>
<td></td>
</tr>
</tbody>
</table>

## Beta-Adrenoceptor Agonists

<table>
<thead>
<tr>
<th>Product</th>
<th>Description</th>
<th>Price</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>SALBUTAMOL</td>
<td>Oral liq 400 mcg per ml – 1% DV Nov-18 to 2021</td>
<td>20.00</td>
<td>150 ml Ventolin</td>
</tr>
<tr>
<td></td>
<td>Inj 500 mcg per ml, 1 ml ampoule</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inj 1 mg per ml, 5 ml ampoule</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Aerosol inhaler, 100 mcg per dose</td>
<td>3.80</td>
<td>200 dose SalAir</td>
</tr>
<tr>
<td></td>
<td>Nebuliser soln 1 mg per ml, 2.5 ml ampoule – 1% DV Oct-18 to 2021</td>
<td>3.93</td>
<td>20 Asthalin</td>
</tr>
<tr>
<td></td>
<td>Nebuliser soln 2 mg per ml, 2.5 ml ampoule – 1% DV Oct-18 to 2021</td>
<td>4.03</td>
<td>20 Asthalin</td>
</tr>
</tbody>
</table>

## Terbutaline Sulfate

<table>
<thead>
<tr>
<th>Product</th>
<th>Description</th>
<th>Price</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Powder for inhalation 250 mcg per dose</td>
<td>9.30</td>
<td>Qvar</td>
</tr>
<tr>
<td></td>
<td>Inj 0.5 mg per ml, 1 ml ampoule</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

## Cough Suppressants

<table>
<thead>
<tr>
<th>Product</th>
<th>Description</th>
<th>Price</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>PHOLCODINE</td>
<td>Oral liq 1 mg per ml</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

## Decongestants

<table>
<thead>
<tr>
<th>Product</th>
<th>Description</th>
<th>Price</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>OXYMETAZOLINE HYDROCHLORIDE</td>
<td>Aqueous nasal spray 0.25 mg per ml</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Aqueous nasal spray 0.5 mg per ml</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PSEUDOEPHEDRINE HYDROCHLORIDE</td>
<td>Tab 60 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Aqueous nasal spray isotonic</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SODIUM CHLORIDE</td>
<td>Aqueous nasal spray isotonic</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SODIUM CHLORIDE WITH SODIUM BICARBONATE</td>
<td>Soln for nasal irrigation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>XYLOMETAZOLINE HYDROCHLORIDE</td>
<td>Aqueous nasal spray 0.05%</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Aqueous nasal spray 0.1%</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Nasal drops 0.05%</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Nasal drops 0.1%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

## Inhaled Corticosteroids

<table>
<thead>
<tr>
<th>Product</th>
<th>Description</th>
<th>Price</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>BECLOMETHASONE DIPROPIONATE</td>
<td>Aerosol inhaler 50 mcg per dose</td>
<td>8.54</td>
<td>200 dose Beclazone 50</td>
</tr>
<tr>
<td></td>
<td></td>
<td>9.30</td>
<td>Qvar</td>
</tr>
<tr>
<td></td>
<td>Aerosol inhaler 100 mcg per dose</td>
<td>12.50</td>
<td>200 dose Beclazone 100</td>
</tr>
<tr>
<td></td>
<td></td>
<td>15.50</td>
<td>Qvar</td>
</tr>
<tr>
<td></td>
<td>Aerosol inhaler 250 mcg per dose</td>
<td>22.67</td>
<td>200 dose Beclazone 250</td>
</tr>
<tr>
<td>BUDESONIDE</td>
<td>Nebuliser soln 250 mcg per ml, 2 ml ampoule</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Nebuliser soln 500 mcg per ml, 2 ml ampoule</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Powder for inhalation 100 mcg per dose</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Powder for inhalation 200 mcg per dose</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Powder for inhalation 400 mcg per dose</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
<table>
<thead>
<tr>
<th>RESPIRATORY SYSTEM AND ALLERGIES</th>
<th>Price (ex man. excl. GST) Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>FLUTICASONE</strong></td>
<td></td>
</tr>
<tr>
<td>Aerosol inhaler 50 mcg per dose</td>
<td>7.50 120 dose Flixotide</td>
</tr>
<tr>
<td>Powder for inhalation 50 mcg per dose</td>
<td>4.68  60 dose Floair</td>
</tr>
<tr>
<td>Powder for inhalation 100 mcg per dose</td>
<td>8.67  60 dose Flixotide Accuhaler</td>
</tr>
<tr>
<td>Aerosol inhaler 125 mcg per dose</td>
<td>13.87 120 dose Flixotide</td>
</tr>
<tr>
<td></td>
<td>7.22 60 dose Floair</td>
</tr>
<tr>
<td>Aerosol inhaler 250 mcg per dose</td>
<td>13.60 120 dose Flixotide</td>
</tr>
<tr>
<td></td>
<td>7.22 60 dose Floair</td>
</tr>
<tr>
<td>Powder for inhalation 250 mcg per dose</td>
<td>27.20  120 dose Flixotide</td>
</tr>
<tr>
<td></td>
<td>10.18 60 dose Floair</td>
</tr>
<tr>
<td></td>
<td>24.51 60 dose Flixotide Accuhaler</td>
</tr>
</tbody>
</table>

**Leukotriene Receptor Antagonists**

<table>
<thead>
<tr>
<th>MONTELUKAST</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 4 mg – 1% DV Jan-20 to 2022</td>
<td>5.25 28 Apo-Montelukast Montelukast Mylan</td>
</tr>
<tr>
<td></td>
<td>4.25 Montelukast Mylan</td>
</tr>
<tr>
<td>Tab 5 mg – 1% DV Jan-20 to 2022</td>
<td>5.50 28 Apo-Montelukast Montelukast Mylan</td>
</tr>
<tr>
<td></td>
<td>4.25 Montelukast Mylan</td>
</tr>
<tr>
<td>Tab 10 mg – 1% DV Jan-20 to 2022</td>
<td>5.65 28 Apo-Montelukast Montelukast Mylan</td>
</tr>
<tr>
<td></td>
<td>3.95 Montelukast Mylan</td>
</tr>
</tbody>
</table>

(Apo-Montelukast Tab 4 mg to be delisted 1 January 2020)
(Apo-Montelukast Tab 5 mg to be delisted 1 January 2020)
(Apo-Montelukast Tab 10 mg to be delisted 1 January 2020)

**Long-Acting Beta-Adrenoceptor Agonists**

<table>
<thead>
<tr>
<th>EFORMOTEROL FUMARATE</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Powder for inhalation 12 mcg per dose</td>
<td></td>
</tr>
<tr>
<td>EFORMOTEROL FUMARATE DIHYDRATE</td>
<td></td>
</tr>
<tr>
<td>Powder for inhalation 4.5 mcg per dose, breath activated (equivalent to eformoterol fumarate 6 mcg metered dose)</td>
<td></td>
</tr>
<tr>
<td>INDACATEROL</td>
<td></td>
</tr>
<tr>
<td>Powder for inhalation 150 mcg per dose</td>
<td>61.00 30 dose Onbrez Breezhaler</td>
</tr>
<tr>
<td>Powder for inhalation 300 mcg per dose</td>
<td>61.00 30 dose Onbrez Breezhaler</td>
</tr>
<tr>
<td>SALMETEROL</td>
<td></td>
</tr>
<tr>
<td>Aerosol inhaler 25 mcg per dose</td>
<td>9.90 120 dose Meterol</td>
</tr>
<tr>
<td></td>
<td>25.00 60 dose Serevent</td>
</tr>
<tr>
<td>Powder for inhalation 50 mcg per dose</td>
<td>25.00  60 dose Serevent Accuhaler</td>
</tr>
</tbody>
</table>

**Inhaled Corticosteroids with Long-Acting Beta-Adrenoceptor Agonists**

<table>
<thead>
<tr>
<th>BUDESONIDE WITH EFORMOTEROL</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Powder for inhalation 100 mcg with eformoterol fumarate 6 mcg</td>
<td></td>
</tr>
<tr>
<td>Powder for inhalation 200 mcg with eformoterol fumarate 6 mcg</td>
<td></td>
</tr>
<tr>
<td>Powder for inhalation 400 mcg with eformoterol fumarate 12 mcg</td>
<td></td>
</tr>
<tr>
<td>Aerosol inhaler 100 mcg with eformoterol fumarate 6 mcg</td>
<td></td>
</tr>
<tr>
<td>Aerosol inhaler 200 mcg with eformoterol fumarate 6 mcg</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>FLUTICASONE FUROATE WITH VILANTEROL</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Powder for inhalation 100 mcg with vilanterol 25 mcg</td>
<td>44.08 30 dose Breo Ellipta</td>
</tr>
</tbody>
</table>

Item restricted (see above); Item restricted (see below)
e.g. Brand indicates brand example only. It is not a contracted product.
FLUTICASONE WITH SALMETEROL
Aerosol inhaler 50 mcg with salmeterol 25 mcg ........................................... 14.58 120 dose RexAir
Powder for inhalation 100 mcg with salmeterol 50 mcg .................................. 33.74 60 dose Seretide
Aerosol inhaler 125 mcg with salmeterol 25 mcg ........................................... 16.83 120 dose RexAir
Powder for inhalation 250 mcg with salmeterol 50 mcg .................................. 44.08 60 dose Seretide

Mast Cell Stabilisers
NEDOCROMIL
Aerosol inhaler 2 mg per dose
SODIUM CROMOGLICATE
Aerosol inhaler 5 mg per dose

Methylxanthines
AMINOPHYLLINE
Inj 25 mg per ml, 10 ml ampoule – 1% DV Nov-17 to 2020 .......................... 124.37 5 DBL Aminophylline
CAFFEINE CITRATE
Oral liq 20 mg per ml (caffeine 10 mg per ml) – 1% DV Nov-19 to 2022 .... 15.10 25 ml Biomed
Inj 20 mg per ml (caffeine 10 mg per ml), 2.5 ml ampoule – 1% DV Nov-19 to 2022 ........................................... 63.25 5 Biomed
THEOPHYLLINE
Tab long-acting 250 mg – 1% DV Jan-20 to 2022 ........................................... 23.02 100 Nuelin-SR
Oral liq 80 mg per 15 ml – 1% DV Jan-20 to 2022 ........................................... 16.60 500 ml Nuelin

Mucolytics and Expectorants
DORNASE ALFA – Restricted see terms below
Nebuliser soln 2.5 mg per 2.5 ml ampoule ................................................... 250.00 6 Pulmozyme
→ Restricted (RS1352)
Initiation – cystic fibrosis
The patient has cystic fibrosis and has been approved by the Cystic Fibrosis Panel.
Initiation – significant mucus production
Limited to 4 weeks treatment
Both:
1 Patient is an in-patient; and
2 The mucus production cannot be cleared by first line chest techniques.
Initiation – pleural emphyema
Limited to 3 days treatment
Both:
1 Patient is an in-patient; and
2 Patient diagnoses with pleural emphyema.
SODIUM CHLORIDE
Nebuliser soln 7%, 90 ml bottle – 1% DV Nov-19 to 2022 .......................... 24.50 90 ml Biomed

Pulmonary Surfactants
BERACTANT
Soln 200 mg per 8 ml vial
## PORACTANT ALFA

<table>
<thead>
<tr>
<th>Description</th>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Soln 120 mg per 1.5 ml vial</td>
<td>425.00</td>
<td>1 Curosurf</td>
</tr>
<tr>
<td>Soln 240 mg per 3 ml vial</td>
<td>695.00</td>
<td>1 Curosurf</td>
</tr>
</tbody>
</table>

## Respiratory Stimulants

**DOXAPRAM**

- Inj 20 mg per ml, 5 ml vial

## Sclerosing Agents

**TALC**

- Powder
- Soln (slurry) 100 mg per ml, 50 ml
## Anti-Infective Preparations

### Antibacterials

**CHLORAMPHENICOL**
- Eye oint 1% – 1% *DV May-20 to 2022* .................................................. 2.48 4 g Chlorsig
- Ear drops 0.5% .......................................................................................... 1.55 5 g Devatis
- Eye drops 0.5% – 1% *DV Nov-19 to 2022* ............................................. 1.54 10 ml Chlorafast
- Eye drops 0.5%, single dose

*(Chlorsig Eye oint 1% to be delisted 1 May 2020)*

**CIPROFLOXACIN**
- Eye drops 0.3% – 1% *DV Jun-18 to 2020* .................................................. 9.99 5 ml Ciprofloxacin Teva

**FRAMYCETIN SULPHATE**
- Ear/eye drops 0.5%

**GENTAMICIN SULPHATE**
- Eye drops 0.3% .......................................................................................... 11.40 5 ml Genoptic

**PROPAMIDINE ISETHIONATE**
- Eye drops 0.1%

**SODIUM FUSIDATE [FUSIDIC ACID]**
- Eye drops 1% ............................................................................................ 5.29 5 g Fucithalmic

**SULPHACETAMIDE SODIUM**
- Eye drops 10%

**TOBRAMYCIN**
- Eye oint 0.3% ............................................................................................ 10.45 3.5 g Tobrex
- Eye drops 0.3% ............................................................................................ 11.48 5 ml Tobrex

### Antifungals

**NATAMYCIN**
- Eye drops 5%

### Antivirals

**ACICLOVIR**
- Eye oint 3% .............................................................................................. 14.92 4.5 g ViruPOS

### Combination Preparations

**CIPROFLOXACIN WITH HYDROCORTISONE**
- Ear drops ciprofloxacin 0.2% with 1% hydrocortisone............................. 16.30 10 ml Ciproxin HC Otic

**DEXAMETHASONE WITH FRAMYCETIN AND GRAMICIDIN**
- Ear/eye drops 500 mcg with framycetin sulphate 5 mg and gramicidin
  50 mcg per ml

**DEXAMETHASONE WITH NEOMYCIN SULPHATE AND POLYMIXIN B SULPHATE**
- Eye oint 0.1% with neomycin sulphate 0.35% and polymyxin b sulphate
  6,000 u per g ......................................................................................... 5.39 3.5 g Maxitrol
- Eye drops 0.1% with neomycin sulphate 0.35% and polymyxin b sulphate
  6,000 u per ml ....................................................................................... 4.50 5 ml Maxitrol
### Anti-Inflammatory Preparations

#### Corticosteroids

**DEXAMETHASONE**

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eye oint 0.1%</td>
<td>5.86</td>
<td>Maxidex</td>
</tr>
<tr>
<td>Eye drops 0.1%</td>
<td>4.50</td>
<td>Maxidex</td>
</tr>
<tr>
<td>Ocular implant 700 mcg</td>
<td>1,444.50</td>
<td>Ozurdex</td>
</tr>
</tbody>
</table>

**FLUMETASONE PIVALATE WITH CLIQUINOL**

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ear drops 0.02% with clioquinol 1%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**TRIAMCINOLONE ACETONIDE WITH GRAMICIDIN, NEOMYCIN AND NYSTATIN**

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eye drops 1 mg with nystatin 100,000 u, neomycin sulphate 2.5 mg and</td>
<td>5.16</td>
<td>Kenacomb</td>
</tr>
<tr>
<td>gramicidin 250 mcg per g</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Restricted (RS1606)**

**Initiation – Diabetic macular oedema**

Ophthalmologist

*Re-assessment required after 12 months*

All of the following:

1. Patients have diabetic macular oedema with pseudophakic lens; and
2. Patient has reduced visual acuity of between 6/9 – 6/48 with functional awareness of reduction in vision; and
3. Either:
   3.1 Patient’s disease has progressed despite 3 injections with bevacizumab; or
   3.2 Patient is unsuitable or contraindicated to treatment with anti-VEGF agents; and
4. Dexamethasone implants are to be administered not more frequently than once every 4 months into each eye, and up to a maximum of 3 implants per eye per year.

**Continuation – Diabetic macular oedema**

Ophthalmologist

*Re-assessment required after 12 months*

Both:

1. Patient’s vision is stable or has improved (prescriber determined); and
2. Dexamethasone implants are to be administered not more frequently than once every 4 months into each eye, and up to a maximum of 3 implants per eye per year.

**Initiation – Women of child bearing age with diabetic macular oedema**

Ophthalmologist

*Re-assessment required after 12 months*

All of the following:

1. Patients have diabetic macular oedema; and
2. Patient has reduced visual acuity of between 6/9 – 6/48 with functional awareness of reduction in vision; and
3. Patient is of child bearing potential and has not yet completed a family; and
4. Dexamethasone implants are to be administered not more frequently than once every 4 months into each eye, and up to a maximum of 3 implants per eye per year. 

continued…

*Item restricted (see ➤ above); ➤ Item restricted (see ➤ below)*

e.g. *Brand* indicates brand example only. It is not a contracted product.
Continuation – Women of child bearing age with diabetic macular oedema

Ophthalmologist

Re-assessment required after 12 months

All of the following:

1. Patient’s vision is stable or has improved (prescriber determined); and
2. Patient is of child bearing potential and has not yet completed a family; and
3. Dexamethasone implants are to be administered not more frequently than once every 4 months into each eye, and up to a maximum of 3 implants per eye per year.

**FLUOROMETHOLONE**

- Eye drops 0.1% .......................................................... 3.09 5 ml  FML

**PREDNISOLONE ACETATE**

- Eye drops 0.12% .......................................................... 7.00 5 ml  Pred Forte
- Eye drops 1% .......................................................... 3.93 10 ml  Prednisolone-AFT

**PREDNISOLONE SODIUM PHOSPHATE**

- Eye drops 0.5%, single dose (preservative free) .......................................................... 38.50 20 dose  Minims Prednisolone

---

### Non-Steroidal Anti-Inflammatory Drugs

**DICLOFENAC SODIUM**

- Eye drops 0.1% .......................................................... 13.80 5 ml  Voltaren Ophtha

**KETOROLAC TROMETAMOL**

- Eye drops 0.5%

---

### Decongestants and Antiallergics

#### Antiallergic Preparations

**LEVOCABASTINE**

- Eye drops 0.05%

**LODOXAMIDE**

- Eye drops 0.1% .......................................................... 8.71 10 ml  Lomide

**OLOPATADINE**

- Eye drops 0.1% .......................................................... 10.00 5 ml  Patanol

**SODIUM CROMOGLICATE**

- Eye drops 2% – 1% DV Jan-20 to 2022 .......................................................... 1.79 5 ml  Rexacrom

### Decongestants

**NAPHAZOLINE HYDROCHLORIDE**

- Eye drops 0.1% .......................................................... 4.15 15 ml  Naphcon Forte

### Diagnostic and Surgical Preparations

#### Diagnostic Dyes

**FLUORESCEIN SODIUM**

- Eye drops 2%, single dose
- Inj 10%, 5 ml vial .......................................................... 125.00 12 Fluorescite
- Ophthalmic strips 1 mg
## SENSORY ORGANS

<table>
<thead>
<tr>
<th>Item</th>
<th>Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>FLUORESCIN SODIUM WITH LIGNOCAINE HYDROCHLORIDE</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eye drops 0.25% with lignocaine hydrochloride 4%, single dose</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>LISSAMINE GREEN</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ophthalmic strips 1.5 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>ROSE BENGAL SODIUM</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ophthalmic strips 1%</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Irrigation Solutions

**MIXED SALT SOLUTION FOR EYE IRRIGATION**

<table>
<thead>
<tr>
<th>Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eye irrigation solution calcium chloride 0.048% with magnesium chloride 0.03%, potassium chloride 0.075%, sodium acetate 0.39%, sodium chloride 0.64% and sodium citrate 0.17%, 15 ml dropper bottle</td>
<td>$5.00</td>
<td></td>
</tr>
<tr>
<td>Eye irrigation solution calcium chloride 0.048% with magnesium chloride 0.03%, potassium chloride 0.075%, sodium acetate 0.39%, sodium chloride 0.64% and sodium citrate 0.17%, 250 ml</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eye irrigation solution calcium chloride 0.048% with magnesium chloride 0.03%, potassium chloride 0.075%, sodium acetate 0.39%, sodium chloride 0.64% and sodium citrate 0.17%, 500 ml bottle</td>
<td>$10.50</td>
<td></td>
</tr>
</tbody>
</table>

**Ocular Anaesthetics**

**OXYBUPROCAINE HYDROCHLORIDE**

Eye drops 0.4%, single dose

**PROXYMETACAINE HYDROCHLORIDE**

Eye drops 0.5%

**TETRACAINE [AMETHOCAINE] HYDROCHLORIDE**

Eye drops 0.5%, single dose

Eye drops 1%, single dose

### Viscoelastic Substances

**HYPROMELLOSE**

<table>
<thead>
<tr>
<th>Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 2%, 1 ml syringe</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 2%, 2 ml syringe</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**SODIUM HYALURONATE [HYALURONIC ACID]**

<table>
<thead>
<tr>
<th>Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 14 mg per ml, 0.85 ml syringe – 1% DV Oct-19 to 2022</td>
<td>$50.00</td>
<td>Healon GV</td>
</tr>
<tr>
<td>Inj 14 mg per ml, 0.55 ml syringe – 1% DV Oct-19 to 2022</td>
<td>$50.00</td>
<td>Healon GV</td>
</tr>
<tr>
<td>Inj 23 mg per ml, 0.6 ml syringe – 1% DV Oct-19 to 2022</td>
<td>$60.00</td>
<td>Healon 5</td>
</tr>
<tr>
<td>Inj 10 mg per ml, 0.85 ml syringe – 1% DV Oct-19 to 2022</td>
<td>$28.50</td>
<td>Healon</td>
</tr>
</tbody>
</table>

**SODIUM HYALURONATE [HYALURONIC ACID] WITH CHONDROITIN SULPHATE**

<table>
<thead>
<tr>
<th>Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 30 mg per ml with chondroitin sulphate 40 mg per ml, 0.35 ml syringe and inj 10 mg sodium hyaluronate [hyaluronic acid] per ml, 0.4 ml syringe</td>
<td>$64.00</td>
<td>Duovisc</td>
</tr>
<tr>
<td>Inj 30 mg per ml with chondroitin sulphate 40 mg per ml, 0.5 ml syringe and inj 10 mg sodium hyaluronate [hyaluronic acid] per ml, 0.55 ml syringe</td>
<td>$74.00</td>
<td>Duovisc</td>
</tr>
<tr>
<td>Inj 30 mg per ml with chondroitin sulphate 40 mg per ml, 0.75 ml syringe</td>
<td>$67.00</td>
<td>Viscoat</td>
</tr>
</tbody>
</table>
### Other

**DISODIUM EDETATE**
- Inj 150 mg per ml, 20 ml ampoule
- Inj 150 mg per ml, 20 ml vial
- Inj 150 mg per ml, 100 ml vial

**RIBOFLAVIN 5-PHOSPHATE**
- Soln trans epithelial riboflavin
- Inj 0.1%
- Inj 0.1% plus 20% dextran T500

### Glaucoma Preparations

#### Beta Blockers

**BETAXOLOL**
- Eye drops 0.25% ......................................................... 11.80 5 ml Betoptic S
- Eye drops 0.5% ......................................................... 7.50 5 ml Betoptic

**TIMOLOL**
- Eye drops 0.25% – 1% DV Sep-17 to 2020 ......................... 1.43 5 ml Arrow-Timolol
- Eye drops 0.25%, gel forming ........................................... 3.30 2.5 ml Timoptol XE
- Eye drops 0.5% – 1% DV Sep-17 to 2020 ......................... 1.43 5 ml Arrow-Timolol
- Eye drops 0.5%, gel forming ........................................... 3.78 2.5 ml Timoptol XE

(Timoptol XE Eye drops 0.25%, gel forming to be delisted 1 January 2020)

#### Carbonic Anhydrase Inhibitors

**ACETAZOLAMIDE**
- Tab 250 mg – 1% DV Sep-17 to 2020 ....................... 17.03 100 Diamox
- Inj 500 mg

**BRINZOLAMIDE**
- Eye drops 1%

**DORZOLAMIDE**
- Eye drops 2%

**DORZOLAMIDE WITH TIMOLOL**
- Eye drops 2% with timolol 0.5% – 1% DV Jan-19 to 2021 .......... 2.87 5 ml Dortimopt

#### Miotics

**ACETYLCOLINE CHLORIDE**
- Inj 20 mg vial with diluent

**CARBACHOL**
- Inj 150 mcg vial

**PILOCARPINE HYDROCHLORIDE**
- Eye drops 1% .............................................................. 4.26 15 ml Isopto Carpine
- Eye drops 2% .............................................................. 5.35 15 ml Isopto Carpine
- Eye drops 2%, single dose
- Eye drops 4% .............................................................. 7.99 15 ml Isopto Carpine

---

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
### SENSORY ORGANS

<table>
<thead>
<tr>
<th>Prostaglandin Analogues</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>BIMATOPROST</strong></td>
<td>$3.30</td>
<td>Bimatoprost Multichem</td>
</tr>
<tr>
<td>Eye drops 0.03% – 1% DV Feb-19 to 2021</td>
<td>3 ml</td>
<td></td>
</tr>
<tr>
<td><strong>LATANOPROST</strong></td>
<td>$1.57</td>
<td>Teva</td>
</tr>
<tr>
<td>Eye drops 0.005% – 1% DV Apr-19 to 2021</td>
<td>2.5 ml</td>
<td></td>
</tr>
<tr>
<td><strong>TRAVOPROST</strong></td>
<td>$7.30</td>
<td>Travopt</td>
</tr>
<tr>
<td>Eye drops 0.004% – 1% DV Jan-18 to 2020</td>
<td>5 ml</td>
<td></td>
</tr>
</tbody>
</table>

### Sympathomimetics

<table>
<thead>
<tr>
<th>APRACONIDINE</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eye drops 0.5%</td>
<td>$19.77</td>
<td>Iopidine</td>
</tr>
<tr>
<td><strong>BRIMONIDINE TARTRATE</strong></td>
<td>$4.29</td>
<td>Arrow-Brimonidine</td>
</tr>
<tr>
<td>Eye drops 0.2% – 1% DV Feb-18 to 2020</td>
<td>5 ml</td>
<td></td>
</tr>
<tr>
<td><strong>BRIMONIDINE TARTRATE WITH TIMOLOL</strong></td>
<td>$7.15</td>
<td></td>
</tr>
<tr>
<td>Eye drops 0.2% with timolol 0.5%</td>
<td>15 ml</td>
<td></td>
</tr>
</tbody>
</table>

### Mydriatics and Cycloplegics

<table>
<thead>
<tr>
<th>Anticholinergic Agents</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ATROPINE SULPHATE</strong></td>
<td>$17.36</td>
<td>Atropt</td>
</tr>
<tr>
<td>Eye drops 0.5%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eye drops 1%, single dose</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eye drops 1% – 1% DV Sep-17 to 2020</td>
<td>15 ml</td>
<td></td>
</tr>
<tr>
<td><strong>CYCLOPENTOLATE HYDROCHLORIDE</strong></td>
<td>$8.76</td>
<td>Cyclogyl</td>
</tr>
<tr>
<td>Eye drops 0.5%, single dose</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eye drops 1%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eye drops 1%, single dose</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>TROPICAMIDE</strong></td>
<td>$7.15</td>
<td>Mydriacyl</td>
</tr>
<tr>
<td>Eye drops 0.5%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eye drops 0.5%, single dose</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eye drops 1%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eye drops 1%, single dose</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Sympathomimetics

<table>
<thead>
<tr>
<th>PHENYLEPHRINE HYDROCHLORIDE</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eye drops 2.5%, single dose</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eye drops 10%, single dose</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Ocular Lubricants

<table>
<thead>
<tr>
<th>CARBOMER</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ophthalmic gel 0.3%, single dose</td>
<td>$8.25</td>
<td>Poly Gel</td>
</tr>
<tr>
<td>Ophthalmic gel 0.2%</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>CARMELLOSE SODIUM WITH PECTIN AND GELATINE</strong></td>
<td>$8.36</td>
<td></td>
</tr>
<tr>
<td>Eye drops 0.5%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eye drops 0.5%, single dose</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eye drops 1%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eye drops 1%, single dose</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

1. Item restricted (see ➡ above);
2. Item restricted (see ➡ below)
3. *e.g. Brand* indicates brand example only. It is not a contracted product.
<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>HYPROMELLOSE</td>
<td>$3.92 Per 15 ml Methopt</td>
<td></td>
</tr>
<tr>
<td>HYPROMELLOSE WITH DEXTRAN</td>
<td>$2.30 Per 15 ml Poly-Tears</td>
<td></td>
</tr>
<tr>
<td>MACROGL 400 AND PROPYLENE GLYCOL</td>
<td>$4.30 Per 24 Systane Unit Dose</td>
<td></td>
</tr>
<tr>
<td>PARAFFIN LIQUID WITH SOFT WHITE PARAFFIN</td>
<td>$3.63 Per 3.5 g Poly-Visc</td>
<td></td>
</tr>
<tr>
<td>PARAFFIN LIQUID WITH WOOL FAT</td>
<td>$3.68 Per 15 ml Vistil Forte</td>
<td></td>
</tr>
<tr>
<td>POLYVINYL ALCOHOL</td>
<td>$3.68 Per 15 ml Vistil Forte</td>
<td></td>
</tr>
<tr>
<td>RETINOL PALMITATE</td>
<td>$3.80 Per 5 g VitA-POS</td>
<td></td>
</tr>
<tr>
<td>SODIUM HYALURONATE [HYALURONIC ACID]</td>
<td>$22.00 Per 10 ml Hylo-Fresh</td>
<td></td>
</tr>
</tbody>
</table>

**Other Otological Preparations**

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACETIC ACID WITH PROPYLENE GLYCOL</td>
<td>$3.80 Per 10 ml</td>
<td></td>
</tr>
<tr>
<td>DOCUSATE SODIUM</td>
<td>$3.63 Per 3.5 g Poly-Visc</td>
<td></td>
</tr>
</tbody>
</table>

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
### Agents Used in the Treatment of Poisonings

#### Antidotes

<table>
<thead>
<tr>
<th>Drug</th>
<th>Formulation</th>
<th>Price</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACETYLICYSTEINE</td>
<td>Tab eff 200 mg</td>
<td>$58.76</td>
<td>10 DBL Acetylcysteine</td>
</tr>
<tr>
<td></td>
<td>Inj 200 mg per ml, 10 ml ampoule – 1% DV Sep-18 to 2021</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AMYL NITRITE</td>
<td>Liq 98% in 3 ml capsule</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DIGOXIN IMMUNE FAB</td>
<td>Inj 38 mg vial</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inj 40 mg vial</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ETHANOL</td>
<td>Liq 96%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ETHANOL WITH GLUCOSE</td>
<td>Inj 10% with glucose 5%, 500 ml bottle</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ETHANOL, DEHYDRATED</td>
<td>Inj 100%, 5 ml ampoule</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inj 96%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>FLUMAZENIL</td>
<td>Inj 0.1 mg per ml, 5 ml ampoule – 1% DV Dec-18 to 2021</td>
<td>$132.68</td>
<td>10 Hameln</td>
</tr>
<tr>
<td>HYDROXOCOBALAMIN</td>
<td>Inj 5 g vial</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inj 2.5 g vial</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NALOXONE HYDROCHLORIDE</td>
<td>Inj 400 mcg per ml, 1 ml ampoule – 1% DV Aug-18 to 2021</td>
<td>$22.60</td>
<td>5 DBL Naloxone Hydrochloride</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PRALIDOXIME IODIDE</td>
<td>Inj 25 mg per ml, 20 ml ampoule</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SODIUM NITRITE</td>
<td>Inj 30 mg per ml, 10 ml ampoule</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SODIUM THIOSULFATE</td>
<td>Inj 250 mg per ml, 10 ml vial</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inj 250 mg per ml, 50 ml vial</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inj 500 mg per ml, 10 ml vial</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inj 500 mg per ml, 20 ml ampoule</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SOYA OIL</td>
<td>Inj 20%, 500 ml bag</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inj 20%, 500 ml bottle</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Antitoxins

<table>
<thead>
<tr>
<th>Drug</th>
<th>Formulation</th>
</tr>
</thead>
<tbody>
<tr>
<td>BOTULISM ANTITOXIN</td>
<td>Inj 250 ml vial</td>
</tr>
<tr>
<td>DIPHTHERIA ANTITOXIN</td>
<td>Inj 10,000 iu vial</td>
</tr>
</tbody>
</table>
Antivenoms

RED BACK SPIDER ANTIVENOM
Inj 500 u vial

SNAKE ANTIVENOM
Inj 50 ml vial

Removal and Elimination

CHARCOAL
Oral liq 200 mg per ml ................................................................. 43.50 250 ml Carbosorb-X

DEFERASIROX – Restricted see terms below

- Tab 125 mg dispersible ............................................. 276.00 28 Exjade
- Tab 250 mg dispersible ............................................. 552.00 28 Exjade
- Tab 500 mg dispersible ............................................. 1,105.00 28 Exjade

- Restricted (RS1444)

Initiation
Haematologist
Re-assessment required after 2 years

All of the following:
1. The patient has been diagnosed with chronic iron overload due to congenital inherited anaemia; and
2. Deferasirox is to be given at a daily dose not exceeding 40 mg/kg/day; and
3. Any of the following:
   3.1 Treatment with maximum tolerated doses of deferiprone monotherapy or deferiprone and desferrioxamine combination therapy have proven ineffective as measured by serum ferritin levels, liver or cardiac MRI T2*; or
   3.2 Treatment with deferiprone has resulted in severe persistent vomiting or diarrhoea; or
   3.3 Treatment with deferiprone has resulted in arthritis; or
   3.4 Treatment with deferiprone is contraindicated due to a history of agranulocytosis (defined as an absolute neutrophil count (ANC) of < 0.5 cells per µL) or recurrent episodes (greater than 2 episodes) of moderate neutropenia (ANC 0.5 - 1.0 cells per µL).

Continuation
Haematologist
Re-assessment required after 2 years

Either:
1. For the first renewal following 2 years of therapy, the treatment has been tolerated and has resulted in clinical improvement in all three parameters namely serum ferritin, cardiac MRI T2* and liver MRI T2* levels; or
2. For subsequent renewals, the treatment has been tolerated and has resulted in clinical stability or continued improvement in all three parameters namely serum ferritin, cardiac MRI T2* and liver MRI T2* levels.

DEFERIPRONE – Restricted see terms below

- Tab 500 mg ................................................................. 533.17 100 Ferriprox
- Oral liq 100 mg per ml ............................................................. 266.59 250 ml Ferriprox

- Restricted (RS1445)

Initiation
Patient has been diagnosed with chronic iron overload due to congenital inherited anaemia or acquired red cell aplasia.

DESFERRIOXAMINE MESILATE
Inj 500 mg vial – 1% DV Mar-19 to 2021 ......................................................... 84.53 10 DBL Desferrioxamine Mesylate for Inj BP

DICOBALT EDETATE
Inj 15 mg per ml, 20 ml ampoule
<table>
<thead>
<tr>
<th>VARIOUS</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>DIMERCAPROL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 50 mg per ml, 2 ml ampoule</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DIMERCAPTOSUCCINIC ACID</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cap 100 mg</td>
<td></td>
<td>e.g. PCNZ, Optimus Healthcare, Chemet</td>
</tr>
<tr>
<td>Cap 200 mg</td>
<td></td>
<td>e.g. PCNZ, Optimus Healthcare, Chemet</td>
</tr>
<tr>
<td>SODIUM CALCIUM EDETATE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 200 mg per ml, 2.5 ml ampoule</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 200 mg per ml, 5 ml ampoule</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Antiseptics and Disinfectants

#### CHLORHEXIDINE
- **Soln 4%** ................................................................. 1.86 50 ml healthE
- **Soln 5%** ................................................................. 15.50 500 ml healthE

#### CHLORHEXIDINE WITH CETRIMIDE
- Crm 0.1% with cetrimide 0.5%
- Foaming soln 0.5% with cetrimide 0.5%

#### CHLORHEXIDINE WITH ETHANOL
- **Soln 0.5% with ethanol 70%, non-staining (pink) 100 ml** ........................................ 2.65 1 healthE
- **Soln 2% with ethanol 70%, non-staining (pink) 100 ml** ........................................ 3.54 1 healthE
- **Soln 0.5% with ethanol 70%, non-staining (pink) 25 ml** ........................................ 1.55 1 healthE
- **Soln 0.5% with ethanol 70%, staining (red) 100 ml** ........................................ 2.90 1 healthE
- **Soln 2% with ethanol 70%, staining (red) 100 ml** ........................................ 3.86 1 healthE
- **Soln 0.5% with ethanol 70%, non-staining (pink) 500 ml** ................................ 5.45 1 healthE
- **Soln 0.5% with ethanol 70%, staining (red) 500 ml** ........................................ 5.90 1 healthE
- **Soln 2% with ethanol 70%, staining (red) 500 ml** ........................................ 9.56 1 healthE

#### IODINE WITH ETHANOL
- **Soln 1% with ethanol 70%, 100 ml** .................................................. 9.30 1 healthE

#### ISOPROPYL ALCOHOL
- **Soln 70%, 500 ml** .................................................. 5.65 1 healthE

#### POVIDONE-IODINE
- **Vaginal tab 200 mg**
- **Restricted (RS1354)**

**Initiation**

Rectal administration pre-prostate biopsy.

- **Oint 10%** ................................................................. 3.27 25 g Betadine
- **Soln 10% – 1% DV Nov-19 to 2021** ........................................ 2.55 100 ml Riodine
- **Soln 5%** .................................................................
- **Soln 7.5%** ............................................................
- **Soln 10%, – 1% DV Dec-19 to 2022** ........................................ 3.83 15 ml Riodine
- **Pad 10%** ................................................................. 5.40 500 ml Riodine
- **Swab set 10%** ..........................................................

#### POVIDONE-IODINE WITH ETHANOL
- **Soln 10% with ethanol 30%** ............................................................... 10.00 500 ml Betadine Skin Prep
- **Soln 10% with ethanol 70%** ...............................................................
<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST) $</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>SODIUM HYPOCHLORITE Soln</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contrast Media</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Iodinated X-ray Contrast Media</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DIATRIZOATE MEGLUMINE WITH SODIUM AMIDOTRIZOATE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oral liq 660 mg per ml with sodium amidotrizoate 100 mg per ml, 100 ml bottle</td>
<td>22.50</td>
<td>100 ml Gastrografin</td>
</tr>
<tr>
<td>Inj 260 mg with sodium amidotrizoate 40 mg per ml, 250 ml bottle</td>
<td>80.00</td>
<td>1 Urografin</td>
</tr>
<tr>
<td>DIATRIZOATE SODIUM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oral liq 370 mg per ml, 10 ml sachet</td>
<td>156.12</td>
<td>50 Ioscan</td>
</tr>
<tr>
<td>IODISED OIL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 38% w/w (480 mg per ml), 10 ml ampoule</td>
<td>410.00</td>
<td>1 Lipiodol Ultra Fluid</td>
</tr>
<tr>
<td>IODIXANOL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 270 mg per ml (iodine equivalent), 50 ml bottle</td>
<td>220.00</td>
<td>10 Visipaque</td>
</tr>
<tr>
<td>Inj 320 mg per ml (iodine equivalent), 50 ml bottle</td>
<td>220.00</td>
<td>10 Visipaque</td>
</tr>
<tr>
<td>Inj 270 mg per ml (iodine equivalent), 100 ml bottle</td>
<td>430.00</td>
<td>10 Visipaque</td>
</tr>
<tr>
<td>Inj 320 mg per ml (iodine equivalent), 100 ml bottle</td>
<td>430.00</td>
<td>10 Visipaque</td>
</tr>
<tr>
<td>Inj 320 mg per ml (iodine equivalent), 200 ml bottle</td>
<td>850.00</td>
<td>10 Visipaque</td>
</tr>
<tr>
<td>IOHEXOL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 240 mg per ml (iodine equivalent), 50 ml bottle</td>
<td>75.00</td>
<td>10 Omnipaque</td>
</tr>
<tr>
<td>Inj 300 mg per ml (iodine equivalent), 20 ml bottle</td>
<td>57.00</td>
<td>10 Omnipaque</td>
</tr>
<tr>
<td>Inj 300 mg per ml (iodine equivalent), 50 ml bottle</td>
<td>75.00</td>
<td>10 Omnipaque</td>
</tr>
<tr>
<td>Inj 300 mg per ml (iodine equivalent), 100 ml bottle</td>
<td>150.00</td>
<td>10 Omnipaque</td>
</tr>
<tr>
<td>Inj 350 mg per ml (iodine equivalent), 20 ml bottle</td>
<td>59.00</td>
<td>10 Omnipaque</td>
</tr>
<tr>
<td>Inj 350 mg per ml (iodine equivalent), 50 ml bottle</td>
<td>75.00</td>
<td>10 Omnipaque</td>
</tr>
<tr>
<td>Inj 350 mg per ml (iodine equivalent), 75 ml bottle</td>
<td>114.00</td>
<td>10 Omnipaque</td>
</tr>
<tr>
<td>Inj 350 mg per ml (iodine equivalent), 100 ml bottle</td>
<td>150.00</td>
<td>10 Omnipaque</td>
</tr>
<tr>
<td>Inj 350 mg per ml (iodine equivalent), 200 ml bottle</td>
<td>290.00</td>
<td>10 Omnipaque</td>
</tr>
</tbody>
</table>

Non-iodinated X-ray Contrast Media

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST) $</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>BARIUM SULPHATE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Powder for oral liq 20 mg per g (2% w/w), 22.1 g sachet</td>
<td>507.50</td>
<td>50 E-Z-Cat Dry</td>
</tr>
<tr>
<td>Oral liq 400 mg per ml (40% w/v, 30% w/w), bottle</td>
<td>17.39</td>
<td>30 g Varibar - Thin Liquid</td>
</tr>
<tr>
<td>Oral liq 600 mg per g (60% w/w), tube</td>
<td>36.51</td>
<td>454 g E-Z-Paste</td>
</tr>
<tr>
<td>Oral liq 400 mg per ml (40% w/v), bottle</td>
<td>155.35</td>
<td>250 ml Varibar - Honey</td>
</tr>
<tr>
<td>Enema 1,250 mg per ml (125% w/v), 500 ml bag</td>
<td>282.30</td>
<td>12 Liquibar</td>
</tr>
<tr>
<td>Oral liq 22 mg per g (2.2% w/w), 250 ml bottle</td>
<td>175.00</td>
<td>24 CT Plus+</td>
</tr>
<tr>
<td>Oral liq 600 mg per g (60% w/w), tube</td>
<td>220.00</td>
<td>24 CT Plus+</td>
</tr>
<tr>
<td>Oral liq 1 mg per ml (0.1% w/v, 0.1% w/v), 450 ml bottle</td>
<td>441.12</td>
<td>24 VoLumen</td>
</tr>
<tr>
<td>Oral liq 20.9 mg per ml (2.1% w/v, 2% w/w), 250 ml bottle</td>
<td>140.94</td>
<td>24 Readi-CAT 2</td>
</tr>
<tr>
<td>Powder for oral soln 97.65% w/w, 300 g bottle</td>
<td>237.76</td>
<td>24 X-Opaque-HD</td>
</tr>
<tr>
<td>Oral liq 400 mg per ml (40% w/v, 30% w/w), 20 ml bottle</td>
<td>52.35</td>
<td>3 Tagitol V</td>
</tr>
<tr>
<td>Oral liq 1,250 mg per ml (125% w/v), 2,000 ml bottle</td>
<td>91.77</td>
<td>1 Liquibar</td>
</tr>
</tbody>
</table>

BARIUM SULPHATE WITH SODIUM BICARBONATE

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST) $</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grans eff 382.2 mg per g with sodium bicarbonate 551.3 mg per g, 4 g sachet</td>
<td>102.93</td>
<td>50 E-Z-Gas II</td>
</tr>
</tbody>
</table>
### Paramagnetic Contrast Media

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price</th>
<th>Quantity</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>CITRIC ACID WITH SODIUM BICARBONATE Powder 382.2 mg per g with sodium bicarbonate 551.3 mg per g, 4 g sachet</td>
<td>e.g. E-Z-GAS II</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GADOBENIC ACID Inj 334 mg per ml, 10 ml vial</td>
<td>324.74</td>
<td>10</td>
<td>Multihance</td>
</tr>
<tr>
<td>GADOBUTROL Inj 604.72 mg per ml (equivalent to 1 mmol per ml), 5 ml prefilled syringe</td>
<td>120.00</td>
<td>5</td>
<td>Gadovist 1.0</td>
</tr>
<tr>
<td>GADOBUTROL Inj 604.72 mg per ml (equivalent to 1 mmol per ml), 7.5 ml prefilled syringe</td>
<td>180.00</td>
<td>5</td>
<td>Gadovist 1.0</td>
</tr>
<tr>
<td>GADOBUTROL Inj 604.72 mg per ml (equivalent to 1 mmol per ml), 15 ml prefilled syringe</td>
<td>700.00</td>
<td>10</td>
<td>Gadovist 1.0</td>
</tr>
<tr>
<td>GADODIAMIDE Inj 287 mg per ml, 10 ml prefilled syringe</td>
<td>200.00</td>
<td>10</td>
<td>Omniscan</td>
</tr>
<tr>
<td>GADODIAMIDE Inj 287 mg per ml, 5 ml vial</td>
<td>120.00</td>
<td>10</td>
<td>Omniscan</td>
</tr>
<tr>
<td>GADODIAMIDE Inj 287 mg per ml, 15 ml prefilled syringe</td>
<td>320.00</td>
<td>10</td>
<td>Omniscan</td>
</tr>
<tr>
<td>GADOTERIC ACID Inj 279.32 mg per ml (0.5 mmol per ml), 10 ml prefilled syringe</td>
<td>24.50</td>
<td>1</td>
<td>Dotarem</td>
</tr>
<tr>
<td>GADOTERIC ACID Inj 279.32 mg per ml (0.5 mmol per ml), 15 ml bottle</td>
<td>34.50</td>
<td>1</td>
<td>Dotarem</td>
</tr>
<tr>
<td>GADOTERIC ACID Inj 279.32 mg per ml (0.5 mmol per ml), 15 ml prefilled syringe</td>
<td>41.00</td>
<td>1</td>
<td>Dotarem</td>
</tr>
<tr>
<td>GADOXETATE DISODIUM Inj 181.43 mg per ml (equivalent to 0.25 mmol per ml), 10 ml prefilled syringe</td>
<td>300.00</td>
<td>1</td>
<td>Primovist</td>
</tr>
<tr>
<td>MEGLUMINE GADOPENTETATE Inj 469 mg per ml, 10 ml prefilled syringe</td>
<td>95.00</td>
<td>5</td>
<td>Magnevist</td>
</tr>
<tr>
<td>MEGLUMINE IOTROXATE Inj 105 mg per ml, 100 ml bottle</td>
<td>150.00</td>
<td>100 ml</td>
<td>Biliscopin</td>
</tr>
<tr>
<td>Ultrasound Contrast Media</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PERFLUTRENN Inj 1.1 mg per ml, 1.5 ml vial</td>
<td>180.00</td>
<td>1</td>
<td>Definity</td>
</tr>
<tr>
<td>PERFLUTRENN Inj 1.1 mg per ml, 1.5 ml vial</td>
<td>720.00</td>
<td>4</td>
<td>Definity</td>
</tr>
</tbody>
</table>

### Diagnostic Agents

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price</th>
<th>Quantity</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>ARGinine Inj 50 mg per ml, 500 ml bottle</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ARGinine Inj 100 mg per ml, 300 ml bottle</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
VARIOUS

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
</table>

HISTAMINE ACID PHOSPHATE
Nebuliser soln 0.6%, 10 ml vial
Nebuliser soln 2.5%, 10 ml vial
Nebuliser soln 5%, 10 ml vial

MANNITOL
Powder for inhalation

METHACHOLINE CHLORIDE
Powder 100 mg

SECRETIN PENTAHYDROCHLORIDE
Inj 100 u ampoule

SINCALIDE
Inj 5 mcg per vial

### Diagnostic Dyes

BONNEY’S BLUE DYE
Soln

INDIGO CARMINE
Inj 4 mg per ml, 5 ml ampoule
Inj 8 mg per ml, 5 ml ampoule

INDOCYANINE GREEN
Inj 25 mg vial

METHYLTHIONINIUM CHLORIDE [METHYLENE BLUE]
Inj 5 mg per ml, 10 ml ampoule

PATENT BLUE V
Inj 2.5%, 2 ml ampoule

### Irrigation Solutions

CHLORHEXIDINE WITH CETRIMIDE
Irrigation soln 0.015% with cetrimide 0.15%, 500 ml bottle

**Restricted (RS1683)**

Initiation
Re-assessment required after 3 months
All of the following:
1. Patient has burns that are greater than 30% of total body surface area (BSA); and
2. For use in the perioperative preparation and cleansing of large burn areas requiring debridement/skin grafting; and
3. The use of 30 ml ampoules is impractical due to the size of the area to be covered.

Continuation
Re-assessment required after 3 months
The treatment remains appropriate for the patient and the patient is benefiting from the treatment.

Irrigation soln 0.015% with cetrimide 0.15%, 30 ml ampoule – 1% DV

**Aug-18 to 2021**

<table>
<thead>
<tr>
<th>Price</th>
<th>Quantity</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>29.76</td>
<td>30</td>
<td>Pfizer</td>
</tr>
</tbody>
</table>

GLYCINE
Irrigation soln 1.5%, 3,000 ml bag – 1% DV

**Sep-18 to 2021**

<table>
<thead>
<tr>
<th>Price</th>
<th>Quantity</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>31.20</td>
<td>4</td>
<td>B Braun</td>
</tr>
</tbody>
</table>
### SODIUM CHLORIDE

<table>
<thead>
<tr>
<th>Description</th>
<th>Price (ex man. excl. GST) $</th>
<th>Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Irrigation soln 0.9%, 3,000 ml bag – 1% DV Sep-18 to 2021</td>
<td>26.80</td>
<td>4 B Braun</td>
</tr>
<tr>
<td>Irrigation soln 0.9%, 30 ml ampoule – 1% DV Sep-18 to 2021</td>
<td>7.00</td>
<td>20 Interpharma</td>
</tr>
<tr>
<td>Irrigation soln 0.9%, 1,000 ml bottle – 1% DV Jun-18 to 2021</td>
<td>14.90</td>
<td>10 Baxter Sodium Chloride 0.9%</td>
</tr>
<tr>
<td>Irrigation soln 0.9%, 250 ml bottle – 1% DV Aug-18 to 2021</td>
<td>17.64</td>
<td>12 Fresenius Kabi</td>
</tr>
</tbody>
</table>

### WATER

<table>
<thead>
<tr>
<th>Description</th>
<th>Price (ex man. excl. GST) $</th>
<th>Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Irrigation soln, 3,000 ml bag – 1% DV Sep-18 to 2021</td>
<td>28.80</td>
<td>4 B Braun</td>
</tr>
<tr>
<td>Irrigation soln, 1,000 ml bottle – 1% DV Jun-18 to 2021</td>
<td>17.30</td>
<td>10 Baxter Water for Irrigation</td>
</tr>
<tr>
<td>Irrigation soln, 250 ml bottle – 1% DV Aug-18 to 2021</td>
<td>17.64</td>
<td>12 Fresenius Kabi</td>
</tr>
</tbody>
</table>

### Surgical Preparations

#### BISMUTH SUBNITRATE AND IODOFORM PARAFFIN
- Paste

#### DIMETHYL SULFOXIDE
- Soln 50%
- Soln 99%

#### PHENOL
- Inj 6%, 10 ml ampoule

#### PHENOL WITH IOXAGLIC ACID
- Inj 12%, 10 ml ampoule

#### TROMETAMOL
- Inj 36 mg per ml, 500 ml bottle
### Cardioplegia Solutions

**ELECTROLYTES**

- **Inj 15 mmol/l sodium chloride, 9 mmol/l potassium chloride, 1 mmol/l potassium hydrogen 2-ketoglutarate, 4 mmol/l magnesium chloride, 18 mmol/l histidine hydrochloride, 180 mmol/l histidine, 2 mmol/l tryptophan, 30 mmol/l mannitol, 0.015 mmol/l calcium chloride, 1,000 ml bag**
  - e.g. Custodiol-HTK

- **Inj aspartic acid 10.43 mg per ml, citric acid 0.22476 mg per ml, glutamic acid 11.53 mg per ml, sodium phosphate 0.1725 mg per ml, potassium chloride 2.15211 mg per ml, sodium citrate 1.80768 mg per ml, sodium hydroxide 6.31 mg per ml and trometamol 11.2369 mg per ml, 364 ml bag**
  - e.g. Cardioplegia Enriched Paed. Soln.

- **Inj aspartic acid 8.481 mg per ml, citric acid 0.8188 mg per ml, glutamic acid 9.375 mg per ml, sodium phosphate 0.6285 mg per ml, potassium chloride 2.5 mg per ml, sodium citrate 6.585 mg per ml, sodium hydroxide 5.133 mg per ml and trometamol 9.097 mg per ml, 527 ml bag**
  - e.g. Cardioplegia Enriched Solution

- **Inj citric acid 0.07973 mg per ml, sodium phosphate 0.06119 mg per ml, potassium chloride 2.181 mg per ml, sodium chloride 1.788 mg ml, sodium citrate 0.6412 mg per ml and trometamol 5.9 mg per ml, 523 ml bag**
  - e.g. Cardioplegia Base Solution

- **Inj 110 mmol/l sodium, 16 mmol/l potassium, 1.2 mmol/l calcium, 16 mmol/l magnesium and 160 mmol/l chloride, 1,000 ml bag**
  - e.g. Cardioplegia Solution AHB7832

- **Inj 143 mmol/l sodium, 16 mmol/l potassium, 16 mmol/l magnesium and 1.2 mmol/l calcium, 1,000 ml bag**
  - e.g. Cardioplegia Electrolyte Solution

**MONOSODIUM GLUTAMATE WITH SODIUM ASPARTATE**

- Inj 42.68 mg with sodium aspartate 39.48 mg per ml, 250 ml bottle

**MONOSODIUM L-ASPARTATE**

- Inj 14 mmol per 10 ml, 10 ml

### Cold Storage Solutions

**SODIUM WITH POTASSIUM**

- Inj 29 mmol/l with potassium 125 mmol/l, 1,000 ml bag
### Extemporaneously Compounded Preparations

<table>
<thead>
<tr>
<th></th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ACETIC ACID</strong></td>
<td>Per Brand or Generic</td>
<td></td>
</tr>
<tr>
<td><strong>ALUM</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>ARACHIS OIL [PEANUT OIL]</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>ASCORBIC ACID</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>BENZOIN</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>BORIC ACID</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>CARBOXYMETHYLCELLULOSE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>CETRIMIDE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>CHLORHEXIDINE GLUCONATE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>CHLOROFORM</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>CLOVE OIL</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>COAL TAR</strong></td>
<td>36.25 Per Midwest</td>
<td></td>
</tr>
<tr>
<td><strong>CODEINE PHOSPHATE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>COLLODION FLEXIBLE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>COMPOUND HYDROXYBENOZOATE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>CYSTEAMINE HYDROCHLORIDE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>DITHRANOL</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>GLUCOSE [DEXTROSE]</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Item restricted (see ➔ above); Item restricted (see ➔ below)

*Note: Brand indicates brand example only. It is not a contracted product.*
### Extemporaneously Compounded Preparations

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>GLYCERIN WITH SODIUM SACCHARIN Suspension – 1% DV Jul-19 to 2022</td>
<td>$30.95 473 ml</td>
<td>Ora-Sweet SF</td>
</tr>
<tr>
<td>GLYCERIN WITH SUCROSE Suspension – 1% DV Jul-19 to 2022</td>
<td>$30.95 473 ml</td>
<td>Ora-Sweet</td>
</tr>
<tr>
<td>GLYCEROL Liq – 1% DV Sep-17 to 2020</td>
<td>$3.28 500 ml</td>
<td>healthE Glycerol BP Liquid</td>
</tr>
<tr>
<td>HYDROCORTISONE Powder – 1% DV Sep-17 to 2020</td>
<td>$49.95 25 g</td>
<td>ABM</td>
</tr>
<tr>
<td>LACTOSE Powder</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MAGNESIUM HYDROXIDE Paste</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MENTHOL Crystals</td>
<td></td>
<td></td>
</tr>
<tr>
<td>METHADONE HYDROCHLORIDE Powder</td>
<td></td>
<td></td>
</tr>
<tr>
<td>METHYL HYDROXYBENZOEATE Powder – 1% DV Jul-19 to 2022</td>
<td>$8.98 25 g</td>
<td>Midwest</td>
</tr>
<tr>
<td>METHYLCELLULOSE Powder – 1% DV Jul-19 to 2022</td>
<td>$36.95 100 g</td>
<td>Midwest</td>
</tr>
<tr>
<td>Suspension – 1% DV Jul-19 to 2022</td>
<td>$30.95 473 ml</td>
<td>Ora-Plus</td>
</tr>
<tr>
<td>METHYLCELLULOSE WITH GLYCERIN AND SODIUM SACCHARIN Suspension – 1% DV Jul-19 to 2022</td>
<td>$30.95 473 ml</td>
<td>Ora-Blend SF</td>
</tr>
<tr>
<td>METHYLCELLULOSE WITH GLYCERIN AND SUCROSE Suspension – 1% DV Jul-19 to 2022</td>
<td>$30.95 473 ml</td>
<td>Ora-Blend</td>
</tr>
<tr>
<td>OLIVE OIL Liq</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PARAFFIN Liq</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PHENOBARBITONE SODIUM Powder</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PHENOL Liq</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PILOCARPINE NITRATE Powder</td>
<td></td>
<td></td>
</tr>
<tr>
<td>POLYHEXAMETHYLENE BIGUANIDE Liq</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Povidone K30 Powder</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SALICYLIC ACID Powder</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SILVER NITRATE Crystals</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SODIUM BICARBONATE Powder BP – 1% DV Jan-20 to 2022</td>
<td>$10.05 500 g</td>
<td>Midwest</td>
</tr>
</tbody>
</table>

**Note:** Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
## EXTEMPORANEOUNSLY COMPOUNDED PREPARATIONS

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST) $ Per</th>
<th>Item restricted (see above); Item restricted (see below)</th>
</tr>
</thead>
<tbody>
<tr>
<td>SODIUM CITRATE Powder</td>
<td></td>
<td>e.g. Brand indicates brand example only. It is not a contracted product.</td>
</tr>
<tr>
<td>SODIUM METABISULFITE Powder</td>
<td></td>
<td></td>
</tr>
<tr>
<td>STARCH Powder</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SULPHUR Precipitated Sublimed</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SYRUP Liq (pharmaceutical grade) – 1% DV Jan-20 to 2022</td>
<td>14.95 500 ml</td>
<td>Midwest</td>
</tr>
<tr>
<td>THEOBROMA OIL Oint</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TRI-SODIUM CITRATE Crystals</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TRICHLORACETIC ACID Grans</td>
<td></td>
<td></td>
</tr>
<tr>
<td>UREA Powder BP</td>
<td></td>
<td></td>
</tr>
<tr>
<td>WOOL FAT Oint, anhydrous</td>
<td></td>
<td></td>
</tr>
<tr>
<td>XANTHAN Gum 1%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ZINC OXIDE Powder</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Food Modules

Carbohydrate

**→ Restricted (RS1467)**

Initiation – Use as an additive

Any of the following:

1. Cystic fibrosis; or
2. Chronic kidney disease; or
3. Cancer in children; or
4. Cancers affecting alimentary tract where there are malabsorption problems in patients over the age of 20 years; or
5. Faltering growth in an infant/child; or
6. Bronchopulmonary dysplasia; or
7. Premature and post premature infant; or
8. Inborn errors of metabolism.

Initiation – Use as a module

For use as a component in a modular formula made from at least one nutrient module and at least one further product listed in Section D of the Pharmaceutical Schedule or breast milk.

Note: Patients are required to meet any Special Authority criteria associated with all of the products used in the modular formula.

CARBOHYDRATE SUPPLEMENT – Restricted see terms above

- Powder 95 g carbohydrate per 100 g, 368 g can
- Powder 96 g carbohydrate per 100 g, 400 g can  
  e.g. Polycal

Fat

**→ Restricted (RS1468)**

Initiation – Use as an additive

Any of the following:

1. Patient has inborn errors of metabolism; or
2. Faltering growth in an infant/child; or
3. Bronchopulmonary dysplasia; or
4. Fat malabsorption; or
5. Lymphangiectasia; or
6. Short bowel syndrome; or
7. Infants with necrotising enterocolitis; or
8. Biliary atresia; or
9. For use in a ketogenic diet; or
10. Chyle leak; or
11. Ascites; or
12. Patient has increased energy requirements, and for whom dietary measures have not been successful.

Initiation – Use as a module

For use as a component in a modular formula made from at least one nutrient module and at least one further product listed in Section D of the Pharmaceutical Schedule or breast milk.

Note: Patients are required to meet any Special Authority criteria associated with all of the products used in the modular formula.

LONG-CHAIN TRIGLYCERIDE SUPPLEMENT – Restricted see terms above

- Liquid 50 g fat per 100 ml, 200 ml bottle  
  e.g. Calogen
- Liquid 50 g fat per 100 ml, 500 ml bottle  
  e.g. Calogen
SPECIAL FOODS

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>e.g. Liquigen</td>
</tr>
<tr>
<td>e.g. MCT Oil</td>
</tr>
</tbody>
</table>

**MEDIUM-CHAIN TRIGLYCERIDE SUPPLEMENT** – Restricted see terms on the previous page

1. Liquid 50 g fat per 100 ml, 250 ml bottle
2. Liquid 95 g fat per 100 ml, 500 ml bottle

**WALNUT OIL** – Restricted see terms on the previous page

1. Liq

**PROTEIN**

**Restricted (RS1469)**

**Initiation – Use as an additive**

Either:
1. Protein losing enteropathy; or
2. High protein needs.

**Initiation – Use as a module**

For use as a component in a modular formula made from at least one nutrient module and at least one further product listed in Section D of the Pharmaceutical Schedule or breast milk.

Note: Patients are required to meet any Special Authority criteria associated with all of the products used in the modular formula.

**PROTEIN SUPPLEMENT** – Restricted see terms above

1. Powder 5 g protein, 0.67 g carbohydrate and 0.6 g fat per 6.6 g, 275 g can
2. Powder 6 g protein per 7 g, can
3. Powder 89 g protein, < 1.5 g carbohydrate and 2 g fat per 100 g, 225 g can

**Other Supplements**

**BREAST MILK FORTIFIER**

Powder 0.2 g protein, 0.7 g carbohydrate and 0.02 g fat per 1 g sachet
e.g. FM 85
Powder 0.5 g protein, 1.2 g carbohydrate and 0.08 g fat per 2 g sachet
e.g. S26 Human Milk Fortifier
can
Powder 0.6 g protein and 1.4 g carbohydrate per 2.2 g sachet
e.g. Nutricia Breast Milk Fortifer

**CARBOHYDRATE AND FAT SUPPLEMENT** – Restricted see terms below

1. Powder 72.7 g carbohydrate and 22.3 g fat per 100 g, 400 g can
e.g. Super Soluble Duocal

**Restricted (RS1212)**

**Initiation**

Both:
1. Infant or child aged four years or under; and
2. Any of the following:
   2.1 Cystic fibrosis; or
   2.2 Cancer in children; or
   2.3 Faltering growth; or
   2.4 Bronchopulmonary dysplasia; or
   2.5 Premature and post premature infants.
**Food/Fluid Thickeners**

**NOTE:**
While pre-thickened drinks and supplements have not been included in Section H, DHB hospitals may continue to use such products for patients with dysphagia, provided that:

- use was established prior to 1 July 2013; and
- the product has not been specifically considered and excluded by PHARMAC; and
- use of the product conforms to any applicable indication restrictions for similar products that are listed in Section H (for example, use of thickened high protein products should be in line with the restriction for high protein oral feed in Section H).

PHARMAC intends to make a further decision in relation to pre-thickened drinks and supplements in the future, and will notify of any change to this situation.

CAROB BEAN GUM WITH MAIZE STARCH AND MALTODEXTRIN  
Powder  
e.g. Feed Thickener  
Karicare Aptamil

GUAR GUM  
Powder  
e.g. Guarcol

MAIZE STARCH  
Powder  
e.g. Resource Thicken  
Up; Nutilis

MALTODEXTRIN WITH XANTHAN GUM  
Powder  
e.g. Instant Thick

MALTODEXTRIN WITH XANTHAN GUM AND ASCORBIC ACID  
Powder  
e.g. Easy Thick

**Metabolic Products**

**→ Restricted (RS1232)**

**Initiation**  
Any of the following:

1. For the dietary management of homocystinuria, maple syrup urine disease, phenylketonuria (PKU), glutaric aciduria, isovaleric acidemia, propionic acidemia, methylmalonic acidemia, tyrosinaemia or urea cycle disorders; or
2. Patient has adrenoleukodystrophy; or
3. For use as a supplement to the Ketogenic diet in patients diagnosed with epilepsy.

**Glutaric Aciduria Type 1 Products**

AMINO ACID FORMULA (WITHOUT LYSINE AND LOW TRYPTOPHAN)  
→ Restricted see terms above

- Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can  
e.g. GA1 Anamix Infant

- Powder 25 g protein and 51 g carbohydrate per 100 g, 500 g can  
e.g. XLYS Low TRY Maxamaid
### Homocystinuria Products

**AMINO ACID FORMULA (WITHOUT METHIONINE)** – **Restricted** see terms on the previous page

- Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can
- Powder 25 g protein and 51 g carbohydrate per 100 g, 500 g can
- Powder 39 g protein and 34 g carbohydrate per 100 g, 500 g can
- Liquid 8 g protein, 7 g carbohydrate, 3.8 g fat and 0.25 g fibre per 100 ml, 125 ml bottle

*Example brands:* HCU Anamix Infant, XMET Maxamaid, XMET Maxamum, HCU Anamix Junior LQ

### Isovaleric Acidaemia Products

**AMINO ACID FORMULA (WITHOUT LEUCINE)** – **Restricted** see terms on the previous page

- Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can
- Powder 25 g protein and 51 g carbohydrate per 100 g, 500 g can
- Powder 39 g protein and 34 g carbohydrate per 100 g, 500 g can

*Example brands:* IVA Anamix Infant, XLEU Maxamaid, XLEU Maxamum

### Maple Syrup Urine Disease Products

**AMINO ACID FORMULA (WITHOUT ISOLEUCINE, LEUCINE AND VALINE)** – **Restricted** see terms on the previous page

- Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can
- Powder 39 g protein and 34 g carbohydrate per 100 g, 500 g can
- Liquid 8 g protein, 7 g carbohydrate, 3.8 g fat and 0.25 g fibre per 100 ml, 125 ml bottle

*Example brands:* MSUD Anamix Infant, MSUD Maxamum, MSUD Anamix Junior LQ

---

*Item restricted (see above); Item restricted (see below)*

*e.g. Brand indicates brand example only. It is not a contracted product.*
### Phenylketonuria Products

**AMINO ACID FORMULA (WITHOUT PHENYLALANINE)** – **Restricted** see terms on page 223

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Protein</th>
<th>Carbohydrate</th>
<th>Fat</th>
<th>Fibre</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Powder 20 g protein</td>
<td>2.5 g</td>
<td>0.22 g</td>
<td>27.8 g</td>
<td>e.g. Phlexy-10</td>
<td></td>
</tr>
<tr>
<td>Powder 36 g protein</td>
<td>32 g</td>
<td>12.5 g</td>
<td>100 g</td>
<td>e.g. PKU Lophlex Powder (unflavoured)</td>
<td></td>
</tr>
<tr>
<td>Powder 13.1 g protein</td>
<td>49.5 g</td>
<td>5.3 g</td>
<td>100 g</td>
<td>e.g. PKU Anamix Junior (van/choc/unfl)</td>
<td></td>
</tr>
<tr>
<td>Powder 39 g protein</td>
<td>34 g</td>
<td>per 100 g</td>
<td>500 g</td>
<td>e.g. PKU Anamix Infant</td>
<td></td>
</tr>
<tr>
<td>Powder 8.33 g protein</td>
<td>8.8 g</td>
<td>per 20 g sachet</td>
<td>e.g. XP Maxamum</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liquid 10 g protein</td>
<td>4.4 g</td>
<td>0.25 g</td>
<td>100 ml, 62.5 ml bottle</td>
<td>e.g. Phlexy-10</td>
<td></td>
</tr>
<tr>
<td>Liquid 20 g protein</td>
<td>8.8 g</td>
<td>0.34 g</td>
<td>100 ml, 125 ml bottle</td>
<td>e.g. PKU Lophlex LQ 10</td>
<td></td>
</tr>
<tr>
<td>Liquid 8 g protein</td>
<td>7 g</td>
<td>0.25 g</td>
<td>100 ml, bottle</td>
<td>e.g. PKU Lophlex LQ 20</td>
<td></td>
</tr>
<tr>
<td>Liquid 16 g protein</td>
<td>7 g</td>
<td>0.27 g</td>
<td>100 ml, 125 ml bottle</td>
<td>e.g. PKU Lophlex LQ 20</td>
<td></td>
</tr>
<tr>
<td>Liquid 6.7 g protein</td>
<td>5.1 g</td>
<td>2 g</td>
<td>100 ml, 250 ml carton</td>
<td>e.g. Easiphen</td>
<td></td>
</tr>
<tr>
<td>Semi-solid 18.3 g protein</td>
<td>18.5 g</td>
<td>0.92 g</td>
<td>100 g, 109 g pot</td>
<td>e.g. PKU Lophlex Sensations 20 (berries)</td>
<td></td>
</tr>
</tbody>
</table>

### Propionic Acidaemia and Methylmalonic Acidaemia Products

**AMINO ACID FORMULA (WITHOUT ISOLEUCINE, METHIONINE, THREONINE AND VALINE)** – **Restricted** see terms on page 223

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Protein</th>
<th>Carbohydrate</th>
<th>Fat</th>
<th>Fibre</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Powder 13.1 g protein</td>
<td>49.5 g</td>
<td>23 g</td>
<td>5.3 g</td>
<td>e.g. MMA/PA Anamix Infant</td>
<td></td>
</tr>
<tr>
<td>Powder 25 g protein</td>
<td>51 g</td>
<td>per 100 g</td>
<td>500 g</td>
<td>e.g. XMTVI Maxamaid</td>
<td></td>
</tr>
<tr>
<td>Powder 39 g protein</td>
<td>34 g</td>
<td>per 100 g</td>
<td>500 g</td>
<td>e.g. XMTVI Maxamum</td>
<td></td>
</tr>
</tbody>
</table>
**Protein Free Supplements**

**PROTEIN FREE SUPPLEMENT** – *Restricted* see terms on page 223

- Powder nil added protein and 67 g carbohydrate per 100 g, 400 g can  
  *e.g. Energivit*

**Tyrosinaemia Products**

**AMINO ACID FORMULA (WITHOUT PHENYLALANINE AND TYROSINE)** – *Restricted* see terms on page 223

- Powder 36 g protein, 32 g carbohydrate and 12.5 g fat per 100 g, 36 g sachet  
  *e.g. TYR Anamix Junior*
- Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can  
  *e.g. TYR Anamix Infant*
- Powder 25 g protein and 51 g carbohydrate per 100 g, 400 g can  
  *e.g. XPHEN, TYR Maxamaid*
- Liquid 8 g protein, 7 g carbohydrate, 3.8 g fat and 0.25 g fibre per 100 ml, 125 ml bottle  
  *e.g. TYR Anamix Junior LQ*

**Urea Cycle Disorders Products**

**AMINO ACID SUPPLEMENT** – *Restricted* see terms on page 223

- Powder 25 g protein and 65 g carbohydrate per 100 g, 200 g can  
  *e.g. Dialamine*
- Powder 79 g protein per 100 g, 200 g can  
  *e.g. Essential Amino Acid Mix*

**X-Linked Adrenoleukodystrophy Products**

**GLYCEROL TRIERUCATE** – *Restricted* see terms on page 223

- Liquid, 1,000 ml bottle

**GLYCEROL TRIOLEATE** – *Restricted* see terms on page 223

- Liquid, 500 ml bottle

**Specialised Formulas**

**Diabetic Products**

- *Restricted (RS1215)*

Initiation

Any of the following:

1. For patients with type I or type II diabetes suffering weight loss and malnutrition that requires nutritional support; or
2. For patients with pancreatic insufficiency; or
3. For patients who have, or are expected to, eat little or nothing for 5 days; or
4. For patients who have a poor absorptive capacity and/or high nutrient losses and/or increased nutritional needs from causes such as catabolism; or
5. For use pre- and post-surgery; or
6. For patients being tube-fed; or
7. For tube-feeding as a transition from intravenous nutrition.

Item restricted (see above); Item restricted (see below)

*e.g. Brand* indicates brand example only. It is not a contracted product.
### SPECIAL FOODS

**LOW-GI ENTERAL FEED 1 KCAL/ML – Restricted** see terms on the previous page

<table>
<thead>
<tr>
<th>Description</th>
<th>Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Liquid 5 g protein, 9.6 g carbohydrate and 5.4 g fat per 100 ml, 1,000 ml bottle</td>
<td>$7.50</td>
<td>Glucerna Select RTH (Vanilla)</td>
</tr>
<tr>
<td>Liquid 4.3 g protein, 11.3 g carbohydrate and 4.2 g fat per 100 ml, 1,000 ml bag</td>
<td></td>
<td>e.g. Nutrison Advanced Diason</td>
</tr>
</tbody>
</table>

**LOW-GI ORAL FEED 1 KCAL/ML – Restricted** see terms on the previous page

<table>
<thead>
<tr>
<th>Description</th>
<th>Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Liquid 4.5 g protein, 9.8 g carbohydrate, 4.4 g fat and 1.9 g fibre per 100 ml, can</td>
<td>$2.10</td>
<td>Sustagen Diabetic (Vanilla)</td>
</tr>
<tr>
<td>Powder 11 g protein, 62 g carbohydrate and 1 g fat per sachet.</td>
<td>$4.50</td>
<td>Vivonex TEN (80 g)</td>
</tr>
<tr>
<td>Liquid 2.5 g protein, 11 g carbohydrate and 3.5 g fat per 100 ml, 250 ml carton</td>
<td></td>
<td>e.g. Elemental 028 Extra</td>
</tr>
<tr>
<td>Liquid 4 g protein, 17.6 g carbohydrate and 1.7 g fat per 100 ml, 1,000 ml bag</td>
<td></td>
<td>e.g. Nutrison Advanced Peptisorb</td>
</tr>
<tr>
<td>Liquid 6.75 g protein, 18.4 g carbohydrate and 5.5 g fat per 100 ml, bottle.</td>
<td>$18.06</td>
<td>Vital</td>
</tr>
<tr>
<td>Powder 13.7 g protein, 62.9 g carbohydrate and 17.5 g fat per 100 g, 400 g can</td>
<td></td>
<td>e.g. Peptamen Junior</td>
</tr>
<tr>
<td>Powder 13.8 g protein, 59 g carbohydrate and 18 g fat per 100 g, 400 g can</td>
<td></td>
<td>e.g. MCT Pepdite; MCT Pepdite 1+</td>
</tr>
</tbody>
</table>

### Elemental and Semi-Elemental Products

#### Restricted (RS1216)

**Initiation**

Any of the following:

1. Malabsorption; or
2. Short bowel syndrome; or
3. Enterocutaneous fistulas; or
4. Eosinophilic enteritis (including oesophagitis); or
5. Inflammatory bowel disease; or
6. Acute pancreatitis where standard feeds are not tolerated; or
7. Patients with multiple food allergies requiring enteral feeding.

**AMINO ACID ORAL FEED – Restricted** see terms above

<table>
<thead>
<tr>
<th>Description</th>
<th>Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Powder 11 g protein, 62 g carbohydrate and 1 g fat per sachet.</td>
<td>$4.50</td>
<td>Vivonex TEN (80 g)</td>
</tr>
</tbody>
</table>

**AMINO ACID ORAL FEED 0.8 KCAL/ML – Restricted** see terms above

<table>
<thead>
<tr>
<th>Description</th>
<th>Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Liquid 2.5 g protein, 11 g carbohydrate and 3.5 g fat per 100 ml, 250 ml carton</td>
<td></td>
<td>e.g. Elemental 028 Extra</td>
</tr>
</tbody>
</table>

**PEPTIDE-BASED ENTERAL FEED 1 KCAL/ML – Restricted** see terms above

<table>
<thead>
<tr>
<th>Description</th>
<th>Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Liquid 4 g protein, 17.6 g carbohydrate and 1.7 g fat per 100 ml, 1,000 ml bag</td>
<td></td>
<td>e.g. Nutrison Advanced Peptisorb</td>
</tr>
</tbody>
</table>

**PEPTIDE-BASED ENTERAL FEED 1.5 KCAL/ML – Restricted** see terms above

<table>
<thead>
<tr>
<th>Description</th>
<th>Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Liquid 6.75 g protein, 18.4 g carbohydrate and 5.5 g fat per 100 ml, bottle.</td>
<td>$18.06</td>
<td>Vital</td>
</tr>
</tbody>
</table>

**PEPTIDE-BASED ORAL FEED – Restricted** see terms above

<table>
<thead>
<tr>
<th>Description</th>
<th>Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Powder 13.7 g protein, 62.9 g carbohydrate and 17.5 g fat per 100 g, 400 g can</td>
<td></td>
<td>e.g. Peptamen Junior</td>
</tr>
<tr>
<td>Powder 13.8 g protein, 59 g carbohydrate and 18 g fat per 100 g, 400 g can</td>
<td></td>
<td>e.g. MCT Pepdite; MCT Pepdite 1+</td>
</tr>
</tbody>
</table>
SPECIAL FOODS

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per</td>
<td></td>
</tr>
</tbody>
</table>

**PEPTIDE-BASED ORAL FEED 1 KCAL/ML – Restricted** see terms on the previous page

- Liquid 5 g protein, 16 g carbohydrate and 1.69 g fat per 100 ml, carton...........4.95
  - 237 ml Peptamen OS 1.0 (Vanilla)

**Fat Modified Products**

**FAT-MODIFIED FEED – Restricted** see terms below

- Powder 12.9 g protein, 69.1 g carbohydrate and 12.9 g fat per 100 g,
  - 400 g can e.g. Monogen

**Initiation**

Any of the following:

1. Patient has metabolic disorders of fat metabolism; or
2. Patient has a chyle leak; or
3. Modified as a modular feed, made from at least one nutrient module and at least one further product listed in Section D of the Pharmaceutical Schedule, for adults.

Note: Patients are required to meet any Special Authority criteria associated with all of the products used in the modular formula.

**Hepatic Products**

**Hepatic Oral Feed – Restricted** see terms above

- Powder 11 g protein, 64 g carbohydrate and 20 g fat per 100 g, can.............78.97
  - 400 g Heparon Junior

**High Calorie Products**

**ENTERAL FEED 2 KCAL/ML – Restricted** see terms above

- Liquid 7.5 g protein, 20 g carbohydrate and 10 g fat per 100 ml, bottle...........5.50
  - 500 ml Nutrison Concentrated
- Liquid 8.4 g protein, 21.9 g carbohydrate, 9.1 g fat and 0.5 g fibre per 100 ml, bottle.................................................................11.00
  - 1,000 ml TwoCal HN RTH (Vanilla)

**ORAL FEED 2 KCAL/ML – Restricted** see terms above

- Liquid 8.4 g protein, 22.4 g carbohydrate, 8.9 g fat and 0.8 g fibre per 100 ml, bottle.................................................................1.90
  - 200 ml Two Cal HN
High Protein Products

**HIGH PROTEIN ENTERAL FEED 1.25 KCAL/ML – Restricted** see terms below

- Liquid 6.3 g protein, 14.2 g carbohydrate and 4.9 g fat per 100 ml,
  1,000 ml bottle

  >> Restricted (RS1327)

**Initiation**

Both:

1. The patient has a high protein requirement; and
2. Any of the following:
   - 2.1 Patient has liver disease; or
   - 2.2 Patient is obese (BMI > 30) and is undergoing surgery; or
   - 2.3 Patient is fluid restricted; or
   - 2.4 Patient’s needs cannot be more appropriately met using high calorie product.

**HIGH PROTEIN ENTERAL FEED 1.28 KCAL/ML – Restricted** see terms below

- Liquid 6.3 g protein, 14.1 g carbohydrate, 4.9 g fat and 1.5 g fibre per 100 ml, 1,000 ml bag

  >> Restricted (RS1327)

**Initiation**

Both:

1. The patient has a high protein requirement; and
2. Any of the following:
   - 2.1 Patient has liver disease; or
   - 2.2 Patient is obese (BMI > 30) and is undergoing surgery; or
   - 2.3 Patient is fluid restricted; or
   - 2.4 Patient’s needs cannot be more appropriately met using high calorie product.

Infant Formulas

**AMINO ACID FORMULA – Restricted** see terms on the next page

- Powder 1.95 g protein, 8.1 g carbohydrate and 3.5 g fat per 100 ml, 400 g can

- Powder 13 g protein, 49 g carbohydrate and 23 g fat per 100 g, 400 g can

- Powder 13.3 g protein, 56 g carbohydrate and 22 g fat per 100 g, 400 g can

- Powder 13.5 g protein, 52 g carbohydrate and 24.5 g fat per 100 g, can .........53.00 400 g Neocate Unflavoured

- Powder 14.8 g protein, 51.4 g carbohydrate and 23 g fat per 100 g, can .........53.00 400 g Neocate Junior Vanilla

- Powder 15 g protein, 56 g carbohydrate and 20 g fat per 100 g, can ............43.60 400 g Alfamino Junior

- Powder 16 g protein, 51.4 g carbohydrate and 21 g fat per 100 g, can ..........53.00 400 g Neocate Junior Vanilla

- Powder 2.2 g protein, 7.8 g carbohydrate and 3.4 g fat per 100 ml, can ........53.00 400 g Elecare LCP (Unflavoured)

- Powder 2.2 g protein, 7.8 g carbohydrate and 3.4 g fat per 100 ml, can ..........53.00 400 g Elecare (Unflavoured) (Vanilla)

(Neocate Junior Vanilla Powder 16 g protein, 51.4 g carbohydrate and 21 g fat per 100 g, can to be delisted 1 April 2020)
**SPECIAL FOODS**

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
</table>

**→ Restricted (RS1471)**

**Initiation**

Any of the following:

1. Extensively hydrolysed formula has been reasonably trialled and is inappropriate due to documented severe intolerance or allergy or malabsorption; or
2. History of anaphylaxis to cows' milk protein formula or dairy products; or
3. Eosinophilic oesophagitis.

Note: A reasonable trial is defined as a 2-4 week trial.

**Continuation**

Both:

1. An assessment as to whether the infant can be transitioned to a cows' milk protein, soy, or extensively hydrolysed infant formula has been undertaken; and
2. The outcome of the assessment is that the infant continues to require an amino acid infant formula.

**EXTENSIVELY HYDROLYSED FORMULA – Restricted** see terms below

- Powder 1.6 g protein, 7.5 g carbohydrate and 3.1 g fat per 100 ml, 900 g can ............................................................................................................30.42 900 g Allerpro 1
- Powder 1.6 g protein, 7.8 g carbohydrate and 3.2 g fat per 100 ml, 900 g can ............................................................................................................30.42 900 g Allerpro 2
- Powder 14 g protein, 53.4 g carbohydrate and 27.3 g fat per 100 g, 450 g can e.g. Aptamil Gold+ Pepti Junior

**→ Restricted (RS1502)**

**Initiation**

Any of the following:

1. Both:
   1.1 Cows' milk formula is inappropriate due to severe intolerance or allergy to its protein content; and
   1.2 Either:
      1.2.1 Soy milk formula has been reasonably trialled without resolution of symptoms; or
      1.2.2 Soy milk formula is considered clinically inappropriate or contraindicated; or
2. Severe malabsorption; or
3. Short bowel syndrome; or
4. Intractable diarrhoea; or
5. Biliary atresia; or
6. Cholestatic liver diseases causing malabsorption; or
7. Cystic fibrosis; or
8. Proven fat malabsorption; or
9. Severe intestinal motility disorders causing significant malabsorption; or
10. Intestinal failure; or
11. For step down from Amino Acid Formula.

Note: A reasonable trial is defined as a 2-4 week trial, or signs of an immediate IgE mediated allergic reaction.

**Continuation**

Both:

1. An assessment as to whether the infant can be transitioned to a cows' milk protein or soy infant formula has been undertaken; and
2. The outcome of the assessment is that the infant continues to require an extensively hydrolysed infant formula.

**FRUCTOSE-BASED FORMULA**

Powder 14.6 g protein, 49.7 g carbohydrate and 30.8 g fat per 100 g, 400 g can e.g. Galactomin 19

---

* Item restricted (see → above); Item restricted (see → below)

* e.g. *Brand* indicates brand example only. It is not a contracted product.
## LACTOSE-FREE FORMULA

| Powder 1.3 g protein, 7.3 g carbohydrate and 3.5 g fat per 100 ml, 900 g can | e.g. Karicare Aptamil Gold De-Lact |
| Powder 1.5 g protein, 7.2 g carbohydrate and 3.6 g fat per 100 ml, 900 g can | e.g. S26 Lactose Free |

## LOW-CALCIUM FORMULA

| Powder 14.6 g protein, 53.7 g carbohydrate and 26.1 g fat per 100 g, 400 g can | e.g. Locasol |

## PAEDIATRIC ORAL/ENTERAL FEED 1 KCAL/ML – Restricted see terms below

| Liquid 2.6 g protein, 10.3 g carbohydrate, 5.4 g fat and 0.6 g fibre per 100 ml, bottle | 2.35 | 125 ml | Infatrini |

**Initiation – Fluid restricted or volume intolerance with faltering growth**

Both:

1. Either:
   1.1 The patient is fluid restricted or volume intolerant; or
   1.2 The patient has increased nutritional requirements due to faltering growth; and

2. Patient is under 18 months old and weighs less than 8kg.

Note: ‘Volume intolerant’ patients are those who are unable to tolerate an adequate volume of infant formula to achieve expected growth rate. These patients should have first trialled appropriate clinical alternative treatments, such as concentrating, fortifying and adjusting the frequency of feeding.

## PRETERM FORMULA – Restricted see terms below

| Liquid 2.2 g protein, 8.4 g carbohydrate and 4.4 g fat per 100 ml, bottle | 0.75 | 100 ml | S26 LBW Gold RTF |
| Liquid 2.3 g protein, 8.6 g carbohydrate and 4.2 g fat per 100 ml, 90 ml bottle | e.g. Pre Nan Gold RTF |
| Liquid 2.6 g protein, 8.4 g carbohydrate and 3.9 g fat per 100 ml, 70 ml bottle | e.g. Karicare Aptamil Gold+Preterm |

**Initiation**

For infants born before 33 weeks' gestation or weighing less than 1.5 kg at birth.

## THICKENED FORMULA

| Powder 1.8 g protein, 8.1 g carbohydrate and 3.3 g fat per 100 ml, 900 g can | e.g. Karicare Aptamil Thickened AR |

## Ketogenic Diet Products

## HIGH FAT FORMULA – Restricted see terms below

| Powder 14.4 g protein, 2.9 g carbohydrate and 69.2 g fat per 100 g, can | 35.50 | 300 g | Ketocal 4:1 (Unflavoured) |
| Powder 15.3 g protein, 7.2 g carbohydrate and 67.7 g fat per 100 g, can | 35.50 | 300 g | Ketocal 3:1 (Unflavoured) |

**Initiation**

For patients with intractable epilepsy, pyruvate dehydrogenase deficiency or glucose transported type-1 deficiency and other conditions requiring a ketogenic diet.
Paediatric Products

**Restricted (RS1473)**

Initiation

Both:

1. Child is aged one to ten years; and
2. Any of the following:
   1. The child is being fed via a tube or a tube is to be inserted for the purposes of feeding; or
   2. Any condition causing malabsorption; or
   3. Faltering growth in an infant/child; or
   4. Increased nutritional requirements; or
   5. The child is being transitioned from TPN or tube feeding to oral feeding; or
   6. The child has eaten, or is expected to eat, little or nothing for 3 days.

**PAEDIATRIC ENTERAL FEED 0.76 KCAL/ML – Restricted see terms above**

- Liquid 2.5 g protein, 12.5 g carbohydrate, 3.3 g fat and 0.7 g fibre per 100 ml, bag..........................4.00 500 ml Nutrini Low Energy Multifibre RTH

**PAEDIATRIC ENTERAL FEED 1 KCAL/ML – Restricted see terms above**

- Liquid 2.8 g protein, 11.2 g carbohydrate and 5 g fat per 100 ml, bag........2.68 500 ml Pediasure RTH
- Liquid 2.8 g protein, 12.3 g carbohydrate and 4.4 g fat per 100 ml, 500 ml bag

**PAEDIATRIC ENTERAL FEED 1.5 KCAL/ML – Restricted see terms above**

- Liquid 4.1 g protein, 18.5 g carbohydrate, 6.7 g fat and 0.8 g fibre per 100 ml, bag..........................6.00 500 ml Nutrini Energy Multi Fibre
- Liquid 4.1 g protein, 18.5 g carbohydrate and 6.7 g fat per 100 ml, 500 ml bag

**PAEDIATRIC ORAL FEED 1 KCAL/ML – Restricted see terms above**

- Liquid 4.2 g protein, 16.7 g carbohydrate and 7.5 g fat per 100 ml, bottle........1.07 200 ml Pediasure (Chocolate)
- Liquid 4.2 g protein, 16.7 g carbohydrate and 7.5 g fat per 100 ml, can.........1.34 250 ml Pediasure (Vanilla)

**PAEDIATRIC ORAL FEED 1.5 KCAL/ML – Restricted see terms above**

- Liquid 3.4 g protein, 18.8 g carbohydrate and 6.8 g fat per 100 ml, 200 ml bottle
- Liquid 4.0 g protein, 18.8 g carbohydrate, 6.8 g fat and 1.5 g fibre per 100 ml, 200 ml bottle

Renal Products

**LOW ELECTROLYTE ENTERAL FEED 1.8 KCAL/ML – Restricted see terms below**

- Liquid 8.1 g protein, 14.74 g carbohydrate, 9.77 g fat and 1.26 g fibre per 100 ml, bottle..........................6.08 500 ml Nepro HP RTH

**Restricted (RS1229)**

Initiation

For patients with acute or chronic kidney disease.

**LOW ELECTROLYTE ORAL FEED – Restricted see terms on the next page**

- Powder 7.5 g protein, 59 g carbohydrate and 26.3 g fat per 100 g, 400 g can

*e.g. Brand* indicates brand example only. It is not a contracted product.
SPECIAL FOODS

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
</table>

- **Restricted (RS1227)**
  - **Initiation**
  - For children (up to 18 years) with acute or chronic kidney disease.
  - **LOW ELECTROLYTE ORAL FEED 1.8 KCAL/ML**
    - Liquid 8 g protein, 14.74 g carbohydrate, 9.77 g fat and 1.26 g fibre per 100 ml, carton.................................................................2.67 220 ml Nepro HP (Strawberry) Nepro HP (Vanilla)

- **Restricted (RS1228)**
  - **Initiation**
  - For patients with acute or chronic kidney disease.
  - **LOW ELECTROLYTE ORAL FEED 2 KCAL/ML – Restricted see terms below**
    - Liquid 9.1 g protein, 19 g carbohydrate and 10 g fat per 100 ml, carton........3.31 237 ml Novasource Renal (Vanilla)
    - Liquid 3 g protein, 25.5 g carbohydrate and 9.6 g fat per 100 ml, 237 ml bottle
    - Liquid 7.5 g protein, 20 g carbohydrate and 10 g fat per 100 ml, 125 ml carton e.g. Renilon 7.5

- **Restricted (RS1228)**
  - **Initiation**
  - For patients with acute or chronic kidney disease.
  - **LOW CARBOHYDRATE ORAL FEED 1.5 KCAL/ML – Restricted see terms below**
    - Liquid 6.2 g protein, 10.5 g carbohydrate and 9.32 g fat per 100 ml, bottle......1.66 237 ml Pulmocare (Vanilla)

- **Restricted (RS1230)**
  - **Initiation**
  - For patients with CORD and hypercapnia, defined as a CO2 value exceeding 55 mmHg.
  - **HIGH ARGININE ORAL FEED 1.4 KCAL/ML – Restricted see terms below**
    - Liquid 10.1 g protein, 15 g carbohydrate, 4.5 g fat and 0 g fibre per 100 ml, carton.................................................................4.00 178 ml Impact Advanced Recovery

- **Restricted (RS1231)**
  - **Initiation**
  - Three packs per day for 5 to 7 days prior to major gastrointestinal, head or neck surgery.
  - **PREOPERATIVE CARBOHYDRATE FEED 0.5 KCAL/ML – Restricted see terms below**
    - Oral liq 0 g protein, 12.6 g carbohydrate and 0 g fat per 100 ml, 200 ml bottle.................................................................................6.80 4 preOp

- **Restricted (RS1415)**
  - **Initiation**
  - Maximum of 400 ml as part of an Enhanced Recovery After Surgery (ERAS) protocol 2 to 3 hours before major abdominal surgery.
### Standard Feeds

**Restricted (RS1214)**

**Initiation**

Any of the following:

1. For patients with malnutrition, defined as any of the following:
   1.1 BMI < 18.5; or
   1.2 Greater than 10% weight loss in the last 3-6 months; or
   1.3 BMI < 20 with greater than 5% weight loss in the last 3-6 months; or
2. For patients who have, or are expected to, eat little or nothing for 5 days; or
3. For patients who have a poor absorptive capacity and/or high nutrient losses and/or increased nutritional needs from causes such as catabolism; or
4. For use pre- and post-surgery; or
5. For patients being tube-fed; or
6. For tube-feeding as a transition from intravenous nutrition; or
7. For any other condition that meets the community Special Authority criteria.

**ENTERAL FEED 1.5 KCAL/ML – Restricted** see terms above

- Liquid 6 g protein, 18.3 g carbohydrate and 5.8 g fat per 100 ml, bag............ 7.00 1,000 ml Nutrison Energy
- Liquid 6 g protein, 18.4 g carbohydrate, 5.8 g fat and 1.5 g fibre per 100 ml, 1,000 ml bag

**ENTERAL FEED 1 KCAL/ML – Restricted** see terms above

- Liquid 4 g protein, 13.6 g carbohydrate and 3.4 g fat per 100 ml, bottle ......... 5.29 1,000 ml Osmolite RTH
- Liquid 4 g protein, 14.1 g carbohydrate, 3.47 g fat and 1.76 g fibre per 100 ml, bottle

**ENTERAL FEED 1.2 KCAL/ML – Restricted** see terms above

- Liquid 5.55 g protein, 15.1 g carbohydrate, 3.93 g fat and 2 g fibre per 100 ml, 1,000 ml bag

**ENTERAL FEED WITH FIBRE 0.83 KCAL/ML – Restricted** see terms above

- Liquid 5.5 g protein, 8.8 g carbohydrate, 2.5 g fat and 1.5 g fibre per 100 ml, bottle

---

*Item restricted (see ➥ above); Item restricted (see ➥ below)*

*e.g. Brand indicates brand example only. It is not a contracted product.*
### ORAL FEED – Restricted see terms on the previous page

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Brand or Manufacturer</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Powder 15.9 g protein, 57.4 g carbohydrate and 14 g fat per 100 g, can</td>
<td>Ensure (Chocolate)</td>
<td>$26.00</td>
</tr>
<tr>
<td>Powder 20.8 g protein, 61 g carbohydrate and 9.4 g fat per 100 g, can</td>
<td>Fortisip (Vanilla)</td>
<td>$8.54</td>
</tr>
<tr>
<td>Powder 23 g protein, 65 g carbohydrate and 2.5 g fat per 100 g, can</td>
<td>Sustagen Hospital Formula Active (Choc)</td>
<td>$26.00</td>
</tr>
<tr>
<td>Powder 23 g protein, 65 g carbohydrate and 2.5 g fat per 100 g, can</td>
<td>Sustagen Hospital Formula Active (Van)</td>
<td>$840 g</td>
</tr>
</tbody>
</table>

Note: Community subsidy of Sustagen Hospital Formula is subject to both Special Authority criteria and a manufacturer's surcharge. Higher subsidy by endorsement is available for patients meeting the following endorsement criteria; fat malabsorption, fat intolerance or chyle leak.

### ORAL FEED 1 KCAL/ML – Restricted see terms on the previous page

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Brand or Manufacturer</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Liquid 3.8 g protein, 23 g carbohydrate and 12.7 g fibre per 100 ml, 237 ml carton</td>
<td>e.g. Resource Fruit Beverage</td>
<td>$2.52</td>
</tr>
</tbody>
</table>

### ORAL FEED 1.5 KCAL/ML – Restricted see terms on the previous page

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Brand or Manufacturer</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Liquid 5.5 g protein, 21.1 g carbohydrate and 4.81 g fat per 100 ml, can</td>
<td>Ensure Plus (Vanilla)</td>
<td>$1.33</td>
</tr>
<tr>
<td>Liquid 6.25 g protein, 20.2 g carbohydrate and 4.92 g fat per 100 ml, carton</td>
<td>Ensure Plus (Banana)</td>
<td>$1.26</td>
</tr>
<tr>
<td>Liquid 4 g protein and 33.5 g carbohydrate per 100 ml, 200 ml bottle</td>
<td>e.g. Fortijuice</td>
<td>$1.50</td>
</tr>
<tr>
<td>Liquid 6 g protein, 18.4 g carbohydrate and 5.8 g fat per 100 ml, 200 ml bottle</td>
<td>e.g. Fortisip</td>
<td>$1.33</td>
</tr>
<tr>
<td>Liquid 6 g protein, 18.4 g carbohydrate, 5.8 g fat and 2.3 g fibre per 100 ml, 200 ml bottle</td>
<td>e.g. Fortisip Multi Fibre</td>
<td>$1.33</td>
</tr>
</tbody>
</table>
Bacterial and Viral Vaccines

DIPHTHERIA, TETANUS, PERTUSSIS AND POLIO VACCINE – Restricted see terms below

- Inj 30 IU diphtheria toxoid with 30IU tetanus toxoid, 25 mcg pertussis toxoid, 25 mcg pertussis filamentous haemagglutinin, 8 mcg pertactin and 80 D-antigen units poliomyelitis virus in 0.5 ml syringe
  - 0% DV Sep-17 to 2020 ................................................................. 0.00 10 Infanrix IPV

- Restricted (RS1387)

Initiation

Any of the following:

1. A single dose for children up to the age of 7 who have completed primary immunisation; or
2. A course of up to four vaccines is funded for catch up programmes for children (to the age of 10 years) to complete full primary immunisation; or
3. An additional four doses (as appropriate) are funded for (re-)immunisation for patients post HSCT, or chemotherapy; pre- or post splenectomy; pre- or post solid organ transplant, renal dialysis and other severely immunosuppressive regimens; or
4. Five doses will be funded for children requiring solid organ transplantation.

Note: Please refer to the Immunisation Handbook for appropriate schedule for catch up programmes

DIPHTHERIA, TETANUS, PERTUSSIS, POLIO, HEPATITIS B AND HAEMOPHILUS INFLUENZAE TYPE B VACCINE – Restricted see terms below

- Inj 30 IU diphtheria toxoid with 40 IU tetanus toxoid, 25 mcg pertussis toxoid, 25 mcg pertussis filamentous haemagglutinin, 8 mcg pertactin, 80 D-antigen units poliomyelitis virus, 10 mcg hepatitis B surface antigen in 0.5 ml syringe (1) and inj 10 mcg haemophilus influenzae type B vaccine vial –
  - 0% DV Sep-17 to 2020 ................................................................. 0.00 10 Infanrix-hexa

- Restricted (RS1478)

Initiation

Any of the following:

1. Up to four doses for children up to and under the age of 10 for primary immunisation; or
2. An additional four doses (as appropriate) are funded for (re-)immunisation for children up to and under the age of 10 who are patients post haematopoietic stem cell transplantation, or chemotherapy; pre or post splenectomy; pre- or post solid organ transplant, renal dialysis and other severely immunosuppressive regimens; or
3. Up to five doses for children up to and under the age of 10 receiving solid organ transplantation.

Note: A course of up-to four vaccines is funded for catch up programmes for children (up to and under the age of 10 years) to complete full primary immunisation. Please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes.

Bacterial Vaccines

ADULT DIPHTHERIA AND TETANUS VACCINE

- Inj 2 IU diphtheria toxoid with 20 IU tetanus toxoid in 0.5 ml syringe –
  - 0% DV Jul-17 to 2020 ................................................................. 0.00 5 ADT Booster

- Restricted (RS1386)

Initiation

Any of the following:

1. For vaccination of patients aged 45 and 65 years old; or
2. For vaccination of previously unimmunised or partially immunised patients; or

continued…
BACILLUS CALMETTE-GUERIN VACCINE – **Restricted** see terms below

Inj Mycobacterium bovis BCG (Bacillus Calmette-Guerin), Danish strain 1331, live attenuated, vial Danish strain 1331, live attenuated, vial with diluent...

**Initiation**

All of the following:

1. Living in a house or family with a person with current or past history of TB; and
2. Having one or more household members or carers who within the last 5 years lived in a country with a rate of TB > or equal to 40 per 100,000 for 6 months or longer; and
3. During their first 5 years will be living 3 months or longer in a country with a rate of TB > or equal to 40 per 100,000.

**Note:** A list of countries with high rates of TB are available at [http://www.health.govt.nz/tuberculosis](http://www.health.govt.nz/tuberculosis) (Search for Downloads) or [www.bcgatlas.org/index.php](http://www.bcgatlas.org/index.php)

DIPHTHERIA, TETANUS AND PERTUSSIS VACCINE – **Restricted** see terms below

Inj 2 IU diphtheria toxoid with 20 IU tetanus toxoid, 8 mcg pertussis toxoid, 8 mcg pertussis filamentous haemagglutinin and 2.5 mcg pertactin in 0.5 ml syringe – **0% DV Sep-17 to 2020**

**Initiation**

Any of the following:

1. A single dose for pregnant women in the second or third trimester of each pregnancy; or; or
2. A single dose for parents or primary caregivers of infants admitted to a Neonatal Intensive Care Unit or Specialist Care Baby Unit for more than 3 days, who had not been exposed to maternal vaccination at least 14 days prior to birth; or; or
3. A course of up to four doses is funded for children from age 7 up the age of 18 years inclusive to complete full primary immunisation; or
4. An additional four doses (as appropriate) are funded for (re-)immunisation for patients post haematopoietic stem cell transplantation or chemotherapy; pre or post splenectomy; pre- or post solid organ transplant, renal dialysis and other severely immunosuppressive regimens.

**Note:** Tdap is not registered for patients aged less than 10 years. Please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes.

HAEMOPHILUS INFLUENZAE TYPE B VACCINE – **Restricted** see terms below

Inj Haemophilus Influenzae type B polysaccharide 10 mcg conjugated to tetanus toxoid as carrier protein 20-40 mcg; prefilled syringe plus vial 0.5 ml – **0% DV Sep-17 to 2020**

**Initiation**

*Therapy limited to 1 dose*

Any of the following:

1. For primary vaccination in children; or
continued…

2 An additional dose (as appropriate) is funded for (re-)immunisation for patients post haematopoietic stem cell transplantation, or chemotherapy; functional asplenic; pre or post splenectomy; pre- or post solid organ transplant, pre- or post cochlear implants, renal dialysis and other severely immunosuppressive regimens; or

3 For use in testing for primary immunodeficiency diseases, on the recommendation of an internal medicine physician or paediatrician.

MENINGOCOCCAL (A, C, Y AND W-135) CONJUGATE VACCINE – Restricted see terms below

Inj 4 mcg or each meningococcal polysaccharide conjugated to a total of approximately 48 mcg of diphtheria toxoid carrier per 0.5 ml vial –

0% DV Jul-17 to 2020.................................................................0.00 1 Menactra

Initiation
Either:

1 Any of the following:
   1.1 Up to three doses and a booster every five years for patients pre- and post splenectomy and for patients with HIV, complement deficiency (acquired or inherited), functional or anatomic asplenia or pre or post solid organ transplant; or
   1.2 One dose for close contacts of meningococcal cases; or
   1.3 A maximum of two doses for bone marrow transplant patients; or
   1.4 A maximum of two doses for patients following immunosuppression*; or

2 Both:
   2.1 Person is aged between 13 and 25 years, inclusive; and
   2.2 Either:
      2.2.1 One dose for individuals who are entering within the next three months, or in their first year of living in boarding school hostels, tertiary education halls of residence, military barracks, or prisons; or
      2.2.2 One dose for individuals who are currently living in boarding school hostels, tertiary education halls of residence, military barracks, or prisons, from 1 December 2019 to 30 November 2020.

Notes: children under seven years of age require two doses 8 weeks apart, a booster dose three years after the primary series and then five yearly.

*Immunosuppression due to steroid or other immunosuppressive therapy must be for a period of greater than 28 days.

MENINGOCOCCAL C CONJUGATE VACCINE – Restricted see terms below

Inj 10 mcg in 0.5 ml syringe –

0% DV Jul-17 to 2020.................................................................0.00 1 Neisvac-C

Initiation
Any of the following:

1 Up to three doses and a booster every five years for patients pre- and post splenectomy and for patients with HIV, complement deficiency (acquired or inherited), functional or anatomic asplenia or pre or post solid organ transplant; or

2 One dose for close contacts of meningococcal cases; or

3 A maximum of two doses for bone marrow transplant patients; or

4 A maximum of two doses for patients following immunosuppression*.

Notes: children under seven years of age require two doses 8 weeks apart, a booster dose three years after the primary series and then five yearly.

*Immunosuppression due to steroid or other immunosuppressive therapy must be for a period of greater than 28 days.

PNEUMOCOCCAL (PCV10) CONJUGATE VACCINE – Restricted see terms on the next page

mcg of pneumococcal polysaccharide serotypes 1, 5, 6B, 7F, 9V,
14 and 23F; 3 mcg of pneumococcal polysaccharide serotypes 4,
18C and 19F in 0.5 ml prefilled syringe –

0% DV Sep-17 to 2020............0.00 10 Synflorix

Item restricted (see above); Item restricted (see below)

E.g. Brand indicates brand example only. It is not a contracted product.
VACCINES

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

➡️ **Restricted (RS1585)**

**Initiation**

Either:
1. A primary course of four doses for previously unvaccinated individuals up to the age of 59 months inclusive; or
2. Up to three doses as appropriate to complete the primary course of immunisation for individuals under the age of 59 months who have received one to three doses of PCV13.

Note: Please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes

**PNEUMOCOCCAL (PCV13) CONJUGATE VACCINE – Restricted see terms below**

<table>
<thead>
<tr>
<th>Inj 30.8 mcg of pneumococcal polysaccharide serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F in 0.5 ml syringe</th>
<th>0% DV Jul-17 to 2020</th>
<th>0.00</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1</td>
<td>Prevenar 13</td>
</tr>
<tr>
<td></td>
<td>10</td>
<td>Prevenar 13</td>
</tr>
</tbody>
</table>

➡️ **Restricted (RS1586)**

**Initiation – High risk children who have received PCV10**

*Therapy limited to 1 dose*

One dose is funded for high risk children (over the age of 17 months and under 18 years) who have previously received four doses of PCV10.

**Initiation – High risk children aged under 5 years**

*Therapy limited to 4 doses*

Both:
1. Up to an additional four doses (as appropriate) are funded for children aged under 5 years for (re-)immunisation; and
2. Any of the following:
   2.1 On immunosuppressive therapy or radiation therapy, vaccinate when there is expected to be a sufficient immune response; or
   2.2 With primary immune deficiencies; or
   2.3 With HIV infection; or
   2.4 With renal failure, or nephrotic syndrome; or
   2.5 Who are immune-suppressed following organ transplantation (including haematopoietic stem cell transplant); or
   2.6 With cochlear implants or intracranial shunts; or
   2.7 With cerebrospinal fluid leaks; or
   2.8 Receiving corticosteroid therapy for more than two weeks, and who are on an equivalent daily dosage of prednisone of 2 mg/kg per day or greater, or children who weigh more than 10 kg on a total daily dosage of 20 mg or greater; or
   2.9 With chronic pulmonary disease (including asthma treated with high-dose corticosteroid therapy); or
   2.10 Pre term infants, born before 28 weeks gestation; or
   2.11 With cardiac disease, with cyanosis or failure; or
   2.12 With diabetes; or
   2.13 With Down syndrome; or
   2.14 Who are pre- or post-splenectomy, or with functional asplenia.

**Initiation – High risk adults and children 5 years and over**

*Therapy limited to 4 doses*

Up to an additional four doses (as appropriate) are funded for (re-)immunisation of patients 5 years and over with HIV, for patients pre or post haematopoietic stem cell transplantation, or chemotherapy; pre- or post splenectomy; functional asplenia, pre- or post-solid organ transplant, renal dialysis, complement deficiency (acquired or inherited), cochlear implants, or primary immunodeficiency.

**Initiation – Testing for primary immunodeficiency diseases**

For use in testing for primary immunodeficiency diseases, on the recommendation of an internal medicine physician or paediatrician.

Note: Please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes

**PNEUMOCOCCAL (PPV23) POLYSACCHARIDE VACCINE – Restricted see terms on the next page**

<table>
<thead>
<tr>
<th>Inj 575 mcg in 0.5 ml prefilled syringe (25 mcg of each 23 pneumococcal serotype)</th>
<th>0% DV Jul-17 to 2020</th>
<th>0.00</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1</td>
<td>Pneumovax 23</td>
</tr>
</tbody>
</table>

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

239
VACCINES

<table>
<thead>
<tr>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>(ex man. excl. GST)</td>
<td>$ Per</td>
</tr>
</tbody>
</table>

**Viral Vaccines**

HEPATITIS A VACCINE – Restricted see terms below

- Inj 720 ELISA units in 0.5 ml syringe – 0% DV Sep-17 to 2020 0.00 1 Havrix Junior
- Inj 1440 ELISA units in 1 ml syringe – 0% DV Sep-17 to 2020 0.00 1 Havrix

Initiation

Any of the following:

1. Two vaccinations for use in transplant patients; or
2. Two vaccinations for use in children with chronic liver disease; or
3. One dose of vaccine for close contacts of known hepatitis A cases.

HEPATITIS B RECOMBINANT VACCINE

- Inj 5 mcg in 0.5 ml vial – 0% DV Jul-17 to 2020 0.00 1 HBvaxPRO

**SALMONELLA TYPHI VACCINE** – Restricted see terms below

- Inj 25 mcg in 0.5 ml syringe

**Viral Vaccines**

HEPATITIS A VACCINE – Restricted see terms below

- Inj 720 ELISA units in 0.5 ml syringe – 0% DV Sep-17 to 2020 0.00 1 Havrix Junior
- Inj 1440 ELISA units in 1 ml syringe – 0% DV Sep-17 to 2020 0.00 1 Havrix

Initiation

Any of the following:

1. Two vaccinations for use in transplant patients; or
2. Two vaccinations for use in children with chronic liver disease; or
3. One dose of vaccine for close contacts of known hepatitis A cases.

HEPATITIS B RECOMBINANT VACCINE

- Inj 5 mcg in 0.5 ml vial – 0% DV Jul-17 to 2020 0.00 1 HBvaxPRO

- Item restricted (see ✧ above); ✧ Item restricted (see ✧ below)
e.g. Brand indicates brand example only. It is not a contracted product.
### Vaccines

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>❌ Restricted (RS1588)</th>
<th>Initiation</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Any of the following:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1. For household or sexual contacts of known acute hepatitis B patients or hepatitis B carriers; or</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2. For children born to mothers who are hepatitis B surface antigen (HBsAg) positive; or</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3. For children up to and under the age of 18 years inclusive who are considered not to have achieved a positive serology and require additional vaccination or require a primary course of vaccination; or</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4. For HIV positive patients; or</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5. For hepatitis C positive patients; or</td>
<td></td>
<td></td>
</tr>
<tr>
<td>6. For patients following non-consensual sexual intercourse; or</td>
<td></td>
<td></td>
</tr>
<tr>
<td>7. For patients following immunosuppression; or</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8. For solid organ transplant patients; or</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9. For post-haematopoietic stem cell transplant (HSCT) patients; or</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10. Following needle stick injury.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| Inj 10 mcg in 1 ml vial | $0.00 | 1. HBvaxPRO |

<table>
<thead>
<tr>
<th>❌ Restricted (RS1588)</th>
<th>Initiation</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Any of the following:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1. For household or sexual contacts of known acute hepatitis B patients or hepatitis B carriers; or</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2. For children born to mothers who are hepatitis B surface antigen (HBsAg) positive; or</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3. For children up to and under the age of 18 years inclusive who are considered not to have achieved a positive serology and require additional vaccination or require a primary course of vaccination; or</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4. For HIV positive patients; or</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5. For hepatitis C positive patients; or</td>
<td></td>
<td></td>
</tr>
<tr>
<td>6. For patients following non-consensual sexual intercourse; or</td>
<td></td>
<td></td>
</tr>
<tr>
<td>7. For patients following immunosuppression; or</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8. For solid organ transplant patients; or</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9. For post-haematopoietic stem cell transplant (HSCT) patients; or</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10. Following needle stick injury; or</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11. For dialysis patients; or</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12. For liver or kidney transplant patients.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| Inj 20 mcg per 1 ml prefilled syringe | $0.00 | 1. Engerix-B |

<table>
<thead>
<tr>
<th>❌ Restricted (RS1671)</th>
<th>Initiation</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Any of the following:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1. For household or sexual contacts of known acute hepatitis B patients or hepatitis B carriers; or</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2. For children born to mothers who are hepatitis B surface antigen (HBsAg) positive; or</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3. For children up to and under the age of 18 years inclusive who are considered not to have achieved a positive serology and require additional vaccination or require a primary course of vaccination; or</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4. For HIV positive patients; or</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5. For hepatitis C positive patients; or</td>
<td></td>
<td></td>
</tr>
<tr>
<td>6. For patients following non-consensual sexual intercourse; or</td>
<td></td>
<td></td>
</tr>
<tr>
<td>7. For patients following immunosuppression; or</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8. For solid organ transplant patients; or</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9. For post-haematopoietic stem cell transplant (HSCT) patients; or</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10. Following needle stick injury; or</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11. For dialysis patients; or</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12. For liver or kidney transplant patients.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| Inj 40 mcg per 1 ml vial – 0% DV Jul-17 to 2020 | $0.00 | 1. HBvaxPRO |

Products with Hospital Supply Status (HSS) are in bold
Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
**HUMAN PAPILLOMAVIRUS (6, 11, 16, 31, 33, 45, 52 AND 58) VACCINE [HPV] – Restricted see terms below**

- Inj 270 mcg in 0.5 ml syringe – 0% DV Jun-17 to 2020

  - 0.00

  - 10

  - Gardasil 9

**INFLUENZA VACCINE**

- Inj 60 mcg in 0.5 ml syringe (paediatric quadrivalent vaccine)

  - 9.00

  - 1

  - Fluarix Tetra

**INFLUENZA VACCINE**

- Inj 60 mcg in 0.5 ml syringe (paediatric quadrivalent vaccine)

  - 9.00

  - 1

  - Fluarix Tetra

**INFLUENZA VACCINE**

- Inj 60 mcg in 0.5 ml syringe (paediatric quadrivalent vaccine)

  - 9.00

  - 1

  - Fluarix Tetra

**INFLUENZA VACCINE**

- Inj 60 mcg in 0.5 ml syringe (paediatric quadrivalent vaccine)

  - 9.00

  - 1

  - Fluarix Tetra
continued...

1. Diabetes; or
2. Chronic renal disease; or
3. Any cancer, excluding basal and squamous skin cancers if not invasive; or
4. Autoimmune disease; or
5. Immune suppression or immune deficiency; or
6. HIV; or
7. Transplant recipient; or
8. Neuromuscular and CNS diseases/disorders; or
9. Haemoglobinopathies; or
10. Is a child on long term aspirin; or
11. Has a cochlear implant; or
12. Errors of metabolism at risk of major metabolic decompensation; or
13. Pre and post splenectomy; or
14. Down syndrome; or
15. Child who has been hospitalised for respiratory illness or has a history of significant respiratory illness.

Inj 60 mcg in 0.5 ml syringe (quadrivalent vaccine) ................................................. 90.00

10 Influvac Tetra

Restricted (RS1674)

Initiation – People over 65

The patient is 65 years of age or over.

Initiation – cardiovascular disease for patients 3 years and over

Any of the following:

1. Ischaemic heart disease; or
2. Congestive heart failure; or
3. Rheumatic heart disease; or
4. Congenital heart disease; or
5. Cerebro-vascular disease.

Note: hypertension and/or dyslipidaemia without evidence of end-organ disease is excluded from funding.

Initiation – chronic respiratory disease for patients 3 years and over

Either:

1. Asthma, if on a regular preventative therapy; or
2. Other chronic respiratory disease with impaired lung function.

Note: asthma not requiring regular preventative therapy is excluded from funding.

Initiation – Other conditions for patients 3 years and over

Either:

1. Any of the following:
   1.1 Diabetes; or
   1.2 chronic renal disease; or
   1.3 Any cancer, excluding basal and squamous skin cancers if not invasive; or
   1.4 Autoimmune disease; or
   1.5 Immune suppression or immune deficiency; or
   1.6 HIV; or
   1.7 Transplant recipient; or
   1.8 Neuromuscular and CNS diseases/disorders; or
   1.9 Haemoglobinopathies; or
   1.10 Is a child on long term aspirin; or
   1.11 Has a cochlear implant; or
   1.12 Errors of metabolism at risk of major metabolic decompensation; or
1.13 Pre and post splenectomy; or
1.14 Down syndrome; or
1.15 Is pregnant; or
1.16 Is a child aged four and under who has been hospitalised for respiratory illness or has a history of significant respiratory illness; or

2 Patients in a long-stay inpatient mental health care unit or who are compulsorily detained long-term in a forensic unit within a DHB hospital.

MEASLES, MUMPS AND RUBELLA VACCINE – Restricted see terms below

Injection, measles virus 1,000 CCID50, mumps virus 5,012 CCID50, Rubella virus 1,000 CCID50; prefilled syringe/ampoule of diluent
0.5 ml – 0% DV Sep-17 to 2020 .......................................................... 0.00 10 Priorix

Restricted (RS1487)
Initiation – first dose prior to 12 months
Therapy limited to 3 doses
Any of the following:
1 For primary vaccination in children; or
2 For revaccination following immunosuppression; or
3 For any individual susceptible to measles, mumps or rubella.

Initiation – first dose after 12 months
Therapy limited to 2 doses
Any of the following:
1 For primary vaccination in children; or
2 For revaccination following immunosuppression; or
3 For any individual susceptible to measles, mumps or rubella.

Note: Please refer to the Immunisation Handbook for appropriate schedule for catch up programmes.

POLIOMYELITIS VACCINE – Restricted see terms below

Inj 80 D-antigen units in 0.5 ml syringe – 0% DV Jul-17 to 2020 ................. 0.00 1 IPOL

Restricted (RS1398)
Initiation
Therapy limited to 3 doses
Either:
1 For partially vaccinated or previously unvaccinated individuals; or
2 For revaccination following immunosuppression.

Note: Please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes.

RABIES VACCINE
Inj 2.5 IU vial with diluent

ROTAVIRUS ORAL VACCINE – Restricted see terms below

Oral susp live attenuated human rotavirus 1,000,000 CCID50 per dose, prefilled oral applicator – 0% DV Sep-17 to 2020 .......................................... 0.00 10 Rotarix

Restricted (RS1590)
Initiation
Therapy limited to 2 doses
Both:
1 First dose to be administered in infants aged under 14 weeks of age; and
2 No vaccination being administered to children aged 24 weeks or over.

VARICELLA VACCINE [CHICKENPOX VACCINE] – Restricted see terms on the next page

Inj 2000 PFU prefilled syringe plus vial – 0% DV Sep-17 to 2020 ................. 0.00 1 Varilrix
10 Varilrix
Restricted (RS1591)
Initiation – primary vaccinations
*Therapy limited to 1 dose*
Either:
1. Any infant born on or after 1 April 2016; or
2. For previously unvaccinated children turning 11 years old on or after 1 July 2017, who have not previously had a varicella infection (chickenpox).

Initiation – other conditions
*Therapy limited to 2 doses*
Any of the following:
1. Any of the following:
   - for non-immune patients:
     1.1 With chronic liver disease who may in future be candidates for transplantation; or
     1.2 With deteriorating renal function before transplantation; or
     1.3 Prior to solid organ transplant; or
     1.4 Prior to any elective immunosuppression*; or
     1.5 For post exposure prophylaxis who are immune competent inpatients; or
2. For patients at least 2 years after bone marrow transplantation, on advice of their specialist; or
3. For patients at least 6 months after completion of chemotherapy, on advice of their specialist; or
4. For HIV positive patients non immune to varicella with mild or moderate immunosuppression on advice of HIV specialist; or
5. For patients with inborn errors of metabolism at risk of major metabolic decompensation, with no clinical history of varicella; or
6. For household contacts of paediatric patients who are immunocompromised, or undergoing a procedure leading to immune compromise where the household contact has no clinical history of varicella; or
7. For household contacts of adult patients who have no clinical history of varicella and who are severely immunocompromised or undergoing a procedure leading to immune compromise where the household contact has no clinical history of varicella.

Note: * immunosuppression due to steroid or other immunosuppressive therapy must be for a treatment period of greater than 28 days

VARICELLA ZOSTER VACCINE [SHINGLES VACCINE] – Restricted see terms below

Varicella zoster virus (Oka strain) live attenuated vaccine [shingles vaccine] ................................................................. 0.00 1 Zostavax

Restricted (RS1720)
Initiation – people aged 65 years
*Therapy limited to 1 dose*
One dose for all people aged 65 years.

Initiation – people aged between 66 and 80 years
*Therapy limited to 1 dose*
One dose for all people aged between 66 and 80 years inclusive from 1 April 2018 and 31 December 2020.

Diagnostic Agents

TUBERCULIN PPD [MANTOUX] TEST
Inj 5 TU per 0.1 ml, 1 ml vial – 0% DV Jul-17 to 2020 ................................................. 0.00 1 Tubersol
## Optional Pharmaceuticals

**NOTE:**
In addition to the products expressly listed here in Part III: Optional Pharmaceuticals, a range of hospital medical devices are listed in an addendum to Part III which is available at [www.pharmac.govt.nz](http://www.pharmac.govt.nz). The Optional Pharmaceuticals listed in the addendum are deemed to be listed in Part III, and the Rules of the Pharmaceutical Schedule applying to products listed in Part III apply to them.

### BLOOD GLUCOSE DIAGNOSTIC TEST METER

<table>
<thead>
<tr>
<th>Description</th>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 meter with 50 lancets, a lancing device, and 10 diagnostic test strips</td>
<td>$20.00</td>
<td>CareSens N Premier</td>
</tr>
<tr>
<td></td>
<td>$10.00</td>
<td>Caresens N</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Caresens N POP</td>
</tr>
</tbody>
</table>

### BLOOD GLUCOSE DIAGNOSTIC TEST STRIP

<table>
<thead>
<tr>
<th>Description</th>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood glucose test strips</td>
<td>$10.56</td>
<td>CareSens N</td>
</tr>
<tr>
<td>Test strips</td>
<td>$10.56</td>
<td>CareSens PRO</td>
</tr>
</tbody>
</table>

### BLOOD KETONE DIAGNOSTIC TEST STRIP

<table>
<thead>
<tr>
<th>Description</th>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Test strips</td>
<td>$15.50</td>
<td>KetoSens</td>
</tr>
</tbody>
</table>

### DUAL BLOOD GLUCOSE AND BLOOD KETONE DIAGNOSTIC TEST METER

<table>
<thead>
<tr>
<th>Description</th>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Meter with 50 lancets, a lancing device, and 10 blood glucose diagnostic test strips</td>
<td>$20.00</td>
<td>CareSens Dual</td>
</tr>
</tbody>
</table>

### MASK FOR SPACER DEVICE

<table>
<thead>
<tr>
<th>Description</th>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Small</td>
<td>$2.20</td>
<td>e-chamber Mask</td>
</tr>
</tbody>
</table>

### PEAK FLOW METER

<table>
<thead>
<tr>
<th>Description</th>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low Range</td>
<td>$9.54</td>
<td>Mini-Wright AFS Low Range</td>
</tr>
<tr>
<td>Normal Range</td>
<td>$9.54</td>
<td>Mini-Wright Standard</td>
</tr>
</tbody>
</table>

### PREGNANCY TEST - HCG URINE

<table>
<thead>
<tr>
<th>Description</th>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cassette</td>
<td>$12.00</td>
<td>Smith BioMed Rapid Pregnancy Test</td>
</tr>
</tbody>
</table>

### SODIUM NITROPRUSSIDE

<table>
<thead>
<tr>
<th>Description</th>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Test strip</td>
<td>$22.00</td>
<td>Ketostix</td>
</tr>
</tbody>
</table>

### SPACER DEVICE

<table>
<thead>
<tr>
<th>Description</th>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>220 ml (single patient)</td>
<td>$2.95</td>
<td>e-chamber Turbo</td>
</tr>
<tr>
<td>510 ml (single patient)</td>
<td>$5.12</td>
<td>e-chamber La Grande</td>
</tr>
<tr>
<td>800 ml</td>
<td>$6.50</td>
<td>Volumatic</td>
</tr>
</tbody>
</table>
INDEX: Generic Chemicals and Brands

- Symbols -

8-methoxypsoralen ........................................ 56
A -
A-Scabies ........................................... 53
Abacavir sulphate .................................. 86
Abacavir sulphate with lamivudine ............... 86
Abiciximab ........................................ 152
Abristerone acetate .................................. 144
Acarbose .............................................. 8
Accuretic 10 ........................................... 38
Accuretic 20 ........................................... 38
Acetazolamide ....................................... 207
Acetic acid
Extemporaneously Compounded Preparations ...
Genito-Urinary ........................................ 58
Acetic acid with hydroxyquinoline, glycerol and ricinoleic acid ........................................ 58
Acetic acid with propylene glycol ................... 209
Acetylsalicyclic acid ................................ 207
Acetilcisteine ........................................ 210
Acelorovin
Infections ............................................. 89
Sensory .................................................. 203
Acelorovin-Claris .................................... 89
Acid Citrate Dextrose A ................................ 30
Acidev .................................................. 5
Acipimox ............................................... 46
Acitretin .............................................. 56
Aclasta .................................................. 94
Acmctrma .............................................. 185
Actinomycin D ........................................ 129
Adalat 10 .............................................. 43
Adalat Oros .......................................... 43
Adalimumab ......................................... 152
Adapalene ............................................. 53
Adefovir dipivoxil .................................... 88
Adenocor ............................................. 40
Adenosine ............................................. 40
Adenuric ............................................. 99
Adrenaline ............................................ 47
ADT Booster ......................................... 236
Adult diphtheria and tetanus vaccine ............ 236
Advantan ............................................. 55
Advate ................................................ 29
Adynovate ........................................... 29
Aerrane .............................................. 104
Afinitor ............................................... 193
Aflibercept .......................................... 162
Agents Affecting the Renin-Angiotensin System ...
Agents for Parkinsonism and Related Disorders ...
Agents Used in the Treatment of Poisonings ....
Ajmaline .............................................. 40
Alanase ............................................... 195
Albendazole .......................................... 83
Aldurazyme .......................................... 15
Alecsena .............................................. 137
Alectinib ............................................ 137
Alendronate sodium ................................ 94
Alendronate sodium with colecalciferol .......... 94
Alfalcacidol .......................................... 21
Alfamino Junior ...................................... 229
Aftenantil ........................................... 108
Aglucosidase alfa .................................. 13
Alinia ................................................... 84
Allerpro 1 ........................................... 230
Allerpro 2 ........................................... 230
Allersothe ........................................... 196
Allmercap ............................................ 131
Allopurinol .......................................... 98
Alpha tocopheryl ................................... 22
Alpha tocopheryl acetate .......................... 22
Alpha Adrenoceptor Blockers ..................... 39
Alphamox ............................................ 76
Alphamox 125 ....................................... 76
Alphamox 250 ....................................... 76
Alprolix .............................................. 28
Alprostadil hydrochloride .......................... 48
Alteplase ............................................ 33
Alum .................................................. 218
Aluminium chloride ................................ 26
Aluminium hydroxide ................................ 5
Aluminium hydroxide with magnesium hydroxide and simeticone ................................... 5
Amantadine hydrochloride ......................... 103
AmBisome ......................................... 80
Ambrisentan ......................................... 48
Ametheracine
Nervous .............................................. 107
Sensory .............................................. 206
Amikacin ........................................... 72
Amiloride hydrochloride ............................ 44
Amiloride hydrochloride with furosemide .... 44
Amiloride hydrochloride with hydrochlorothiazide ........................................ 44
Aminolevulinic acid hydrochloride .............. 146
Aminophylline ...................................... 201
Amiodarone hydrochloride ......................... 40
Amisulpride ........................................ 117
Amitriptyline ...................................... 110
Amlodipine .......................................... 42
Amorolfine .......................................... 52
Amoxicillin ......................................... 76
Amoxicillin with clavulanic acid ................... 76
Amphotericin B
Alimentary .......................................... 19
Infections ........................................... 80
Amsacrine .......................................... 132
Amyl nitrite .......................................... 210
Anabolic Agents .................................... 62
Anaesthetics ......................................... 104
Anagrelide hydrochloride .......................... 132
Analgesics .......................................... 107
Anastrozole .......................................... 146
Andriol Testocaps ................................... 62
Androderm .......................................... 62
Androgen Agonists and Antagonists ............. 62
Anorl Ellaip .......................................... 197
Antabuse ............................................ 126
Antacids and Antiflatulents ......................... 5
Anti-Infective Agents .............................. 58
Anti-Infective Preparations ......................... 52
Dermatological ..................................... 52
Sensory .............................................. 203
Anti-Inflammatory Preparations ................. 204
Antiacne Preparations ............................. 53
Antiallergy Preparations ......................... 195
Antianaemias ......................................... 24
Antirrhythmics ...................................... 40
Antibacterials ....................................... 72
Anticholinergic Agents ............................ 196
Anticholinesterases ................................ 94
Antidepressants ..................................... 110
Antidiarrhoeals and Intestinal
Anti-Inflammatory Agents ......................... 5
Antiepilepsy Drugs ................................ 112
Antifibrinolytics, Haemostatics and Local Sclerosants ........................................ 26
Antifibriotics ........................................ 197
Antifungals .......................................... 80
Antihypotensives .................................. 41
Antimigraine Preparations ......................... 115
Antimycobacterials ................................ 82
Antinausea and Vertigo Agents .................. 116
Antiparasitics ....................................... 83
Antipruritic Preparations ......................... 53
Antipsychotic Agents .............................. 117
Antiretrovirals ..................................... 85
Antirheumatoid Agents ......................... 94
Antiseptics and Disinfectants .................... 212
Antispasmodics and Other Agents ............ 247
<table>
<thead>
<tr>
<th>Chemical/Brand</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Argireglin [Vasopressin]</td>
<td>71</td>
</tr>
<tr>
<td>Aripiprazole</td>
<td>117</td>
</tr>
<tr>
<td>Aripiprazole Sandoz</td>
<td>117</td>
</tr>
<tr>
<td>Aristocort</td>
<td>56</td>
</tr>
<tr>
<td>Arrow - Clopid</td>
<td>32</td>
</tr>
<tr>
<td>Arrow-Amitriptyline</td>
<td>110</td>
</tr>
<tr>
<td>Arrow-Bendrofluazide</td>
<td>44</td>
</tr>
<tr>
<td>Arrow-Brimonid</td>
<td>208</td>
</tr>
<tr>
<td>Arrow-Calcium</td>
<td>17</td>
</tr>
<tr>
<td>Arrow-Diazepam</td>
<td>120</td>
</tr>
<tr>
<td>Arrow-Fluoxetine</td>
<td>112</td>
</tr>
<tr>
<td>Arrow-Lamotrigine</td>
<td>113</td>
</tr>
<tr>
<td>Arrow-Losartan &amp; Hydrochlorothiazide</td>
<td>39</td>
</tr>
<tr>
<td>Arrow-Morpheine LA</td>
<td>109</td>
</tr>
<tr>
<td>Arrow-Norfloxac</td>
<td>77</td>
</tr>
<tr>
<td>Arrow-Omniadazole</td>
<td>84</td>
</tr>
<tr>
<td>Arrow-Quinapril 10</td>
<td>38</td>
</tr>
<tr>
<td>Arrow-Quinapril 20</td>
<td>38</td>
</tr>
<tr>
<td>Arrow-Quinapril 5</td>
<td>38</td>
</tr>
<tr>
<td>Arrow-Roxithromycin</td>
<td>75</td>
</tr>
<tr>
<td>Arrow-Sertraline</td>
<td>112</td>
</tr>
<tr>
<td>Arrow-Timolol</td>
<td>207</td>
</tr>
<tr>
<td>Arrow-Tolterodine</td>
<td>61</td>
</tr>
<tr>
<td>Arrow-Topiramate</td>
<td>114</td>
</tr>
<tr>
<td>Arrow-Tramadol</td>
<td>110</td>
</tr>
<tr>
<td>Arsenic trioxide</td>
<td>132</td>
</tr>
<tr>
<td>Artemether with lumefantrine</td>
<td>83</td>
</tr>
<tr>
<td>Artesunate</td>
<td>84</td>
</tr>
<tr>
<td>Articaine hydrochloride</td>
<td>105</td>
</tr>
<tr>
<td>Articaine hydrochloride with adrenaline</td>
<td>105</td>
</tr>
<tr>
<td>Asacol</td>
<td>6</td>
</tr>
<tr>
<td>Asamaz</td>
<td>6</td>
</tr>
<tr>
<td>Ascorbic acid</td>
<td></td>
</tr>
<tr>
<td>Alimentary</td>
<td>21</td>
</tr>
<tr>
<td>Extemporaneously Compounded</td>
<td></td>
</tr>
<tr>
<td>Preparations</td>
<td>218</td>
</tr>
<tr>
<td>Aspen Adrenaline</td>
<td>47</td>
</tr>
<tr>
<td>Aspirin</td>
<td></td>
</tr>
<tr>
<td>Blood</td>
<td>31</td>
</tr>
<tr>
<td>Nervous</td>
<td>107</td>
</tr>
<tr>
<td>Asthalin</td>
<td>199</td>
</tr>
<tr>
<td>Atazanavir sulphate</td>
<td>87</td>
</tr>
<tr>
<td>Atenolol</td>
<td>41</td>
</tr>
<tr>
<td>Atenolol-AFT</td>
<td>41</td>
</tr>
<tr>
<td>ATGAM</td>
<td>193</td>
</tr>
<tr>
<td>Ativan</td>
<td>121</td>
</tr>
<tr>
<td>Atomoxetine</td>
<td>123</td>
</tr>
<tr>
<td>Atorvastatin</td>
<td>45</td>
</tr>
<tr>
<td>Atovaquone with proguanil hydrochloride</td>
<td>84</td>
</tr>
<tr>
<td>Atracurium besylate</td>
<td>100</td>
</tr>
<tr>
<td>Atropine sulphate</td>
<td></td>
</tr>
<tr>
<td>Cardiovascular</td>
<td>40</td>
</tr>
<tr>
<td>Sensory</td>
<td>208</td>
</tr>
<tr>
<td>Atripted</td>
<td>208</td>
</tr>
<tr>
<td>Aubagio</td>
<td>121</td>
</tr>
<tr>
<td>Augmentin</td>
<td>76</td>
</tr>
<tr>
<td>Auroxir</td>
<td>111</td>
</tr>
<tr>
<td>Avelox</td>
<td>77</td>
</tr>
<tr>
<td>Avelox IV 400</td>
<td>77</td>
</tr>
<tr>
<td>Avonex</td>
<td>122</td>
</tr>
<tr>
<td>Avonex Pen</td>
<td>122</td>
</tr>
<tr>
<td>Azactidine</td>
<td>130</td>
</tr>
<tr>
<td>Azactidine Dr Reddy's</td>
<td>130</td>
</tr>
<tr>
<td>Azatam</td>
<td>78</td>
</tr>
<tr>
<td>Azamun</td>
<td>193</td>
</tr>
<tr>
<td>Azathiotriprine</td>
<td>193</td>
</tr>
<tr>
<td>Azithromycin</td>
<td>74</td>
</tr>
<tr>
<td>Azol</td>
<td>65</td>
</tr>
<tr>
<td>AZT</td>
<td>86</td>
</tr>
<tr>
<td>Aztreonam</td>
<td>78</td>
</tr>
<tr>
<td>B -</td>
<td></td>
</tr>
<tr>
<td>Bacillus calmaete-guerin (BCG)</td>
<td>193</td>
</tr>
<tr>
<td>Bacillus calmaete-guerin vaccine</td>
<td>237</td>
</tr>
<tr>
<td>Baclofen</td>
<td>100</td>
</tr>
<tr>
<td>Batural and Viral Vaccines</td>
<td>236</td>
</tr>
<tr>
<td>Batural Vaccines</td>
<td>236</td>
</tr>
<tr>
<td>Balanced Salt Solution</td>
<td>206</td>
</tr>
<tr>
<td>Barium sulphate</td>
<td>213</td>
</tr>
<tr>
<td>Barium sulphate with sodium bicarbonate</td>
<td>213</td>
</tr>
<tr>
<td>Barrier Creams and Emollients</td>
<td>53</td>
</tr>
<tr>
<td>Basilihimab</td>
<td>163</td>
</tr>
<tr>
<td>BCG Vaccine</td>
<td>237</td>
</tr>
<tr>
<td>BD PosiFlush</td>
<td>36</td>
</tr>
<tr>
<td>Beclazone 100</td>
<td>199</td>
</tr>
<tr>
<td>Beclazone 250</td>
<td>199</td>
</tr>
<tr>
<td>Beclazone 50</td>
<td>199</td>
</tr>
<tr>
<td>Beclomethasone dipropionate</td>
<td>195, 199</td>
</tr>
<tr>
<td>Bee venom</td>
<td>195</td>
</tr>
<tr>
<td>Bendamustine hydrochloride</td>
<td>128</td>
</tr>
<tr>
<td>Bendrofluazide</td>
<td>44</td>
</tr>
<tr>
<td>Bendrofluomethezide [Bendrofluazide]</td>
<td>44</td>
</tr>
<tr>
<td>Benzathine benzylpenicillin</td>
<td>76</td>
</tr>
<tr>
<td>Benzatropine mesylate</td>
<td>103</td>
</tr>
<tr>
<td>Benzbramor AL 100</td>
<td>99</td>
</tr>
<tr>
<td>Benzbramorone</td>
<td>99</td>
</tr>
<tr>
<td>Benzozone</td>
<td>105</td>
</tr>
<tr>
<td>Benzocaine with tetracaine hydrochloride</td>
<td>105</td>
</tr>
<tr>
<td>Benzoiz</td>
<td>218</td>
</tr>
<tr>
<td>Benzoil peroxide</td>
<td>53</td>
</tr>
<tr>
<td>Benztop</td>
<td>103</td>
</tr>
<tr>
<td>Benzyadime hydrochloride</td>
<td>19</td>
</tr>
<tr>
<td>Benzyadime hydrochloride with cetpyridinium chloride</td>
<td>19</td>
</tr>
<tr>
<td>Benzylenolicin sodium</td>
<td>Penicillin</td>
</tr>
<tr>
<td>INDEX: Generic Chemicals and Brands</td>
<td></td>
</tr>
<tr>
<td>------------------------------------</td>
<td></td>
</tr>
<tr>
<td><strong>G</strong> ........................................ 76</td>
<td></td>
</tr>
<tr>
<td>Beractant .................................. 201</td>
<td></td>
</tr>
<tr>
<td>Beta Cream .................................. 55</td>
<td></td>
</tr>
<tr>
<td>Beta Ointment ................................ 55</td>
<td></td>
</tr>
<tr>
<td>Beta Scalp ................................... 56</td>
<td></td>
</tr>
<tr>
<td>Beta-Adrenergic Agonists ............. 199</td>
<td></td>
</tr>
<tr>
<td>Beta-Adrenergic Blockers ............. 41</td>
<td></td>
</tr>
<tr>
<td>Betadine ..................................... 212</td>
<td></td>
</tr>
<tr>
<td>Betadine Skin Prep. ...................... 212</td>
<td></td>
</tr>
<tr>
<td>Betahistine dihydrochloride ........ 116</td>
<td></td>
</tr>
<tr>
<td>Betaine ....................................... 14</td>
<td></td>
</tr>
<tr>
<td>Betaloc CR .................................. 42</td>
<td></td>
</tr>
<tr>
<td>Betamethasone ............................ 63</td>
<td></td>
</tr>
<tr>
<td>Betamethasone dipropionate .......... 55</td>
<td></td>
</tr>
<tr>
<td>Betamethasone dipropionate with calcium chloride ............... 56</td>
<td></td>
</tr>
<tr>
<td>Betamethasone sodium phosphate with betamethasone acetate ...... 63</td>
<td></td>
</tr>
<tr>
<td>Betamethasone valerate ............... 55-56</td>
<td></td>
</tr>
<tr>
<td>Betamethasone valerate with cliroquinol ...................... 56</td>
<td></td>
</tr>
<tr>
<td>Betamethasone valerate with fusidate [Fusidic acid] ........... 56</td>
<td></td>
</tr>
<tr>
<td>Betaxolol ..................................... 207</td>
<td></td>
</tr>
<tr>
<td>Betnovate .................................... 55</td>
<td></td>
</tr>
<tr>
<td>Betoptic ...................................... 207</td>
<td></td>
</tr>
<tr>
<td>Betoptic S .................................... 207</td>
<td></td>
</tr>
<tr>
<td>Bevacizumab ................................ 163</td>
<td></td>
</tr>
<tr>
<td>Bezafibrate .................................. 45</td>
<td></td>
</tr>
<tr>
<td>Bezalip ....................................... 45</td>
<td></td>
</tr>
<tr>
<td>Bezalip Retard .............................. 45</td>
<td></td>
</tr>
<tr>
<td>Bicalutamide ................................ 144</td>
<td></td>
</tr>
<tr>
<td>Bicillin LA .................................. 76</td>
<td></td>
</tr>
<tr>
<td>BiCNU ......................................... 129</td>
<td></td>
</tr>
<tr>
<td>BiCNU Heritage ............................ 129</td>
<td></td>
</tr>
<tr>
<td>Bile and Liver Therapy ................ 8</td>
<td></td>
</tr>
<tr>
<td>Biliscopin .................................... 214</td>
<td></td>
</tr>
<tr>
<td>Bimatoprost .................................. 208</td>
<td></td>
</tr>
<tr>
<td>Bimatoprost Multichem .................. 208</td>
<td></td>
</tr>
<tr>
<td>Binarex ....................................... 144</td>
<td></td>
</tr>
<tr>
<td>Binocrit ...................................... 24</td>
<td></td>
</tr>
<tr>
<td>Biodone ........................................ 109</td>
<td></td>
</tr>
<tr>
<td>Biodone Extra Forte ..................... 109</td>
<td></td>
</tr>
<tr>
<td>Biodone Forte ............................... 109</td>
<td></td>
</tr>
<tr>
<td>Biotin ......................................... 14</td>
<td></td>
</tr>
<tr>
<td>Bisacodyl .................................... 13</td>
<td></td>
</tr>
<tr>
<td>Bismuth subgallate ...................... 218</td>
<td></td>
</tr>
<tr>
<td>Bismuth subnitrate and iodoform paraffin ...................... 216</td>
<td></td>
</tr>
<tr>
<td>Bisoprolol fumarate ..................... 41</td>
<td></td>
</tr>
<tr>
<td>Bivalirudin .................................. 30</td>
<td></td>
</tr>
<tr>
<td>Bleomycin sulphate ....................... 129</td>
<td></td>
</tr>
<tr>
<td>Blood glucose diagnostic test meter ........................................ 246</td>
<td></td>
</tr>
<tr>
<td>Blood glucose diagnostic test strip ........................................... 246</td>
<td></td>
</tr>
<tr>
<td>Blood ketone diagnostic test strip ........................................... 246</td>
<td></td>
</tr>
<tr>
<td>Bonney’s blue dye ......................... 215</td>
<td></td>
</tr>
<tr>
<td>Boostrix ...................................... 237</td>
<td></td>
</tr>
<tr>
<td>Boric acid .................................... 218</td>
<td></td>
</tr>
<tr>
<td>Bortezomib ................................... 132</td>
<td></td>
</tr>
<tr>
<td>Bosantan ..................................... 48</td>
<td></td>
</tr>
<tr>
<td>Bosantan Dr Reddy’s ..................... 48</td>
<td></td>
</tr>
<tr>
<td>Bosvate ....................................... 41</td>
<td></td>
</tr>
<tr>
<td>Botox .......................................... 100</td>
<td></td>
</tr>
<tr>
<td>Botulism antitoxin ....................... 210</td>
<td></td>
</tr>
<tr>
<td>Bplex .......................................... 21</td>
<td></td>
</tr>
<tr>
<td>Bree Elipta ................................... 200</td>
<td></td>
</tr>
<tr>
<td>Brevis 1/28 .................................... 58</td>
<td></td>
</tr>
<tr>
<td>Bridion ....................................... 101</td>
<td></td>
</tr>
<tr>
<td>Brilinta ...................................... 32</td>
<td></td>
</tr>
<tr>
<td>Brimonidine tartrate ..................... 208</td>
<td></td>
</tr>
<tr>
<td>Brimonidine tartrate with timolol .............. 208</td>
<td></td>
</tr>
<tr>
<td>Brinol .......................................... 130</td>
<td></td>
</tr>
<tr>
<td>Brinzolamide ................................. 207</td>
<td></td>
</tr>
<tr>
<td>Bromocriptine ................................ 103</td>
<td></td>
</tr>
<tr>
<td>Brufen SR .................................... 101</td>
<td></td>
</tr>
<tr>
<td>Budesonide .................................. 5</td>
<td></td>
</tr>
<tr>
<td>Budesonide with efomorol .............. 200</td>
<td></td>
</tr>
<tr>
<td>Burmenamide ................................ 44</td>
<td></td>
</tr>
<tr>
<td>Bufufen ....................................... 106</td>
<td></td>
</tr>
<tr>
<td>Bupivaclaine hydrochloride ............ 105</td>
<td></td>
</tr>
<tr>
<td>Bupivaclaine hydrochloride with adrenaline .......... 105</td>
<td></td>
</tr>
<tr>
<td>Bupivaclaine hydrochloride with fentanyl ............. 106</td>
<td></td>
</tr>
<tr>
<td>Bupivaclaine hydrochloride with glucose ................... 106</td>
<td></td>
</tr>
<tr>
<td>Buprenorphine Naloxone BNM .......... 126</td>
<td></td>
</tr>
<tr>
<td>Buprenorphine with naloxone .......... 126</td>
<td></td>
</tr>
<tr>
<td>Bupropion hydrochloride .............. 126</td>
<td></td>
</tr>
<tr>
<td>Burinex ....................................... 44</td>
<td></td>
</tr>
<tr>
<td>Buscopan ..................................... 7</td>
<td></td>
</tr>
<tr>
<td>Buserelin .................................... 66</td>
<td></td>
</tr>
<tr>
<td>Buspirone hydrochloride .............. 120</td>
<td></td>
</tr>
<tr>
<td>Busulan ..................................... 129</td>
<td></td>
</tr>
<tr>
<td>- C - .................................................</td>
<td></td>
</tr>
</tbody>
</table>
INDEX: Generic Chemicals and Brands

Ceftaroline fosamil ........................................ 74
Ceftazidime ........................................ 73
Ceftazidime Mylan .................................. 73
Ceftriaxone ........................................ 73
Ceftriaxone-AFT .................................. 73
Cefuroxime ........................................ 73
Cefuroxime Actavis .................................. 73
Celecoxib ........................................ 101
Celecoxib Pfizer .................................. 101
Celiprolol .......................................... 41
CellCept ........................................... 194
Celol .................................................. 41
Centrally-Acting Agents ...................... 43
Cephalexin ABM ................................ 73
Cetirizine hydrochloride ......................... 196
Cetomacrogol ........................................ 54
Cetomacrogol with glycerol ..................... 54
Cetritode ............................................ 218
Cetuximab .......................................... 164
Charcoal ............................................. 211
Chemotherapeutic Agents ..................... 128
Chickenpox vaccine ............................... 244
Chlorambucil ...................................... 129
Chloral hydrate ..................................... 122
Chlorhexidine gluconate .......................... 212
Chlorhexidine gluconate Alimentary .... 19
Extemporaneously Compounded
Preparations ....................................... 218
Genito-Urinary ..................................... 58
Chlorhexidine with cetirizine ................. 212, 215
Chlorhexidine with ethanol .................. 212
Chlorform ........................................... 218
Chloroquine phosphate ......................... 84
Chlorothiazide .................................... 45
Chlorpheniramine maleate ..................... 196
Chlorpromazine hydrochloride .............. 117
Chlorsig ............................................. 203
Chlophazol [Chlophazol] ....................... 45
Chlorthalidone .................................... 45
Choice Load 375 .................................. 59
Choice TT380 Short ................................ 59
Choice TT380 Standard ......................... 59
Cholestyramine ................................... 45
Choline salicylate with cetalconium chloride .. 19
Choriogonadotropin alfa ....................... 66
Ciclopirox olamine ................................ 52
Ciclosporin ....................................... 146
Cidofovir ......................................... 89
Cilazapril ........................................... 38
Cilazapril with hydrochlorothiazide ....... 38
Cilicaine ........................................... 76
Cilicaine VK ...................................... 76
Cimetidine .......................................... 7
Cinacalcet ......................................... 62
Cinchoaine hydrochloride with hydrocortisone ... 6
Ciprofloxacin ..................................... 77
Ciprofloxacin Teva ................................ 203
Ciprofloxacin with hydrocortisone ....... 203
Ciproxin HC Otic ................................ 203
Circadin ............................................ 51
Clinicians Multivit & Mineral
Boost .................................................. 20
Clinicians Renal Vit. ............................. 20
Clonazepam ........................................ 112
Clonidine .......................................... 43
Clonidine BNM ................................... 43
Clonidine hydrochloride ....................... 43
Clomipramine hydrochloride ............... 110
Clomifene citrate ................................ 65
Colchicine ........................................... 82
Colistin sulphometh [Colestimethate] ....... 78
Colistin-Link ..................................... 78
Colloidial bismuth subcitrate ............... 8
Colofac ............................................. 7
Colony-Stimulating Factors ................. 33
Coloxyl ............................................... 12
Compound electrolytes ....................... 34, 36
Compound electrolytes with glucose
[Dextrose] ........................................... 34, 36
Compound hydroxybenzoate .......... 218
Compound sodium lactate
[Hartmann's solution] ......................... 34
Concerta ............................................ 124
Condylone .......................................... 57
Contraceptives ................................... 58
Contrast Media ................................... 213
Copaxone .......................................... 122
Cordarone-X ...................................... 40
Corticosteroids .................................... 55
Dermatological .................................... 55
Hormone Preparations ....................... 63
Corticotrerin (ovine) ......................... 66
Cosentynx ......................................... 183
Cosmegan .......................................... 129
Cough Suppressants ......................... 199
Creon ............................................... 11
Creon 10000 ...................................... 11
Creon 25000 ..................................... 11
Crotamiton ........................................ 53
Crystaderm ........................................ 52
CT Plus+ .......................................... 213
Clove oil ........................................... 218
Clozapine .......................................... 118
Clozaril ............................................. 118
Clustran ............................................ 115
Co-trimoxazole ................................... 79
Coal tar ............................................. 218
Coal tar with salicylic acid and sulphur .... 56
Cocaine hydrochloride ...................... 106
Cocaine hydrochloride with adrenaline ... 106
Codeine phosphate ............................. 218
Extemporaneously Compounded Preparations ........................................... 18
Nervous ........................................... 108
Cogentin ............................................ 103
Colaspase [L-asparaginase] ................. 133
Colchicine .......................................... 99
Colecalciferol ..................................... 22
Colestimethate ................................... 78
Colestipol hydrochloride ................. 45
Colgout ............................................. 99
Colifoam ........................................... 6
Colistin sulphomethate ........................... 78
Contraceptives ................................... 58
Contrast Media ................................... 213
Copaxone .......................................... 122
Cordarone-X ...................................... 40
Corticosteroids .................................... 55
Dermatological .................................... 55
Hormone Preparations ....................... 63
Corticotrerin (ovine) ......................... 66
Cosentynx ......................................... 183
Cosmegan .......................................... 129
Cough Suppressants ......................... 199
Creon ............................................... 11
Creon 10000 ...................................... 11
Creon 25000 ..................................... 11
Crotamiton ........................................ 53
Crystaderm ........................................ 52
CT Plus+ .......................................... 213
INDEX: Generic Chemicals and Brands

DBL Gentamicin.................................
DBL Ergometrine................................
DBL Docetaxel..................................
DBL Cefotaxime.................................
DBL Pethidine Hydrochloride..............
DBL Rocuronium Bromide...................
DBL Vinristine Sulfate......................
De-Worm........................................
Decongestants................................
Antiallergs...................................
Decozol...........................................
Deferasirox...................................
Defibrotide....................................
Definity.........................................
Demeclocycline hydrochloride...........
Denosumab.....................................
Deolate.........................................
Deoxycoformycin.............................
Depo-Medrol...................................
Depo-Provera..................................
Depo-Testosterone...........................
Deprim...........................................
DermAssist.....................................
Dermal...........................................
Desferrioxamine mesilate..................
Desflurane.....................................
Desmopressin acetate........................
Desmopressin-PH&T...........................
Devatis.........................................
Dexamethasone............................... 63
Hormone Preparations...................... 204
Dexamethasone phosphate...................
Dexamethasone with framycetin and
gramicidin......................................
Dexamethasone with neomycin
sulphate and polymyxin B sulphate...........
Dexamethasone with
tobramycin.................................... 204
Dexemafetamine sulfate.....................
Dexametadetomide...........................
Dexamethone...................................
Dexrazoxane................................. 143
Dextrose
Alimentary...................................... 9
Blood............................................ 34
Extemporaneously Compounded
Preparations................................ 218
Dextrose with sodium citrate and
citric acid [Acid Citrate Dextrose
A].................................................. 30
DHC Continus.................................. 108
Diabetes........................................ 8
Diacomit....................................... 114
Diagnostic Agents...........................
Vaccines....................................... 245
Various....................................... 214
Diagnostic and Surgical Preparations...
Diamide Relief...................................
Diamox.......................................... 207
Diatrizoate meglumine with sodium
amidotrizoate................................. 213
Diatrizoate sodium............................ 213
Alimentary..................................... 9
Cardiovascular............................... 48
Dichlorobenzyl alcohol with
amylnetacresol............................... 19
Diclofenac Sandoz............................ 101
Diclofenac sodium............................
Musculoskeletal.............................. 101
Sensory........................................ 205
Dicobalt edetate.............................. 211
Diflucan........................................ 80
Diflucortolone valerate..................... 55
Digestives Including Enzymes............ 11
Digoxin......................................... 40
Diphenoxylate hydrochloride with
atropine sulphate........................... 5
Diphtheria antitoxin.......................... 210
Diphtheria, tetanus and pertussis
vaccine.......................................... 237
Diphtheria, tetanus, pertussis and
hepatitis B and haemophilus
influenzae type B vaccine.................. 236
Dipyridamole................................. 32
Disodium edetate............................ 207
Disodium hydrogen phosphate with
sodium dihydrogen phosphate............. 218
Disopyramide phosphate.................... 40
Disulfiram..................................... 126
INDEX: Generic Chemicals and Brands

Dithranol........................................ 218
Diuretics........................................ 44
Dobutamine........................................ 47
Dobutamine-hameln.......................... 47
Docetaxel.......................................... 143
Docusate sodium............................... 12
Alimentary........................................ 12
Sensory........................................... 209
Docusate sodium with sennosides........ 12
Dolutegravir....................................... 88
Domperidone...................................... 116
Donepezil hydrochloride.................... 125
Donepezil-Rex.................................... 125
Dopamine hydrochloride..................... 47
Doxpress.......................................... 111
Domase alpha..................................... 201
Dortimopt.......................................... 207
Dorzolamide...................................... 207
Dorzolamide with timolol.................... 207
Dostinex.......................................... 65
Dosulepin [Dothiepin] hydrochloride..... 111
Dosulepin Mylan.................................. 111
Dotarem........................................... 214
Dothiepin......................................... 111
Doxapram.......................................... 202
Doxazosin.......................................... 39
Doxepin hydrochloride....................... 111
Doxine............................................. 78
Doxorubicin Ebewe.............................. 129
Doxorubicin hydrochloride.................. 129
Doxycline.......................................... 78
DP Loh HC......................................... 55
DP-Allopurinol.................................... 98
Dr Reddy’s Omeprazole...................... 8
Droletan.......................................... 116
Droperidol......................................... 116
Droperidol Panpharma....................... 116
Drugs Affecting Bone Metabolism........ 94
Dual blood glucose and blood ketone
diagnostic test meter......................... 246
Duolin.............................................. 196
Duovisc............................................ 206
Duride............................................. 46
Dynastat.......................................... 102
Dysport............................................ 100
- E -
e-chamber La Grande........................... 246
e-chamber Mask.................................. 246
e-chamber Turbo.................................. 246
E-Mycin............................................ 75
E-Z-Cat Dry....................................... 213
E-Z-Gas II......................................... 213
E-Z-Paste.......................................... 213
Econazole nitrate.............................. 52
Edrophonium chloride....................... 94
Efavirenz......................................... 85
Efavirenz with emtricitabine and
tenofovir disoproxil......................... 86
Effient.............................................. 32
Efomoterol fumarate......................... 200
Efomoterol fumarate dihydrate........... 200
Efrenonacog alfa [Recombinant
factor IX].......................................... 28
Efudix.............................................. 57
Elaprase............................................ 15
Elecare (Unflavoured)......................... 229
Elecare (Vanilla)............................... 229
Elecare LCP (Unflavoured).................. 229
Electral............................................ 36
Electrolytes..................................... 217
Eleyso............................................. 17
Elocon............................................. 55
Elocon Alcohol Free........................... 55
Eltrombopag..................................... 26
Emend Tri-Pack.................................. 116
EMLA............................................... 107
Emtricitabine..................................... 86
Emtricitabine with tenofovir
disoproxi.......................................... 89
Emtriva........................................... 86
Emulsifying ointment......................... 54
Enalapril maleate............................... 38
Enbrel............................................. 147
Endocrine Therapy............................. 144
Endoxan.......................................... 129
Enerlyte.......................................... 36
Engerix-B........................................ 241
Enliax XR......................................... 111
Enoxaparin sodium................----------- 31
Ensure (Chocolate)............................. 235
Ensure (Vanilla)............................... 235
Ensure Plus (Banana)......................... 235
Ensure Plus (Chocolate)..................... 235
Ensure Plus (Fruit of the
Forest).............................................. 235
Ensure Plus (Vanilla)......................... 235
Ensure Plus HN................................. 234
Ensure Plus HN RTH........................... 234
Entacapone...................................... 103
Entapone.......................................... 103
Entecavir......................................... 88
Entecavir Sandoz............................... 88
Entresto 24/26................................... 39
Entresto 49/51................................... 39
Entresto 97/103................................. 39
Enzymes.......................................... 98
Ephedrine........................................ 47
Eplim IV.......................................... 114
Epirubicin Ebewe.............................. 129
Epirubicin hydrochloride............... 129
Eplerenone........................................ 44
Epoetin alfa....................................... 24
Epoetin beta..................................... 25
Epoprostenol..................................... 51
Eptacog alfa [Recombinant factor
VIII]................................................. 28
Eptifibatide........................................ 32
Eribulin............................................ 164
Ergometrine maleate.......................... 59
Ergotamine tartrate with
caffeine.......................................... 115
Erlotinib.......................................... 138
Ertapenem.......................................... 72
Erythromycin IV.................................. 75
Erythromycin (as ethylsuccinate)........ 75
Erythromycin (as lactobionate).......... 75
Erythromycin (as stearate)................ 75
Esbrief............................................ 198
Escitalopram..................................... 112
Escitalopram-Aptex............................ 112
Esmolol hydrochloride....................... 41
Estradot.......................................... 64
Etanercept........................................ 147
Ethambutol hydrochloride.................. 82
Ethanol............................................ 210
Ethanol with glucose......................... 210
Ethanol, dehydrated......................... 210
Ethics Aspirin.................................... 107
Ethics Aspirin EC............................... 31
Ethics Enalapril................................. 38
Ethics Lisinopril................................. 38
Ethinylolestradiol.............................. 65
Ethinylolestradiol with
desogestrel....................................... 58
Ethinylolestradiol with
levonorgestrel................................. 58
Ethinylolestradiol with
norethisterone................................. 58
Ethosuximide..................................... 113
Ethyl chloride................................. 106
Etomidate........................................ 104
Etophos.......................................... 133
Etoside........................................... 133
Etoside (as phosphate)....................... 133
Etoricoxib........................................ 101
Etravirine......................................... 85
Everet............................................. 113
Everolimus....................................... 193
Evista............................................ 97
Exelon............................................ 125
Exemestane....................................... 146
Exjade............................................ 211
Extemporaneously Compounded
Preparations................................. 218
<table>
<thead>
<tr>
<th>Chemical Name</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Flucytosine</td>
<td>82</td>
</tr>
<tr>
<td>Fludara Oral</td>
<td>130</td>
</tr>
<tr>
<td>Fludarabine Ebewe</td>
<td>130</td>
</tr>
<tr>
<td>Fludarabine phosphate</td>
<td>130</td>
</tr>
<tr>
<td>Fludrocortisone acetate</td>
<td>63</td>
</tr>
<tr>
<td>Fluids and Electrolytes</td>
<td>34</td>
</tr>
<tr>
<td>Flumazenil</td>
<td>210</td>
</tr>
<tr>
<td>Flumetasone pivatele with clioquinol</td>
<td>204</td>
</tr>
<tr>
<td>Fluocortolone caprote with fluorotolone pivatele and cinchocaine</td>
<td>7</td>
</tr>
<tr>
<td>Fluorouracil sodium</td>
<td>130</td>
</tr>
<tr>
<td>Fluorouracil Ebewe</td>
<td>130</td>
</tr>
<tr>
<td>Fluoxetine hydrochloride</td>
<td>206</td>
</tr>
<tr>
<td>Fluorescein sodium</td>
<td>205</td>
</tr>
<tr>
<td>Fluorescein sodium with lignocaine hydrochloride</td>
<td>206</td>
</tr>
<tr>
<td>Fluoconazole</td>
<td>80</td>
</tr>
<tr>
<td>Fusidic acid</td>
<td>52, 56</td>
</tr>
<tr>
<td>Gac엘</td>
<td>108</td>
</tr>
<tr>
<td>Gadobenica acid</td>
<td>214</td>
</tr>
<tr>
<td>Gadobutrol</td>
<td>214</td>
</tr>
<tr>
<td>Gadodiamide</td>
<td>214</td>
</tr>
<tr>
<td>Gadoterica acid</td>
<td>214</td>
</tr>
<tr>
<td>Gadolast 1.0</td>
<td>214</td>
</tr>
<tr>
<td>Gadoxetate disodium</td>
<td>214</td>
</tr>
<tr>
<td>Galsulfase</td>
<td>14</td>
</tr>
<tr>
<td>Galumeta</td>
<td>10</td>
</tr>
<tr>
<td>Galvus</td>
<td>10</td>
</tr>
<tr>
<td>Ganciclovir</td>
<td>89</td>
</tr>
<tr>
<td>Gardasil 9</td>
<td>242</td>
</tr>
<tr>
<td>Gardodol</td>
<td>8</td>
</tr>
<tr>
<td>Gastrografin</td>
<td>213</td>
</tr>
<tr>
<td>Gazvy</td>
<td>171</td>
</tr>
<tr>
<td>Gelfitin</td>
<td>138</td>
</tr>
<tr>
<td>Gelatine, suscinylated</td>
<td>37</td>
</tr>
<tr>
<td>Gelofusine</td>
<td>37</td>
</tr>
<tr>
<td>Gemcitabine</td>
<td>131</td>
</tr>
<tr>
<td>Gemcitabine Ebewe</td>
<td>131</td>
</tr>
<tr>
<td>Gemfibrozil</td>
<td>45</td>
</tr>
<tr>
<td>Genoptic</td>
<td>203</td>
</tr>
<tr>
<td>Gentamicin sulphate</td>
<td>72</td>
</tr>
<tr>
<td>Gfisidic acid</td>
<td>52, 56</td>
</tr>
<tr>
<td>Dermatological</td>
<td>52, 56</td>
</tr>
<tr>
<td>Infections</td>
<td>79</td>
</tr>
<tr>
<td>Sensory</td>
<td>203</td>
</tr>
<tr>
<td>Gestrinone</td>
<td>65</td>
</tr>
<tr>
<td>Gilenya</td>
<td>121</td>
</tr>
<tr>
<td>Ginet</td>
<td>58</td>
</tr>
<tr>
<td>Glatiramer acetate</td>
<td>122</td>
</tr>
<tr>
<td>Glaucoma Preparations</td>
<td>207</td>
</tr>
<tr>
<td>Glucal Chevrolet</td>
<td>88</td>
</tr>
<tr>
<td>Glibenclamide</td>
<td>10</td>
</tr>
<tr>
<td>Gilclazide</td>
<td>10</td>
</tr>
<tr>
<td>Gilolan</td>
<td>146</td>
</tr>
<tr>
<td>Glipizide</td>
<td>10</td>
</tr>
<tr>
<td>Glivec</td>
<td>139</td>
</tr>
<tr>
<td>Glizide</td>
<td>10</td>
</tr>
<tr>
<td>Glucagen Hypokit</td>
<td>9</td>
</tr>
<tr>
<td>Glucagone hydrochloride</td>
<td>9</td>
</tr>
<tr>
<td>Glucan Select (Vanilla)</td>
<td>227</td>
</tr>
<tr>
<td>Glucan Select RTH (Vanilla)</td>
<td>227</td>
</tr>
<tr>
<td>Glucobay</td>
<td>8</td>
</tr>
<tr>
<td>Glucose [Dextrose]</td>
<td>9</td>
</tr>
<tr>
<td>Glucose with potassium chloride</td>
<td>35</td>
</tr>
<tr>
<td>Glucose with potassium chloride and</td>
<td></td>
</tr>
<tr>
<td>INDEX: Generic Chemicals and Brands</td>
<td></td>
</tr>
<tr>
<td>-------------------------------------</td>
<td></td>
</tr>
<tr>
<td>Sodium chloride .......................... 35</td>
<td></td>
</tr>
<tr>
<td>Glucose with sodium chloride .......... 35</td>
<td></td>
</tr>
<tr>
<td>Glucose with sucrose and fructose ....... 9</td>
<td></td>
</tr>
<tr>
<td>Glycerin with sodium saccharin ........ 219</td>
<td></td>
</tr>
<tr>
<td>Glycerin with sucrose .................. 219</td>
<td></td>
</tr>
<tr>
<td>Glycerol</td>
<td></td>
</tr>
<tr>
<td>Alimentary ............................... 12</td>
<td></td>
</tr>
<tr>
<td>Extemporaneously Compound Preparations 219</td>
<td></td>
</tr>
<tr>
<td>Glycerol with paraffin ................. 54</td>
<td></td>
</tr>
<tr>
<td>Glyceryl trinitrate</td>
<td></td>
</tr>
<tr>
<td>Alimentary ................................... 7</td>
<td></td>
</tr>
<tr>
<td>Cardiovascular............................ 46</td>
<td></td>
</tr>
<tr>
<td>Glycine...................................... 215</td>
<td></td>
</tr>
<tr>
<td>Glycopyrronium............................ 197</td>
<td></td>
</tr>
<tr>
<td>Glycopyrronium bromide............... ... 7</td>
<td></td>
</tr>
<tr>
<td>Glycopyrronium with indicaterol ....... 197</td>
<td></td>
</tr>
<tr>
<td>Glypressin.................................... 71</td>
<td></td>
</tr>
<tr>
<td>Glytrin....................................... 46</td>
<td></td>
</tr>
<tr>
<td>Gonadorelin................................... 66</td>
<td></td>
</tr>
<tr>
<td>Goserelin..................................... 66</td>
<td></td>
</tr>
<tr>
<td>Granisetron.................................. 116</td>
<td></td>
</tr>
<tr>
<td>- H -</td>
<td></td>
</tr>
<tr>
<td>Habitol....................................... 127</td>
<td></td>
</tr>
<tr>
<td>Habitol (Fruit)............................. 127</td>
<td></td>
</tr>
<tr>
<td>Habitol (Mint).................. .................. 127</td>
<td></td>
</tr>
<tr>
<td>Haem arginate.............................. 15</td>
<td></td>
</tr>
<tr>
<td>Haemophilia influenza type B vaccine ........................................ 237</td>
<td></td>
</tr>
<tr>
<td>Haldol......................................... 119</td>
<td></td>
</tr>
<tr>
<td>Haldol Concentrate........................ 119</td>
<td></td>
</tr>
<tr>
<td>Haloperidol................................. 118</td>
<td></td>
</tr>
<tr>
<td>Haloperidol decanoate.................... 119</td>
<td></td>
</tr>
<tr>
<td>Hartmann's solution..................... 34</td>
<td></td>
</tr>
<tr>
<td>Harvoni....................................... 88</td>
<td></td>
</tr>
<tr>
<td>Havix.......................................... 240</td>
<td></td>
</tr>
<tr>
<td>Havix Junior.................................. 240</td>
<td></td>
</tr>
<tr>
<td>HBvaxPRO...................................... 240–241</td>
<td></td>
</tr>
<tr>
<td>Healon......................................... 206</td>
<td></td>
</tr>
<tr>
<td>Healon 5........................................ 206</td>
<td></td>
</tr>
<tr>
<td>Healon GV...................................... 206</td>
<td></td>
</tr>
<tr>
<td>healthE Calamine Aqueous Cream BP ............... 53</td>
<td></td>
</tr>
<tr>
<td>healthE Dimethicone 10% .......... ........ 53</td>
<td></td>
</tr>
<tr>
<td>healthE Dimethicone 4% Lotion .......... 52</td>
<td></td>
</tr>
<tr>
<td>healthE Dimethicone 5% .................... 53</td>
<td></td>
</tr>
<tr>
<td>healthE Fatty Cream ....................... 54</td>
<td></td>
</tr>
<tr>
<td>healthE Glycerol BP Liquid ............. 219</td>
<td></td>
</tr>
<tr>
<td>healthE Urea Cream ....................... 55</td>
<td></td>
</tr>
<tr>
<td>Heparin sodium.............................. 31</td>
<td></td>
</tr>
<tr>
<td>Heparinised saline...................... 31</td>
<td></td>
</tr>
<tr>
<td>Heparon Junior.............................. 228</td>
<td></td>
</tr>
<tr>
<td>Hepatitis A vaccine ..................... 240</td>
<td></td>
</tr>
<tr>
<td>Hepatitis B recombinant ................ 240</td>
<td></td>
</tr>
<tr>
<td>vaccine .......................................... 240</td>
<td></td>
</tr>
<tr>
<td>Hepsera........................................ 88</td>
<td></td>
</tr>
<tr>
<td>Herceptin..................................... 188</td>
<td></td>
</tr>
<tr>
<td>Hiberix........................................ 237</td>
<td></td>
</tr>
<tr>
<td>Hiprex.......................................... 79</td>
<td></td>
</tr>
<tr>
<td>Histaclear.................................... 196</td>
<td></td>
</tr>
<tr>
<td>Histamine acid phosphate............... 215</td>
<td></td>
</tr>
<tr>
<td>Holoxan....................................... 129</td>
<td></td>
</tr>
<tr>
<td>Hormone Replacement Therapy .......... 64</td>
<td></td>
</tr>
<tr>
<td>HPV........................................... 242</td>
<td></td>
</tr>
<tr>
<td>Humalog Mix 25............................. 9</td>
<td></td>
</tr>
<tr>
<td>Humalog Mix 50.............................. 9</td>
<td></td>
</tr>
<tr>
<td>Human papillomavirus (6, 11, 16, 18, 206</td>
<td></td>
</tr>
<tr>
<td>31, 33, 45, 52 and 58) vaccine [HPV]........ 242</td>
<td></td>
</tr>
<tr>
<td>Humatin........................................ 72</td>
<td></td>
</tr>
<tr>
<td>Humira......................................... 152</td>
<td></td>
</tr>
<tr>
<td>HumiraPen..................................... 152</td>
<td></td>
</tr>
<tr>
<td>Hyaluronic acid</td>
<td></td>
</tr>
<tr>
<td>Alimentary .................................. 19</td>
<td></td>
</tr>
<tr>
<td>Sensory....................................... 206, 209</td>
<td></td>
</tr>
<tr>
<td>Hyaluronic acid with lidocaine [lignocaine] 19</td>
<td></td>
</tr>
<tr>
<td>Hyaluronidase.............................. 98</td>
<td></td>
</tr>
<tr>
<td>Hybloc......................................... 41</td>
<td></td>
</tr>
<tr>
<td>Hydralazine hydrochloride............. 48</td>
<td></td>
</tr>
<tr>
<td>Hydrocortisone.................. .................. 133</td>
<td></td>
</tr>
<tr>
<td>Hydrocortisone acetate</td>
<td></td>
</tr>
<tr>
<td>Alimentary .................................. 6</td>
<td></td>
</tr>
<tr>
<td>Dermatological........................... 55</td>
<td></td>
</tr>
<tr>
<td>Hydrocortisone acetate with pramoxine hydrochloride .......... 6</td>
<td></td>
</tr>
<tr>
<td>Hydrocortisone acetate and paraffin liquid and lanolin .......... 55</td>
<td></td>
</tr>
<tr>
<td>Hydrocortisone butyrate ............... 55, 57</td>
<td></td>
</tr>
<tr>
<td>Hydrocortisone with miconazole ........ 56</td>
<td></td>
</tr>
<tr>
<td>Hydrocortisone with natamycin and neomycin .......... 56</td>
<td></td>
</tr>
<tr>
<td>Hydrogen peroxide ....................... 52</td>
<td></td>
</tr>
<tr>
<td>Hydroxocobalamin</td>
<td></td>
</tr>
<tr>
<td>Alimentary .................................. 21</td>
<td></td>
</tr>
<tr>
<td>Various....................................... 210</td>
<td></td>
</tr>
<tr>
<td>Hydroxychloroquine...................... 94</td>
<td></td>
</tr>
<tr>
<td>Hydroxyurea.................................. 133</td>
<td></td>
</tr>
<tr>
<td>Hygroton..................................... 45</td>
<td></td>
</tr>
<tr>
<td>Hylo-Fresh.................................... 209</td>
<td></td>
</tr>
<tr>
<td>Hycosine butylbromide.................. 7</td>
<td></td>
</tr>
<tr>
<td>Hycosine hydrobromide.................. 116</td>
<td></td>
</tr>
<tr>
<td>Hyperuricaemia and Antigout ........... 98</td>
<td></td>
</tr>
<tr>
<td>Hypromellose............................... 206, 209</td>
<td></td>
</tr>
<tr>
<td>Hypromellose with dextran ............. 209</td>
<td></td>
</tr>
<tr>
<td>Ibfamox.......................... .................. 76</td>
<td></td>
</tr>
<tr>
<td>Ibuprofen.................................... 101</td>
<td></td>
</tr>
<tr>
<td>Icatibant.................................... 195</td>
<td></td>
</tr>
<tr>
<td>Idarubicin hydrochloride................ 130</td>
<td></td>
</tr>
<tr>
<td>Idarucizumab................................ 28</td>
<td></td>
</tr>
<tr>
<td>Idursulfase.................................. 15</td>
<td></td>
</tr>
<tr>
<td>Ifosfamide................................... 129</td>
<td></td>
</tr>
<tr>
<td>Ildorel........................................ 48</td>
<td></td>
</tr>
<tr>
<td>Ilomedin..................................... 51</td>
<td></td>
</tr>
<tr>
<td>Iloprost....................................... 51</td>
<td></td>
</tr>
<tr>
<td>Imaging Agents............................ 146</td>
<td></td>
</tr>
<tr>
<td>Imatinib mesilate.......................... 139</td>
<td></td>
</tr>
<tr>
<td>Imatinib-AFT................................. 139</td>
<td></td>
</tr>
<tr>
<td>Imipenem with cilastatin .............. 72</td>
<td></td>
</tr>
<tr>
<td>Imipenem+Cilastatin RBX................ 72</td>
<td></td>
</tr>
<tr>
<td>Imipramine hydrochloride.............. 111</td>
<td></td>
</tr>
<tr>
<td>Imiquimod.................................... 57</td>
<td></td>
</tr>
<tr>
<td>Immune Modulators....................... 91</td>
<td></td>
</tr>
<tr>
<td>Immunosuppressants...................... 146</td>
<td></td>
</tr>
<tr>
<td>Impact Advanced Recovery .............. 233</td>
<td></td>
</tr>
<tr>
<td>Imuran......................................... 193</td>
<td></td>
</tr>
<tr>
<td>Incruce Ellipta................................ 197</td>
<td></td>
</tr>
<tr>
<td>Indacaterol.................................. 200</td>
<td></td>
</tr>
<tr>
<td>Indapamide................................... 45</td>
<td></td>
</tr>
<tr>
<td>Indigo carmine............................. 215</td>
<td></td>
</tr>
<tr>
<td>Indinavir..................................... 87</td>
<td></td>
</tr>
<tr>
<td>Indocyanine green........................ 215</td>
<td></td>
</tr>
<tr>
<td>Indomethacin............................... 102</td>
<td></td>
</tr>
<tr>
<td>Infanrix IPV.................................. 236</td>
<td></td>
</tr>
<tr>
<td>Infanrix-hexa............................... 236</td>
<td></td>
</tr>
<tr>
<td>Infatrin....................................... 231</td>
<td></td>
</tr>
<tr>
<td>Infliximab.................................... 164</td>
<td></td>
</tr>
<tr>
<td>Influenza vaccine....................... 242</td>
<td></td>
</tr>
<tr>
<td>Infuvac Tetra.................................. 243</td>
<td></td>
</tr>
<tr>
<td>Inhaled Corticosteroids................. 199</td>
<td></td>
</tr>
<tr>
<td>Inspra.......................................... 44</td>
<td></td>
</tr>
<tr>
<td>Insulin aspart......................... .................. 10</td>
<td></td>
</tr>
<tr>
<td>Insulin aspart with insulin aspart protamine................. 9</td>
<td></td>
</tr>
<tr>
<td>Insulin glargine........................... 9</td>
<td></td>
</tr>
<tr>
<td>Insulin glulisine........................... 10</td>
<td></td>
</tr>
<tr>
<td>Insulin isophane......................... 9</td>
<td></td>
</tr>
<tr>
<td>Insulin lispro.............................. 10</td>
<td></td>
</tr>
<tr>
<td>Insulin lispro with insulin lispro protamine................. 9</td>
<td></td>
</tr>
<tr>
<td>Insulin neutral........................... 10</td>
<td></td>
</tr>
<tr>
<td>Insulin neutral with insulin isophane .......... 9</td>
<td></td>
</tr>
<tr>
<td>Integrin..................................... 32</td>
<td></td>
</tr>
<tr>
<td>Intelement................................. 85</td>
<td></td>
</tr>
<tr>
<td>Interferon alfa-2a...................... 91</td>
<td></td>
</tr>
<tr>
<td>Interferon alfa-2b...................... 92</td>
<td></td>
</tr>
<tr>
<td>Interferon beta-1-alpha................. 122</td>
<td></td>
</tr>
<tr>
<td>Interferon beta-1-beta................. 122</td>
<td></td>
</tr>
<tr>
<td>Interferon gamma......................... 92</td>
<td></td>
</tr>
<tr>
<td>INDEX: Generic Chemicals and Brands</td>
<td></td>
</tr>
<tr>
<td>------------------------------------</td>
<td></td>
</tr>
<tr>
<td>Intra-uterine device..................</td>
<td>59</td>
</tr>
<tr>
<td>Invanz..................................</td>
<td>72</td>
</tr>
<tr>
<td>Invega Sustenna.......................</td>
<td>119</td>
</tr>
<tr>
<td>Iodine..................................</td>
<td>70</td>
</tr>
<tr>
<td>Iodine with ethanol...................</td>
<td>212</td>
</tr>
<tr>
<td>Iodised oil............................</td>
<td>213</td>
</tr>
<tr>
<td>Iodixanol................................</td>
<td>213</td>
</tr>
<tr>
<td>Iohexol..................................</td>
<td>213</td>
</tr>
<tr>
<td>Iopidine................................</td>
<td>208</td>
</tr>
<tr>
<td>Isocan...................................</td>
<td>213</td>
</tr>
<tr>
<td>IPOL.....................................</td>
<td>244</td>
</tr>
<tr>
<td>Ipratropium bromide...................</td>
<td>196</td>
</tr>
<tr>
<td>Iressa...................................</td>
<td>138</td>
</tr>
<tr>
<td>Irinotecan Actavis 100..................</td>
<td>133</td>
</tr>
<tr>
<td>Irinotecan hydrochloride..............</td>
<td>133</td>
</tr>
<tr>
<td>Iron polymaltose......................</td>
<td>18</td>
</tr>
<tr>
<td>Iron sucrose...........................</td>
<td>18</td>
</tr>
<tr>
<td>Irrigation Solutions...................</td>
<td>215</td>
</tr>
<tr>
<td>Isentress................................</td>
<td>88</td>
</tr>
<tr>
<td>Isentress HD............................</td>
<td>88</td>
</tr>
<tr>
<td>Ismo 40 Retard..........................</td>
<td>46</td>
</tr>
<tr>
<td>Ismo-20..................................</td>
<td>46</td>
</tr>
<tr>
<td>Isoflurane................................</td>
<td>104</td>
</tr>
<tr>
<td>Isoniazid................................</td>
<td>82</td>
</tr>
<tr>
<td>Isoniazid with rifampicin.............</td>
<td>82</td>
</tr>
<tr>
<td>Isoprenaline [Isoproterenol]..........</td>
<td>47</td>
</tr>
<tr>
<td>Isopropyl alcohol.....................</td>
<td>212</td>
</tr>
<tr>
<td>Isoperitoneal...........................</td>
<td>47</td>
</tr>
<tr>
<td>Isopin...................................</td>
<td>43</td>
</tr>
<tr>
<td>Isoptin SR................................</td>
<td>43</td>
</tr>
<tr>
<td>Isoto Carpine.........................</td>
<td>207</td>
</tr>
<tr>
<td>Isosorbide mononitrate..................</td>
<td>46</td>
</tr>
<tr>
<td>Isotretinoin............................</td>
<td>53</td>
</tr>
<tr>
<td>Isphagnula (psyllium) husk.............</td>
<td>12</td>
</tr>
<tr>
<td>Isradipine..............................</td>
<td>42</td>
</tr>
<tr>
<td>Itch-Soothe................................</td>
<td>53</td>
</tr>
<tr>
<td>Itraconazole............................</td>
<td>80</td>
</tr>
<tr>
<td>Itrazone..................................</td>
<td>80</td>
</tr>
<tr>
<td>Ivalabridge.............................</td>
<td>41</td>
</tr>
<tr>
<td>Ivermectin..............................</td>
<td>83</td>
</tr>
<tr>
<td>Ketamine-Claris..........................</td>
<td>104</td>
</tr>
<tr>
<td>Ketamine-Claris..........................</td>
<td>104</td>
</tr>
<tr>
<td>Ketocal 3:1 (Unflavoured)...............</td>
<td>231</td>
</tr>
<tr>
<td>Ketocal 4:1 (Unflavoured)...............</td>
<td>231</td>
</tr>
<tr>
<td>Ketocal 4:1 (Vanilla)..................</td>
<td>231</td>
</tr>
<tr>
<td>Ketocanazole...........................</td>
<td>118</td>
</tr>
<tr>
<td>Dermatological..........................</td>
<td>52</td>
</tr>
<tr>
<td>Infections................................</td>
<td>80</td>
</tr>
<tr>
<td>Ketoprofen..............................</td>
<td>102</td>
</tr>
<tr>
<td>Keytruda..................................</td>
<td>191</td>
</tr>
<tr>
<td>Kivexa....................................</td>
<td>86</td>
</tr>
<tr>
<td>Klacid.....................................</td>
<td>75</td>
</tr>
<tr>
<td>Klean Prep..................................</td>
<td>12</td>
</tr>
<tr>
<td>Konakion MM..............................</td>
<td>29</td>
</tr>
<tr>
<td>Konsyl-D...................................</td>
<td>12</td>
</tr>
<tr>
<td>Kovan.....................................</td>
<td>16</td>
</tr>
<tr>
<td>L-asparaginase...........................</td>
<td>133</td>
</tr>
<tr>
<td>L-ornithine L-aspartate..................</td>
<td>8</td>
</tr>
<tr>
<td>Labetalol..................................</td>
<td>41</td>
</tr>
<tr>
<td>Lactosamide.............................</td>
<td>113</td>
</tr>
<tr>
<td>Lactose...................................</td>
<td>219</td>
</tr>
<tr>
<td>Lacosamide.............................</td>
<td>113</td>
</tr>
<tr>
<td>Lamotrigine.............................</td>
<td>113</td>
</tr>
<tr>
<td>Lanoxin...................................</td>
<td>40</td>
</tr>
<tr>
<td>Lanozin PG...............................</td>
<td>40</td>
</tr>
<tr>
<td>Lansoprazole............................</td>
<td>8</td>
</tr>
<tr>
<td>Lanyus...................................</td>
<td>9</td>
</tr>
<tr>
<td>Lanyus SoloStar..........................</td>
<td>9</td>
</tr>
<tr>
<td>Lanzol Relief............................</td>
<td>8</td>
</tr>
<tr>
<td>Lapatinib...................................</td>
<td>139</td>
</tr>
<tr>
<td>Largactil...............................</td>
<td>117</td>
</tr>
<tr>
<td>Larinol....................................</td>
<td>15</td>
</tr>
<tr>
<td>Lasis.....................................</td>
<td>44</td>
</tr>
<tr>
<td>Latanoprost.............................</td>
<td>208</td>
</tr>
<tr>
<td>Lax-Suppositories.......................</td>
<td>13</td>
</tr>
<tr>
<td>Lax-Tabs...................................</td>
<td>13</td>
</tr>
<tr>
<td>Laxatives..................................</td>
<td>11</td>
</tr>
<tr>
<td>Laxsol....................................</td>
<td>12</td>
</tr>
<tr>
<td>Ledipasvir with sofosbuvir...........</td>
<td>88</td>
</tr>
<tr>
<td>Leflunomide............................</td>
<td>94</td>
</tr>
<tr>
<td>Leflunomide............................</td>
<td>94</td>
</tr>
<tr>
<td>Lenalidomide............................</td>
<td>133</td>
</tr>
<tr>
<td>Letrozole...............................</td>
<td>146</td>
</tr>
<tr>
<td>Letrozole...............................</td>
<td>146</td>
</tr>
<tr>
<td>Leukotriene Receptor Antagonists......</td>
<td>200</td>
</tr>
<tr>
<td>Leunase.................................</td>
<td>133</td>
</tr>
<tr>
<td>Leuprolin acetate........................</td>
<td>66</td>
</tr>
<tr>
<td>Leuprolin acetate........................</td>
<td>66</td>
</tr>
<tr>
<td>Leustatin...............................</td>
<td>130</td>
</tr>
<tr>
<td>Levetiracetam...........................</td>
<td>113</td>
</tr>
<tr>
<td>Levetiracetam-AFT......................</td>
<td>113</td>
</tr>
<tr>
<td>Levlen ED.................................</td>
<td>58</td>
</tr>
<tr>
<td>Levocabastine...........................</td>
<td>205</td>
</tr>
<tr>
<td>Levocarnitine...........................</td>
<td>16</td>
</tr>
<tr>
<td>Levodopa with benserazide............</td>
<td>104</td>
</tr>
<tr>
<td>Levodopa with carbidopa..............</td>
<td>104</td>
</tr>
<tr>
<td>Levomepromazine........................</td>
<td>118</td>
</tr>
<tr>
<td>Levomepromazine........................</td>
<td>118</td>
</tr>
<tr>
<td>hydrochloride...........................</td>
<td>118</td>
</tr>
<tr>
<td>Levonorgestrel..........................</td>
<td>59</td>
</tr>
<tr>
<td>Levosimendan............................</td>
<td>46</td>
</tr>
<tr>
<td>Levothyroxine............................</td>
<td>70</td>
</tr>
<tr>
<td>Lidocaine [Lignocaine]..................</td>
<td>106</td>
</tr>
<tr>
<td>Lidocaine [Lignocaine]..................</td>
<td>106</td>
</tr>
<tr>
<td>hydrochloride...........................</td>
<td>106</td>
</tr>
<tr>
<td>Lidocaine [Lignocaine] hydrochloride...</td>
<td>106</td>
</tr>
<tr>
<td>with adrenaline..........................</td>
<td>106</td>
</tr>
<tr>
<td>Lidocaine [Lignocaine] hydrochloride...</td>
<td>106</td>
</tr>
<tr>
<td>with adrenaline and tetracaine.......</td>
<td>107</td>
</tr>
<tr>
<td>Lidocaine [Lignocaine] hydrochloride...</td>
<td>107</td>
</tr>
<tr>
<td>with chlorhexidine.....................</td>
<td>107</td>
</tr>
<tr>
<td>Lidocaine [Lignocaine] hydrochloride...</td>
<td>107</td>
</tr>
<tr>
<td>with phenylephrine.....................</td>
<td>107</td>
</tr>
<tr>
<td>Lignocaine...............................</td>
<td>107</td>
</tr>
<tr>
<td>Lipozomal...............................</td>
<td>107</td>
</tr>
<tr>
<td>Linezolid..................................</td>
<td>79</td>
</tr>
<tr>
<td>Linezolid Kabi...........................</td>
<td>79</td>
</tr>
<tr>
<td>Lioresal Intrathecal....................</td>
<td>100</td>
</tr>
<tr>
<td>Lithothryonine sodium..................</td>
<td>70</td>
</tr>
<tr>
<td>Lipid......................................</td>
<td>45</td>
</tr>
<tr>
<td>Lipid-Modifying Agents...............</td>
<td>45</td>
</tr>
<tr>
<td>Lipiodol Ultra Fluid...................</td>
<td>213</td>
</tr>
<tr>
<td>Liquibar...................................</td>
<td>213</td>
</tr>
<tr>
<td>Lisinopril..................................</td>
<td>38</td>
</tr>
<tr>
<td>Lissamine green.........................</td>
<td>206</td>
</tr>
<tr>
<td>Lithicarb FC.............................</td>
<td>118</td>
</tr>
<tr>
<td>Lithium carbonate......................</td>
<td>118</td>
</tr>
<tr>
<td>LMX4......................................</td>
<td>106</td>
</tr>
<tr>
<td>Livial.....................................</td>
<td>213</td>
</tr>
<tr>
<td>Lomestate...............................</td>
<td>57</td>
</tr>
<tr>
<td>Lomestate...............................</td>
<td>57</td>
</tr>
<tr>
<td>Lomestat.................................</td>
<td>57</td>
</tr>
<tr>
<td>Lomatrigine.............................</td>
<td>113</td>
</tr>
<tr>
<td>Lomestat.................................</td>
<td>57</td>
</tr>
<tr>
<td>Long-Acting Beta-Adrenoceptor.........</td>
<td>129</td>
</tr>
<tr>
<td>Long-Acting Beta-Adrenoceptor.........</td>
<td>129</td>
</tr>
<tr>
<td>Long-Acting Beta-Adrenoceptor.........</td>
<td>129</td>
</tr>
<tr>
<td>Lipid......................................</td>
<td>45</td>
</tr>
<tr>
<td>Lipozomal...............................</td>
<td>107</td>
</tr>
<tr>
<td>Lipid-Modifying Agents...............</td>
<td>45</td>
</tr>
<tr>
<td>Lipiodol Ultra Fluid...................</td>
<td>213</td>
</tr>
<tr>
<td>Liquibar...................................</td>
<td>213</td>
</tr>
<tr>
<td>Lisinopril..................................</td>
<td>38</td>
</tr>
<tr>
<td>Lissamine green.........................</td>
<td>206</td>
</tr>
<tr>
<td>Lithicarb FC.............................</td>
<td>118</td>
</tr>
<tr>
<td>Lithium carbonate......................</td>
<td>118</td>
</tr>
<tr>
<td>LMX4......................................</td>
<td>106</td>
</tr>
<tr>
<td>Local Preparations for Anal and Rectal Disorders.................</td>
<td>6</td>
</tr>
<tr>
<td>Locoid....................................</td>
<td>55</td>
</tr>
<tr>
<td>Locioid Crelo...........................</td>
<td>55</td>
</tr>
<tr>
<td>Locoid Lipocream.......................</td>
<td>55</td>
</tr>
<tr>
<td>Lodi.......................................</td>
<td>40</td>
</tr>
<tr>
<td>Lodoxamide.............................</td>
<td>205</td>
</tr>
<tr>
<td>Logem.....................................</td>
<td>113</td>
</tr>
<tr>
<td>Lori.............................. ........</td>
<td>205</td>
</tr>
<tr>
<td>Lorum.......................... ..........</td>
<td>129</td>
</tr>
<tr>
<td>Long-Acting Beta-Adrenoceptor.........</td>
<td>129</td>
</tr>
<tr>
<td>Long-Acting Beta-Adrenoceptor.........</td>
<td>129</td>
</tr>
<tr>
<td>Long-Acting Beta-Adrenoceptor.........</td>
<td>129</td>
</tr>
<tr>
<td>Long-Acting Beta-Adrenoceptor.........</td>
<td>129</td>
</tr>
</tbody>
</table>
Magnesium sulphate

Magnesium oxide

Magnesium chloride

Madopar Rapid

Madopar HBS

Madopar 62.5

Madopar 250

Methylprednisolone acetate

Methylprednisolone aceponate

Methylphenidate hydrochloride

Methadone hydrochloride

Methohexital sodium

Methotrexate

Methotrexate Ebewe

Methotrexate Sandoz

Methosalen

m-Eslon

m-Amoxiclav

m-Ampicillin

Mcgral 3350 with ascorbic acid, potassium chloride and sodium chloride

Macrogl 3350 with potassium chloride, sodium bicarbonate and sodium chloride

Macrogl 3350 with potassium chloride, sodium bicarbonate, sodium chloride and sodium sulphate

Macrogl 400 and propylene glycol

Madopar 125

Madopar 250

Madopar 62.5

Madopar HBS

Madopar Rapid

Mafenide acetate

Magnesium amino acid chelate

Magnesium chloride

Magnesium hydroxide

Alimentary

Extemporaneously Compounded Preparations

Methenamine (Hexamine)

hippurate

Methoxyflurane

Methyl aminolevulinate hydrochloride

Methyl hydroxybenzoate

Methylcellulose

Methylcellulose with glycerin and sodium saccharin

Methylcellulose with glycerin and sucrose

Methyldopa

Methyldopa Mylan

Methylene blue

Methylhydroxynicotinate

Methylisonic acid [Methylene blue]

Methylxanthines

Metformin hydrochloride

Mexiteline hydrochloride

Mexiteline Hydrochloride USP

Micardis

Micardis HCT

Micardis Plus

Micardis Post

Micardis Post

Miconazole nitrate

Dermatological

INDEX: Generic Chemicals and Brands
### INDEX: Generic Chemicals and Brands

<table>
<thead>
<tr>
<th>Section</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Genito-Urinary</td>
<td>58</td>
</tr>
<tr>
<td>Micreme</td>
<td>58</td>
</tr>
<tr>
<td>Micreme H</td>
<td>56</td>
</tr>
<tr>
<td>Microgynon 20 ED</td>
<td>58</td>
</tr>
<tr>
<td>Microgynon 50 ED</td>
<td>58</td>
</tr>
<tr>
<td>Midazolam</td>
<td>123</td>
</tr>
<tr>
<td>Midodrine</td>
<td>41</td>
</tr>
<tr>
<td>Mifepristone</td>
<td>59</td>
</tr>
<tr>
<td>Mirtazapine</td>
<td>111</td>
</tr>
<tr>
<td>Misoprostol</td>
<td>7</td>
</tr>
<tr>
<td>Mitomycin C</td>
<td>130</td>
</tr>
<tr>
<td>Mitoxantrone</td>
<td>130</td>
</tr>
<tr>
<td>Mivacron</td>
<td>100</td>
</tr>
<tr>
<td>Mivacurium chloride</td>
<td>100</td>
</tr>
<tr>
<td>Mixed salt solution for eye irrigation</td>
<td>206</td>
</tr>
<tr>
<td>Modafinil</td>
<td>125</td>
</tr>
<tr>
<td>Modavigil</td>
<td>125</td>
</tr>
<tr>
<td>Moloxole</td>
<td>13</td>
</tr>
<tr>
<td>Mometasone furoate</td>
<td>55</td>
</tr>
<tr>
<td>Monosodium glutamate with sodium aspartate</td>
<td>217</td>
</tr>
<tr>
<td>Monosodium l-aspartate</td>
<td>217</td>
</tr>
<tr>
<td>Montelukast</td>
<td>200</td>
</tr>
<tr>
<td>Montelukast Mylan</td>
<td>200</td>
</tr>
<tr>
<td>Morococog alfa [Recombinant factor VIII]</td>
<td>28</td>
</tr>
<tr>
<td>Morphine hydrochloride</td>
<td>109</td>
</tr>
<tr>
<td>Morphine sulphate</td>
<td>109</td>
</tr>
<tr>
<td>Morfetis</td>
<td>103</td>
</tr>
<tr>
<td>Mouth and Throat</td>
<td>19</td>
</tr>
<tr>
<td>Movapo</td>
<td>103</td>
</tr>
<tr>
<td>Moxifloxacin</td>
<td>77</td>
</tr>
<tr>
<td>Moxifloxacin Kabi</td>
<td>77</td>
</tr>
<tr>
<td>Mozobil</td>
<td>33</td>
</tr>
<tr>
<td>Mucolitics and Expectorants</td>
<td>201</td>
</tr>
<tr>
<td>Mucosothe</td>
<td>106</td>
</tr>
<tr>
<td>Multithane</td>
<td>214</td>
</tr>
<tr>
<td>Multiple Sclerosis Treatments</td>
<td>121</td>
</tr>
<tr>
<td>Multivitamin and mineral supplement</td>
<td>20</td>
</tr>
<tr>
<td>Multivitamin renal</td>
<td>20</td>
</tr>
<tr>
<td>Multivitamins</td>
<td>20</td>
</tr>
</tbody>
</table>

- **Muscle Relaxants and Related Agents** | 100 |
- **Mvite** | 20 |
- **Myambutol** | 82 |
- **MycoNail** | 52 |
- **Mydriacyl** | 208 |
- **Mydriatics and Cycloplegics** | 208 |
- **Mylan Atenolol** | 41 |
- **Mylan Clomiphene** | 65 |
- **Mylan Midazolam** | 123 |
- **Mylan Neomycin** | 129 |
- **Myzyne** | 13 |
- **Nadolol** | 42 |
- **Naglazyme** | 14 |
- **Naloxone hydrochloride** | 210 |
- **Naltracore** | 126 |
- **Nalatrexone hydrochloride** | 126 |
- **Naphazoline hydrochloride** | 205 |
- **Naphcon Forte** | 205 |
- **Naprosyn SR 1000** | 102 |
- **Naprosyn SR 750** | 102 |
- **Naproxen** | 102 |
- **Naropin** | 107 |
- **Natalizumab** | 121 |
- **Natamycin** | 203 |
- **Natulan** | 134 |
- **Nausafix** | 117 |
- **Nausalcym** | 116 |
- **Navelbine** | 144 |
- **Nedocromil** | 201 |
- **Nefopam hydrochloride** | 108 |
- **Neisvac-C** | 238 |
- **Ne-B12** | 21 |
- **Neocate Gold (Unflavoured)** | 229 |
- **Neocate Junior Vanilla** | 229 |
- **Neoral** | 146 |
- **Neostigmine methylsulphate** | 94 |
- **Neostigmine methylsulphate with glycopyronium bromide** | 94 |
- **Neosynephrine HCL** | 47 |
- **Nepro HP (Strawberry)** | 233 |
- **Nepro HP (Vanilla)** | 233 |
- **Nepro HP RTH** | 232 |
- **Neulastim** | 34 |
- **Neupogen** | 33 |
- **NeuroTabs** | 17 |
- **Nevirapine** | 85 |
- **Nevirapine Alphapharm** | 85 |
- **Nicardipine hydrochloride** | 42 |
- **Nicolaridil** | 48 |
- **Nicotine** | 127 |
- **Nicotinic acid** | 46 |
- **Nifedipine** | 43 |
- **Nifuran** | 43 |
- **Nilotinib** | 140 |
- **Nilstat** | 19 |
- **Alimentary** | 19 |
- **Genito-Urinary** | 58 |
- **Infections** | 80 |
- **Nimodipine** | 43 |
- **Nintedanib** | 197 |
- **Nitazoxamide** | 84 |
- **Nitrates** | 46 |
- **Nitazepam** | 123 |
- **Nitroderm TTS 10** | 46 |
- **Nitroderm TTS 5** | 46 |
- **Nitrofurantoin** | 79 |
- **Nitrolingual Pump Spray** | 46 |
- **Nivestim** | 33 |
- **Nivolumab** | 190 |
- **Nodia** | 5 |
- **Noflam 250** | 102 |
- **Noflam 500** | 102 |
- **Non-Steroidal Anti-Inflammatory Drugs** | 101 |
- **Nanocag gamma, [Recombinant factor IX]** | 29 |
- **Norethisterone** | 59 |
- **Genito-Urinary Hormone Preparations** | 66 |
- **Norethisterone with mestranol** | 58 |
- **Noradrenaline** | 100 |
- **Norflex** | 100 |
- **Norflaxacin** | 77 |
- **Norday 28** | 59 |
- **Nomison** | 123 |
- **Norpress** | 111 |
- **Nortriptyline hydrochloride** | 111 |
- **Norvir** | 87 |
- **Novasource Renal (Vanilla)** | 233 |
- **Novatretin** | 56 |
- **NovoMix 30 FlexPen** | 9 |
- **NovoRapid FlexPen** | 10 |
- **NovoSeven RT** | 28 |
- **Noxafil** | 80 |
- **Nozinan** | 118 |
- **Nuelin** | 201 |
- **Nuelin-SR** | 201 |
- **Nutriini Energy Multi Fibre** | 232 |
- **Nutriini Low Energy Multi Fibre RTH** | 232 |
- **Nutris 800 Complete Multi Fibre** | 234 |
- **Nutris Concentrated** | 228 |
- **Nutris Energy** | 234 |
- **Nyefax Retard** | 43 |
INDEX: Generic Chemicals and Brands

Nystatin
  Alimentary .................................. 19
  Dermatological ............................. 52
  Genito-Urinary ................................ 58
  Infections ...................................... 80

O/W Fatty Emulsion Cream ............ 54
Obinutuzumab ............................... 171
Obsetric Preparations ................. 59
Ocrelizumab .................................. 121
Ocrevus .......................................... 121
Octocog alfa [Recombinant factor
VIII] (Advate) ......................... 29
Octocog alfa [Recombinant factor
VIII] (Kogenate FS) .................. 29
Octreotide ......................................... 145
Ocular Lubricants ........................... 208
Oestradiol ............................................. 64–65
Oestradiol valerate ...................... 64
Oestradiol with norethisterone
acetate ............................................. 64
Oestriol
  Genito-Urinary ................................ 60
  Hormone Preparations .................... 65
  Oestrogens ....................................... 60
  Oestrogens (conjugated equine) ...... 64
  Oestrogens with
  medroxyprogesterone
  acetate ............................................. 65
Ofev ................................................. 197
Oil in water emulsion .................... 54
Oily phenol [Phenol oily] ............. 7
Olanzapine ....................................... 118–119
Olive oil ............................................. 219
Olopatadine ....................................... 205
Olsalazine ......................................... 6
Omalizumab ....................................... 172
Omeprazole ........................................ 8
Omeprazole actavis 10 ................... 8
Omeprazole actavis 20 .................... 8
Omeprazole actavis 40 ................... 8
Omezol IV ........................................... 8
Omnipaque ......................................... 213
Omnican ........................................... 214
Omitrope ............................................ 66
Onbrez Breezhaler ......................... 200
Oncaspar ........................................... 134
Oncaspar LYO ..................................... 134
OncoTICE .......................................... 193
Ondansetron ..................................... 117
Ondansetron Kabi ......................... 117
Ondansetron ODT-DRLA ............... 117
Ondansetron-Claris ....................... 117
One-Alpha .......................................... 21
Onrex ................................................. 117
Opdivo ................................................. 190

Optional Pharmaceuticals ............. 246
Ora-Blend ......................................... 219
Ora-Blend SF ................................. 219
Ora-Plus ........................................... 219
Ora-Sweet ......................................... 219
Ora-Sweet SF ................................. 219
Oratane ............................................. 53
Oron Temozolomide ....................... 134
Omnitrope ........................................... 260
Omniscan ........................................... 260
Omnipaque ......................................... 260
Omezol IV ........................................... 260
Olsalazine ........................................... 260

Pexsig .................................................. 43

Paracetamol .......................................... 108
Paracetamol Kabi ............................ 108
Paracetamol with codeine ............... 110
Parafin
  Alimentary ....................................... 12
  Dermatological ................................ 54
  Extemporaneously Compounded
  Preparations .................................... 219
Parafin liquid with soft white
paraffin ............................................. 209
Parafin liquid with wool fat .......... 209
Parafin with wool fat ..................... 55
Paraldehyde ....................................... 112
Parecoxib .......................................... 102
Paromomycin ..................................... 72
Paroxetine ......................................... 112
Paser .................................................... 83
Patanol ................................................. 205
Patent blue V ..................................... 215
Paxam .................................................... 120
Pazopanib ......................................... 140
Peak flow meter ............................... 246
Peanut oil .......................................... 218
Pedialyte - Bubblegum ................. 36
Pediasure (Chocolate) ................. 232
Pediasure (Strawberry) ................ 232
Pediasure (Vanilla) ......................... 232
Pediasure RTH ................................. 232
Pegasparase ...................................... 134
Pegasys ............................................... 92
Pegfilgrastim ..................................... 34
Pegylated interferon alfa-2a .......... 92
Pembrolizumab ............................... 191
Pemetrexed ........................................ 131
Penicillamine ..................................... 94
Penicillin G ........................................ 76
Penicillin V ........................................ 76
Pentacarinat ...................................... 84
Pentagastrin ...................................... 65
Pentamidine isethionate ................. 84
Pentasa ............................................... 6
Pentostatin [Deoxycoformycin] .... 134
Pentoxifylline [Oxpentifylline] ..... 48
Peptamen OS 1.0 (Vanilla) ............ 228
Peptoforme .......................................... 7
Perfluoren .......................................... 214
Perhexiline maleate .......................... 43
Pericyazine ......................................... 118
Perindopril ......................................... 38
Perjeta ................................................ 173
Permethrin ......................................... 53
Perigrin ............................................... 57
Pertuzumab ......................................... 173
Peteha ................................................... 83
Pethidine hydrochloride ............... 110

- P -

Pacifen ............................................. 100
Paclitaxel ......................................... 143
Paclitaxel Ebeew ................. 143
Paliperidone ....................................... 119
Pamidronate disodium ................. 94
Pamisol ............................................. 91
Pan-Penicillin G Sodium ............... 76
Pancreatic enzyme ......................... 11
Pancuronium bromide ................. 100
Pantoprazole ...................................... 8
Panop Relief ................................. 8
Papaverine hydrochloride ............ 48
Paper wasp venom ......................... 195
Para-aminesaliclic Acid ............ 83
Paracare ............................................. 108
Paracare Double Strength ........... 108
Paracetamol .......................................... 108
Paracetamol Kabi ............................ 108
Paracetamol with codeine ............ 110
Parafin
  Alimentary ....................................... 12
  Dermatological ................................ 54
  Extemporaneously Compounded
  Preparations .................................... 219
Parafin liquid with soft white
paraffin ............................................. 209
Parafin liquid with wool fat .......... 209
Parafin with wool fat ..................... 55
Paraldehyde ....................................... 112
Parecoxib .......................................... 102
Paromomycin ..................................... 72
Paroxetine ......................................... 112
Paser .................................................... 83
Patanol ................................................. 205
Patent blue V ..................................... 215
Paxam .................................................... 120
Pazopanib ......................................... 140
Peak flow meter ............................... 246
Peanut oil .......................................... 218
Pedialyte - Bubblegum ................. 36
Pediasure (Chocolate) ................. 232
Pediasure (Strawberry) ................ 232
Pediasure (Vanilla) ......................... 232
Pediasure RTH ................................. 232
Pegasparase ...................................... 134
Pegasys ............................................... 92
Pegfilgrastim ..................................... 34
Pegylated interferon alfa-2a .......... 92
Pembrolizumab ............................... 191
Pemetrexed ........................................ 131
Penicillamine ..................................... 94
Penicillin G ........................................ 76
Penicillin V ........................................ 76
Pentacarinat ...................................... 84
Pentagastrin ...................................... 65
Pentamidine isethionate ................. 84
Pentasa ............................................... 6
Pentostatin [Deoxycoformycin] .... 134
Pentoxifylline [Oxpentifylline] ..... 48
Peptamen OS 1.0 (Vanilla) ............ 228
Peptoforme .......................................... 7
Perfluoren .......................................... 214
Perhexiline maleate .......................... 43
Pericyazine ......................................... 118
Perindopril ......................................... 38
Perjeta ................................................ 173
Permethrin ......................................... 53
Perigrin ............................................... 57
Pertuzumab ......................................... 173
Peteha ................................................... 83
Pethidine hydrochloride ............... 110
INDEX: Generic Chemicals and Brands

Pfizer Exemestane .............................................. 146
Pharmacy Health SLS-free.......................... 54
Pharmacy Health Sorbolene with
Glycerin.................................................. 54
Pheburane.................................................... 17
Phenasen......................................................... 132
Phenelzine sulphate.......................... 111
Phenindione.................................................... 31
Phenobarbital .......................... 113, 123
Phenobarbitone sodium ............. 219
Phenol
Extemporaneously Compounded
Preparations ........................................ 219
Various...................................................... 216
Phenol oily...................................................... 7
Phenol with ioxaglic acid .............. 216
Phenothrin..................................................... 53
Phenoxybenzamine
hydrochloride.............................. 39
Phenoxymethylpenicillin [Penicillin V] ........................................ 76
Phentolamine mesylate............... 40
Phenylenephine hydrochloride
Cardiovascular........................................ 47
Sensory...................................................... 208
Phenytoin..................................................... 113
Phenytoin sodium ...................... 112, 114
Phlocodine................................................... 199
Phosphorus................................................... 36
Phytomenadione........................ 29
Picibanil...................................................... 194
Pilocarpine hydrochloride .......... 207
Pilocarpine nitrate......................... 219
Pimafucort ................................................. 56
Pindolol....................................................... 42
Pine tar with trolamine laurilsulfate
and fluorescein.......................... 56
Pinetarsol..................................................... 56
Pioglitazone................................................. 10
Piperacillin with tazobactam........ 76
Pipethiazine palmitate................. 120
Pituitary and Hypothalamic
Hormones and Analogues .............. 66
Pivmecillinam........................................... 79
Pizotifen..................................................... 116
PKU Anamix Junior LQ (Berry)........ 225
PKU Anamix Junior LQ
(Orange) ................................................. 225
PKU Anamix Junior LQ
(Unflavoured) ............................................ 225
Plaquenil...................................................... 94
Plasma-Lyte 148 ......................... 34
Plasma-Lyte 148 & 5% Glucose .... 34
Piendil ER..................................................... 42
Plerixafor..................................................... 33
Pneumococcal (PCV10) conjugate
vaccine ................................................. 238
Pneumococcal (PCV13) conjugate
vaccine ................................................. 239
Pneumococcal (PPV23) polysaccharide vaccine ......................................... 239
Pneumovax 23 ........................................... 239
Podophyllotoxin.......................... 57
Polidocanol............................................... 27
Poly-Visc................................................... 209
Polyxamer.................................................... 12
Poly Gel..................................................... 208
Poly-Tears................................................... 209
Potassium chloride potassium chloride chloride.................................. 35, 37
Potassium citrate.......................... 61
Potassium dihydrogen phosphate.......................... 35
Potassium iodate
Alimentary.............................................. 17
Hormone Preparations................. 70
Potassium iodate with iodine........ 18
Potassium perchlorate................. 70
Potassium permanganate ............. 56
Povidone K30............................................ 219
Povidone.................................................. 212
Povidone-iode............................................ 212
Povidone-iode with ethanol........... 212
Pradaxa...................................................... 30
Pramerlix................................................... 210
Pramipexole hydrochloride .......... 104
Prasugrel................................................... 32
Pravastatin.................................................. 45
Praxbind..................................................... 28
Praziquantel.............................................. 83
Prazosin...................................................... 40
Precedex.................................................... 104
Pred Forte................................................ 205
Prednisolone.......................... 64
Prednisolone acetate................. 205
Prednisolone sodium phosphate.................................. 205
Prednisolone- AFT.......................... 205
Prednisone................................................. 64
Pregabalin................................................. 114
Pregabalin Pfizer......................... 114
Pregnancy test - hCG urine............ 246
preOp............................................. 233
Presolol..................................................... 41
Prevenar 13.............................................. 239
Prezista..................................................... 87
Prilocaline hydrochloride ............ 107
Prilocaline hydrochloride with
felypressin............................................. 107
Primaacor................................................. 48
Pramiquine phosphate.................. 84
Primidone................................................. 114
Primolut N................................................. 66
Primovist................................................. 214
Prixir.......................... 244
Pronbenecid.............................................. 100
Procainamide.......................... 76
Procarbazine hydrochloride........... 134
Prochlorperazine......................... 117
Procyclidine hydrochloride........... 103
Procystox................................................. 129
Progesterone........................................... 59
Propilicem................................................. 9
Proglycem................................................. 9
Progynova.................................................. 64
Prolia....................................................... 96
Promethazine hydrochloride......... 196
Propafenone hydrochloride ........... 41
Propamidine isethionate................. 203
Propofol.................................................... 105
Propranolol.............................................. 42
Propylthiouracil................................. 70
Prostyn E2.............................................. 59
Prostyn VR.................................................. 48
Protamine sulphate....................... 31
Protonamide............................................. 83
Protirelin.................................................. 71
Proveblue.................................................. 215
Prorvera.................................................... 65
Provera HD.............................................. 65
Proxymetacaine hydrochloride...... 206
Pseudoephedrine
hydrochloride................................. 199
PSM Citalopram................................. 111
Psoriasis and Eczema
Preparations.......................................... 56
PTU......................................................... 70
Pulmocare (Vanilla)..................... 233
Pulmonary Surfactants................. 201
Pulmozyme.............................................. 201
Puri-nethol............................................. 131
Puria....................................................... 22
Pyrazinamide.......................................... 83
Pyridostigmine bromide................. 94
Pyridoxil-5-phosphate................ 16
Pyridoxine hydrochloride.............. 21
Pyrimethamine............................... 84
Pytazen SR............................................... 32
**INDEX: Generic Chemicals and Brands**

### Q
- Q 300........................................85
- Quetapen................................118
- Quetiapine................................118
- Quinapril................................38
- Quinapril with hydrochlorothiazide 38
- Quinine dihydrochloride...........84
- Quinine sulphate.......................85
- Qvar.......................................199

### R
- Rifaximin............................................
- Rifampicin...........................................
- Rifadin.............................................
- Rifampicin........................................
- Rilutek.............................................
- Riluzole...........................................103
- Ringer’s solution..........................35
- Riodine...........................................212
- Risedronate Sandoz........................94
- Risedronate sodium.......................94
- Rispedal Consta..............................120
- Risperidone......................................119–120
- Risperon...........................................119
- Ritalin..............................................124
- Ritalin LA..........................................124
- Ritalin SR..........................................124
- Ritonavir..........................................87
- Rituximab.........................................174
- Rivaroxaban.....................................31
- Rivastigmine...................................125
- Rivolin.............................................146
- Ropin..............................................104
- Ropinirole hydrochloride.............104
- Ropivacaine hydrochloride 107
- Ropivacaine hydrochloride with fentanyl 107
- Ropivacaine Kabi...........................107
- Rose bengal sodium.......................206
- Rotarix............................................244
- Rotavirus oral vaccine....................244
- Roxane.............................................5
- Roxithromycin.................................75
- Rubifen............................................124
- Rubifen SR.........................................124
- RuA..................................................75
- Ruxolitinib.......................................141

### S
- S26 LBW Gold RTF.........................231
- Sacubitril with valsartan...............39
- Sal/Air...........................................199
- Salazopyrin......................................6
- Salazopyrin EN...........................................
- Salbutamol.........................................199
- Salbutamol with ipratropium bromide 196
- Salicylic acid....................................219
- Salmeterol.......................................200
- Salmonella typhi vaccine................240
- Sandimmun......................................146
- Sandimigran......................................116
- Sandostatin LAR..............................145
- Sapropterin Dihydrochloride...........16
- Scalp Preparations...........................56
- Scandonest 3%.................................107
- Sclerosing Agents..............................202
- Scopoderm TTS.................................116
- Sebixole...........................................52
- Secretin pentalahydrochloride.........215
- Secukinumab...................................183
- Sedatives and Hypnotics................122
- Sebri Breezhaler.............................197
- Selegiline hydrochloride................104
- Sennosides......................................13
- Sensipar..........................................62
- Serevent.........................................200
- Srevent Accuhaler..........................201
- Sertraline.........................................112
- Serotena..........................................112
- Sevoflurane......................................105
- Sevredol..........................................109
- Shingles vaccine............................245
- Silendafil...........................................50
- Situximab...........................................184
- Silver nitrate.....................................
- Dermatological...............................57
- Extemporaneously Compounded...219
- Preparations..............................
- Simeticone........................................5
- Simulect.........................................163
- Simxavastin....................................45
- Simxavastin Mylan...........................45
- Sicalide...........................................215
- Sinemet............................................104
- Sinemet CR.......................................104
- Sirolimus.........................................194
- Siterone............................................62
- Slow-Lopresor....................42
- Smith BioMed Rapid Pregnancy Test...246
- Snake antivenom............................211
- Soda bicarbonate..............................37
- Sodium acetate...............................35
- Sodium acid phosphate....................36
- Sodium alginate with magnesium alginate 5
- Sodium alginate with sodium bicarbonate and calcium carbonate 5
- Sodium aurothiomalate....................94
- Sodium benzoate.............................17
- Sodium bicarbonate..........................
INDEX: Generic Chemicals and Brands

Sodium chloride
Blood........................................36-37
Respiratory.................................199, 201
Various.......................................216

Sodium chloride with sodium bicarbonate.......199

Sodium citrate
Alimentary......................................5
Extemporeaneously Compounded
Preparations................................220

Sodium citrate with sodium chloride and potassium chloride........31

Sodium citrate with sodium lauryl sulphocetate..........13

Sodium citro-tartrate.................61

Sodium cromoglicate
Alimentary......................................6
Respiratory....................................196, 201
Sensory........................................205

Sodium dihydrogen phosphate
[Sodium acid phosphate].........................36

Sodium fluoride.................................17

Sodium fusidate [Fusidic acid]
Dermatological....................................52
Infections...........................................79
Sensory...........................................203

Sodium hyaluronate [Hyaluronic acid]
Alimentary........................................19
Sensory...........................................206, 209

Sodium hyaluronate [Hyaluronic acid] with chondroitin sulphate......206

Sodium hypochlorite.............................213
Sodium metabisulphite.........................220
Sodium nitrite......................................210

Sodium nitroprusside
Cardiovascular....................................48
Optional Pharmaceuticals......................246

Sodium phenylbutyrate.........................17

Sodium phosphate with phosphoric acid.........................13

Sodium polystyrene sulphonate.................37

Sodium stibogluconate.........................85
Sodium tetradecyl sulphate...............27
Sodium thiosulphate.........................210
Sodium valproate................................114
Sodium with potassium.........................217
Solian.............................................117

Solifenacin Mylan.................61
Solifenacin succinate.........................61

Solu-Cortef.......................................63
Solu-Medrol......................................64
Solu-Medrol Act-O-Vial.........................64
Somatropin.......................................66
Sotalol.............................................42
Soya oil...........................................210
Spacer device......................................246

Span-K.............................................37
Specialised Formulas.........................226
Spiolto Respimat.........................197
Spiractin..........................................44
Spiramycin.......................................85
Spiriva.............................................197
Spironolactone.................................44
Sprycel............................................137
Standard Feeds.................................234
Staphylococcal....................................76
Starch.............................................220
Stavudine..........................................86
Sterculia with frangula.................12
SterolClear.......................................196
Stosolid..........................................112
Stimulants / ADHD Treatments..............123
Striperentol.......................................114
Stocrin.............................................85
Strattera.........................................123
Streptomycin sulphate.......................72
Stromectol.......................................83
Suboxone..........................................126
Sucrafate..........................................8
Sucrose..........................................108
Sugammadex......................................101
Sulphadiazine.....................................52
Sulfasalazine......................................6
Sulindac..........................................102
Sulphacetamide sodium.......................203
Sulphadiazine.....................................79
Sulphur...........................................220
Sulpirix..........................................117
Sumatriptan.....................................115
Sunitinib..........................................141
Sunscreen, proprietary.........................57
Suprane..........................................104
Surgical Preparations.........................216
Sustagen Diabetic (Vanilla)...................227

Sustagen Hospital Formula Active
(Choc).............................................235
Sustagen Hospital Formula Active
(Van)..............................................235
Sutent.............................................141
Suxamethonium chloride...............100
Sylvany..........................................184
Symmetrel.......................................103
Sympathomimetics.............................47
Synacthen........................................66
Synacthen Depot.................................66
Synflorin..........................................238
Syntometrine.....................................59
Syrup.............................................220
Systane Unit Dose.............................209
Tacrolimus......................................146

- T -

Taliglucerase alfa..................................17
Tamboctor.........................................40
Tamoxifen citrate...............................146
Tamoxifen Sandoz...............................146
Tamsulosin hydrochloride.....................60
Tamsulosin-Rex.................................60
Tarceva..........................................138
Tasigna............................................140
Tasmar............................................104
Tecfidera.........................................121
Tegretol..........................................112
Tegretol CR.......................................112
Teicoplanin.......................................79
Temaccord........................................134
Temazepam........................................134
Temazolomide....................................134
Tenecteplase.....................................33
Tenofovir disoproxil.........................88
Tenofovir Disopropil Teva.....................88
Tenoxicam.........................................102
Terazosin..........................................40
Tertiflavin.........................................82
Terbutaline........................................60
Terbutaline sulphate...........................199
Teriflunomide....................................121
Teriparadie........................................98
Terlipressin.......................................71
Testosterone......................................62
Testosterone cipionate.......................62
Testosterone esters............................62
Testosterone undecanoate....................62
Tetrabenzaine....................................103
Tetracaine [Amethocaine] hydrochloride
Nervous.........................................107
Sensory...........................................206
Tetracosactide [Tetracosactrin]..............66
Tetracosactrin.....................................66
Tetracycllin Wolff................................78
Tetracycline........................................78
Thalidomide.....................................135
Thaionoid.........................................135
Theobroma oil....................................220
Theophylline.....................................201
Thiamine hydrochloride......................21
Thioguanine.......................................132
Thiopenal [Thiopentone] sodium.............105
Thiopenale........................................105
Thiopentone.......................................105
Thiopentone.......................................105
Thiopentone.......................................105
Thiopentone.......................................105
Thiopentone.......................................105
Throupin..........................................27
Thymol glycercin.................................20
Thyroid and Antithyroid
Preparations.....................................70
INDEX: Generic Chemicals and Brands

Thyrotropin alfa.......................... 66
Ticagrelor................................. 32
Ticarcillin with clavulanic acid...... 76
 Ticlopidine............................... 32
 Tigecycline.............................. 78
 Ticlopidine.............................. 102
 Timolol.................................... 207
 Timolol maleate.......................... 42
 Timoptol XE.............................. 207
 Tiotropium bromide..................... 197
 Tiotropium bromide with olodaterol... 197
 Tivicay.................................... 88
 TMP........................................ 79
 TOBI....................................... 72
 Tobradex.................................. 204
 Tobramycin
 Infections................................. 72
 Sensory................................... 203
 Tobramycin Mylan........................ 72
 Tobrex.................................... 203
 Tocilizumab.............................. 185
 Tofranil.................................... 110
 Tolcapone................................ 104
 Tolterodine tartrate..................... 61
 Topamax.................................. 114
 Topicaïne................................ 106
 Topical Products for Joint and Muscular Pain... 102
 Topiramate............................... 114
 Topiramate Actavis...................... 114
 Tracrium.................................. 100
 Tramadol hydrochloride............... 110
 Tramal 100................................ 110
 Tramal 50.................................. 110
 Tramal SR 100............................ 110
 Tramal SR 150............................ 110
 Tramal SR 200............................ 110
 Tranexamic acid......................... 27
 Tranexamic-AFT......................... 27
 Tranylcypromine sulpha te............. 111
 Trastuzumab............................. 188
 Trastuzumab emtansine............... 189
 Travoprost............................... 208
 Travopt................................. 208
 Treatments for Dementia............. 125
 Treatments for Substance Dependence........ 126
 Tretinoin
 Dermatological.......................... 53
 Oncology................................ 136
 Trexate................................... 131
 Tri-sodium citrate...................... 220
 Triamcinolone acetonide
 Alimentary............................... 19
 Dermatological.......................... 56
 Hormone Preparations............... 64
 Triamcinolone acetonide with
 gramicidin, neomycin and
 nystatin................................. 204
 Triamcinolone acetonide with
 neomycin sulphate, gramicidin
 and nystatin............................ 56
 Triamcinolone hexacetonide........ 64
 Triazolam................................ 123
 Trichloracetic acid..................... 220
 Trichosteen.............................. 84
 Trientine dihydrochloride............ 17
 Trimethoprim............................ 79
 Trimethoprim with sulphamethoxazole
 [Co-trimoxazole]....................... 79
 Trometamol.............................. 216
 Tropicamide............................. 208
 Tropisetron.............................. 117
 Tropisetron-AFT........................ 117
 Tuberculin PPD [Mantoux] test....... 245
 Tubersol.................................. 245
 Two Cal HN.............................. 228
 TwoCal HN RTH (Vanilla)............. 228
 Tykerb................................... 139
 Tysabri................................... 121
 Ulitbro Breezehaler..................... 197
 Ultraproct............................... 7
 Umeclidinium............................ 197
 Umeclidinium with vilanterol........ 197
 Univent................................... 196
 Ural........................................ 61
 Urea
 Dermatological.......................... 55
 Extemporaneously Compounded
 Preparations............................ 220
 Urex Forte............................... 243
 Urogfralin............................... 213
 Urokine.................................. 33
 Urologicals.............................. 60
 Uromitexan.............................. 144
 Ursodeoxycholic acid................... 11
 Ursosan................................. 11
 Utrogestan................................ 59
 - V -
 Vaclovir.................................. 89
 Valaciclovir............................. 89
 Valganciclovir......................... 89
 Valganciclovir Mylan................. 89
 Vancomycin............................. 79
 Varenicline............................. 127
 Varenicline Pfizer..................... 127
 Varibar - Honey......................... 213
 Varibar - Nectar......................... 213
 Varibar - Pudding...................... 213
 Varibar - Thin Liquid.................. 213
 Varicella vaccine [Chickenpox
 vaccine]................................. 244
 Varicella zoster vaccine [Shingles
 vaccine]................................. 245
 Varilrix................................... 244
 Vasodilators............................. 48
 Vasopressin.............................. 71
 Vasopressin Agents..................... 71
 Vecuronium bromide................... 100
 Vedafil................................... 50
 Velcade................................... 132
 Veletri................................... 51
 Venclexa................................ 136
 Venetoclax.............................. 136
 Venlafaxine............................. 111
 Venofer................................... 18
 Ventavis................................... 51
 Ventolin................................. 199
 Vepesid................................. 133
 Verapamil hydrochloride............. 43
 Verto 16.................................. 116
 Verpamil SR.............................. 43
 Vesanoil................................. 136
 Vexazone................................. 10
 Vfend...................................... 81
 Vignatrin.................................. 114
 Vildagluptin.............................. 10
 Vildagluptin with metformin
 hydrochloride......................... 10
 Vimpat................................. 113
 Vinblastine sulphate................... 144
 Vincristine sulphate................... 144
 Vinorelbine.............................. 144
 Viral Vaccines......................... 240
 Virmunne Suspension............... 85
 ViruPOS................................. 203
 Viscocat.................................. 206
 Visipaque.................................. 213
 Vistil Forte............................. 209
 Vit.D3..................................... 22
 Vita-POS.................................. 209
 Vital........................................ 227
 Vitamin B complex..................... 21
 Vitamin B6 25........................... 21
 Vitamins................................. 20
 Vivonex TEN......................... 227
 Volibris.................................. 48
 Voltaren................................. 101
 Voltaren D............................... 101
 Voltaren Ophtha......................... 205
 Volumatic............................... 246
 VoLumen................................. 213
 Voriconazole............................ 81
<table>
<thead>
<tr>
<th>Chemicals and Brands</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Votrient</td>
<td>140</td>
</tr>
<tr>
<td>Vttack</td>
<td>81</td>
</tr>
<tr>
<td>Warfarin sodium</td>
<td>31</td>
</tr>
<tr>
<td>Wart Preparations</td>
<td>57</td>
</tr>
<tr>
<td>Water</td>
<td></td>
</tr>
<tr>
<td>Blood</td>
<td>36</td>
</tr>
<tr>
<td>Various</td>
<td>216</td>
</tr>
<tr>
<td>Wool fat</td>
<td></td>
</tr>
<tr>
<td>Dermatological</td>
<td>55</td>
</tr>
<tr>
<td>Extemporaneously Compounded Preparations</td>
<td>220</td>
</tr>
<tr>
<td>X-Opaque-HD</td>
<td>213</td>
</tr>
<tr>
<td>Xanthan</td>
<td>220</td>
</tr>
<tr>
<td>Xarelto</td>
<td>31</td>
</tr>
<tr>
<td>Xifaxan</td>
<td>8</td>
</tr>
<tr>
<td>Xolair</td>
<td>172</td>
</tr>
<tr>
<td>Xylocaine</td>
<td>106</td>
</tr>
<tr>
<td>Xylometazoline hydrochloride</td>
<td>199</td>
</tr>
<tr>
<td>Xyntha</td>
<td>28</td>
</tr>
<tr>
<td>Yellow jacket wasp venom</td>
<td>195</td>
</tr>
<tr>
<td>Zanamivir</td>
<td>91</td>
</tr>
<tr>
<td>Zantac</td>
<td>7</td>
</tr>
<tr>
<td>Zapril</td>
<td>38</td>
</tr>
<tr>
<td>Zarontin</td>
<td>113</td>
</tr>
<tr>
<td>Zavedos</td>
<td>130</td>
</tr>
<tr>
<td>Zeffix</td>
<td>88</td>
</tr>
<tr>
<td>Zeltam</td>
<td>88</td>
</tr>
<tr>
<td>Ziagen</td>
<td>86</td>
</tr>
<tr>
<td>Zidovudine [AZT]</td>
<td>86</td>
</tr>
<tr>
<td>Zidovudine [AZT] with lamivudine</td>
<td>86</td>
</tr>
<tr>
<td>Zimybe</td>
<td>46</td>
</tr>
<tr>
<td>Zinc</td>
<td></td>
</tr>
<tr>
<td>Alimentary</td>
<td>19</td>
</tr>
<tr>
<td>Dermatological</td>
<td>53</td>
</tr>
<tr>
<td>Zinc and castor oil</td>
<td>54</td>
</tr>
<tr>
<td>Zinc chloride</td>
<td>19</td>
</tr>
<tr>
<td>Zinc oxide</td>
<td>220</td>
</tr>
<tr>
<td>Zinc sulphate</td>
<td>19</td>
</tr>
<tr>
<td>Zinc with wool fat</td>
<td>54</td>
</tr>
<tr>
<td>Zincaps</td>
<td>19</td>
</tr>
<tr>
<td>Zinforo</td>
<td>74</td>
</tr>
<tr>
<td>Zinnat</td>
<td>73</td>
</tr>
<tr>
<td>Ziprasidone</td>
<td>119</td>
</tr>
<tr>
<td>Zista</td>
<td>196</td>
</tr>
<tr>
<td>Zithromax</td>
<td>74</td>
</tr>
<tr>
<td>Zoladex</td>
<td>66</td>
</tr>
<tr>
<td>Zoledronic acid</td>
<td></td>
</tr>
<tr>
<td>Hormone Preparations</td>
<td>63</td>
</tr>
<tr>
<td>Musculoskeletal</td>
<td>94</td>
</tr>
<tr>
<td>Zoledronic acid Mylan</td>
<td>63</td>
</tr>
<tr>
<td>Zopiclone</td>
<td>123</td>
</tr>
<tr>
<td>Zostavix</td>
<td>245</td>
</tr>
<tr>
<td>Zostrix</td>
<td></td>
</tr>
<tr>
<td>Zostrix HP</td>
<td>107</td>
</tr>
<tr>
<td>Zuclopenthixol acetate</td>
<td>119</td>
</tr>
<tr>
<td>Zuclopenthixol decanoate</td>
<td>120</td>
</tr>
<tr>
<td>Zuclopenthixol hydrochloride</td>
<td>119</td>
</tr>
<tr>
<td>Zudone</td>
<td>119</td>
</tr>
<tr>
<td>Zyban</td>
<td>126</td>
</tr>
<tr>
<td>Zypine</td>
<td>118</td>
</tr>
<tr>
<td>Zypine ODT</td>
<td>118</td>
</tr>
<tr>
<td>Zyprexa Relprevv</td>
<td>119</td>
</tr>
<tr>
<td>Zytila</td>
<td>144</td>
</tr>
<tr>
<td>Zyvox</td>
<td>79</td>
</tr>
</tbody>
</table>

INDEX: Generic Chemicals and Brands